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Abstract 
Microfluidic technology has recently emerged as an invaluable tool in the development 
of PET radiochemical methods allowing the quantities of precursors/reagents/solvents 
to be significantly reduced thus facilitating timely isolation of the final radiolabelled 
product. 1-5 The Advion NanoTek microfluidic system has been used to optimise model 
reactions designed to evaluate the status of the system and validate investigations. It 
was noted that the use of conventional phase-transfer agent (Kryptofix® 222/K2CO3) 
causes blockages to the micro-channels wherein the radiochemical reactions take 
place. We have demonstrated that tetraethylammonium bicarbonate is a viable 
alternative to the traditional phase-transfer agent, for the radiosynthesis of 
[18F]fluoroarenes, using a microreactor, via a key range of radiosynthetic strategies 
(Figure 1). Of particular benefit, in a microreactor, was the performance of 
tetraethylammonium bicarbonate where the occurrence of blocked reactors 
experienced with the conventional phase-transfer agent was eliminated thus 
dramatically increasing productivity.6 
 
Figure 1: Key methods use to evaluate tetraethylammonium bicarbonate as a phase-transfer agent in the radiosynthesis of 
ethyl 4-[18F]fluorobenzoate. 
Various diaryliodonium salts have been synthesised via conventional methods and 
reacted with tetraethylammonium [18F]fluoride, to generate ethyl 4- and 3-
[18F]fluorobenzoate with the synthesis of the 4-position regioisomer, generally, 
producing higher radiochemical yields. Excellent radiochemical yields and selectivity 
v 
 
were achieved for both isomers when using precursors bearing a 4-anisyl ring. The 
selectivity of the nucleophilic attack of [18F]fluoride on a diaryliodonium salt has been 
clearly demonstrated using electron-neutral and electron-rich derivatives.  
In addition, the Eckert & Ziegler Modular-Lab was used to generate a simple 
[18F]fluoroarene from a diaryliodonium salt using tetraethylammonium [18F]fluoride as 
the radiofluorinating agent. Radiochemical yields were low but comparable to those 
achieved when using the conventional phase-transfer agent, thus, proving that this 
new reagent may be used as a radiofluorinating agent in automated batch 
radiofluorinations. 
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1 Introduction 
It is of great value to the drug discovery industry to be able to image and observe 
molecular events in vivo and in real-time in order to create detailed images of 
fundamental biochemical and physiological processes within living organisms. Such 
imagery is essential to the development of new approaches to the assessment of 
disease and the design of possible drug candidates. There is, therefore, a continuous 
need to create and develop imaging techniques to further improve selectivity, 
sensitivity, and tissue specificity. 
1.1 Positron-emission tomography with fluorine-18 
Imaging techniques such as Magnetic Resonance Imaging (MRI), X-rays and ultrasound 
typically provide sound structural detail but little or no information on events at a 
metabolic or molecular level. These imaging techniques therefore rely on structural 
abnormalities associated with a disease to provide a credible diagnosis. However, 
other techniques such as Positron-Emission Tomography (PET) and Single-Photon 
Emission Computed Tomography (SPECT) are able to image biological context in real-
time and in living patients. These techniques use radioactive labels designed to be 
tissue or receptor specific to produce detailed pictures of the intended target. 
1.1.1 Positron-emission tomography 
Positron-Emission Tomography (PET) is a powerful, non-invasive molecular imaging 
technique used to gain valuable information on specific biological and pharmacological 
processes taking place in the human body. Positron-emitting radioisotopes (e.g. 15O, 
13N, 11C, 18F) are incorporated into a biologically active molecule, allowing for the non-
invasive imaging and quantification of pharmacological and biological processes whilst 
minimising the disruption to their pharmacodynamic properties. PET experiments can, 
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therefore, provide crucial information regarding the metabolism, biochemical 
mechanism, and receptor/enzyme interaction of potential drug candidates to the drug 
discovery and development industry. 1, 2 
PET is employed in both research and medicine, and currently being used extensively 
in clinical oncology, neurology and cardiology. Over 90% of PET scans performed today 
are used to gain oncological information. PET scans can be useful in diagnosis, staging 
and monitoring response to treatment of cancers such as Hodgkin’s lymphoma, non-
Hodgkin lymphoma and lung cancer. Other types of solid tumours have displayed 
strong uptake of established imaging agents, on a case-by case basis, which is 
especially useful in identifying secondary tumours or the reoccurrence of a highly 
active primary tumour which has been removed through surgery. 
PET is used in neurology on the basis that areas of high radioactivity are associated 
with elevated levels of brain activity, which is correlated to cerebral blood flow. 
Oxygen-15 labelled water, can be used to achieve this but must be administered 
directly from a medical cyclotron, due to the 2-minute half-life of the isotope. Other 
mechanisms have been exploited to greater understand a variety of neurological 
disorders in neuropsychology, psychiatry, sterotatic surgery, and seizure focus, 
wherein there is greater uptake of imaging agents. Alzheimer’s disease however, can 
be differentiated from other dementing processes as this disorder greatly decreases 
brain metabolism of both glucose and oxygen in tandem. The use therefore of an 
oxygen labelled imaging agent, alongside radiolabelled glucose can be used to make 
early diagnoses of this Alzheimer’s disease. 
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PET has also developed as a clinical imaging technique for the quantitative assessment 
of myocardial perfusions and advanced coronary artery disease in cardiology. This is 
mainly thanks to the rapid growth of PET as an imaging modality in oncology, 
increasing the availability of PET instrumentation to imaging departments. Tracers 
labelled with Rubidium-82 can be used to measure blood circulation in the arteries of 
the heart, whilst radiolabelled glucose can be used to differentiate healthy cardiac 
tissue from damaged tissue, such as that generated by a heart attack.  
Radiolabelled glucose has also been used to identify infection-associated inflammatory 
response to infectious diseases and has been shown to be a feasible technique for 
studying skeletal muscles during exercise, in musculo-skeletal studies.3  
1.1.2 Positron emission 
Positron Emission is a form of radioactive decay in which a positron and a neutrino are 
ejected from an unstable, proton-rich nucleus to produce a neutron. The positron 
emitted travels only a very short distance before colliding with an electron. Upon 
collision, the positron and the electron are annihilated to produce two γ-rays, each 511 
keV in energy, which then travel at 180° to each other. In PET imaging studies, these γ-
rays are detected by a 360° camera which uses a computer to construct a 3D image 
based on the sites of annihilation. Interference from background γ-radiation is negated 
as only pairs of γ-rays detected at 180° apart and of the corresponding energy are used 
to form the image. This mode of radioactive decay forms the basis for PET imaging 
(Image 2). 
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Image 2: (a) Positron and an electron annihilate producing two 511 keV photons travelling in opposite directions, (b) the 
coincidental photons are detected by the circular gamma ray detectors array of the PET camera. Taken from 4. 
As well as positron emission, the same radioisotopes can also decay concurrently via 
electron capture (EC). This mode of decay occurs when an unstable, proton-rich 
nucleus captures an electron which then combines with a proton to produce a 
neutron. This also results in the release of γ-rays, however these γ-rays are not emitted 
at 180° to one another and can therefore be ignored in the imaging process. 
Fortunately, most of the commonly used positron-emitting radioisotopes decay 
predominantly via positron emission.  
1.1.3 Radioisotopes in PET imaging 
Positron emitting isotopes can be generated by particle accelerators called cyclotrons. 
These machines focus a beam of either protons or deuterons, of a required energy 
range, onto a target system specifically chosen to produce a particular radioisotope 
following a nuclear reaction (Table 1). There are many positron-emitting radioisotopes 
available to the radiochemist, some of which are low mass atoms found naturally in 
biomolecules. The use of these elements is favourable as exchanging for the 
radioisotope derivative imparts no effect on the biological activity of the molecule of 
interest.  
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Isotope Half-life 
t1/2 (min) 
Positron 
Energy 
(MeV) 
Mean Positron 
Range in water 
(mm)
5
  
Nuclear 
Reaction 
 
Target Product Decay 
Product 
Decay 
mode 
PET:EC 
11
C 20.4 0.96 1.03 
14
N(p, α)
11
C N2(+O2) 
N2(+H2) 
[
11
C]CO2 
[
11
C]CH4 
11
B 100 
13
N 9.97 1.19 1.32 
16
O(p, α)
13
N H2O 
H2O+ 
EtOH 
[
13
N]NOx 
[
13
N]NH3 
13
C 100 
15
O 2.04 1.7 2.01 
15
N(d ,n)
15
O N2(+O2) [
15
O]O2 
15
N 100 
18
F 109.7 0.64 0.64 
18
O(p, n)
18
F 
20
Ne(d, α)
18
F 
[
18
O]H2O 
Ne(+F2) 
18
F
- 
[
18
F]F2 
18
O 97:3 
68
Ga
 
67.7 1.90 2.24 
66
Zn(α, 2n)
68
Ge 
68
Ge→
68
Ga 
66
Zn 
68
Ge
 68
Zn
 
89:11 
Table 1: The most commonly used radionuclides in PET, showing their half-lives, the nuclear reactions for their production, target 
products, decay products and decay modes (N.B. EC = Electron Capture) 
Unfortunately, many of these radioisotopes have half-lives short enough to present a 
synthetic challenge to the radiochemist. Ideally, the imaging agent should be 
synthesised, purified, analysed and formulated within three half-lives to ensure that 
sufficient radioactivity is administered to a subject undergoing a PET scan. This had 
necessitated the preparation of imaging agents in close proximity to the PET scanning 
facilities permitting the rapid transportation of an imaging agent to the scanning site. 
Modern radiochemistry facilities integrate radiochemistry laboratories, radioactivity 
generators, cyclotrons and PET scanning facilities in one convenient location. This has 
led to the development of compact or ‘mini’ cyclotrons able to generate the key 
radioisotopes such as carbon-11 and fluorine-18. These machines are considerably 
smaller than conventional cyclotrons and have only been made possible by advances in 
technology, target design, and software control. Additionally, “on-line” synthesis of 
imaging agents, wherein the radiotracer is synthesised on specially designed modules 
attached to the cyclotron, is also becoming more common. 
When designing an imaging agent, the timescale of the biological process to be studied 
should be commensurate with the half-life of the isotope selected. A process with a 
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relatively long half-life, such as amino acid utilization (e.g. S-adenosyl methionine has a 
half-life of 100 min) would require an imaging agent bearing the fluorine-18 (109.7 
min) or carbon-11 (20.4 min) radioisotope. A faster process, such as cerebral blood 
flow, may use a radionuclide with a much shorter half-life, such as oxygen-15 (2.04 
min).  
1.1.4 Fluorine in pharmaceuticals 
Drug candidates containing one or more fluorine atoms are common throughout all 
fields of drug development (Figure 3). It has been estimated that up to 20% of 
pharmaceuticals prescribed or administered as part of a treatment strategy contain a 
fluorine atom.6 The use of fluorine may induce a variety of useful properties into drug 
molecules, such as enhanced metabolic stability, selective reactivity, enhanced binding 
interactions, and changes to physical properties. 
 
Figure 3: Graph to show drugs launched containing fluorine (1957-2006). Taken from 7. 
 Introduction 
 
7 
 
Fluorine is small in size and the most electronegative element resulting in different 
reactivity between fluorinated compounds and the hydrocarbon counterpart have 
dominated design considerations. Fluorine also has a van der Waals radius and 
electronegativity similar to that of oxygen. These characteristics have allowed fluorine 
to be used as a substitute for either hydrogen or oxygen in numerous examples of drug 
design.  
Element (X) Van der Waals 
radius (Å) 
Electronegativity 
(Pauling Scale) 
Bond Length of C-X 
[Å] 
Hydrogen 1.20 2.20 1.09 
Oxygen 1.52 3.44 1.43 
Fluorine 1.47 3.98 1.35 
Table 2: Van der Waals radius, electronegativity and bond lengths to carbon of various atoms. 
Trifluoromethyl groups have also been used as alternative to a range of other species 
including phenyl, tert-butyl, isopropyl and methyl groups. Despite their isosteric 
mimicry, fluoro and trifluoromethyl groups will undoubtedly have a profound effect on 
the physical and/or biological properties of a molecule. The strong electron-
withdrawing nature of fluorine also has a profound affect on the acidity of 
neighbouring functional groups. Amines become less basic with both β- and γ- fluorine 
substitution. These inductive effects may even alter pKa values with δ-substitution. 
This affect may even be cumulative with successive substitutions lowering pKa. 
Pyridines, quinolines and anilines also experience a fall in basicity with the introduction 
of a fluorine substituent but these affects are attenuated by the aromatic nature of 
these compounds. Carboxylic acids, alcohols, heterocycles and phenols also become 
more acidic with fluorine substitution in adjacent positions. 
Changes to pKa values are an important consideration to lead optimisation studies as 
physiochemical properties (solubility, log D), binding affinities and absorption, 
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distribution, metabolism and excretion (ADME) become altered. Drugs associated with 
effective central nervous system (CNS) activity benefit from enhanced membrane 
penetration resulting from fewer positive charges, no negative charges and greater 
lipophilicity (cLogP, cLogD).  
Aside from the inductive effects fluorine induces on neighbouring functionalities, 
fluorine substitution plays an important role in direct binding interactions. Lipitor 
(Atorvastatin) 1, the biggest selling pharmaceutical worldwide, is a type 2 statin used 
to lower cholesterol (Figure 4).  
 
Figure 4: Lipitor (Avorvastatin) 
The drug is prescribed to patients in order to reduce the amount of biosynthetic 
cholesterol produced by the patient, as well as to offset plaque accumulation and 
vascular constriction associated with increased blood pressure. The drug is a potent 
inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HNG-CoA 
reductase) which is the rate-limiting enzyme of cholesterol biosynthesis in larger 
mammals. Atorvastatin, as well as other type 2 statins are all characterised by 
containing an essential fluorophenyl group. It has been proposed that this 
fluorophenyl group is stacked underneath the guanidinium group of Arg590, resulting in 
a direct polar interaction between the arginine nitrogen ε atoms and the fluorine. This 
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is a major example of binding interactions determining the mode of action for a 
successful organofluorine drug. 
The fluorination of drug molecules would be expected to produce a substantial effect 
upon the dipolar interactions. However, the change in binding potency of a fluorinated 
compound against the hydrocarbon parent is often quite small. In many examples, if 
direct bonding interactions are taking place then a mild effect on overall binding 
suggests that the effects on bipolar interactions are minimal. The fluorination of 
alkanes will decrease lipophilicity as the compound becomes more polar. However, the 
addition of fluorine or trifluoromethyl groups to aryl rings or to positions adjacent to a 
π-system or heteroatom containing functional group, increases lipophilicity and may 
strongly polarise the parent molecule. Fluorination may have only modest effects on 
the binding affinity as weak repulsive interactions are counterbalanced against the 
increase in hydrophobicity. The weak interaction could be a desirable outcome as a 
particularly labile site of metabolic oxidation can be blocked by fluorination without 
any major changes to target affinity. These qualities encourage the inclusion of 
fluorine into drug candidates, which is of major significance to the radiochemist as the 
fluorine-18 isotope becomes commonly used to radiolabel such compounds for non-
invasive imaging using PET. 
1.1.5 Fluorine-18 in PET imaging 
Fluorine-18 is now considered to be the radionuclide of choice for PET imaging. 
Widespread use of the most commonly used PET tracer 2-[18F]fluoro-2-deoxy-D-
glucose  ([18F]FDG) 2 (Figure 5) which images areas of enhanced metabolism thereby 
improving diagnosis and evaluating the effectiveness of treatments in oncology, has 
spurred the global interest in PET studies.8 
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Figure 5: 2-[18F]fluoro-2-deoxy-D-glucose 2 ([18F]FDG) 
The use of fluorine-18 has the following advantages: 
 Fluorine-18 has a relatively long half-life (109.7 min) which allows sufficient 
time for multi-step synthetic labelling reactions and transportation of the 
radiolabelled product to the site of injection. This allows for multiple patients 
to be scanned from a single delivery at a PET centre. 
 The positron emitted from fluorine-18 has a low positron energy (0.64 MeV). 
This means that the distance travelled by the positron is minimised before 
coming into contact with an electron. This short distance travelled from the 
point of emission to the site of γ-ray initiation, greatly improves the resolution 
of images and accuracy of detection. Compare this to oxygen-15, which has a 
positron energy of 1.72 MeV, allowing the positron to travel further from the 
site of emission and therefore increasing the uncertainty in the origin of the -
rays. 
 Fluorine-18 has a half-life relevant to the time scale of most biological 
processes. Other radioisotopes such as nitrogen-13 and oxygen-15 have half-
lives so short that during the time taken between production and 
administration of the radiolabelled agent, its radioactivity has decreased to a 
level insufficient for accurate imaging.  
 Fluorine-18 decays almost purely by positron emission (97%). This is important 
as decay via other means can produce unwanted side products, and requires a 
higher patient dose to obtain the same degree of data capture for the 
radiographer. 
 Fluorine-18 decays to the form the harmless decay product, oxygen-18. This is 
vital as some positron emitting atoms decay to form products that emit 
harmful α or β particles. For example, copper-64 decays to forms nickel-64 and 
zinc-64. 
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 Fluorine may conveniently replace a hydrogen atom attached to carbon, 
however the fluorine atom is more isosteric to oxygen which has a similar bond 
length to carbon. The fluorine atom may therefore also substitute for a 
hydroxyl group and not disrupt the isoelectronics nor reduce the ability to form 
a hydrogen bond.9 
Fluorine-18 also has the advantage of being to be produced in high levels of 
radioactivity. This has the following advantages: 
 Multiple doses of an imaging agent can be administered per production run. 
The high levels of activity can be divided amongst several syntheses which are 
then, in turn, administered to patients. 
 Higher levels of activity, combined with the convenient half-life also allow the 
imaging agents to be transported significant distances; from the location of 
isotope production to site of administration. 
 The ratio of radioactivity to injection volumes is higher when large amounts of 
activity are generated. This is particularly important when injecting into small 
mammals for pre-clinical imaging. 
1.1.6 Production of flourine-18 
By far the most common reagent for electrophilic fluorination is [18F]F2 which can be 
obtained from the nuclear reactions of either 20Ne(d, α)18F, or 18O(p, n)18F. It may be 
used as [18F]F2, which would limit the radiochemical yield (RCY) to 50%, or converted 
into the less reactive derivative acetyl hypofluorite ([18F]CH3COOF) reducing the 
maximum RCY even further. Due to the low specific activity (SA) of the [18F]F2, 
nucleophilic fluorine chemistry remains the dominant force in PET radiotracer 
production as this methodology leads to higher RCY and material yield (Figure 6). 
 Introduction 
 
12 
 
 
Figure 6: Key definitions used throughout radiochemistry 
There are several possible ways to produce the fluorine-18 ion10 but the most widely 
used method is from a cyclotron through the proton irradiation of 18O-enriched 
water.11 Small, compact cyclotrons are now capable of producing high activities of 
fluorine-18 from the nuclear reaction, 18O(p, n)18F, with typical production yields of 
180mCi/μA at saturation of the target. The ABT Biomarker Generator will, generally, 
produce 1mCi/min during bombardment until saturation.12 An advantage to this 
method is that the fluorine-18 is obtained as “non-carrier-added” (NCA). This means 
that the stable isotope is not required in order to obtain the radioisotope in a reactive 
form which is, therefore produced with a high SA (‘carrier-added’ or CA, denotes that a 
stable isotope has been added to aid the isolation of the target isotope). This is a vital 
characteristic of successful imaging agents as a low SA would mean that the target 
Specific Radioactivity (SA):  
Specific Radioactivity (Specific Activity) is the ratio of [18F]fluoride ion radioactivity 
compared to its mass of carrier or total fluoride ion. SA is usually presented in GBq/µmol. 
Radiochemical Yield (RCY): 
The yield of a radiochemical reaction expressed as a fraction of the radioactivity 
originally present. If the RCY has accounted for the decay in radioactivity which has 
occurred during the radiosynthesis, then the term is ‘decay corrected’ radiochemical 
yield or RCY(DC). If not, then the term ‘non-decay corrected’ radiochemical yield or 
RCY(NDC) is used. 
Radiochemical Purity (RCP): 
The quantity of the desired radioactive compound expressed as a percentage of the total 
radioactive products present. 
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would be saturated with non-radioactive fluorine ligands and so reduce any localised 
signal from the bound radioligand. Radioligands with high SA also allow for small mass 
doses to be injected into humans thereby reducing the chemical dose and the 
potential toxicity. 
The [18F]fluoride ion is obtained in [18O]-H2O making the ion unreactive due to its high 
degree of hydration. Most of the water must be removed in order to generate the 
reactive nucleophilic fluorine-18 ion. Usually, this ion is then solubilised in an organic 
solvent for impending reactions to take place. This is conventionally achieved by 
adsorption of [18F]fluoride ion onto an ion exchange resin to allow for the recovery of 
the bulk of the [18O]-H2O.
13 This is followed by the elution of the [18F]fluoride ion from 
the resin using a phase-transfer agent (PTA) such as Kryptofix®222/K2CO3 and dissolved 
in a small volume of solvent (e.g. 95:5 MeCN/H2O). The water is then removed from 
this solution by repeated cycles of azeotropic evaporation with MeCN. The addition of 
a cryptand to the basic solution allows the potassium ion to become solubilised in a 
polar aprotic solvent, allowing for separation of the [18F]fluoride ion which therefore 
increases in reactivity. After the drying step has removed the [18O]H2O, the 
[18F]fluoride/PTA complex is then resolubilised in the reaction solvent. The vessel 
material is of important consideration as some of the fluorine-18 ion can become 
adsorbed onto the vessel wall.14 It should be noted that this is a typical procedure only 
and variations can be made. 
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Scheme 1: Flowchart to show the preparation of the fluorine-18 ion 
The above procedure is general but small variations can be made, for example, the 
base and the counterion are interchangeable. It is of great importance to separate the 
cation, thereby making the [18F]fluoride as nucleophilic as possible. This also renders 
the fluoride ion prone to protonation hence why the majority of reactions using the 
[18F]fluoride ion are conducted under weakly basic conditions. Unfortunately, this 
limits the availability of precursors as those used for labelling should not be a ready 
source of protons. 
Although this is currently the leading method for labelling preparation, cyclotron 
produced [18F]fluoride ions are still considered to be heavily laden with contaminants. 
These will arise from various sources throughout the procedure: 
 Free radicals from the irradiated water. 
 Other radionuclide from the bombardment process. 
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 Metal ions already present in the water.15 
 Impurities delivered from ion exchange resin and through contact with other 
materials. 
 Atmospheric carbon and others contaminants present on all equipment used. 
 Impurities in the reagents/solvents. 
The naked fluoride is virtually never obtained despite best attempts to dry or 
dehydrate. The complete removal is water is a difficult process which can also add 
possible impurities. Each step towards the dehydration of the [18F]fluoride will serve to 
increase its nucleophilicity. Generally speaking, however, it only seems more 
important to ensure the [18F]fluoride is as dry as possible when conducting more 
difficult reactions such as aromatic nucleophilic substitution reactions. Less rigorous 
drying may be required for water tolerant reactions such as aliphatic nucleophilic 
substitution reactions. Radiofluorination methods may even be conducted in water 
and also assist in preventing adsorption of fluorine-18 ions onto the vessel wall. 
There have been several attempts made to purify the cyclotron produced fluoride ion 
including the conversion to [18F]fluorotrimethylsilane 4.16, 17 This is then distilled out 
before being hydrolysed back to the fluorine-18 ion (Scheme 2). 
 
Scheme 2: Purification of the [18F]fluoride ion from the conversion into fluorotrimethylsilane 
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1.2 Methods for labelling with the fluorine-18 ion 
The vast majority of synthetic strategies to fluorine-18 labelling can be divided into 
two distinct groups: 1) direct fluorination, where the fluorine-18 isotope is introduced 
directly onto the target molecule of interest in one step; and 2) indirect fluorination, 
where the fluorine-18 isotope is first introduced onto a prosthetic group which is 
subsequently attached to the group of interest.  These prosthetic groups are normally 
small [18F]fluorinated alkyl or aryl groups which also contain reactive functionality. This 
second approach often requires a multi-step synthesis and is generally only used for 
labelling complex biological molecules which may not be able to tolerate the 
conditions imposed by direct fluorination methods.  
Methods involving the fluorination may also be broken down into two clear categories:  
‘nucleophilic’ using the fluorine-18 ion, and ‘electrophilic’ which generally uses [18F]F2 
and derived reagents. Nucleophilic fluorination processes have dominated synthetic 
strategies in the past as greater selectivity and SA is achievable whilst the [18F]fluoride 
is produced in larger quantities. Electrophilic [18F]fluorinations are less favoured for 
several reasons: 
1) they generally produce radiolabelled products with low SA due to the carrier-
added method of [18F]F2 production, 
2) the maximum RCY is 50%. The massive excess of F2 means that it is extremely 
improbable that 18F—18F will be generated, and only 18F—19F will react with the 
precursor, hence the maximum RCY being 50%. Most of the fluorinating agent 
will be 19F—19F. 
3) labelling with [18F]F2 is generally unspecific and can therefore lead to multiple 
[18F]-labelled products. 
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However, there are strategies towards some of the most widely used PET agents that 
rely on electrophilic fluorine-18 reactions.18, 19 For example, the first synthesis of the 
PET tracer [18F]FDG 2 was completed using electrophilic fluorination.20  
 
Scheme 3: Electrophilic [18F]fluorination using acetyl [18F]hypofluorite for the preparation of [18F]FDG20, 21 
Softer and more selective electrophilic fluorinating agents have recently been 
developed such as N-[18F]fluorobenzenesulfonimide which is used to prepare and label 
fluorinated ketones and allylic fluorides. 22 However, this still requires additional 
synthetic steps and retains the low SA restriction even when high SA [18F]F2 is 
employed. 
Whilst there now exists many different strategies to [18F]fluorination, all methods 
suffer from inconsistent RCYs and SA. There are several reasons for this: 
 The amount of [18F]fluorine produced by a cyclotron is inconsistent. As the 
radioisotope is produced by bombarding a target with accelerated protons, 
varying proportions (approx. 1 in every 1800) protons interacts with 
[18O]oxygen atoms to create fluorine-18 beam. This varies according to the 
general performance on the cyclotron. 
 The output of cyclotrons will vary by age, manufacturer, maintenance and 
environment. 
 Specific activity will differ across the same reactions types due to the varying 
degrees of contamination from fluorine-19, caused by the changes in the 
environment, equipment and reagents/solvents used. 
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 Trace but varying quantities of water and/or acid can vary the degree of 
reactivity of the fluoride. A greater volume of water will hydrate the fluoride 
ion and therefore reduce the ‘hardness’ of the nucleophile. The presence of 
acid will protonate the fluoride and produce, the less reactive, HF. 
 As nano-quantities of fluorine-18 are used in reactions, they are, generally, very 
sensitive to small changes in the reaction conditions, thereby varying RCYs. 
Despite these issues, the value of fluorine-18 chemistry for positron emission 
tomography significantly outweighs the drawbacks of the radiosynthetic methods. 
1.2.1 Balz-Schiemann and Wallach reactions 
One of the earliest methods to introduce fluorine-18 into a compound was the Balz-
Schiemann approach (Scheme 4). In this procedure, an aryldiazonium 
tetrafluoroborate, 6 undergoes an fluorine-18 exchange to give aryldiazonium 
tetra[18F]fluoroborate, 7 followed by a thermal decomposition to give the 
[18F]fluoroarene, 8.23 
 
Scheme 4: The Balz-Schiemann reaction for the synthesis of [18F]fluorarenes23 
This approach has long been used to incorporate a fluoride ion into a position 
originally occupied by an aryl amino group. However, it carries with it one major 
disadvantage. Only one of the four fluorides on the tetrafluoroborate ion can possibly 
be the fluorine-18 isotope. This limits the SA of the radiolabelling process to 25% of the 
theoretical maximum as the result is more often the [19F]fluorinated product. Using a 
non-fluorine containing counterion (e.g. aryldiazonium tetrachloroborate) helps avoid 
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the problem. However, this leads to significant transfer of the chloride which then 
requires separation from the desired fluoro compound which may prove difficult in the 
time required. Side reactions of the diazononium salt with residual water or other 
trace species also limit the capacity of the Balz-Schiemann approach.  
The Wallach reaction also produces [18F]fluoroarenes but by the acidic decomposition 
of a triazene precursor, 9 in the presence of the fluorine-18 ion (Scheme 5).24 
 
Scheme 5: The Wallach reaction for the synthesis of [18F]fluoroarenes25, 26 
The reaction is considered to go via a diazonium salt intermediate, which may be 
obtained through protonation of the triazene. Attempts to optimise this reaction by 
varying the acid, solvent, and reaction stoichiometry have been made. Despite this, the 
reaction is still low yielding. 
Balz-Schiemann and Wallach reactions are now rarely used in fluorine-18 radiolabelling 
due their low RCYs and the emergence of more successful alternatives. 
1.2.2 Electrochemical radiofluorination 
Electrochemical oxidative fluorination represents one approach towards the 
production of a fluoroarenes using a fluoride ion but without the need for strong 
activating groups to promote a nucleophilic exchange. By removing an electron from a 
phenyl ring, fluoride can easily react with the cation formed to generate an aryl radical. 
This intermediate can be further oxidised to produce an aryl cation which undergoes 
rearomatisation by loss of a proton to produce the fluoroarenes (Scheme 6).27 
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Scheme 6: ECNECB Mechanism of electrochemical nucleophilic fluorination 
Resichel and co-workers have used this process to generate fluorine-18 labelled amino 
acids.28 Previous work form within the group found that fluorobenzene could be 
generated in a electrolysis cell, using Et3N.HF with MeCN as the electrolyte, in the 
presence of [18F]fluoride.29 This work was extended towards the synthesis of 
[18F]fluorophenylalanine (Scheme 7).28 The reaction showed a large degree of 
dependence upon the nature of the protecting groups at the amino and carboxylic 
functionality. Generally, however, RCYs were low with the best results (10.5 ± 2.5%) 
achieved using methyl and TFA groups (to protect the acid and amino functionality, 
respectively) temperatures of between -10°C and 0°C and using Et3N.3HF as the 
supporting electrolyte (Scheme 7). These conditions generated a carrier-added product 
and therefore a product low in SA (1.2 GBq/mol). Despite these results, the short 
reaction times and efficient methodology leaves scope to pursue this ‘mild 
fluorination’ approach towards the generation of simple [18F]fluoroarenes. 
 
Scheme 7: Electrochemical radiofluorination of protected phenylalanine28 
1.2.3 [18F]Fluoride umpolung strategies 
The major advantage of using the [18F]fluoride compared to the  electrophilic 
counterpart is that the nucleophilic specie can be produced in higher levels of SA. 
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Methods for oxidising the [18F]fluoride to an electrophilic reagent would create 
opportunities to synthesise a large range of radiotracers inaccessible via conventional 
nucleophilic radiochemistry. Ritter and colleagues have reported the synthesis of a 
palladium-based electrophilic fluorinating agent derived from fluoride, which allows 
for the late-stage fluorination of aromatic targets (Scheme 8).30 Previous work 
focussed on the electrophilic fluorination of palladium aryl complexes using F-TEDA.31 
Palladium(II) aryl complexes are oxidised which subsequently allow the formation of 
the aryl carbon-fluorine bond via reductive elimination from palladium (IV) aryl 
fluoride complexes. Careful consideration led to the design of a stable and highly 
fluorophilic complex, in a high oxidation state which allows for the transfer of a ligand 
to a nucleophile whilst undergoing reduction of the metal centre. Treatment of this 
complex with KF afforded the palladium fluoride complex in excellent yields and short 
reaction times. The authors propose that nucleophilic attack would only occur at the 
anti-bonding palladium-fluorine orbital (σ*Pd-F). No other LUMO lobe is available for 
nucleophilic attack because the aromatic ligands block the trajectories. Essentially, this 
is an SN2 reaction at the fluorine atom with the palladium complex acting as a leaving 
group. The [18F]PdIV complex was then synthesised from [18F]KF/18-crown-6 in 10 min 
at RT before being combined with the palladium(II)-aryl and the mixture heated to 85 
°C for 10 min. Three different, highly functionalised [18F]aryl fluorides 17–19 could be 
accessed in RCYs (DC) ranging from 10–33% and in good SA (ca. 40 GBq/μmol).30 
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Scheme 8: Palladium-based electrophilic fluorinating agent derived from [18F]fluoride, allowing for late stage radiofluorination of 
aromatic targets.30  
1.2.4 Aryl umpolung strategies 
Gouveneur and colleagues have reasoned that the coupling of phenol derivatives with 
[18F]fluoride could be achieved via an aryl umpolung strategy, using an external 
reagent, to oxidise the phenolic entity to an electrophile.32 Oxidation of the electron-
rich aromatic compound creates an electrophilic species which undergoes attack by 
the fluoride ion and subsequent dearomatisation. Rearomatisation is achieved using 
an acid to afford the desired compound (Scheme 9). 
 
Scheme 9: Aryl Umpolung Strategy 
4-tert-Butylphenol was synthesised as the electron-rich nature of this compound is 
representative of functionality present on some radiotracers used clinically. 4-
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[18F]Fluorophenol is also a versatile prosthetic group used in the indirect radiolabelling 
of more complex biomolecules. An optimised approach to the synthesis of 4-tert-
butylphenol was used to radiolabel with [18F]fluoride. The precursor is combined with 
tetra-n-butylammonium [18F]fluoride ([18F]TBAF) and trifluoroacetic acid (TFA) before 
the diacetoxyiodobenzene (DIB) is introduced. Rearomatisation using TFA gave the 
desired product in 21% RCY (DC). Using this optimised protocol, various 4-tert-butyl 
substituted phenols 20 were radiolabelled with RCYs (DC) of up to 32% being 
achieved.32 
 
Scheme 10: One-pot oxidative fluorination32 
This approach was proven to tolerate substitution at the ortho and meta positions of 
the aromatic substrate. The procedure is also rapid enough to allow for post-
fluorination reactions to be performed without significant loss of activity. The 
promising result for the formation of 2-bromo-4-[18F]fluorophenol 23 also prompted 
the authors to examine the scope for cross-coupling with phenylboronic acid via a 
Suzuki-Miyaura reaction (Scheme 11). 4-[18F]Fluoro-2-phenylphenol 24 was achieved 
via this synthesis in > 95% RCY (DC) thereby potentiating the approach towards 
prosthetic group chemistry and expanding the range of possible targets.32 
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Scheme 11: Suzuki-Miyaura coupling post-radiofluorination32 
1.2.5 Enzyme catalysed [18F]fluorination 
The use of enzymes to generate fluorine-18 labelled radiotracers under aqueous 
conditions, and at RT, is an attractive approach to the synthesis of potential imaging 
agents. They are also chemoselective and produce few side products. O’Hagan and co-
workers have pioneered work in this field and first reported an example of the 
formation of a C-F bond by an enzyme (E.C.2.5.1.63) isolated from the bacterium, 
Streptomcyes cattleya.33 The enzyme, now called fluorinase, was used to produce 5’-
[18F]fluoro-5’-deoxyadenosine  (5’-[18F]FDA) 27 from S-adenosyl-L-methionine (SAM) 
26 (Scheme 12). Initial RCYs were low (ca. 1%) however, upon addition of a second 
enzyme, L-amino acid oxidase, the L-methionine by-product is consumed and 
equilibrium is shifted to favour the formation of 5’-[18F]FDA resulting in RCYs > 90%. 
This process was used to generate 5’-[18F]fluoro-5’-deoxyinosine (5’-[18F]FDI) and 5’-
[18F]fluoro-5’-deoxy-D-ribose (5’-[18F]FDR) in RCYs of up to 95% in < 2 h. 
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Scheme 12: Radiosynthesis of 5’-[18F]fluoro-5’-deoxyadenosine (5’-[18F]FDA) using fluorinase33 
These are highly efficient processes as a millimolar concentrations of enzyme (mM) 
can be used with picomolar concentrations of [18F]fluoride ion, therefore the enzyme is 
present in considerable excess. More recently, an efficient synthesis of 5-[18F]FDR has 
been accomplished by combining the fluorinase enzyme with a nucleoside hydrolase in 
a sequential one-pot reaction.34 Good RCYs (DC) have been achieved and the stability 
of the enzyme demonstrated. Research into expanding the scope for this novel 
method of radiolabelling is on-going and may create diagnostic tools for future PET 
studies. 
1.2.6 Nucleophilic aromatic substitution 
Nucleophilic aromatic substitution is by far the most successful approach for 
introducing fluorine-18 into aromatic positions. This procedure uses nucleophilic 
[18F]fluoride to displace a good leaving group. Typical leaving groups in order of 
increasing ability are: I<Br<Cl<F<NO2≈N
+Me3. The N
+Me3 leaving group is particularly 
beneficial to the radiochemist, especially when used witht eh perchlorate, chloride or 
triflate counterions as separation of the labelled product from the precursor is 
facilitated by the large difference in charge. The disadvantage, however, in the 
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competing formation of [18F]fluoromethane, a volatile radioactive compound which 
must heighten rigour in health and safety protocols in any radiochemistry laboratory. 
Normally, the leaving group is ortho or para to at least one electron-withdrawing 
group. This is often necessary as nucleophilic aromatic substitution only works well on 
electron-deficient rings.  
Nucleophilic aromatic substitution is used favourably by chemists for radiolabelling 
despite usually requiring harsh reaction conditions (high temperatures and polar 
organic solvents). This is because as most reactions are simple one-pot, one-step 
pathways capable of achieving high RCYs and high SAs. This also saves time which is 
crucial when working within a window of two to three half-lives.  One such example is 
the synthesis of [18F]haloperidol 29 which binds to a large number of neurotransmitter 
receptors (Scheme 13).35 
 
Scheme 13: Direct synthesis of [18F]haloperidol from the nitro precursor35 
Only a very few examples exist of reactions with an electron-withdrawing group in the 
meta-position.  The preparation of the mGluR5 radioligand, [18F]FMTEB 31 is one of 
the few examples.36, 37 However, only a very low RCY has been obtained (Scheme 14). 
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Scheme 14: The synthesis of [18F]FMTEB36 
1.2.7 Radiolabelling of triarylsulfoniums 
A method for radiolabelling aromatic compounds with [18F] fluoride has been 
developed based on the principles of nucleophilic aromatic substitution (SNAr) using 
triarylsulfonium salts. This particular method is applicable to a various halogen-
substituted aryl systems including non-activated and deactivated aryl rings, plus 
amides. Studies indicate that sulfonium salts have the potential to be optimised for 
labelling non-activated and deactiviated aryl rings that have Hammett σP substituted 
constants of greater than -0.170. 
High radiochemical yields of [18F]-4-fluoroiodobenzene from X represents a ready 
source of X for subsequent use in palladium catalysed C-C bond forming reactions.38 
 
Figure 7: Radiosynthesis of [18F]fluoro-iodo-benzene from a sulfonium salt.38 
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This approach to radiolabelling [18F]fluoroarenes is relatively new but may have vast 
applications in the future of the radiosynthetic chemistry for PET imaging. 
1.2.8 Indirect radiolabelling methods 
The radiochemist faces a significant challenge in the radiofluorination of electron-rich 
arenes and macromolecules which may be not be appropriate to a direct, single-step 
labelling strategy. Such targets require the preparation of a reactive species bearing 
the fluorine-18 isotope (a prosthetic group) which is subsequently used to label the 
target compound and generate the desired imaging agent. These labelling agents may 
be aliphatic or aromatic and the target may be a small molecule or a large 
macromolecule, such as a peptide or protein. 
1.2.8.1 Aliphatic prosthetic groups 
An important group of labelling agents are the functionalised, straight-chain aliphatic 
[18F]fluorides. These molecules are commonly prepared from the reaction of the 
[18F]fluoride ion with ,-bi-functional precursors. Short-chain -[18F]fluoroalkyl 
agents are the most common with [18F]fluoromethyl bromide and 2-[18F]fluoroethyl 
tosylate being the most frequently used. While tosylates are generally preferred for 
[18F]fluoroethylation,39 bromides appear to be more beneficial for 
[18F]fluoromethylation.  For example, Zessin and co-workers have reported the 
synthesis of the [18F]fluoromethyl analogue of (+)-McN5652 ([18F]FMe-McN) 36 as a 
new potential tracer for the serotonin transporter.40 Cyclotron produced [18F]fluoride 
was used to generate [18F]bromofluoromethane from  dibromomethane, using an 
automated synthesis platform. This [18F]fluoromethylation agent was then combined 
with the thiolate presursor 35 to produce the desired target in  a typically low RCY of 
5% but in high SA. The initial radiofluorination step was performed in 25% RCY and 
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99% RCP. The radiotracer was then shown to be stable for 1 h in a 0.11 M sodium 
bicarbonate solution containing 50% propylene glycol (Scheme 15). 
 
Scheme 15: Radiosynthesis of (+)-trans-1,2,3,5,6,10b-hexayhdro-6- [4-[18F]fluoromethylthio)phenyl]-pyrrolo-[2,1-a]iso-quinoline 
([18F]FMe-McN)40 
[18F]Fluoroethyl tosylate is far more reactive than the bromide derivative and may be 
produced and used in situ to generate radiotracers. This labelling agent has been 
applied to the synthesis of several radiotracers including, for example, 2--
carbomethoxy-3--(4-chlorophenyl)-8-(2-[18F]fluoroethyl)nortropane ([18F]FECNT) 40 – 
a brain dopamine transporter (DAT).41 2-[18F]Fluoroethyltosylate 38 was first prepared 
before being used to alkylate 2--carbomethoxy-3-(4-chlorophenyl)nortropane 39 to 
generate the desired target in 21% RCY (Scheme 16). Excellent imaging results were 
achieved suggesting that this agent may be superior for mapping brain dopamine 
transporters in humans using PET.41 
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Scheme 16: Radiosynthesis of [18F]FECNT41 
 [18F]Fluoroethyl aryl sulfonates of higher reactivity, such as nosylate derivatives, have 
also been produced in this manner. Pike and coworkers investigated a series of novel 
[18F]fluoroethyl derivatives bearing a less electron-rich aryl group, i.e. benzenesulfonyl, 
brosyl, nosyl, and 3, 4-dibromobenzenesulfonyl groups.42 All reagents gave excellent 
RCYs (64–87%) of [18F]FECNT in short reaction times. Results showed that these 
reagents offer high reactivity and straight-forward syntheses from stable precursors 
suggesting such agents (particularly 3,4-dibromobenzenesulfonate) should be 
considered as alternatives to [18F]fluoroethyltosylate.42 
1.2.8.2 Aromatic Prosthetic Groups 
The lack of leaving groups required for nucleophilic substitution makes direct 
incorporation of fluorine-18 into peptides and proteins very difficult with only low 
levels of SA achievable. The harsh reaction conditions required of direct 
radiofluorination using [18F]fluoride (high temperature, strongly basic) cause 
denaturation and decomposition of the sensitive biomolecules such as peptides, 
proteins, oligonucleotides and antibodies. The development of prosthetic groups for 
the radiolabelling of these biomolecules has, therefore, become widespread and could 
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emerge as a very important class of imaging agent. [18F]Fluoroalkylating agents have, 
conventionally, been used in the indirect labelling of small, simple molecules whilst 
prosthetic groups prepared in a similar fashion for [18F]fluoroamidation and 
[18F]fluoroacylation are generally used to radiolabel biomolecules under mild reaction 
conditions. 
1.2.8.3 Amine Reactive Prosthetic Groups 
The formation of a stable amide bond between the amino group of a 
biomacromolecule and a prosthetic labelling agent presents an attractive strategy 
towards radiolabelling peptides and proteins. A vast number of potential prosthetic 
groups are, therefore, designed with the intention of coupling to proteins via an amino 
functionality present on an amino acid residue (N-terminus RNH2 or lysine NH2) or via 
an alkylamine linker. N-Succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) 45 is one of the 
most commonly used prosthetic groups for labelling via acylation. Published 
radiosyntheses of [18F]SFB have generally involved three steps in multiple vessels: (1) 
[18F]fluorination of an appropriate aromatic precursor, (2) formation of the 4-
[18F]fluorobenzoate salt, and (3) conversion of the salt of [18F]SFB.43 However, more 
versatile approaches have recently been presented. For example, Tang and co-workers 
developed an efficient preparation based on a convenient, one-pot procedure 
consisting of [18F]flourination of ethyl 4-(trimethylammoniumtriflate)benzoate 42, 
saponification to generate the [18F]fluorobenzoate salt 44 with tetrapropylammonium 
hydroxide, and conversion of the [18F]fluorobenzoate salt to [18F]SFB .44 The resultant 
[18F]SFB was used to label Avastin, an angiogenesis inhibitor used to treat various 
cancers, through [18F]fluorobenzoylation of an amino residue. 
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Scheme 17: Radiosynthesis of [18F]SFB44 
The drawback to this strategy lies in the difficulty in automating the process. Reducing 
the number of synthetic steps involved, helps circumvent this issue. Carroll and co-
workers developed a single-step synthesis of [18F]SFB using diaryliodonium salts 
(Scheme 18).45 The required precursor 46 was subjected to [18F]fluorination by reacting 
with [18F]KF/K222 complex in DMF for 5 min at 130 °C and in a Pyrex reaction vial. RCYs 
of 23% were achieved.  
 
Scheme 18: Single-step radiosynthesis of [18F]SFB45 
There are other [18F]fluorinated compounds which also serve as prosthetic groups, 
such as 4-[18F]fluorophenacyl bromide 47, N-succinimidyl-4-([18F-
fluoromethyl)benzoate 48, 3-[18F]-5-nitrobenzimidate 49, methyl 2-[18F]-
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fluoropropionate 50, 2-[18F]fluoroacetic acid 51, and N-succinimidyl-8-[4’-
[18F]fluorobenzyl)amino]suberate 52 (Scheme 19). 
 
Scheme 19: Prosthetic groups for indirect labelling with fluorine-18 
1.2.8.4 Thiol-Reactive Prosthetic Groups 
The thiol group present in cysteine residues is also frequently targeted for the 
formation of conjugates with prosthetic groups. The rarity with which this residue is 
found allows for thiol reactive agents to modify biomolecules at specific sites and 
induce a means of high chemoselectivity. Due to its excellent selectivity, 1-[3-(2-
fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione) ([18F]FPyME) 55 is becoming an 
interesting alternative to more commonly used prosthetic groups. This 
[18F]fluoropyridine-based maleimide reagent is used for the indirect labelling of 
proteins and peptides via selective conjugation with a thiol residue. de Bruin prepared 
[18F]FPyME in 28–37% RCY in 110 min using a three-step strategy (Scheme 20).46 
Excellent chemoselectivity was observed upon comparing thiol and amino groups in a 
small hexapeptide before the prosthetic group was conjugated to 8-kDa proteins. 
Pleasingly, high yields of the conjugated end product were achieved in short reaction 
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times demonstrating the value of this thiol-selective, fluorine-18 reagent for the 
prosthetic labelling of peptides and proteins.  
 
Scheme 20: Radiosynthesis of [18F]FPyME46 
Wüest and coworkers have used [18F]FDG 1 as a precursor for the synthesis of 
[18F]fluorinated peptides and proteins.47 The popular imaging agent was converted to 
[18F]FDG-maleimidehexyloxime ([18F]FDG-MHO) 58 using N-(6-
aminoxyhexyl)maleimide 57 in 80% EtOH heated to 100 °C for 15 min (Scheme 21). 
RCYs of up to 69% were achieved, following radio-HPLC purification, in a total synthesis 
time of 45 min. The chemoselective conjugation of [18F]FDG-MHO to thiol groups was 
investigated using the reaction with tripeptide glutathione (GSH) and the annexin A5 
protein, which contains only one cysteine residue. Excellent RCYs were observed, even 
at low protein concentration levels, making [18F]FDG-MHO a promising prosthetic 
group for chemoselective [18F]labelling of thiol residues.47 
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Scheme 21: Radiosynthesis of [18F]FGD-MHO followed by the radiolabelling of GSH47 
1.2.8.5 Carboxylic Acid Reactive Prosthetic Groups 
The formation of an amide using an [18F]fluorinated amine to target an activated 
carboxylic acid group is another possible strategy towards indirect labelling of a 
biomolecule. However, there are restrictions which make this approach less popular 
than others. The target compound must, for example, bear an activated carboxylic 
group whilst not having free amine functionality which would promote inter- and 
intramolecular cross-linking. Protection of the free amine would be necessary and 
require a deprotection step thereby lengthening and complicating the total 
radiosynthesis. Despite this, Shai and colleagues used this approach to successfully 
label insulin in high specific radioactivity.48 Cyclotron produced fluorine-18 was used to 
generate 4-([18F]fluoromethyl)benzoylaminobutane-4-amine ([18F]FMBAA) which was 
then coupled to a protected insulin derivative. A simple deprotection step was then 
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used to produce the final product which was found to retain the essential biological 
properties of native insulin.48 
1.2.8.6 Other Prosthetic Groups 
4-[18F]Fluorobenzaldehyde ([18F]FBA) was developed to exploit the efficient and 
chemoselective oxime formation possible between a hydrazone and aldehyde group. 
This simple [18F]fluoroarene can be generated in a single-step and in high RCY to 
produce a prosthetic group  with sufficient in vivo stability for chemoselectively 
labelling biomacromolecules under mild conditions. Jeong and co-workers have 
reported a novel and simple preparation of [18F]FBA followed by successful conjugation 
with hydrazinonicotinic acid – human serum albumin conjugate (HYNIC-HSA) via 
hydrazine formation (Scheme 22).49 Non-carrier added [18F]FBA was prepared by the 
nucleophilic substitution of 4-trimethylammonium benzaldehyde triflate with 
[18F]fluoride in the presence of tetrabutylammonium bicarbonate. The conjugation 
efficiency of HYNIC-HSA with [18F]FBA was up to 90% which demonstrates that this 
simple [18F]fluoroarene is an important prosthetic radiolabelling agent.49 
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Scheme 22: Radiosynthesis of fluorine-18 labelled HSA 
Fluorine-18 labelled imidate esters react with proteins at lysine residues to form stable 
amidine bonds. Methyl 3-[18F]fluoro-5-nitrobenzimidate has been prepared in a two-
step reaction and found to be stable in borate buffered solution at room temperature 
with less than 10% hydrolysis over two hours.50 
Isothiocyantes labelled with fluorine-18 react readily with amines to form thioureas. 
Fluorine-18 labelled isothiocyanates have been synthesised and conjugated to 
oligonucleotides, proteins and benzylamine.51-53 Unfortunately, due to the low stability 
of [18F]benzylfluorides, significant defluorination was observed as the conjugate was 
investigated in vivo. 
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Scheme 23: (a) Radiolabelling through fluorine-18 imidate esters (b) Radiolabelling through fluorine-18 labelled isothiocyanates 
1.2.9 Reactions with diaryliodonium salts 
The severe limitation to typical aromatic nucleophilic substitution reactions with the 
[18F]fluoride ion is the inability to label electron-rich arenes. Best attempts using the 
Balz-Schiemann and Wallach reactions have been inefficient. A new and improved 
method for the incorporation of [18F]fluoride into arenes was introduced using 
diaryliodonium salts 72 (Scheme 24).54 The advantage of this method is the 
applicability to both electron-rich and electron-deficient arenes.55 
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Scheme 24: [18F]Fluoride labelling of arenes through reactions of diaryliodonium salts with the [18F]fluoride ion. 
The regioselectivity of the reaction is determined by the stereoelectronic properties of 
the substitutents; generally, the more electron-deficient aromatic ring will selectively 
incorporate the fluoride nucleophile. However, an ortho-substituent on one of the aryl 
rings preferentially directs fluoride to that ring – the so-called “ortho” affect.55-58 The 
RCYs of the radiofluorinated target can therefore be increased by the strategic 
modification of electronic and steric properties of the substitutents, and reaction 
conditions.56 The benefits realised from utilising diaryliodonium salts in both direct and 
indirect radiofluorination chemistry, has been the motivation for their extensive use 
and practice within this research group and the PET radiochemistry community. For 
this reason, diaryliodonium salts warrant further discussion. 
1.3 Iodine, hypervalency and diaryliodonium salts 
Hypervalent iodine reagents were discovered in 1886 when German chemist, Conrad 
Willgerodt first prepared (dichloroiodo)benzene.59 Willgerodt later went on the publish 
the first comprehensive book in this field in 191460 but it wasn’t until nearly 60 years 
later when widespread interest in this class of compounds was established. Several 
reviews61-65 and books66, 67 were then published covering all aspects of hypervalent 
iodine chemistry, and now molecules of this type are widely used in organic synthesis. 
Interest in this field has recently accelerated, partly due to developments in the 
application of diaryl-3-iodanes in cross-coupling reactions68-75 and their application in 
the synthesis of imaging agents for PET.54, 76-81Many more reviews have subsequently 
been published (Table 3), the most significant of which has been the Symposium-in-
Print Tetrahedron issue dedicated to recent advances and applications of hypervalent 
iodine chemistry in concert with the 3rd International Conference on Hypervalent 
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Iodine Chemistry (ICHCI2010) compiled by Wirth and Quideau.82 Herein this review is a 
brief summary of hypervalent iodine (III) compounds before focussing on diaryl-3-
iodanes and their application to the synthesis of imaging agents for PET. 
Year Authors Title Reference 
1990 R.M. Moriarty 
K. Vaid 
Carbon-carbon bond formation via hypervalent iodine oxidations 
83
 
1994 O. Prakash 
N. Saini 
P.K. Sharma 
Hypervalent iodine reagents in the synthesis of heterocyclic compounds 
84
 
1996 P.J. Stang 
V.V. Zhdankin 
Organic Polyvalent Iodine Compounds 
85
 
1996 Y. Kita 
T. Takada 
H. Tohma 
Hypervalent iodine reagents in organic synthesis: nucleophilic substitution of 
p-substituted phenol ethers 
86
 
1997 T. Kitamura 
Y. Fujiwara 
Recent progress in the use of hypervalent iodine reagents in organic 
synthesis. A review 
87
 
1997 A. Varvoglis Chemical Transformations induced by hypervalent iodine reagents 
88
 
1999 T. Wirth 
U.H. Hirt 
Hypervalent iodine compounds. Recent advances in synthetic applications 
89
 
2003 P. Dauban 
R.H.Dodd 
Iminoiodanes and C-N bond formation in organic synthesis 
90
 
2004 H. Tohm 
Y. Kita 
Hypervalent iodine reagents for the oxidation of alcohols and their 
application to complex molecule synthesis 
91
 
2005 R.M. Moriarty Organohypervalent Iodine: Development, Applications and Future Directions 
92
 
2006 T. Wirth Hypervalent iodine chemistry in synthesis: Scope and new directions 
93
 
2006 R.D. 
Richardson 
T. Wirth 
Hypervalent iodine goes catalytic 
94
 
2007 N.R. Deprez 
M.S. Sanford 
Reactions of hypervalent iodine reagents with palladium: mechanisms and 
applications in organic synthesis 
95
 
2008 B.Olofsson Diaryliodonium salts: A Journey from Obscurity  to Fame 
96
 
2009 T. Dohi 
Y. Kita 
Hypervalent iodine reagents as a new entrance to organocatalysts 
97
 
2011 M.S. Yusubov 
A.V. Maskaev 
V.V. Zhdankin 
Iodonium Salts in Organic Synthesis 
98
 
Table 3: Notable reviews of hypervalent iodine chemistry since 1990 
1.3.1 Iodine and hypervalency 
Molecules containing elements from groups 15-18 bearing more electrons in the 
valence shell than the octet are termed hypervalent molecules. Despite being 
commonly found in the monovalent form (oxidation state: -1) the large size and 
polarisablility of iodine, allows for hypervalency.99 Hypervalent iodine molecules 
generally fall in to two classes of compounds; iodine (III) compounds, termed 3-
iodanes according to IUPAC recommendations, and iodine (V) compounds or 5-
iodanes (the lambda notation refers to non-standard bonding). 
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The iodine atom of 3-iodanes has a pseudotrigonal bipyramidal geometry with two 
heteroatom ligands in axial positions, whilst the least electronegative group and 
remaining lone pairs of electrons occupy the equatorial positions. This is true of every 
class of iodine (III) compound67 – IL3, RIL2, R2IL, and R3I (L = heteroatom ligand, R = 
carbon atom ligand). In the hypervalent model, bonding in RIL2 uses a non-hybridised 
5p orbital in the linear L-I-L hypervalent bond (Figure 8). Two electrons from the 
doubly-occupied 5p orbital, and one electron from each of the ligands generate a 3-
centre-4-electron bond (3c-4e or hypervalent bond).100 These bonds are highly 
polarisable and are longer and weaker than the standard covalent bond. The remaining 
group is bound by a standard -covalent bond with 5sp2 hybridisation.101, 102 Organo-
iodine (III) compounds, termed organo-3-iodanes, possess 10 electrons in the valence 
shell and hence are classed as hypervalent [10-I-3] species. (The electronic structures 
of hypervalent moieties are described in [N-X-L] format, in which N is the number of 
electrons associated with the central atom X, and L is the number of ligands bound.103) 
The iodine of the highly polarised L-I-L bond is strongly electrophilic. As the two lower 
energy orbitals (the bonding and non-bonding orbitals) of the three molecular orbitals 
produced by the 3c-4e bond are filled, partial positive charge develops on the iodine 
whilst partial negative charge develops on the axial heteroatom ligands. This is 
because the filled nonbonding orbital has a node about the central iodine atom.66  
 
Figure 8. Pseudotrigonal bipyramidal geometry and molecular orbital of the 3c-4e bond. 
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Aryl 5-iodanes exist as a square pyramid structure with four heteroatom ligands in 
basal positions and an aryl group occupying the remaining apical position (Figure 9). 
Two orthogonal 3c-4e bonds allow the iodine to accommodate the heteroatom ligands 
whilst the apical, aryl group is bound via a hybridised 5sp orbital.67 
 
Figure 9. Square pyramid geometry of the 3-iodane 
Cyclic-5-iodanes, such as IBX (2-iodoxybenzoic acid) and Dess-Martin periodinane 
(DMP) are commonly used as mild and highly selective oxidants of alcohols and 
amines. IBX can also effect the oxidative transformation of several other functional 
groups.93 However, despite recent advances and rising interest, 5-iodanes continue to 
have few synthetic applications, when compared to the iodine (III) species. The 
chemistry of 5-iodanes has been far less developed, with the first comprehensive 
review of their synthetic application published only recently.104 This report, therefore, 
will focus exclusively on the 3-iodanes. 
1.3.2 Structure of organo-3-iodanes 
The pseudotrigonal bipyramidal geometry of the 3-iodanes, whilst in the solid state 
has been observed across all known organo-3-iodanes published to date. 
Interestingly, this also includes dicyano(pentafluorophenyl)-3-iodane, which despite 
the stability of the cyanide anion, exhibits bonding through the carbon for all three 
ligands and is therefore considered to be of the R3I-type.
105 
 Introduction 
 
43 
 
 
Figure 10: Molecular structure and intermolecular contacts of PhF5I(CN)2
105 
X-Ray crystallography and powder diffraction studies of the solid state structures have 
shown that most 3-iodanes exist as polymeric structures,106-108 often including 
secondary bonding interactions,107, 109 depending on the functionality of the 
compound. There is little consistency throughout the structures published so far with 
the formation of monomers,108 dimers110 and trimers111 all possible. Bond angles 
around the L-I-L bonds have also varied, resulting in difficulty in identifying a trend 
within the solid state structures.  
This observation is also true of the same compounds in solution, as many of the known 
3-iodanes have shown to have one ligand with strong ionic character.66 This is 
especially true of the diaryl-3-iodanes (R2IL). In polar solvents, cryoscopic and 
conductance measurements have revealed these compounds as having dissociated 
into the solvated iodonium ions and counterions.67 Generalising the true structure of 
3-iodanes in solution is avoided as the nature of the ligand,112 concentration of 
solution113 and type of solvent112 into which the compound is dissolved, has bearing 
upon the structure adopted. 
This argument has resulted in iodine (III) compounds often being referred to as “salts,” 
but this does not reflect the true structure of these species. For example, Ph2ICl is 
called diphenyliodonium chloride because the I-Cl bond (3.06 Å) is longer than the 
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average covalent bond (2.56 Å).114 However, X-ray crystal structure determination has 
found that Ph2ICl has a trigonal bipyramid geometry with 10 electrons in the valent 
shell of the iodine atom (Figure 11).115 This is contrasting to the tetrahedral geometry 
suggested by the term ‘onium’. Onium salts, such as ammonium or phosphonium salts, 
include eight electrons in the valent shell of the positively charged atom and are not 
hypervalent. The valency shell of the iodine in Ph2ICl has 10 electrons and is, therefore, 
hypervalent. 116 (Regardless of this, the terms ‘diaryl-3-iodane’ and ‘diaryliodonium 
salt’ have been used interchangeably throughout the recent surge of interest in this 
research and, therefore, also within this report.) 
 
Figure 11: Structure and bonding in chloro(diphenyl)-3-iodane compared and theoretical structure of diphenyliodonium 
chloride115 
1.3.3 Reactivity of organo-3-iodanes 
The versatility of organo-3-iodanes has encouraged their employment in diverse 
synthetic strategies. These compounds have the ability to react via a multitude of 
different possible mechanisms, some of which have received far greater attention than 
others, due to their involvement in more significant syntheses within organic 
chemistry. 
1.3.3.1 Ligand Exchange 
One of the most important modes of reaction involves an exchange of ligand on the 
iodine atom, whilst leaving the oxidation state (III) unchanged. This process, termed a 
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‘ligand exchange’, has been intensely studied but elucidation of a detailed mechanism 
is ongoing. Heteroatom ligands of organo-3-iodanes are readily displaced by 
nucleophiles via either an associative or dissociative mechanism (Figure 12).63 There is 
considerable evidence to support the associative approach whilst experimental results 
supporting the dissocative pathway are limited.113 The iodine atom of ArIL2 78 is 
electrophilic and reacts with a variety of nucleophiles as they attack the C-I *-orbital 
resulting in the immediate formation of a trans-tetracoordinated iodate 79. This 
intermediate then isomerises to form the cis-iodate with elimination of the 
heteroatom ligand to produce a new aryl-3-iodane 80.  
 
Figure 12: The two possible mechanistic pathways, associative and dissociative, for ligand exchange reactions66 
1.3.3.2 Reductive elimination and hypernucleofugality 
Another key mode of reactivity involving organo-3-iodanes, is the reductive 
elimination of the hypervalent iodine species to the monovalent iodide, with loss of a 
heteroatom ligand (Figure 13). This is often observed in reactions of aryl-3-iodanes.117 
The driving force behind this process lies in the hypernucleofugality of the aryl-3-
iodanyl group. A hypernucleofuge must present two features: a) leaving group ability 
greater than that of a ‘superleaving group’ such as a triflate (OTf) and, b) hypervalent 
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character.117 Reduction of the hypervalent iodine to the univalent iodide of normal 
valency is the origin of the very high leaving group ability of the 3-iodanyl group. An 
increase in entropy is also observed as the single hypervalent specie generates three 
molecules on degradation. The 3-iodanyl group is eliminated with simultaneous 
reduction to an iodoarene and concomitant elimination of the heteroatom ligand 
(Figure 13).  
 
Figure 13: Process of reductive elimination66 
1.3.3.3 Pseudorotation of 3-iodanes  
Organo-3-iodanes are configurationally unstable and undergo facile interconversion 
of stereoisomers due to the large size of the iodine atom. The apical heteroatom 
ligands can mutually exchange sites via repeated pseudorotation (Ψ) about the iodine 
atom. The isomerisation by which the apical ligands exchange with the equatorial 
ligands through the bending of bonds is referred to as ‘Berry-pseudorotation’.118 The 
two apical bonds move concertedly to become equatorial bonds through a square-
based pyramid intermediate structure (Figure 14). This process is of vital importance to 
the reactivity of 3-iodanes as, in the ground state, the most electron-rich or sterically 
demanding substituent is forced to occupy the equatorial position.119 The result is a 
distinct difference in reactivity between the equatorial and axial substituents.119 This 
process has particular bearing on the selective ligand coupling of attacking 
nucleophiles with the substituents of asymmetric diaryl-3-iodanes. 
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Figure 14: Pseodorotation about the iodine of organo-3-iodane 78 
1.3.3.4 Ligand Coupling 
The term ‘ligand coupling’ was introduced by Oae to describe the intermolecular 
coupling of two ligands bound to a hypervalent atom.120 The mechanism still lacks full 
understanding due to facile stereomutation of the trigonal bipyramid structure by 
Berry pseudorotation and rapid intermolecular ligand exchange reactions.66 Studies 
into the thermolysis of diaryl(halo)-3-iodanes have been shown to yield a mixture of 
iodoarenes and haloarenes, as the halogen will always attack the ipso carbon of the 
neighbouring aryl groups.121-123 This reaction mechanism has  formed the theoretical 
basis of the selectivity in the [18F]fluorination of both electron-rich and electron-
deficient arenes from the reactions of diaryl-3-iodanes with nucleophilic 
[18F]fluoride.54 This is the reasoning behind our interest in the diaryl-3-iodane class of 
compounds and, hence, the focus of this review. 
1.3.4 Synthesis of diaryl-3-iodanes 
The earliest preparations of diaryl-3-iodanes were reported in the late nineteenth 
century by Hartmann and Meyer.124 At the time, these compounds were considered 
obscure and for many years, little investigation was made towards developing new and 
efficient synthetic strategies. Vast improvements in preparations were made decades 
later when the popularity of these compounds increased. Innovation towards new, 
efficient methods has continued today as the potential application of hypervalent 
iodine compounds expands further. 
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The most common strategies towards diaryl-3-iodanes typically involve two steps. 
Initially, an aryl iodide specie is oxidized to the iodine (III) equivalent using an inorganic 
oxidant whilst in the presence of an acid. Following this, a ligand exchange reaction 
takes place with an arene or organometallic reagent. A key feature of this second step 
is the electrophilic aromatic substitution (EAS) of the arene by the iodine (III) species, 
which commonly takes place in the presence of an acid, which then generates the 
counterion. Regioselectivity is often achieved by employing lithiated, stannylated, 
silylated aryls and aryl boronic acids. Anion exchange reactions will often be performed 
to create a more diverse range of counterions or to allow more facile isolation of 
products. 
1.3.4.1 Development of conventional synthetic strategies towards diaryl-3-iodanes 
Masson and co-workers made initial gains towards the synthesis of diaryl-3-iodanes in 
the 1930s.125 They discovered that diaryliodonium salts could be prepared from 
reacting iodic acid with a range of aromatic compounds in the presence of sulfuric acid. 
Significant advancements were made by Beringer and co-workers in the 1950s and 
60s, who produced an extensive series of publications on both the synthesis and 
reactivity of diaryliodonium salts.122, 126-141 Their approach concentrated on the 
coupling of arenes with hypervalent iodine species, in the presence of an acid, to yield 
symmetrical and unsymmetrical diaryliodonium salts, bearing both electron-
withdrawing and electron-donating groups (Scheme 25). As expected from EAS 
reactions, the activating and deactivating nature of the substituents influenced both 
the reactivity and the yields. Sulfuric acid was required for the synthesis of salts 
bearing electron-withdrawing substrates135 whereas the reagent combination of acetic 
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anhydride and trifluoroacetic acid was found to be most efficient for those with 
electron-donating groups.133  
 
Scheme 25: Beringer synthesis of diaryliodonium salts  
Regiospecific control in the synthesis of diaryl-3-iodanes was first achieved by Koser 
and co-workers in the synthesis of diaryliodonium tosylates 87, generated from the 
reaction of hydroxy(tosyloxy)iodobenzene (Koser’s reagent) with aryl(trimethyl)silanes 
85.142 It was found that the phenyliodinations proceed with initial cleavage of the 
carbon-silicon bond, thereby creating regiochemical control, regardless of other 
substituents (Scheme 26).142 The regiospecific formation of aryl(2-furyl)iodonium 
tosylates, has also been achieved, following this approach.143 
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R1 R2 Yield 
H H 46% 
2-Me H 42% 
3-Me H 63% 
4-Me H 29% 
H 4-Me 30% 
2-Me 4-Me 59% 
3-Me 2-Me 58% 
4-(SiMe3) H 49% 
3-(SiMe3) H 24% 
4-4’-
(SiMe3)phenyl 
H 27% 
Scheme 26: Regiospecific synthesis of symmetrical and unsymmetrical diaryliodonium salts from Kosers reagent and 
aryl(trimethyl)silanes 
Koser later found that the direct condensation of [hydroxy(tosyloxy)iodo]arenes with 
electron-rich arenes, such as thiophene, can be achieved without the presence of an 
activating group.144  
Following this work, Ochiai and colleagues reported the synthesis of diphenyliodonium 
tetrafluoroborate 89 from the reaction of phenyl(trimethyl)silane 88 with boron 
trifluoride-activated iodosylbenzene (ISB).145 ISB is less reactive than Koser’s reagent 
towards nucleophiles and requires activation by a strong Lewis acid. Boron trifluoride-
activated ISB is reactive enough towards the nucleophilic attack of 88 to afford the 
iodine (III) specie (Scheme 27). 
 
Scheme 27: Ochiai synthesis of diphenyliodonium tetrafluoroborate from BF3-Et2O activated ISB 
In 1992, Kitamura et al found that ISB could also be activated towards ligand exchange 
reactions with arenes by using triflic acid.146 Yields were later improved by using DIB 
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instead of ISB, thus creating the highly reactive [PhI(OAc)2·2TfOH] species in situ. 
Subsequent reactions with electron-rich arenes gave the diaryliodonium triflates in 
good yields and high para-selectivity.147 Substituted diacetoxyiodoarenes have also 
been used, thereby generating a range of functionalised unsymmetrical diaryliodonium 
salts.148 The approach was also used in the generation of TMS-substituted salts, which 
serve as synthetically useful agents in the production of benzyne adducts (Scheme 
28).149 
 
Scheme 28: Kitamura synthesis of (trimethylsily)-substituted diaryliodonium salts 
In efforts to further improve the yield of reactions with phenylsilanes, Stang and co-
workers found that the corresponding arylstannanes show increased reactivity 
towards iodine(III) compounds, due to the decrease in strength of the C-Sn bond. 
Aryl(cyano)iodonium triflates 95, prepared in two steps from the aryl iodide 93a by 
oxidation with pertrifluoroacetic acid and subsequent reaction with Me3SiCN  were 
found to react with tributyltin derivatives under mild conditions and in good yields 
(Scheme 29).150  
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Scheme 29: Stang synthesis of aryl(cyano)iodonium triflates 
Pike and co-workers have extended this work to include the reaction of Koser’s 
reagent with arylstannanes 96 to produce, both substituted and unsubstituted, 
diaryliodium tosylates 87 (Scheme 30).151 This approach was reapplied to form the 
heteroaromatic diaryl-3-iodanes in excellent yield.152 
 
Scheme 30: Pike synthesis of diaryliodonium tosylates from arylstannanes 
Ochiai and co-workers reported a direct, regioselective synthesis of diaryliodonium 
tetraarylborates from diacetoxyiodoarenes, via the transfer of an aryl group from the 
corresponding alkali metal tetraarylborate.153 The tetrafluoroborate salts could be also 
be obtained following an anion exchange. Following this, the use of vinyl- and 
arylboronic acids and esters was also successful in generating both symmetric and 
unsymmetric diaryliodonium tetrafluoroborates via a boron trifluoride catalyzed 
boron-iodane exchange reaction. Products were reported in excellent yields and with 
high regioselectivity.154 
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The use of arylboronic acids was initially developed by Widdowson and colleagues.155 
Previous work from within the group involved the regioselective preparation of 
diaryliodonium salts using aryl-trialkylstannanes as intermediates. However, work 
turned to the corresponding arylboronic acids for two reasons. Firstly, organotin 
compounds are toxic and, therefore, use within the group as intermediates in the 
production of biomolecular imaging agents was undesirable. Secondly, electron-rich 
aryltrialklystannanes are susceptible to protolysis which creates difficulties upon 
purification and formation of the diaryl-3-iodane. Treatment of the arylboronic acid 
with DIB in the presence of triflic acid gave the diaryliodonium triflate whilst reaction 
with Koser’s reagent gave the equivalent tosylate. High yields were achieved before 
the general applicability of the procedure was tested with heteroaryl boronic acids. 
Against these reagents, it was found that Koser’s reagent allowed for the relatively 
facile purification of the tosylate salts when compared to the corresponding triflate.155 
Using a similar method, aryltrifluoroborates have been shown to react with aryliodine 
difluorides to give diaryliodonium tetrafluoroborates.156 
1.3.4.2 Novel syntheses of selected diaryl-3-iodanes 
Stang and co-workers have also developed a novel form of diaryl-3-iodanes, 
constituting conformationally rigid, tetranuclear macrocyclic ring systems termed, 
molecular boxes.157-159 These species have vast potential as anion hosts,160 and in 
molecular electronics,161 nanoscale technology162 and may also provide insight into 
non-covalent bonding.163, 164 The ‘T-shaped’ geometry of 3-iodanes, with approximate 
90° bond angles, allow for the formation of novel macrocyclic tetraiodonium salts. The 
reaction of 4,4’-bis(trimethylsilyl)biphenyl 98 with a bisiodonium triflate 97 in CF3CO2H, 
followed by slow addition of Me3SiOTf gave the cyclotetraaryltetraiodonium salt 99 in 
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good yield (70%) (Scheme 31a).157 Hybrid iodonium-platinum (or palladium) cationic 
tetranuclear macrocyclic boxes have also been synthesised, some of which have 
included a chiral biphosphine ligand bound to the metal 100 (Scheme 31b).157, 158 
 
Scheme 31:Diaryl-3-iodanes in the synthesis of molecular boxes157, 158 
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The first synthesis of chiral diaryliodonium salts was achieved by Ochiai and collegues 
in 1999.165 Tetraphenylstannane was used in the presence of boron trifluoride 
etherate, to convert two chiral precursors i.e. 2-(diacetoxyiodo)- 101 and 2,2’-
bis(diacetoxyiodo)-1,1’-binaphthyls166 into chiral tetrafluoroborate salts 102 (Scheme 
32). Substituted derivatives were also synthesised to in order to achieve the 
asymmetric -phenylation of cyclic -keto esters.  
 
Scheme 32: Ochiai synthesis of diaryl-3-iodanes 
Using a similar approach, Zhdankin recently reported the synthesis of chiral, 
benziodazole-derived phenyl- 104 and alkynyliodonium salts, in which nitrogen acts as 
a ligand attached to the iodine atom (Scheme 33).167 
 
Scheme 33: Zhdankin synthesis of N-functionalized benziodazoles from chiral diaryl-3-iodanes 
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Most synthetic strategies towards diaryl-3-iodanes involve the use of an acid or acidic 
media. This limits the use of substrates to those which do not contain acid-sensitive 
substituents. Beringer and Nathan introduced the synthesis of diaryl-3-iodanes under 
basic conditions in 1969.168 Both aryl- and heteroaryliodonium chlorides were 
synthesised in fair to excellent yields from the reaction of the appropriate aryllithium 
107 with the iodonium transfer agent, trans-(chlorovinyl)iodonium dichloride 106 
(Scheme 34a).168, 169 This compound, prepared from the reaction of iodine trichloride 
with acetylene, is very unstable, highly reactive and not commercially available.168 
However, the synthetic application of this approach remains highly valuable as both 
symmetrical and unsymmetrical salts bearing acid-sensitive substrates can be obtained 
in a regiospecific manner.169 Bis(heteroaryl)iodonium chlorides 110, previously difficult 
to obtain under acidic conditions, have also been successfully prepared from this 
iodonium-transfer procedure (Scheme 34b).170, 171 These compounds may be readily 
converted to the corresponding triflate salts via reaction with trimethylsilyl triflate. 
 
 Introduction 
 
57 
 
Scheme 34: Reactions of aryllithium reagents with trans-chlorovinyliodoso dichloride 
1.3.4.3 Recent developments 
Vast progress has been made recently in the one-pot, direct synthesis of iodonium 
salts from arenes with either iodine or aryl iodides in the presence of an oxidant. This 
approach obviates the isolation of unstable iodine (III) species leading to greater 
substrate scope whilst reducing reaction times and increasing efficiency. 
Significant gains in this field have been recently reported by Olofsson and co-workers. 
m-Chloroperbenzioc acid (mCPBA) was previsously identified as an efficient oxidant in 
the formation of diacyloxyiodoarenes from aryl iodides. It was then envisioned that 
the same reagent could be employed in the oxidation of aryl iodides to form 
diaryliodonium salts directly. Treatment of iodobenzene with mCPBA and trific acid 
with excess benzene afforded diphenyliodonium triflate (Scheme 35a).172 Triflic acid 
was used to activate the oxidant whilst simultaneously forming the salt. This 
operationally simple procedure yielded both symmetrical and unsymmetrical salts 
bearing electron-rich, electron-deficient and heteroatom arenes. Unfortunately, this 
approach was unsuccessful in synthesising symmetric salts from either very electron-
rich or very electron-deficient arenes. However, success was achieved in the synthesis 
of pyridyl(aryl)iodonium salts, previously only obtainable under basic conditions.  
This scope of this method was tested further in attempts to also omit the isolation of 
aryl iodide species and synthesise the reagents in situ, directly from iodine. 
Diphenyliodonium tosylate was, again, formed in high yield from the reaction of 
benzene with iodine, mCPBA and TfOH in either 10 min (at 80 °C) or alternatively, 22 h 
at RT (Scheme 35b). Despite a greater scope of products attainable from the use of aryl 
iodides, the direct synthesis from iodine was further investigated. The latter approach 
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was found to be efficient in the preparation of iodonium salts bearing alkyl and 
halogen substituents, exemplified by the synthesis of bis(4-tert-butyl-phenyl)iodonium 
triflate. Large amounts of reagent were required, however, a 78% yield was achieved 
in just 45 min.173 
Following this work, a direct, one-pot reaction yielding electron-rich and symmetrical 
and unsymmetrical diaryliodonium salts was developed. Toluenesulfonic was used 
instead of triflic acid resulting in the formation diaryliodonium tosylates in good yields 
(Scheme 35c). An in situ anion exchange was also developed, allowing for access to the 
equivalent triflate salts.174 The same method was successfully reapplied to the direct 
synthesis of the triflates from iodine, instead of the aryl iodides (Scheme 35d).174  
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Scheme 35: Development of a one-pot synthesis of diaryliodonium salts from the Olofsson group.172-174 
Recently, the nature of the oxidants employed in these direct, one-pot strategies has 
received further attention. Conventional routes towards diaryliodonium salts have 
realised high-yielding and facile syntheses of diaryl-3-iodanes from aryl iodides and 
the corresponding aromatic partners using stoichiometric amounts of organic and 
inorganic oxidants. However, large quantities of these reagents frequently result in 
high levels of toxic by-products and waste material. This is of vital consideration when 
preforming large scale reactions of this type. The environmentally benign urea-
hydrogen peroxide has recently been employed as an oxidising agent in the formation 
of diaryliodonium triflates175 and trifluoroacetates.176 Peracetic acid (PAA) has also 
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been used with fluoroalcohols, in the synthesis of both unsymmetrical and 
symmetrical diaryliodonium tosylates and triflates.177 High yields and short reaction 
times were achieved from various aryl iodides, except for those bearing an electron-
rich moiety, when combined with an electron-rich aromatic partner. 
The use of fluoroalcohols in the generation of diaryliodonium salts is a recent 
development, introduced by Kita and colleagues. A direct condensation route to diaryl-
3-iodanes, from reactions of various arenes with Koser’s reagent, in both 2,2,2-
trifluoroethanol (TFE) and 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) has also been 
reported (Scheme 36).178 Both solvents were shown to exert a positive effect upon the 
efficiency of the dehydrative condensation of hypervalent iodine reagents towards 
aromatic and heteroaromatic compounds. Short reaction times and high yields were 
achieved under mild conditions from a variety of electron-rich and unsubstituted 
aromatic compounds. The high polarity and low nucleophilicity of these solvents allow 
for the stabilisation of the cationic intermediates proposed to be involved in these 
reactions.179  
 
Scheme 36: Direct dehydrative approach to diaryliodonium(III) salts in fluoroalcohol solvents179 
1.4 Radiofluorination of diaryliodonium salts 
Diaryliodonium salts have been known to react with nucleophiles in arylation reactions 
for many years. However, it wasn’t until 1982 that van der Puy first explored the use of 
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diaryliodonium salts to generate aryl fluorides.180 Since then, these synthetically useful 
species have become of significant importance to the development of radiolabelled 
arenes for use in PET. Many studies into the mechanism of the reaction have been 
conducted. Those presented herein this report are selected examples which best 
represent the most significant aspects of the process. 
1.4.1 Mechanism of nucleophilic substitution of diaryliodonium salts 
The ability of diarylhalonium ions to arylate nucleophiles effectively and under mild 
conditions has been known for many years. However, mechanisms for polar reactions 
of diarylhalonium salts with nucleophiles remained unclear and an explanation for the 
so-called “ortho” affect (Section 1.2.9) was unaccepted. The ease with which electron-
rich species undergo coupling to a nucleophile suggested a mechanism other than 
direct nucleophilic substitution.  In 1992, Grushin and co-workers proposed a “turnstile 
mechanism” (Figure 15) to rationalise many of the anomalous facts associated with the 
reactivity of diaryliodonium salts with nucleophiles.181 
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Figure 15: Turnstile mechanism proposed by Grushin.181 
By investigating the reactivity of halonium derivatives of the quasi-aromatic inorganic 
systems, greater understanding of the mechanism of the reaction between 
diaryliodonium salts and nucleophiles was achieved. The nucleophile attacks the 
positively charged iodine atom of the iodonium cation 116 to form a trivalent 
intermediate following ligand exchange of the counterion. Rapid Berry-pseudorotation 
occurs between intermediates, which leads to two differing transition states 117 and 
118. These transition states undergo a ligand coupling to collapse via reductive syn-
elimination to form two pairs of possible products 121 and 122 or 123 and 124. The 
“ortho” affect is explained as the resulting relief of steric strain in the transition state 
due to the more bulky group aryl substituent occupying an easily attacked equatorial 
position. The predominant conformation places the ortho-substituted aryl ligand and 
the two lone pairs (or ‘phantom’ ligands) in the equatorial positions. Ligand coupling 
leads to the syn-reductive elimination and the transfer of the attacking nucleophile to 
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the ortho-substituted aryl ring. In the absence of ortho- substituents, the favoured 
transition state places the most electron-rich ring in the axial position to stabilise the 
positive charge on the iodine. This results in the formation of the major products 
wherein the nucleophile is selectively incorporated onto the more electron-deficient 
ring which, therefore, adopts the equatorial position.182 
 
Scheme 37: General mechanism for the attack of nucleophile on a diaryliodonium salt183 
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The “ortho” affect is the dominant influence as ortho-substituted aryl ligands have 
been shown to  couple to the nucleophile despite being the more electron-rich of two 
aromatic rings.57 
1.4.2 Regioselectivity in reactions of diaryliodonium salts with fluoride 
This understanding of the mechanism of nucleophilic attack on a diaryliodonium salt 
has been used to influence the regioselectivity of the aromatic substitution process. 
Modifying the electronic and steric properties of the substitutents may be used to 
maximise the yield of the desired products. This is essential when using fluorine-18 
which can only be produced in nano-molar quantities forcing radiosynthetic precursors 
into a vast excess. Pike and colleagues first reported a study on the synthesis of 
[18F]fluoroarenes from the reaction of cyclotron-produced [18F]fluoride ion with 
diaryliodonium salts (Scheme 38).54 A range of diaryliodonium salts bearing various 
substituents were reacted against NCA [18F]fluoride in MeCN and at 85 °C inside a 
sealed and pressurised glassy-carbon vessel. 
 
Scheme 38: Pike radiosynthesis of various [18F]fluoroarenes54 
Generally, the reactions proceeded with attack on the most electron-deficient ring. 
However, the presence of large substituents altered the regioselectivity of the reaction 
by promoting the [18F]fluorination of the more bulky but electron-rich ring. For 
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example, the reaction of 2,4,6-trimethylphenyl(phenyl)iodonium triflate with the 
[18F]KF/Kryptofix®222, gave 2,4,6-trimethyl[18F]fluorobenzene as the sole fluorinated 
product, along with the iodobenzene byproduct. However, the authors reported that 
the critical factor appears to be the bulk at the ortho-position and that a single ortho-
substituent is enough to induce incorporation of the nucleophile on the substituted 
ring. This is in-keeping with the turnstile mechanism proposed by Grushin (Section 
1.4.1).181 In further studies, combining an ortho-substituted ring with an electron-rich 
ring was shown to be a simple means of regiocontrol in [18F]fluorinating 
diaryliodonium salts.148 Reactions wherein the diaryliodonium salts were substituted 
with a 3- or 4- alkoxy group on one ring and alkyl groups on the other gave only the 
alkyl[18F]fluoroarenes when fluorinating using [18F]fluoride (Scheme 39). 
 
R1 R2 RCY (DC) 
(%) 
2-CH3 4-OCH3 64 
3-CH3 4-OCH3 66 
2,4,6-CH3 4-OCH3 67 
3,5-CH3 4-OCH3 45 
4-(CH3)3CCH2 3-OCH3 66 
Scheme 39: Pike syntheses of [18F]fluoroarenes from unsymmetrical diaryliodonium salts. In all cases, the [18F]fluoroarene 129 was 
the sole [18F]fluorinated product. 
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Heteroaryl ligands have also been found to direct the attacking the fluoride 
nucleophile to the target ring of a heteroaryl(aryl)iodonium salt. Carroll and co-
workers used various heteroaromatics and benzoheteroaromatics as the non-target 
ring (NTR) to demonstrate the fluorination of arylheteroaryliodonium  salts.152 The 
work confirmed predictions made by computational techniques used to deduce the 
outcome of the fluorination of heteroaryl(aryl)iodonium tosylates. It was found that 
simple heteroaromatics (furan, thiophene and N-methylpyrole) promote the 
incorporation of fluoride onto the electron-deficient phenyl ring to produce 
fluoroarene. Coenen and coworkers then used the 2-thienyl group to  direct the 
radiofluorination of various arenes using NCA [18F]fluoride.184 The 2-thienyl group is 
electron-rich and less sterically demanding than a phenyl ring which allows the 
introduction of [18F]fluoride onto less electron-rich arenes, such as anisole, in one 
convenient step (Scheme 40). 
 
Scheme 40: Regioselective nucleophilic fluorination of 2-thienyl(aryl)iodonium salts184 
When the target ring was also electron-rich (relative to benzene) the best results were 
achieved using 2-methoxyphenyl(2-thienyl)iodonium bromide which afforded 2-
methoxy-[18F]fluorobenzene in 60% RCY within 20–30 min. The authors reported that 
only the desired [18F]fluoroarenes were produced with no evidence of a 
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radiofluorinated side-product. This in contrast to the later work of Carroll and co-
workers, who also carried out a detailed study of nucleophilic fluorination of 
aryl(thienyl)iodonium salts.185 By analysing the crude reaction mixture of 
diaryliodonium salt reactions by GC-MS, multiple products were detected (Scheme 41) 
strongly suggesting that the process may not be as selective as previously reported. 
Fluorination of 2-thienyl(phenyl)iodonium tosylate revealed the generation of the 
iodoaryl products and those resulting from nucleophilic attack of the counterion on the 
iodonium cation. 
 
Scheme 41: Multiple products generated from the fluorination of 2-thienyl(phenyl)iodonium tosylate.21 
Radiofluorination of 2-thienyl(phenyl)iodonium tosylate was clearly shown to produce 
[18F]2-[18F]fluorothiophene as well as [18F]fluorobenzene. Previous reports describing 
no production of 2-fluorothiophene were conducted in open vessels at elevated 
temperatures and may therefore be misleading and the apparent absence is most 
likely due to the high volatility of 2-fluorothiophene (boiling point 82 °C) which may be 
lost during work-up/analysis. The authors also found that 2-fluorothiophene can be 
very difficult to detect by HPLC and GC, having the tendency to co-elute with other 
fluoroarenes or the injection solvent. The compound is also unstable and has limited 
UV activity making detection by TLC both difficult and inconsistent. 
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Due to the difficulties associated with the use of the 2-thienyl aromatic ring, 
alternative electron-rich species have been used to synthesise target [18F]fluoroarenes. 
Fluoropyridines have found increasing applications in PET as radiolabelling with 
fluorine-18 can be readily achieved in the 2- and 6- positions via nucleophilic aromatic 
substitution. However, fluorine may be labile in this position thereby reducing the 
potential applications of the imaging agent. The 3-labelled regioisomer is considerably 
more difficult to synthesise via the same approach but may benefit from enhanced 
metabolic stability. Carroll and coworkers used 4-methoxyphenyl(heteroaryl)iodonium 
salts 136 and 138 to generate 3-[18F]fluoropyridine 137 and 3-[18F]fluoroquinoline 139 
in good RCYs (55–63% and 22–25%, respectively) (Scheme 42).78 The authors found 
that the desired products were the only fluorinated compounds produced and, 
therefore, the use of 4-methoxyphenyl as the NTR provided sufficient selectivity for 
the process. 
 
Scheme 42: Preparation of 3-[18F]fluoropyridine and 3-[18F]fluoroquinoline.78  
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Pike and colleagues have also, more recently used the 4-methoxyphenyl ring to 
produce a range of substituted [18F]fluoroarenes from the corresponding tosylates 
using a microreactor.186 Excellent yields were recorded when performing reactions in 
DMF with 0.25% H2O at 150 °C for 181 s. The rapid reaction times and temperatures 
are made possible by the use of a microfluidic device which combines reagents under 
high pressure through micro-sized channels. Interestingly, the work also showed that 
fluorinations of diaryliodonium salts were achievable in good yields in the presence of 
a large amounts of water and without the use of a cryptand to prepare the 
[18F]fluoride.186  
1.4.2.1 The “Ortho” Affect 
As described earlier (Sections 1.2.9 and 1.4.1) the incoming nucleophile will 
preferentially be incorporated onto the aryl ring bearing a bulky ortho-substituent.57, 58  
Pike and co-workers were first to report the application of the “ortho” affect in the 
radiofluorination of simple arenes.55 Through a detailed study involving the 
fluorination of various diaryliodonium salts, the regioselectivity was shown to be 
controlled by electronic factors and by the bulk of ortho-substituents on the rings, with 
the latter being the dominant factor. Generally, reactions proceeded by attack on the 
most electron-deficient ring, however, the introduction of steric bulk altered the 
regioselectivity with nucleophilic attack favouring the ring bearing a substituent in the 
ortho-position. A single ortho-substituent was shown to be sufficient to induce attack 
on that ring.55 
This principle has been extensively studied by Pike and co-workers, again, using a 
microreactor to rapidly synthesise ortho-substituted [18F]fluoroarenes from reactions 
with diaryliodonium salts.80 The diaryliodonium salt (2-methylphenyl)(phenyl)-
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iodonium, bearing either the bromide, chloride, iodide or tosylate ions were reacted 
with NCA [18F]fluoride, in different solvents at temperatures of up to 200 °C and 
reaction times of up to 4 min. Each salt produced higher RCYs when using DMF as 
opposed to either MeCN containing a small proportion of water (1.5%) or, for one 
particular salt, anhydrous MeCN. The bromide and tosylate salts produced almost 
quantitative incorporation of [18F]fluoride whereas incorporations were significantly 
lower using the iodide and chloride. Most importantly, in all reactions, 
[18F]fluorotoluene was the major radioactive product and [18F]fluorobenzene was the 
minor radioactive product with selectivity ranging from 2.00 to 3.00. These results 
strongly support the “ortho” affect hypothesis and that a simple methyl substituent 
can induce strong selectivity. In order to gain further understanding, the study was 
extended to a broader range of diaryliodonium salts bearing different ortho-
substituents. Radiofluorination of each salt was performed using either CA or NCA 
[18F]fluoride in either anhydrous or “wet” DMF. Conditions for each reaction were 
optimised to produce impressive RCYs ranging from 51% to 95% (Scheme 43). 
 
Scheme 43: Pike radiosynthesis of various ortho-substituted diaryliodonium salts80 
From the selectivity values produced, the authors were able to deduce that the power 
of ortho-substituents to impart an “ortho” affect was in the following order: 2,6-di-Me 
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> 2,4,6-tri-Me > Br > Me > Et ≈ iPr > H > OMe. Interestingly, an ortho-methoxy 
substitutent failed to induce any selectivity as 2-[18F]fluoroanisole was consistently the 
minor radioactive product, across the study. This shows that the “ortho” affect is not 
purely related to substituent bulk, as suggested by previous studies which have 
focused on ortho-alkyl substituents. The authors propose that the selectivity may be 
enhanced by the presence of one or more hydrophobic groups (e.g. methyl) thus 
creating a lipophilic microenvironment in which the attacking [18F]fluoride ion can act 
as a powerful nucleophile. The fluoride weakens the aryl carbon-iodine bond before 
attacking the locally lipophilic ortho-substituted ring. Substituents with a positive 
inductive effect (e.g. methoxy) oppose this process, whilst substituents with a negative 
inductive effect (e.g. bromide) reinforce it. These are important factors to consider 
when determining the product selectivity of such reactions.  
By applying the “ortho” affect, DiMagno and coworkers have found that even 
exceptionally electron-rich arene rings can be fluorinated with high regioselectivity by 
the reductive elimination reaction of 5-methoxy[2.2]paracyclophan-4-yl-iodonium salt 
143 (Scheme 44) .187 The authors sought to investigate a potential aryl substituent 
which would result in the stereoelectronic control of unidirectional reductive 
emilination (SECURE) from diaryliodonium salts. They hypothesied that if the 
mechanistic assumption of a concerted reductive elimination process is adopted, then 
selective destabilisation of the transition state requires significant steric congestion 
above and/or below the aromatic ring and little steric congestion in the plane of the 
ring. This was achieved using the [2.2]paracyclophane moiety which induces severe, 
out-of-plane steric congestion resulting in the ability to control the nucleophile 
incorporation of the even exceptionally electron-rich arenes (Scheme 44). By 
 Introduction 
 
72 
 
combining the steric and electronic effects, the selectivity of the reductive elimination 
step has been enhanced. However, complex synthetic prodecures are required to 
generate the salts bearing the [2.2]paracyclophane rings. This is especially taxing when 
the target ring is highly functionalised. 
 
Scheme 44: Anisole functionalisation by thermal decomposition187 
1.4.2.2 Mechanistic Studies 
Togni and coworkers have tried to gain a greater understanding of the factors which 
govern the selectivity of the reductive elimination reactions involving a diaryliodonium 
salt and a nucleophile.188 The stationary points of the reaction pathway of a 
diaryliodonium salt bearing a phenyl and anisyl ligand attacked by a bromide 
nucleophile were calculated using density functional theory (DFT). 
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Figure 16: Reaction profile of bromo-4-methoxyaryl-phenyl-iodane giving the relative barrier heights ΔG‡ and their absolute 
differences ΔΔG‡ expressed in terms of Gibbs free energy. Stationary points of the structures are also included. Taken from 188. 
As depicted in the diagram, the reaction of the diaryliodonium salt with the 
nucleophile leads to two T-shaped iodane isomers (TSsyn and TSanti) which are 
connected by a Y-shaped transition state (TSisom). The ensuing ipso-attack of the 
bromide leads to incorporation into either the anisyl of phenyl ring. The reductive 
elimination process begins with one of the two possible iodane isomers. The energy 
barrier to isomerisation is small leading to a fast equilibrium between species which is 
followed by the rate-determining reductive elimination steps to yield the products. The 
selectivity, therefore, is determined by the difference in energy of the barriers to 
reductive elimination between the two possible iodane transition states. This is 
representative of the Curtin-Hammett principle. 
The selectivity predicted for the reaction depicted (Figure 16) was in qualitative 
agreement with the experimental result. The calculated barrier leading to the 
phenylbromide was 2.05 kcal/mol lower in energy, showing that this product is 
favoured, which is reflected in the experimental ratio of the products (9:1). 
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As the hypervalent iodine bond is clearly involved in both possible reductive 
elimination reactions, the authors hypothesised that the properties of this bond are 
likely to influence the selectivity observed. The partial charges of the ipso-atoms were 
obtained from a natural population analysis and used to the compare the polarity of 
the 3c-4e bond in the syn- and anti-isomers. The partial charge on the iodine atom was 
close to +1.0 in both isomers and is compensated by the negative partial charges  on 
the ligand ipso-atoms in the 3c-4e bond. The relevant difference in the polarity of the 
3c-4e bond was found to lie in the ipso-carbon atom of the aryl ligands. Upon 
discovering this, the authors investigated the relationship between the polarity of the 
3c-4e bond and the outcome of the reductive elimination step. A plot of the partial 
charge differences between the ipso-carbon atoms against the corresponding 
theoretical selectivity (ΔΔG‡) revealed that the greater the difference between the 
partial charges of the ipso-carbons, the more pronounced the selectivity (Figure 17). 
Experimental selectivity was found to confirm these predictions. There were, however, 
several cases which did not follow this trend. Further investigation revealed that these 
instances involved aryl ligands bearing bulky substituents further demonstrating the 
role steric hindrance plays in the selectivity of this reaction. Furthermore, the authors 
also noted that the polarity of the 3c-4e bond corresponds to the experimental 
Hammett σ-parameters associated with that directing group. 
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Figure 17: Theoretical selectivity ΔΔG‡ for the functionalization of a phenyl group using different directing groups (X = N3 or Br) 
plotted against the natural charge differences of the ipso-carbon atoms of the aryl ligands in the 3c-4e bond. For each group, the 
Hammett σ-parameters are also shown. Taken from 188. 
1.4.2.3 Evidence to support the formation of bridged dimers and trimers 
Carroll and co-workers have found, through computational chemistry studies on 
crystal structures of dialkynyl iodonium fluorides, that R2I-F is expected to form a 
stable dimer involving a novel unsymmetrical bridge.189 The reactivity of this dimer is 
similar to that of the corresponding monomeric units. Interestingly, this dimer 
formation provides a previously unconsidered, low energy pathway for interconversion 
of the aryl groups, which shows that the specificity of these reactions is purely 
transition state controlled. 
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Figure 18: Geometry (distances in Å and angles in degrees) for (a) the ground state and (b) the transition state of dialkynyl 
iodonium fluoride. Taken from 189.  
Due to the relatively large values for the dimerisation enthalpies, this work was 
extended to investigate higher oligomers.190 Results based on both the enthalpies and 
estimated entropies and the derived free energies revealed that large concentrations 
of trimeric reactants may be possible in the gas phase and, most interestingly, in polar 
organic solvents such as MeCN. The structure of the trimer is in contrast to the dimer, 
in that it may be purely symmetrical. 
This may also suggest an entirely entropically-controlled pathway for axial-equatorial 
interconversion of the ligands. The authors suggest, therefore, that the monomer-
based “turnstile” mechanism proposed by Grushin181 (Section 1.4.1) may have a 
competing pathway. The authors have also proposed that the transition state for 
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disproportionation to R-I and R-F derived from this trimer displays unusual 
coordination around the reacting fluorine, which suggests enhanced stabilisation via 
this pathway. This stable transition state would therefore become a competitive 
reaction species. This becomes particularly important in fluorine-18 reactions where 
the fluoride is present in minute quantities compared to other counterions, which may 
participate in these cyclic structures.190  
Pike and coworkers have conducted mechanistic studies which support the formation 
of bridged dimers in less polar organic solvents, where most reactions involving 
diaryliodonium salts are conducted.191 Previous studies have shown that 
diaryliodonium salts are fully dissociated in aqueous or polar media122 whilst existing 
as anion-bridged dimers held together by iodine-halogen bonds in solid-state 
structures.115, 192 The X-ray structure of an unsymmetrical diaryliodonium salt, 2-
methylphenyl(2-methoxyphenyl)iodonium chloride 147 (Figure 19) was determined 
and shown to have a conformational dimeric structure with the hypervalent iodine as a 
stereogenic centre in both conformers. Quantum chemical calculations suggested that 
147 exists as dimers in MeCN due to the strong secondary bonding interaction 
between the iodine and Cl atoms in the two enantiomeric forms. This arises from the I-
Cl bond which is primarily ionic due to the bond length being 0.64 Å longer than in 
solid PhICl2 (2.46 Å). These calculations appear consistent with LC-MS data which 
showed that dimeric and tetrameric anion-bridged clusters were present in dilute 
organic solution. The authors have suggested that reactions of similar compounds with 
nucleophiles may require dissociation of the dimers or tetramers to promote the 
replacement of chloride ions with fluorine-18 and therefore produce the desired 
compounds.  
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Figure 19: X-ray crystal structure of dimeric 2-methylphenyl(2-methoxyphenyl)iodonium chloride 147, represented in an ORTEP 
drawing. Some bond distances are given. Iodine atoms A and B represent to two conformational monomers M and P, respectively. 
Taken from 191. 
1.4.2.4 Evidence to support nucleophilic aromatic substitution 
It has been suggested that the reaction mechanism may involve nucleophilic aromatic 
substitution, a theory which has been investigated by Coenen and co-workers who 
used different substituted aryl(2-thienyl)iodonium salts to systematically vary the 
electron-density of the target ring and study the mechanism of nucleophilic 
fluorination.184 Investigating the effect of substitution patterns of the target ring 
against RCYs clearly demonstrated the gain in RCYs induced by the “ortho” affect. 
Yields were considerably higher than para- and meta- substituted target rings with the 
latter generating the poorest yields. An optimum precursor concentration of 25 
mmol/L was suggested for working with aryl(2-thienyl)iodonium salts. A more detailed 
insight into the influence of electronic character on the nucleophilic radiofluorination 
was obtained by comparing aryl(2-thienyl)iodonium bromides with substituted phenyl 
rings of differing electron densities. As expected, the RCY generally increased with a 
decrease of the electron density, the exception being the ortho-methoxy derivative. 
Plotting the reaction rates of the radiofluorinations against Hammett substituent 
constants of the groups present on the target ring, reveals a linear relationship 
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corresponding to the inference of an SNAr mechanism for the nucleophilic fluorination 
on aryl(2-thienyl)iodonium salts. The authors also found that DMF was the best 
solvent, which was to be expected as polar, aprotic solvents promote SNAr reactions. 
The optimal temperature was 130 °C with higher temperatures producing lower yields, 
most likely due to the thermal decomposition of the precursors. 
 
Figure 20: Hammett diagram for the radiofluorination on substituted aryl-(2-thienyl)iodonium bromides (130 °C in DMF). Taken 
from 184. 
As ρ (the reaction constant) is positive, the reaction is favoured by electron-
withdrawing groups, which is also in accordance with the SNAr hypothesis. However, it 
was noted that due to the high reactivity of ipso-aryl carbon, the fluorination reaction 
has a low sensitivity to substituent effects in the para-position.184  
Pike and colleagues have studied the radiofluorination of diaryliodonium tosylates 
under aqueous and cryptand-free conditions. Salts with strong electron-withdrawing 
substituents in either para or ortho position gave moderate yields of the desired 
[18F]fluoroarenes. These reactions, therefore, strongly resemble SNAr reactions of non-
hypervalent substrates. Various meta-substituted salts were also tested, RCYs did not 
increase with Hammett values and a mixture of weak electronic and steric effects are 
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believed to be in effect. Interestingly, the authors also found that moderate RCYs were 
achievable when the reaction solvent had a water content of up to 28% and whilst no 
cryptand was used to prepare the nucleophilic fluoride.186  
1.4.2.5 Evidence to support a free radical reactivity 
The use of free radical scavengers have been shown to promote the reproducibility of 
RCYs achieved from the radiofluorination of diaryliodonium salts. Carroll and co-
workers had observed a large variation in the outcome of these reactions, especially 
when using particularly electron-rich precursors.193 Diaryliodonium salts are known to 
undergo various reaction pathways (Section 1.3.3) which include homolytic fission of 
the aryl iodine bond generating aromatic radicals that may initiate undesired 
chemistry. During initial scoping studies on the crude reaction mixture of the 
fluorination process, a selection of protonated products (e.g. anisole) and biaryl 
materials were shown by GC-MS analysis to be present in large amounts. In order to 
reduce the potential for the homolytic pathway to generate such unwanted products 
by in situ generated radicals, a range of radical scavengers were tested. The authors 
found that the use of a radical scavenger significantly improved the reproducibility of 
the fluorination process, especially when using 2,2,6,6-tetramethylpiperidine 1-
oxidanyl (TEMPO). Interestingly, the material yields of the fluoroarene products also 
were substantially increased whilst zero loss to the selectivity of the process was 
observed. This work strongly promotes the suggestion that a homolytic reaction 
pathway is prevalent during the fluorination process, and that using a free radical 
scavenger reduces the variability of reaction results and promotes reproducibility.  
Other groups have had mixed results. Pike and co-workers studied the nucleophilic 
fluorination of diaryliodonium tosylates in the preparation of meta-substituted arenes 
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bearing either electron-donating or electron-withdrawing substituents. The authors 
found that high and consistent RCYS were obtained in the absence of TEMPO (up to 
93% RCY (DC)). However, when this investigation was translated to the radiosynthesis 
of more complex 3-[18F]fluoro-1-[(thiazol-4-yl)ethynyl]benzenes, the presence of 
TEMPO improved reaction yields (up to 2.5-fold greater) whilst retaining product 
selectivity. The authors commented that the benefit of adding TEMPO may depend on 
the structure of the diaryliodonium salt precursor and the consequent susceptibility to 
radical induced decomposition. Diaryliodonium salts are known to be photosensitive194 
and have been used as photoinitiators in polymerisiation reactions.96 The microreactor 
used in this work conducts reactions in the dark thereby potentially suppressing 
photolytic decomposition of the precursors. However, upon scaling-up the reactions to 
activities suitable for imaging studies, TEMPO had no effect upon reactions conducted 
using the microreactor. Upon repeating experiments in an automated batch reactor, 
yields were improved when in the presence of TEMPO. These varied results show that 
the benefit of using free radical scavengers is as yet unexplained and further 
investigation into the presence of a homolytic reaction pathway is needed. 
1.4.2.6 Effect of counterion 
The anion used in diaryliodonium salts is known to strongly effect the reaction 
outcome with the highest RCYs arising from the use of inorganic anions. These ions 
induce an effective ion-pair separation in polar solvents113, 122 but it has also been 
shown that dimeric and trimeric structures are possible in salts bearing these 
counterions in polar solvents.189, 190 A fully dissociated iodonium cation is favourable 
for nucleophilic attack by fluoride, however, anions with high nucleophilicity compete 
with the attacking nucleophile. Conversely, organic counterions are less reactive but 
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exhibit a more pronounced covalent character which induces steric and electronic 
effects local to the iodine centre. A preliminary step becomes necessary in which the 
attacking fluoride must exchange with the organic counteranion before it can form a 
trigonal-bipyramidal transition complex by which the proposed “turnstile” mechanism 
proceeds. Coenen studied the RCYs obtained by reacting [18F]fluoride with 2-
methoxyphenyl(2-thienyl)iodonium salts in DMF at 130 °C whilst varying the 
counterion.184 The results showed that the bromide derivative gave the highest yield, 
proving the aforementioned hypothesis, whilst tosylates produced the lowest. Triflates 
produced surprisingly high RCYs, surpassing those of iodide, possibly due to the 
exceptional leaving group ability. The triflates also showed the fastest reaction kinetics 
with tosylates, once again, producing the poorest results. The authors proposed that 
these findings suggested the incomplete dissociation of diaryliodonium salts, even 
when using the inorganic counterions. NMR studies on the cations revealed the degree 
of dissociation. In the case of fully dissociated iodonium salts, the 1Hortho shifts of the 
cations would be identical, regardless of the nature of the anion. However, clear 
differences in chemical shifts were observed across all anions, especially between 
bromide and tosylate ions. This variation in proton shift and the RCYs produced 
promote the suggestion of a non-fully dissociated reaction pathway and that the 
degree of dissociation and, hence, the RCYs depends upon the nature of the 
counterion.184  
These results are in accordance with previous work by Pike and Aigbirhio which also 
included the study of both inorganic and organic counterions (bromide, chloride, 
triflate, trifluoroacetate).54 In this case, however, the highest RCYs were achieved 
when using the trifluoroacetate anion, which is thought to be the ideal counterion as it 
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is not strongly nucleophilic but sufficiently stable to reduce the covalent nature of the 
bond to iodine thereby lowering the steric and electronic effect in the process. 
Previous work from within this research group on the fluorination of diaryliodonium 
salts has also shown that trifluoroacetate was highly compatible with the preparation 
of complex polyfunctional iodine (III) species and that higher chemical purity is 
achieved when synthesising salts bearing this counterion.195 
1.4.2.7 Effect of solvent 
The solvent used in the radiofluorination of diaryliodonium salts has a large effect on 
the RCY. In the majority of cases, an SNAr reaction requires an aprotic, polar solvent 
such as DMSO, MeCN or DMF. However, DMSO has been found to be inappropriate for 
fluorinations of diaryliodonium salts and produced very poor RCYs. This is attributed to 
the low reduction potential of DMSO causing redox processes between iodine(III) 
species and solvent molecules. The S-O bond also favours a S+—O- polarisation, distinct 
nucleophilicity and therefore, a strong solvation of cations, which lowers their 
reactivity. There is also evidence that DMSO affects diaryliodonium cations in such a 
way that the oxygen atom partially neutralises the positive charge of the iodine(III) 
centre.196, 197 It is most likely that a combination of these factors contributes to the 
general unsuitability of DMSO as a solvent for the fluorination of diaryliodonium salts. 
Coenen and colleagues achieved no labelling reaction when attempting to 
radiosynthesise 1-bromo-4-[18F]fluorobenzene using bis-(4-bromophenyl)iodonium 
bromide in DMSO.184 However, upon changing the solvent to either DMF or 
DMF/dioxane, RCYs (DC) dramatically increased up to 65%. These results are in 
accordance with the work of Wüest who also found DMF to be the superior solvent 
upon radiosynthesising 4-[18F]-fluoroiodobenzene from 4,4’-diiododiphenyliodonium 
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salts with various counterions.198 Both Wüest and Coenen have found that using MeCN 
produced disappointing results which is surprising as many other groups have found 
this solvent to be beneficial to the reaction.55, 152, 199 More recently, Pike and coworkers 
made a direct comparison between DMF, MeCN and MeCN with 1.5% H2O, using a 
microreactor to synthesise ortho-substituted [18F]fluoroarenes from reactions of 
[18F]fluoride with various diaryliodonium salts.80 The results clearly identified DMF as 
the superior solvent with greater RCYs achieved regardless of substituents or 
counterions present. It should be noted, however, that this study was conducted using 
a microfluidic device, wherein the viscosity of the solvent has a significant effect upon 
the outcome of the reaction. Regardless of this, DMF is generally accepted as the 
solvent of choice for the [18F]fluorination of diaryliodonium salts and has been adopted 
by many research groups.200-203 
DiMagno has also found, perhaps counterintuitively, that fluorination of arenes can be 
achieved in excellent yields when fluorinating diaryliodonium salts in non-polar 
solvents such as toluene and benzene.204 Through advanced NMR studies on the 
reaction of diaryliodonium salts with anhydrous tetramethylammonium fluoride, it was 
reported that selectively of the nucleophilic fluorination and the yields of products can 
be optimised by varying the reaction conditions. The low polarity solvents are shown 
to suppress competing side reactions whilst precipitating inorganic salts which may 
catalyse ligand exchange, electron transfer and disproportionation reactions. 
Interestingly, it was also found that excellent conversion to the fluoroarenes can be 
achieved when the total concentration of fluoride is very small, as is the case when 
using the fluorine-18 radioisotope to generate potential PET radiotracers. 
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1.4.3 Radiofluorination of diaryliodonium salt precursors to generate imaging 
agents 
One of the most significant imaging syntheses of a PET imaging agent from a 
diaryliodonium salt precursor, is the Wirth’s synthesis of [18F]-L-DOPA, a vital 
radiotracer in the diagnosis of Parkinson’s disease and other neuroendocrine tumours. 
Several stable but complex diaryliodonium halides were synthesised before reacting 
with NCA [18F]fluoride. Optimal conditions were found when using either MeCN or 
toluene, as the fluorination solvent. The electron-rich anisyl group was used as the NTR 
to achieve low RCYs of <1% (based on HPLC analysis). The disappointing yields mean 
that the  current conditions require further optimisation, however, this is still a 
significant synthesis due to the vast application of the target radiotracer.205 
 
Figure 21: Radiosynthesis of [18F]-L-DOPA from a diaryliodonium salt.205 
Few applications to the preparation of specific radiotracers from diaryliodonium salts 
have been as successful as Zhang’s preparation of [18F]DAA1106, a PET ligand for 
imaging peripheral-type benzodiazepine receptors in the brain.206 The corresponding 
diaryliodonium tosylate precursor was synthesised in excellent RCYs before reacting 
with NCA cyclotron-produced [18F]fluoride to afford the desired product (Scheme 45). 
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Scheme 45: Radiosynthesis of [18F]DAA1106206 
Simple diaryliodonium salt compounds were also synthesised and used as model 
compounds to optimise reaction conditions. Various solvents were tested with the 
most promising results obtained when using DMSO. This is interesting as DMSO has 
been found to be inappropriate for reactions of this type.184 The conventional PTA, 
Kryptofix®222/K2CO3, was replaced by tetrabutylammonium bicarbonate (Bu4N.HCO3) 
which improved the efficiency of the reaction. The results clearly demonstrated the 
selectivity of the reaction with excellent RCYs achieved when using the electron-rich 
anisole as the NPR. The analogous phenyliodonium salt gave the desired product in 
only 3% RCY.   
Katzenellenbogen and colleagues reported the radiosynthesis and biological evaluation 
of two [18F]fluorinated analogues of the PPAR agonist, farglitazar (Scheme 46).207 
Radiosynthesis of 151 was achieved in 35% RCY using [18F]CsF as the [18F]fluorinating 
agent. Interestingly, good yields of the desired compound were achieved when using 
the phenyliodonium tosylate whilst employing the more electron-rich anisole and 
thienyl derivatives afforded no desired product. These potential PET imaging agents 
have been used for the diagnosis of vascular disease and breast cancer and were both 
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shown to be metabolically stable. However, tissue distribution studies showed that 
target tissue uptakes were non-specific and disappointingly low. These compounds, 
therefore, are unlikely to be suitable for effective imaging of breast cancer or vascular 
disease.207 
 
Scheme 46: Radiosynthesis of fluorine-18 labelled analogue of farglitazar 
Kim and co-workers have used diaryliodonium tosylate precursors 152 to develop 
fluorine-18 labelled 2-aryl-6-benzothiazoles 153.208 These compounds could prove to 
be potentially useful PET probes for imaging -amyloid plaques, which seemingly play 
an important neuropathological role in Alzheimers disease. A range of precursors were 
synthesised via conventional pathways before being tested unders various conditions. 
Higher yields were obtained using microwave heating and in the presence of TEMPO. 
Short reaction times, high SAs and RCPs were also achieved. Electron-rich NTRs were 
again used successfully to direct the radiofluorination to the benzothiazole ring with 
best results obtained when using the 3-thienyl derivative.208 
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Scheme 47: Radiosynthesis of 2-aryl-6-[18F]fluorobenzothiazoles208 
Kim and coworkers have, again, used the diaryliodonium tosylate precursor 154 to 
develop a highly efficient synthesis of [18F]flumazenil 155, an important 
radiopharmaceutical agent for the assessment of central benzodiazepine receptor 
concentration (cBZR) in the brain (Scheme 48).209  
 
Scheme 48: Radiosynthesis of [18F]flumazenil209 
PET studies targeting this biomarker have been used to quantitatively evaluate cBZR in 
epilepsy,210 panic disorders,211 the evaluation of cortical damage to the brain following 
an acute stroke,212, 213 as well as other conditions.214, 215 Carbon-11 labelled flumazenil 
([11C]FMZ) has proved to be very useful in such studies but the short half-life of the 
radioisotope restricts administrations to one or two patients per cyclotron-production 
of radioactivity. The fluorine-18 labelled derivative has a similar uptake pattern and 
allows for extended PET studies due to the longer half-life of the radioisotope. Many 
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research groups have attempted to synthesise 155 from the nitro precursor via 
nucleophilic substitution, but RCYs have been disappointingly low (3–10%).216, 217 Kim 
and colleagues have drastically improved yields by adopting the diaryliodonium salt 
approach.209 It was found that the stability of the diaryliodonium salt under basic 
conditions at high temperatures is an important factor in the fluorination process. 
Stability studies revealed that the more electron-rich diaryliodonium tosylates had 
lower stabilities, and that, therefore, 4-methylphenyl-mazenil iodonium tosylate was 
the most attractive precursor for the efficient production of 155. Using optimised 
conditions, studies were extended to large scale production, employing a commercially 
automated device to obtain the desired product in excellent yields and in short 
reaction times. High SAs and reproducible yields were also achieved using the 
automated equipment. 
More recently, Selivanova and coworkers have radiolabelled a novel and potent 
inhibitor of matrix metalloproteinases MMP2/MMP9 157 (Scheme 49).218 The activity 
of these proteases is elevated under many pathological conditions including 
atherosclerotic plaque rupture. Gelatinases MMP2 and MMP9 are of particular 
interest in oncology because of their implication in angiogenesis, cancer cell 
proliferation and metastasis. The aim of the study was to image these active inhibitors, 
in vivo, using radiolabelled (R)-2-(4-(4-fluorobenzamido)phenylsulfonamido)-3-(1H-
indol-3-yl)propanoic acid which showed the best binding properties in vitro.218 
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Scheme 49: Radiosynthesis of a high affinity probe for imaging matrix metalloproteinases 2 and 9.218 
Radiolabelling was achieved in one-step from NCA [18F]fluoride using the 
corresponding diaryliodonium salt precursors 156, followed by deprotection of the 
carboxylic acid functionality. In optimising reaction conditions, different counterions 
were tested when using either 4-anisyl or 2-thienyl as the NTR. It was found that RCYs 
were higher when reaction times were shorter. Reactions either did not occur or gave 
disappointing yields when anhydrous solvents (MeCN, DMF, DMSO) were used. Higher 
yields were achieved using trace amounts of water. The authors suggest that traces of 
water catalyse the formation of the intimate ion-molecule pair (where the molecule is 
the NTR) making the target aromatic ring positively charged and susceptible for 
nucleophilic attack. Ionising solvents such as water may reduce the energy required for 
heterolytic bond cleavage, thereby favouring this pathway over the homolytic. The 
authors also found that the use of free radical scavengers did not improve RCYs, 
thereby supporting the heterolytic bond dissociation argument. In general, the 
precursor bearing anisole leaving group, gave better RCYs than that bearing the 2-
thienyl group, thus, further optimisation of the reaction was performed using the 4-
anisyl derivative. The influence of the counterion was evaluated and found to induce 
significant effect on RCYs. When using the heavily functionalised diaryliodonium salts, 
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RCYs were highest when using inorganic counterions and decreased in the following 
order: perchlorate > bromide > tosylate > triflate. This may be because the bulkier 
organic anions have more covalent character and hinder solvolysis of an iodonium salt, 
limiting the formation of an intimate ion-molecule pair. The target compound was 
reproducibly synthesised and formulated for in vivo application in 10–20% RCY (DC) 
with excellent specific radioactivities (> 90 GBq/μmol) and RCP (> 95%). Pleasingly, 157 
also showed excellent in vivo stability in wild-type mice and shows strong promise as a 
suitable tracer for oncological and atherosclerotic imaging.218  
Raffel and colleagues have also used diaryliodonium salts to develop a new cardiac 
sympathetic radiotracer with kinetic properties advantageous for quantifying regional 
nerve density in PET.219 Initial attempts to generate 4-[18F]fluoro-m-
hydroxyphenethylguanidine (4-[18F]FMHPG) 159 (Scheme 50) from the di-N,N’-Boc-
protected guanidine precursor 158 showed zero incorporation despite varying reaction 
solvent and sources of [18F]fluoride. The addition of water and the presence of TEMPO 
also had no effect.  
 
Scheme 50: Attempts to synthesise 4-[18F]FMHPG in one step from the corresponding diaryliodonium salt precursors 
The authors proposed that, as diaryliodonium salts may decompose under harsh, basic 
conditions, the guanidinyl group might be causing a disturbance to the [18F]fluorination 
reaction. To test this, the di-N,N’-Boc-protected guanidylethyl group of the iodonium 
 Introduction 
 
92 
 
precursor 158 was replaced with an N-Boc-protected aminoethyl group 160 and used 
to generate N-Boc-3-benzyloxy-4-[18F]fluoro-m-tyramine 161 in RCYs of up to ~45 % 
when using DMF with trace amounts of water in the presence of TEMPO (Scheme 51). 
In order to achieve the following deprotection and guanylating steps, a commercially 
available automated radiofluorination system was used. N,N’-Bis-(tert-
butoxycarbonyl)-5-chloro-1H-benzotriazole-1-carboxamidine was proven to be the 
best guanylating agent. RCYs of the desired final product averaged 7 ± 3% (DC) and in 
99% RCP. Good SAs were also achieved (1.2 ± 0.3 Ci/μmol).  
 
Scheme 51: Radiosynthesis of [18F]FMHPG219 
The authors noted that RCYs of the radiofluorination step were significantly lower 
following conversion to the automated radiofluorination system. This exemplifies the 
challenges the radiochemist must face when translating conventional chemistry to 
more complex platforms required for automated radiochemical procedures. Despite 
this, yields were sufficient for microPET imaging studies in rhesus macaque monkeys to 
take place. Biological evaluations were highly encouraging and suggest that this agent 
is capable of providing accurate and robust quantitative measures of regional cardiac 
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sympathetic nerve density in human subjects. If this is the case, then 159 could have 
important implications in diseases associated with cardiac sympathetic dysfunction, 
including sudden death, heart failure, cardiac arryhythmias and diabetic autonomic 
neuropathy. There may also be a clinical role as a diagnostic imaging agent for 
localising adrenergic tumours, such as neuroblastoma and pheochromocytoma, using 
PET.219 
1.4.4 Radiofluorination of diaryliodonium salt precursors to generate prosthetic 
groups used in PET imaging 
Diaryliodonium salts have also been used to produce prosthetic groups for the indirect 
labelling of biological targets. Pike and co-workers used a microfluidic device to study 
the nucleophilic fluorination of diaryliodonium tosylates 164 in the preparation of 
meta-substituted arenes bearing either electron-withdrawing (Table 4) or electron-
donating (Table 5) substituents.199 By using this platform, reaction temperatures 
beyond the boiling point of the solvent were possible and shown to increase RCYs. 
Initially, MeCN was used in the trial reactions as the [18F]fluoride ion is readily 
solubilised in the presence  of the K+ and Kryptofix®222. However, the RCY of m-
[18F]fluoroanisole from the corresponding 2-thienyl salt was greatly improved when 
changing to DMF suggesting that the outcome of the reaction may be dependent upon 
the choice of solvent used. The authors noted that impressive results have been 
obtained previously when [18F]fluorinating ortho-substituted diaryliodonium salts in 
DMF. However, the effect of solvent was not studied in this work and the majority of 
reactions were performed in MeCN. Generally, highest RCYs were achieved when NTRs 
were 3-MeC6H4, 4-MeOC6H4, 2-thienyl, or 5-Me-2-thienyl groups. 
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R Ar Time (s) Temp (°C) RCY (%)  RCY 
Ar[18F]F 
(%) 
Total RCY 
(%) 
-CN 3-CNC6H4 189 160 55  55 
-CN Ph 146 130 25 < 1 26 
-CN 4-OMeC6H4 146 130 82 11 93 
-CN 3-MeC6H4 189 160 76 5 81 
-CN 2-thienyl 189 160 58 2 60 
-CN 5-Me-2-
thienyl 
189 180 78 1 79 
-NO2 4-OMeC6H4 191 130 58 7 65 
-NO2 2-thienyl 140 130 31 4 35 
-NO2 5-Me-2-
thienyl 
189 160 37 2 39 
-CF3 4-OMeC6H4 189 190 53 < 1 54 
-CF3 2-thienyl 236 180 66 0 66 
-CF3 5-Me-2-
thienyl 
189 190 57 0 57 
Table 4: RCYs (DC) of m-[18F]fluoroarenes from the NCA radiofluorination of diaryliodonium tosylates bearing an electron-
withdrawing substituent in the meta-position.199 
R Ar Time (s) Temp (°C) RCY (%) RCY 
Ar[18F]F 
(%) 
Total RCY 
(%) 
-Me Ph 236 160 12 15 27 
-Me 4-OMe 236 180 47 5 52 
-Me 2-thienyl 236 190 26 < 1 27 
-Me 2-thienyl 236 200 82 0 82 
-OMe Ph 236 150 87 6 93 
-OMe 2-thienyl 314 200 9 1 10 
-OMe 4-OMeC6H4 236 180 36 1 37 
Table 5: RCYs (DC) of m-[18F]fluoroarenes from the NCA radiofluorination of diaryliodonium tosylates bearing an electron-donating 
substituent in the meta-position199 
Wüst and co-workers developed a novel approach to radiolabelling more complex 
molecules via transition-metal mediated cross-coupling reactions, using 4-
[18F]fluoroiodobenzene 168 generated from 4,4’-diiododiphenyliodonium salts 167.198  
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Scheme 52: Radiofluorination of 4,4’-diiododiphenyliodonium salts to generate precursors for transition-metal mediated cross-
coupling reactions198 
Various counterions were tested in synthesising 168, with the tosylate and triflate 
precursors producing the most reproducible results compared to the chloride anion. 
Different solvents were also tested with DMF producing the highest results whilst 
MeCN and DMSO generated far lower yields. Microwave heating did not improve RCYs 
but did drastically reduce reaction times – a critical consideration to radiochemical 
syntheses when incorporating short-lived radioisotopes. To reduce the duration of the 
purification process, solid-phase extraction techniques were used as opposed to 
slightly more conventional HPLC methods. In all fluorination experiments, however, 
the formation of diiodobenzene 169 and iodobenzene 93 was observed, originating 
from the thermal decomposition of the iodonium salt. These by-products could not be 
removed by SPE and therefore, acted as competitive ligands in subsequent cross-
coupling reactions. Despite this 168 was successfully used in the Stille coupling 
approach towards the radiosynthesis of two potential radiotracers for monitoring COX-
2 expression via PET 171 and 173 (Scheme 53).220 
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Scheme 53: Radiosynthesis of potential radiotracers for monitoring COX-2 expression via Stille Cross-coupling using 
4-[18F]fluoroiodobenzene220 
Optimised reaction conditions were applied to achieve compounds 171 and 173 in 
RCYs of up to 93% and 68% respectively, based on 4-[18F]fluoroiodobenzene. Wüst has 
also used this approach to synthesise 5-(4-[18F]fluorophenyl)-2-deoxy-uridine 176 
(Scheme 54).221 Radiolabelled nucleosides have attracted significant interest due to the 
central role nucleosides and nucleotides play in biological systems. SPE techniques 
from previous studies were improved upon to completely remove the 1,4-
diiodobenzene by-product and provide chemically and radiochemically pure 168 for 
the cross-coupling reactions.  
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Scheme 54: Radiosynthesis of 5-(4’-[18F]fluorophenyl)-2’deoxy-uridine via a Stille cross-coupling reaction221 
Griffiths and colleagues reported the first synthesis of fluorine-18 radiolabelled 
lapatinib 182 (Scheme 55) - a potential radiotracer for PET imaging of ErbB1/ErbB2 
tyrosine kinase activity, using meta-[18F]fluorobenzaldehyde 178 as the 
radiofluorinating synthon.77 Fluorination of phenyl(3-formylphenyl)iodonium bromide 
177 using anhydrous [18F]CsF in a microwave and in the presence of TEMPO afforded 
the 178. This was immediately converted to the corresponding alcohol 179 by treating 
with aqueous NaBH4 before being converted to meta-[
18F]fluorobenzylbromide 180 by 
reaction with triphenylphosphine dibromide. This was then coupled to the lapatinib 
precursor 181 to produce 182 in 8–12% RCY (NDC) in 140 min. 
 
Scheme 55: Radiosynthesis of [18F]lapatinib 182222 
Pike has developed a rapid, single step synthesis of azido 185 or azidomethyl 187 
bearing [18F]fluoroarenes from reactions of diaryliodonium salts with NCA [18F]fluoride 
(Scheme 56).200 These fluorine-18 bearing synthons have great potential in “click” 
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chemistry and increase the scope of possible radiotracers. By using a microfluidic 
device, previously poorly accessible [18F]-labelled “click” synthons were generated in 
good RCYs and in short reaction times using diaryliodonium salts bearing the 4-anisyl 
NTR 184 and 186. Interestingly, the radiosynthesis of 187 was achieved under “wet” 
conditions thus obviating the drying of cyclotron-produced [18F]fluoride ion and 
therefore enhancing the practicality of the method whilst reducing total reaction 
times. The use of the microfluidic device also allowed for reaction temperatures to be 
greatly extended beyond the boiling points of the reaction solvents, thereby further 
improving RCYs. 
 
Scheme 56: Radiosynthesis of azido- and azidomethyl-substituted [18F]fluoroarenes200 
More recently, Pike and Chun have generated a range of fluorine-18 bearing prosthetic 
groups from various functionalised diaryliodonium salts, to expand the scope for 
producing structurally complex yet valuable, PET radiotracers.203 RCYs (DC) varied with 
position of functional group, choice of electron-rich aryl ring and choice of 
counteranion. Under optimised conditions, fluorine-18 labelled fluorobenzaldehydes, 
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fluorobenzylhalides, fluorobenzoic acid esters and fluorophenyl ketones were obtained 
selectively in 40–73%, 20–55%, 46–89% and 81–98% RCYs, respectively. The use of 
microfluidic device, again, drastically reduced reaction times thereby allowing for high-
throughput of experiments and the rapid optimisation of reaction conditions. Reaction 
temperatures of up to 200 °C were applied when DMF (boiling point = 153°C) was the 
solvent. Experiments in which the use of DMF and MeCN could be compared directly 
showed that considerably higher RCYs were obtained when using the former solvent. 
However, the authors noted that since the products of these reactions are synthons, 
then the reaction conditions for the following steps, and hence the solvent required, 
should be given great consideration. The NTRs varied across the study with higher RCYs 
generally resulting from those precursors bearing (2,4,6-trimethoxy)phenyl ring 
partners. Complete selectivity for the desired radioactive product was only observed, 
however, when using 2-thienyl and 5-methyl-2-thienyl as the NTRs. There was no 
observable difference between the use of chloride or tosylate anions and that the 
manner in which the anion influences the RCYs of these reactions remains unclear.203  
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1.5 Summary 
As discussed above, Imaging techniques such as Magnetic Resonance Imaging (MRI) X-
rays and ultrasound typically provide sound structural detail but little or no 
information on events at a metabolic or molecular level. Positron-Emission 
Tomography (PET) is a powerful, non-invasive molecular imaging technique used to 
gain valuable information on specific biological and pharmacological processes taking 
place in the human body. Positron-emitting radioisotopes are incorporated into a 
biologically active molecule, allowing for the non-invasive imaging and quantification 
of pharmacological and biological processes whilst minimising the disruption to their 
pharmacodynamic properties. Fluorine-18 is now considered to be the radionuclide of 
choice for PET imaging due to the convenient half-life, low positron energy and high 
degree of decay via positron emission. Widespread use of the most commonly used 
PET tracer [18F]FDG 2, which images areas of enhanced metabolism thereby improving 
diagnosis and evaluating the effectiveness of treatments in oncology, has spurred the 
global interest in PET studies. Nucleophilic fluorine-18 chemistry remains the dominant 
force in PET radiotracer production as the [18F]fluoride can be produced in high SA. 
A target arene may be radiolabelled with fluorine-18 via many different methods, of 
which nucleophilic aromatic substitution is the most common. The major drawback to 
this approach, however, lies in the difficulty to radiolabel electron-rich arenes. The 
reactivity of diaryliodonium salts provides access to [18F]fluoroarenes which were 
previously inaccessible via conventional methodology.54 These hypervalent molecules 
have been used extensively to generate potential imaging agents either via direct 
radiolabelling methods or via the generation of fluorine-18 labelled prosthetic groups 
(Section 1.2.8).  
 Introduction 
 
101 
 
The regioselectivity of the reaction involving nucleophilic attack of [18F]fluoride is 
determined by the stereoelectronic properties of the substituents;  generally, the 
more electron-deficient aromatic ring will selectively incorporate the fluoride 
nucleophile, with particular consideration for the electron-density at the ipso carbons 
of vital importance.188 However, an ortho-substituent on one of the aryl rings 
preferentially directs fluoride to that ring – the so-called “ortho” affect.55-58 The RCYs 
of the radiofluorinated target can therefore be increased by the strategic modification 
of electronic and steric properties of the substituents, and reaction conditions.56 
However, there may be many other factors at play as evidence exists to support 
competing reaction mechanisms possibly involving a homolytic pathway (Section 
1.4.2.5) and conventional nucleophilic aromatic substitution (Section 1.4.2.4). It has 
been shown that the configuration of the transition state is crucial to the outcome of 
the reaction with the attacking fluoride showing preference for the aryl group found in 
the equatorial position during the transition state.152 
The counterion of the precursor, as well as the solvent in which the fluorination takes 
place, also have bearing upon the outcome of the reaction, with DMF and MeCN found 
to be the superior solvents.184 Several counterions have been used, however, the 
trifluoroacetyl anion has been found to show good thermal stability (c.f. triflates) 
whilst allowing for facile synthesis of salts bearing this counterion (Section 1.4.2.6). 
Despite being studied extensively, a complete and conclusive description of the 
nucleophilic fluorination of diaryliodonium salts has not been widely accepted. 
Given current understanding of this research field, herein this project, we aimed to 
generate a range of ethyl [18F]fluorobezoates from various diaryliodonium salt 
precursors using advanced radiosynthesis techniques. In doing so, we aim to further 
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understand the mechanism the radiofluorination of these species, thereby aiding the 
potential production of future imaging agents to be used in PET studies. 
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2 Results and Discussion 
2.1 Synthetic Chemistry 
2.1.1 Aims 
Previous work within this research group has focussed on the use of diaryliodonium 
salts to  synthesise all regioisomers of ethyl [18F]fluorobenzoate 188a-c (Figure 22) 
compounds which were previously difficult to prepare due to the limitations of 
nucleophilic aromatic substitution chemistry.223 
 
Figure 22: Regioisomers of ethyl [18F]fluorobenzoate 
The ethyl [18F]fluorobenzoates are desirable targets as the ester functionality may be 
converted to several other chemically useful functional groups for the purposes of 
indirect radiolabelling. 
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Scheme 57: Ester functionality provides access to various other functional groups 
Each regioisomer may also serve as a prosthetic group and contribute to structure-
activity relationship (SAR) studies thus providing important biological information on 
the pharmacodynamics of the imaging agent. Most importantly, ethyl 4-
[18F]fluorobenzoate 188a also serves as a precursor to [18F]SFB, which is the most 
versatile prosthetic group for the incorporation of fluorine-18 into peptides, proteins or 
antibodies.  
In previous work, diaryliodonium trifluoroacetates 189 were used to obtain the 
fluorine-19 isotopomers 188d-f in high selectivity and in excellent yields (Table 6). 
 
Compound Regioisomer Anisyl 
derivative 
Yield of ethyl 
fluorobenzoate 
(%) 
Selectivity of the reaction 
(ethyl fluorobenzoate: 
iodoanisole) 
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189a 2-I 2’-OMe 16 188f 1 : 0 190b 
198 2-I 4’-OMe 29 188f 1 : 0 190a 
189c 3-I 2’-OMe 49 188e 11 : 1 190b 
195 3-I 4’-OMe 70 188e 1 : 0 190a 
189e 4-I 2’-OMe 81 188d 1 : 0 190b 
192 4-I 4’-OMe 74 188d 1 : 0 190a 
Table 6: Synthesis of all regioisomers of ethyl fluorobenzoate224 
The fluorine-18 derivatives have been synthesised previously but in non-optimised 
RCYs (~20%).224 Before being used to radiolabel a biologically active molecule, RCYs 
must be improved and it is this aspect that forms the initial focus of this research 
project. 
 
Figure 23: Regioisomers of ethyl fluorobenzoate 
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Figure 24: Diaryliodonium salt precursors to be the initial target compounds of the project. 
The traditional approach towards the synthesis of diaryliodonium salts which would 
serve as precursors to the ethyl fluorobenzoates (Scheme 58) was undertaken. The 
electron-rich 4-anisyl and 2-thienyl groups were chosen as the NTRs in order to 
promote the formation of the desired targets by directing the fluorination to the 
electron-deficient, ester-bearing ring.  The phenyl group is also electron-rich, relative 
to the ethoxycarbonylphenyl group and so was also included in the study. 
Trifluoroacetates were to be used as counterions as previous work had suggested that 
these species limit the formation of by-products derived from the counterion acting as 
a competing nucleophile (c.f. Br, OTs) whilst exhibiting improved thermal stability 
compared to triflates. 
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The initial focus was to synthesise the appropriate aryl stannanes which would be 
combined with diacetoxyiodoarenes to form the target precursors (Scheme 58). 
 
Scheme 58: Synthetic route to diaryliodonium trifluoroacetates 
2.1.2 Formation of tributylstannyl substituted ethyl benzoates 
As the preferred precursor to the target diaryliodonium salts are ethyl (tri-n-butyltin)-
benzoates, the primary intention was to synthesise compounds 201a-c. The most 
common procedure for the transformation of aryl halides to the corresponding 
arylstannanes is via the formation of an organometallic  (Grignard,225 lithium,226 
zinc227) reagent followed by the reaction with a trialkytin chloride. Alternatively, a 
palladium catalyst may be used with an excess of hexabutylditin to form functionalised 
stannanes from the corresponding aryl halides.228 For this project, initial attempts 
were made using nBuLi in a halogen-metal exchange reaction followed by the addition 
of tri-n-butyltin chloride to form ethyl 4-(tri-n-butyltin)benzoate 201a (Scheme 59). 
 Results and Discussion 
 
108 
 
 
Scheme 59: Metal-halogen exchange reaction followed by addition of SnBu3Cl to form the stannane 
Unfortunately, no stannane was produced despite numerous attempts over a range of 
temperatures and reaction times, evidenced by 1H-NMR and HPLC. We propose that 
this is most likely due to the sensitivity of the ester substituent which may be prone to 
attack from the nucleophilic butyl group resulting in ketone formation, also evidenced 
by crude 1H-NMR. At low temperatures (–100 °C) and over varying reaction times, with 
various equivalents of nBuLi, zero stannane could be observed. Taking into account 
that even the most effective modifications would still only produce disappointing 
yields, this approach was dismissed and the search for a simple, reproducible process 
which would not require the use of an expensive palladium catalyst, was undertaken. 
It was noted that organozinc species could be used in conjunction with the appropriate 
transition-metal catalyst to create a range of polyfunctional compounds.229, 230 The 
preparation of organozinc compounds from aromatic halides requires mild conditions 
when the aromatic ring bears sensitive functional groups such as esters. Suitable 
reaction conditions for the synthesis of aromatic organozinc species were reported by 
Kazmierski and colleagues.231 Aromatic halides were converted to the corresponding 
aromatic organozinc species using acid activated zinc, in the presence of a cobalt (II) 
halide catalyst (Scheme 60).  
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Scheme 60: Preparation of organozinc species 
The catalytic cycle (Scheme 61) is first initiated by the reduction of Co(II)Br2 208 by zinc 
dust which has been previously activated by TFAH. The resulting Co(I)Br then 
undergoes an oxidative insertion into the aryl halide bond to afford the trivalent cobalt 
complex ArCo(III)Br2. This is then reduced to the ArCo(II)Br species by the excess of 
zinc. The catalytic cycle is completed by the transmetallation reaction between 
ArCo(II)Br and the ZnBr2 formed in the two previous steps. This gives the ArZnBr 
product and regenerates 208.232 
 
Scheme 61: Catalytic cycle to show production of ArZnBr232. Zn* = activated zinc.232 
To avoid the formation of alternative products (ArH and Ar-Ar) a 5 min preliminary 
step is introduced using a catalytic amount of allyl chloride. The allyl chloride is fully 
converted into propene, 1,5-hexadiene and the addition product of the allylzinc 
species in MeCN, establishing the catalytic cycle. Previously, PhBr was used to reduce 
the production of ArH by being converted to PhH. It was found however, that a higher 
proportion of PhBr tends to slow down the reaction and produce a significant amount 
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of PhZnBr. It was deemed, therefore that PhBr is not reactive enough to act as an 
additive in this reaction. Allyl chloride was the most beneficial as it is fully converted to 
the compounds mentioned above, all fully separable from the aromatic products. 
Different durations of the preliminary steps were attempted but it was found that a 5 
min preliminary step was sufficient, after testing in a one-step reaction. 
The quantity of the catalyst used was reduced but when using 5% of CoBr2, compared 
to 10%, the reaction was significantly slower. For this reason, the proportion of allyl 
chloride was increased compared to that of the catalyst by bringing up to 3 equiv. 
versus CoBr2. With this, the reaction proceeded rapidly. 
Gosmini and colleges have extended this work by investigating the synthesis of 
functionalised arylstannanes using a method for organozinc preparation (Scheme 
62).233 This approach does not require an expensive palladium catalyst but still 
produces high and reproducible yields under mild conditions. The ArZnBr species 
(Scheme 61) undergoes a transmetallation reaction with Bu3SnCl to form the 
arylstannane 209. 
 
Scheme 62: Gosmini et al preparation of aryl stannanes from aryl halides233 
Zinc dust and CoBr2 208 were introduced to a dry reaction vessel which was then filled 
with N2. MeCN, allyl chloride and a catalytic amount of TFAH were then added and the 
reaction stirred for 5 min. The ethyl iodobenzoate 200a-c and tributyltin chloride were 
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then added simultaneously and the reaction stirred at 50 °C for 1 h to give good yields 
(Table 7). 
 
Isomer 
 
Reaction Time 
(h) 
Average Yield n =  
Ethyl 2-(tri-n-butylstannyl) benzoate 201a 1 53 3 
Ethyl 3-(tri-n-butylstannyl) benzoate 201b 1 56 4 
Ethyl 4-(tri-n-butylstannyl) benzoate 201c 1 67 13 
Table 7: Results of stannylation using cobalt (II) bromide and zinc dust. ‘n’ is the total number of syntheses. 
It is not practical to either store or isolate the intermediate organozinc species 210a-c, 
therefore the addition of tri-n-butyltin chloride is performed immediately following the 
formation of the organozinc species 210. The nucleophilic carbon attacks the 
electrophilic tin eliminating the chloride leaving group, generating a penta-coordinate 
stannyl intermediate where the C-Zn bond is then broken to give the stannane 201a-c 
and ZnICl (Scheme 63). 
 
Scheme 63: Arylstannane formation from aromatic organozinc species 
The differences in yield (Table 7) are small suggesting that neither electronic nor steric 
affects greatly influence the outcome of the reaction. Overall, the yields of the 
stannanes were pleasing due to the robustness of the reaction, short reaction times 
and no need of an expensive palladium catalyst or hazardous butylithium reagents. 
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A major difficulty in the preparation of pure organostannanes lies in their purification. 
The tributyltin compounds are viscous oils or liquids with very high boiling points. 
When working on a microscale, fractional distillations are impractical. In normal phase 
chromatographic purification, organostannanes often elute with the solvent front on 
silica gel, even with a non-polar eluant such as hexane, unless there are also polar 
functionalities present in the molecule. In addition, unsaturated organostannanes are 
sensitive to acid (including silica gel) and protio-destannylation is often observed 
during chromatographic purification.234 To address these issues, purification of 
organostannanes was achieved using reverse phase flash chromatography (C-18 
cartridge).235 This method developed by Farina, requires the stannanes to be loaded 
onto the stationary phase in a 1:1 mixture of DCM and MeCN before eluting with 
MeCN only. However, loading in pure MeCN was found to be equally effective. By 
using an automated flash chromatography system, crude stannanes 201a–c could be 
rapidly purified in a reproducible manner. 
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Figure 25: 1H-NMR of 201c with expansion of n-butyl region 
2.1.3 Formation of diacetoxyiodoarenes 
Diacetoxyiodoarenes are an important class of chemicals best prepared directly from 
iodoarenes and peroxyacids. Diacetoxyiodo-derivatives are readily formed upon 
oxidation of iodoarenes with hydrogen peroxide, in acetic acid and acetic anhydride.236  
 
Scheme 64: Formation of diacetoxyiodoarenes using hydrogen peroxide, acetic acid and acid anhydride 
An alternative approach which avoids the application of the potentially explosive, 
unstable, and highly concentrated hydrogen peroxide  utilises sodium perborate.237 
McKillop and Kemp conducted a survey on the use of sodium perborate for the 
oxidation of functional groups and found that sodium perborate in acetic acid is a 
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highly effective reagent for the oxidation of many different functional groups but most 
importantly, iodoarenes to diacetoxyiodoarenes.238 They found that the choice of 
solvent is an important consideration as simple oxidations are accomplished with ease 
in acetic acid, whilst attempts using alternative acids such as propionic acid were 
unsuccessful. This approach was adopted for the synthesis of diacetoxyiodoarenes 
throughout the project.  
 
Scheme 65: Formation of diacetoxyiodoarenes from corresponding iodoarenes using sodium perborate 
When used in water, sodium perborate releases hydrogen peroxide, but the new 
solution is not a simple mixture of hydrogen peroxide and sodium borate. It has been 
shown using NMR and Raman spectroscopy that when in dilute solution, an 
equilibrium containing peroxoborate anion 217 is established. These peroxoborate 
species are able to produce the hydroperoxide anion 216 at a much lower pH than 
when using hydrogen peroxide directly.238 The ability of the tricoordinate boron 215 to 
accept hydroxyl ion from the hydroperoxide intermediate 218 and act as a leaving 
group, is also a driving force in this reaction.  
 Results and Discussion 
 
115 
 
 
Scheme 66: Reaction pathway to show oxidation process using hydrogen peroxide and a perborate 
When using sodium perborate with acetic acid, a more powerful oxidising species may 
be formed. Generally, sodium perborate does not dissolve freely to any significant 
extent but does so here by reacting first with the acetic acid solvent. This leads to the 
formation of the peracetic acid, which may be responsible for the oxidising properties 
of sodium perborate. There is also good evidence, however, for the production of an 
intermediate peroxy species 226 which most likely contains a B-OOAc species, a more 
powerful oxidising agent.238 
 
Scheme 67: Proposed formation of peracetoxyboron complex from perborate and acetic acid 
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Diacetoxy-4-iodoanisole 205 was prepared from the addition of sodium perborate 
tetrahydrate to a solution of 4-iodoanisole 93b in glacial acetic acid. The mixture was 
heated to 50 °C and stirred for 5–8 h, by which time, the starting material had been 
consumed, according to TLC analysis. 
 
Figure 26: Isolated yields of diacetoxyiodoarenes 
The maximum Isolated yields of the diacetoxyiodoarenes obtained was only ~40% 
which may be due to the low thermal stability of the final products. The electron-rich 
nature of the aryl groups reduces the stability of the hypervalent iodine species and 
promotes the decomposition process which returns the starting materials, which were, 
occasionally, difficult to separate from the desired diacetoxyiodoarenes. Only minor 
modifications to the procedure were made in attempting to elevate yields as 
optimisation of this reaction was not the focus of the project (N.B. 
Diacetoxyiodobenzene 204, DIB, was purchased from fine chemicals suppliers and 
used as received). 
2.1.4 Formation of diaryliodonium salts 
The formation of diaryliodonium salts was based on the Shah-Pike-Widdowson 
synthesis of functionalised unsymmetrical diaryliodonium salts.148 
Diacetoxyiodoarenes were reacted with 2 eq. of trifluoroacetic acid giving the 
intermediate complex, [ArI(OAc)2-2CF3CO2H]. These complexes were then treated in 
situ with the stannylated ethyl benzoate, at –30 °C, before being allowed to warm to 
 Results and Discussion 
 
117 
 
room temperature overnight to give the desired products. The diaryliodonium 
trifluoroacetates were obtained by crystallisation from petroleum 
ether:diethylether:DCM. 
 
Compound Position of 
ester 
functionality 
Ar Yield (%) Appearance 
191 para- 
para- 
para- 
phenyl 56 White crystals 
192 4-anisyl 73 White crystals 
193 2-thienyl 68 White solid 
194 meta- phenyl 56 White crystals 
195 meta- 4-anisyl 55 White crystals 
196 meta- 2-thienyl 56 White solid 
197 ortho- phenyl Trace (by NMR) N/A 
198 ortho- 4-anisyl Trace (by NMR) N/A 
199 ortho- 2-thienyl Trace (by NMR) N/A 
Table 8: Yields and appearances of target iodonium salts 
Having iodonium salts 191–196 available, the focus of the work moved to the 
fluorination of the diaryliodonium salts. 
2.1.4.1 Crystal structure of diaryliodonium salts 
There is evidence to suggest that 3-iodanes exist as polymeric structures in the solid 
state.106-111 It was decided, therefore, that the solid state structure of the 
diaryliodonium salts 191–196 should be investigated. Using a solvent layering 
technique, material suitable for X-ray crystal analysis of 191–196 was produced. 
Compounds 191–193 were shown to exist exclusively in the monomer form, whilst 
compounds 194-196 clearly showed the presence of dimeric, trimeric and tetrameric 
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forms with the dimer dominating the crystal formation. This strongly suggests that 
secondary intermolecular bonding interactions exist on compounds 194-196. This may 
affect the outcome of fluorination reactions as the nucleophile may be obstructed 
from attacking the iodine centre. Berry-pseudorotation is also proposed as being 
integral to the mechanism of fluorination. The formation of rigid oligomers may 
prevent the ligands from freely rotating about the iodine centre thus hindering the 
ligand coupling and formation of the fluoroarene. 
It can also be clearly seen from the crystal structures that, as discussed earlier (Section 
1.3.2) the most electron-rich aryl groups occupy the equatorial position to stabilise the 
positive charge of the iodine induced by the hypervalent bond. This can be seen clearly 
for compounds 192 and 194–196. Interestingly, crystal structures of 191 and 193 both 
show the more electron-rich groups occupying the axial position. This arrangement is 
less preferred than that of the electron-rich in the equatorial position as this group is 
not able to stabilise the hypervalent bond by donating electron-density towards the 
electron-deficeint iodine centre whislt in the axial position. However, as discussed 
(Section 1.4.2.2) it is the arrangement of the transition state which is important to the 
fluorination process and not the arrangement of the ground state.189 
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Figure 27: MS spectra and crystal structure (monomer) of 191 
 
Figure 28: MS spectra and crystal structure of 192 
 
Figure 29: MS spectra and crystal structure (monomer) of 193 
Monomer 
Monomer 
Monomer 
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Figure 30: MS spectra and crystal structure (dimer) of 194 
 
Figure 31: MS spectra and crystal structure (dimer) of 195 
 
Figure 32: MS spectra  showing oligomeric structures and crystal structure (dimer) of 196 
Monomer 
Dimer 
Trimer 
Tetramer 
Monomer 
Dimer 
Trimer Tetramer 
Tetramer Trimer 
Dimer 
Monomer 
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2.1.5 Fluorination of diaryliodonium salts 
Before experimenting with [18F]fluoride, fluorination of the diaryliodonium salts was 
performed using  CsF in dry N, N-dimethylformamide in order to investigate the 
selectivity of the reaction (Scheme 68).  
 
Scheme 68: Fluorination of diaryliodonium salts 191-196 
As discussed earlier (Sections 1.2.9 and 1.4.1) the reaction most likely proceeds via a 
“turnstile mechanism”, incorporating a reductive elimination step, following the 
dissociation of the anion to give the diaryliodonium cation.181 Momomeric iodine 
cations are quite flexible and are therefore able to interconvert through different 
conformations. By doing so, the ligands rapidly interchange through positions relative 
to the anion, which is secondarily bonded to the pivotal hypervalent iodine atom.189 
The nucleophilic fluoride must attack the ipso-carbon atom in the ring which is 
equatorial, from an apical position. The fluoride therefore attacks either of the two 
interconverting isomers to produce two different transition states that yield different 
fluorinated products. The ratio of fluorinated products then depends entirely upon the 
difference in free energies of the two transition states. This would be assuming that 
the fluorination reaction follows the Curtin-Hammett principle which states that the 
relative amounts of products formed from two different conformations of substrate 
are independent of the relative amounts of the conformations and depend solely upon 
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the difference in the free energy of the transition states, provided that the rates of the 
reaction are considerably slower than the rates of conformational interconversion.148   
Where there are no ortho-substitutents present and therefore no “ortho affect” 
(Section 1.4.2.1) is exerted, the nucleophilic fluoride is incorporated into the most 
electron-deficient ring.184 
Compounds 191–196 were fluorinated using CsF in DMF at 130 °C for 1.5 h under N2 
(Scheme 68). Samples were taken (0.3 mL) rapidly cooled to RT, diluted with d7-DMF 
(0.4 mL) and analysed by 19F-NMR in order to observe the selectivity of the reaction. 
Upon fluorinating 191-193, peaks corresponding to the formation of ethyl 4-
fluorobenzoate (δ –107.32 ppm in d7-DMF) were observed in each instance (Figure 33). 
No peaks corresponding to the fluorinated NTR were observed (Table 9). This is in 
accordance with the proposed selectivity of the reaction. The large peak found in each 
spectrum (–76.61, –75.44, and –75.48) correspond to fluorine of the TFA anion of the 
diaryliodonium salt. 
Fluorinated 
Compound 
NTR Non-desired 
product 
19F-NMR δ of non-desired product 
(ppm) 
191 phenyl fluorobenzene –114.18 
192 4-anisyl 4-fluoroanisole –125.61 
193 2-thienyl 2-fluorothiophene –136.74 
Table 9: Table to show 19F-NMR chemical shifts of non-desired fluoroarenes 
Upon fluorination 194–196, using the same method, peaks corresponding to the 
formation of ethyl 3-fluorobenzoate (δ –113.67 ppm in d7-DMF) were observed in each 
instance. Again, peaks corresponding to the fluorinated NTR were not observed, 
further demonstrating the selectivity of the reaction. 
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Figure 33: 19F-NMR to show the formation of ethyl 4-fluorobenzoate from diaryliodonium salts using CsF - from 191 (left) from 192 
(middle) from 193 (right). 
   
Figure 34: 19F-NMR to show the formation of ethyl 3-fluorobenzoate from diaryliodonium salts using CsF - from 194 (left) from 195 
(middle) from 196 (right). 
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2.1.6 Syntheses of trifluoroacetyl(2-ethoxycarbonylphenyl, aryl)-3-iodanes 
As shown earlier (Section 2.1.4) only trace amounts of the  trifluoroacetyl(2-
ethoxycarbonylphenyl, aryl)-3-iodanes 197–199 could be generated using the 
traditional approach.  It could be seen from crude 1H-NMR that reasonable amounts of 
the diaryliodonium salts had been produced, however, there were significant 
challenges in attempting to purify the product. Many different solvents were used in 
attempting to purify by crystallisation but the low yields prevented the formation of 
solid, producing only an oil containing a mixture of starting material, product and 
unwanted side-products. Flash chromatography (DCM:MeOH) resulted in the 
transesterification of the ester functionality resulting in a mixture of the desired 
compounds and the methyl ester derivatives. This was confirmed by HMQC NMR. 
Changing the composition of the mobile phase (DCM:EtOH) frequently resulted in co-
elution of the product with unwanted side-products. Attempts to synthesise the 
corresponding tosylates using m-CPBA,76, 186 with the intention of generating the 
trifluoroacetates by anion exchange, were very low yielding. 
As diaryliodonium salts 191–196 were available for [18F]fluorination reactions, with the 
selectivity of the process having been confirmed, focus of the project moved to the 
radiofluorination of diaryliodonium salts. 
2.1.7 Conclusion 
An unconventinonal approach, obviating the use of hazardous organolithium reagents 
and expensive palladium cataylsts, has been successfully used to generate all 
regiosisomers of ethyl (tri-n-butylstannyl)benzoate in good yields and short reaction 
times. A simple but effective method of chromatography has aided the isolation of the 
desired stannanes in very high purity. These compounds were combined with 
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diacetoxyiodoarenes to produce the 4- and 3- regioisomer diaryliodium salts. These 
compounds demonstrate the regioselectivity of the reaction with fluoride, which 
targets the electron-deficient ring to produce only the desired fluoroarenes, as 
evidenced by 19F-NMR. Crystal structures for the 4- and 3-regioisomers have also been 
determined, which highlight the presence of higher order materials in addition to the 
monomeric species. 
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2.2 Microfluidic Radiochemistry 
For nearly 50 years, PET has been used to investigate a range of medical conditions in 
oncology, neurology, psychiatry, and cardiology. There have been over 1500 
biologically active compounds bearing positron emitting isotopes described in the 
literature.239 However, one tracer, [18F]fluorodeoxyglucose, accounts for over 90% of 
all clinical PET scans due to its broad applicability and availability. Other radiotracers, 
with greater specificity, have the potential to generate greater understanding of 
differing medical conditions but their use has, so far, been restricted to specialist 
facilities.  
Central to the radiopharmaceutical synthesis is the rapid and efficient incorporation of 
a radioactive isotope into a molecule of interest followed by immediate purification 
and formulation. This can pose a significant challenge to the radiochemist, especially 
when using short-lived positron emitting isotopes such as fluorine-18. Radiolabelling 
must occur in the final stages of the synthetic sequence which may involve multiple 
processes concluding with a deprotection step.  Furthermore, as radiotracers must be 
produced as pharmaceutical grade materials, purification and reformulation must be 
considered when planning a radiosynthetic strategy. Large quantities of starting 
radioactivity may be required to compensate for decay, inefficient incorporation and 
losses during purification and dose preparation. Conventional laboratory methods are 
not suitable for radiochemistry practices as they involve personal exposure to 
radiation and are often time-consuming. Automated or robotic equipment capable of 
controlling chemical reactions is required to ensure that the radiochemist can be 
separated from positron emitting isotopes by lead shielding and therefore, protected 
from harmful gamma-rays. This equipment is also capable of reducing the timescale of 
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such processes whilst conveying the necessary degree of reproducibility required of a 
routine production schedule. 
PET radiolabelling methods are also carried out on a small scale due to the minute 
amounts of radioisotope produced by modern cyclotrons. This creates further 
challenges such as radioisotope preconcentration, side reactions, product purification, 
and product analysis. 
2.2.1 Aims 
Recently, there has been great interest within the PET community in the potential 
benefits of microfluidic technology.240 The popularity of microfluidic devices has 
dramatically increased as it has become increasingly apparent that these synthetic 
chemistry platforms bear features which overcome some of the challenges presented 
by radiochemical syntheses. This methodology, coupled with the strict control of the 
reaction parameters, also has the potential to enhance selectivity for the desired 
transformation over by-product generation, improve radiochemical yields (RCYs) and 
thus facilitate the purification of the target radiopharmaceutical. In addition, the high 
degree of reproducibility inherent to this approach is essential for the routine 
production of PET imaging agents. A critical advantage of microfluidic systems, in PET 
radiochemistry, when compared to conventional batch platforms, is that they enable 
multiple reactions to be conducted from a single batch of radioisotope allowing a 
degree of process optimisation not typically associated with short-lived radioisotopes. 
For this reason, a microfluidic device was adopted to investigate the radiosynthesis of 
ethyl [18F]fluorobenzoates from diaryliodonium salts 191-196. 
 Results and Discussion 
 
128 
 
2.2.2 Microfluidics 
Microfluidic devices or microfluidic chips are small devices with an internal network of 
micron-sized channels (typically 10–300 m) capable of performing, controlling and 
processing miniaturised chemical process in a continuous-flow manner.241-243 Most 
microfluidic devices also incorporate mixing units, a heat source and a pumping system 
to control fluid or gas flow. Devices may be constructed from various materials whilst 
flow is generally induced by either mechanical syringes, diaphragm pumps or via an 
electric field to induce electrokinetic flow.  
In microfluidic technology fluids are forced to flow in micro-channels, creating an 
environment different from fluid flow in bulk systems, which is closer to the molecular 
level than conventional flask-based chemistry. This is the principle of miniaturisation 
and is responsible for the significant reduction of reaction times in microfluidics. The 
time required for a single molecule to react from reagent to product through a 
transition state is in the range of 10-14 – 10-13 s, while the time required for all the 
molecules in a flask to react generally ranges from minutes to hours (102 – 104 s). The 
size of molecules is in the range of 10-10 – 10-9m, whilst the size of a flask ranges from 
10-2 – 10 m, which means that there is clear correlation between the size of the 
reaction environment and the reaction time (Figure 35).244 
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Figure 35: Time/Space relationship for chemical reactions. Taken from 244. 
2.2.3 Advantages to Microfluidics 
2.2.3.1 Improved mixing  
Fluid flow in the micro-channels is dominated by viscous forces, as opposed to inertial 
forces, and generally results in the existence of laminar flow regimes with Reynolds 
number (Re) of less than 100.245 Turbulent flow dominates in bulk systems, such as 
round-bottom flasks, where Reynolds number is greater than 1000. Mixing between 
adjacent laminae in micro-channels is diffusion dependent and can be problematic 
leading to inefficient mixing. Despite this, mixing of reagents can be extremely fast246 
provided the channel diameters (diffusion distances) are less than 100 m. This leads 
to a significant improvement in reaction rates when compared to conventional 
laboratory practices.247 
2.2.3.2 Improved surface area-to-volume ratio 
The most important benefit gained upon moving from a bulk laboratory apparatus to a 
microfluidic reactor is the large increase in surface area-to-volume ratio. The typical 
surface area-to-volume ratio of conventional laboratory reactors does not exceed 1000 
m2m-3 whereas microreactor surface area-to volume ratios can be as high as 50000 
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m2m-3. The large surface area-to-volume ratio greatly enhances the mass transport via 
rapid diffusion timescales leading to better mixing and considerably improved heat 
transfer either toward or away from the reactor. Whilst the broad temperature 
profiles in batch reactors can lead to multiple reaction pathways, the narrow 
temperature distribution, characteristic of a microreactor, ideally restricts the reaction 
to the target product (Figure 36). This is enhanced by the fine temperature control 
achievable using a computer-operated microfluidic device. 
 
Figure 36: (left) Comparison between temperature distributions between an ideal hypothetical reaction (black) a batch reaction 
(blue) and a microfluidic reaction (red). (right) Schematic comparison of temperature distributions, to two possible by-product 
forming pathways. Taken from 248. 
High heat exchange coefficients and rapid temperature changes249 are also possible, 
depending upon the materials and heat exchanger used.250  
2.2.3.3 Improved rates of reaction, yields and selectivities 
Due to the improvement in mixing and heat transfer, reactions performed in 
microfluidic devices can be carried out significantly faster with increases in both yield 
and selectivity. Haswell and co-workers have shown that the aldol reaction between an 
aldehyde 229 and a silylenol ether 228 in the presence of tetrabutylammonium 
fluoride (TBAF) reaches completion after 24 h in a typical laboratory reactor, compared 
to just 20 min in a microreactor (Scheme 69).251 
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Scheme 69: Aldol reaction performed in a microreactor 
Many rapid reactions, which show comparable reaction times between batch and 
microfluidic platforms, show significant improvements in yields upon transferring to 
the latter. Large improvements have been shown in Wittig reactions,252, 253 
oxidations,254, 255 coupling reactions,256, 257 and heterocycle formations.258, 259  
2.2.3.4 Rapid optimisation with low volumes 
Optimisation is essential at every step of a synthetic process and any reduction of 
material input and waste reduces the time taken and cost required of optimising 
reaction parameters. Due to the small volumes and short reaction times required, 
rapid optimisation of reaction conditions may be achieved using a microreactor. This is 
often facilitated by the immediate adjustment of conditions possible by controlling the 
microreactor environment with computer software which often accompany 
microfluidic systems (e.g. Advion NanoTek Microfluidic System). 
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Image 1: Graph to show the rapid optimisation of reaction parameters possible using a microfluidic device. In this example, the 
precursor to [18F]fluoride ion solution ratio (v/v) was optimised in the radiosynthesis of the imaging agent [18F]fallypride, at 
different flow rates. Taken from 260. 
2.2.3.5 Exothermic and runaway reactions 
The unique heat transfer properties of micro-channel devices allow for reactions which 
were previously inaccessible on large scales, to be controlled and even manipulated. 
By rapidly cooling microreactors, large exotherms can be reduced creating a safer 
environment whilst improving selectivity. Aromatic nitrations are often dangerous as 
they can be very exothermic and generate explosive by-products. Ducry and Roberge 
used calorimetry to compare the autocatalytic nitration of phenol in a microreactor to 
similar reactions in batch.261 When the reaction was performed in batch, two large 
exotherms were created, leading to an increase in temperature of 55 °C. However, 
upon reaching the equivalent stage, the same reaction increased by only 5 °C when 
being performed in a microreactor (Scheme 70). This rigid temperature control 
provided greater selectivity and higher yields whilst also reducing the formation of by-
products. 
  
Scheme 70: Nitration of Phenol in a microreactor261 
2.2.3.6 Improved efficiency and reduced waste 
Reactions in microreactors typically provide higher yields and greater selectivity than 
batch reactions. Higher concentrations of reagents can be used due to the rapid heat 
transfer achieved in the micro-sized channels. This creates a higher atom economy, 
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thereby reducing the volume of waste material produced and reaction solvent 
required. Some microfluidic reactions may even be performed in neat conditions which 
are often inaccessible in batch reactors due to high exothermicity.  
2.2.3.7 In-line integration of devices 
Many microfluidic reactors allow for the in-line integration of other systems and 
devices. It is possible to monitor reactions in situ using UV/vis or IR analysis to provide 
real-time analysis on the transformation of a reaction. A common practice is to use an 
automated injector to load the reaction bolus onto a HPLC system for inline 
purification of products. By doing so, the speed with which reaction conditions can be 
optimised is further increased as outcomes or yields of microfluidic reactions can be 
immediately deduced. The loss of volatile products is also prevented. 
2.2.3.8 No scale-up required 
The unique mixing process and rapid heat transfer characteristic of microfluidic 
reactors does not allow for reactions to be scaled up. To increase production of a 
desired compound, several microreactors may be used in parallel (the “numbering up” 
principle). With this approach, the need to re-optimise reaction conditions for large 
scale production is negated as yields of reactions are consistent across the assembly of 
multiple microreactors. The savings in terms of time, resources, cost and waste is 
significant. An alternative strategy is to extend the product collection time or increase 
the length of the micro-sized channels used (the “scaling out” principle). This is better 
practice when the use of multiple microreactors employed in parallel is impractical or 
unnecessary, such as the scaling up from milligram quantities to grams.  
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2.2.3.9 Multi-step transformations 
Many microfluidic systems allow for several microreactors to be connected in series 
thereby allowing multiple steps to be performed before isolation of the final products. 
After having demonstrated that peptide bonds could be formed in a microreactor, 
Haswell and co-workers extended their methodology to prepare longer chain 
peptides.262 Using a bespoke microfluidic apparatus, the Dmab ester of Fmoc--alanine 
234 was reacted with DBU to give the free amine which was then reacted with the 
pentafluorophenyl ester of Boc--alanine to form a protected dipeptide 236 (Scheme 
71). Reaction conditions were optimised to improve yields from 25% to 96%, based on 
the amount of Dmab ester present at the end of the reaction.262 
 
Scheme 71: Multi-step synthesis of  dipeptide in a microreactor262 
2.2.3.10 Improved safety 
As well enhanced control of potential exotherms, the low volumes of reagents 
required in microfluidic syntheses allows for far less potentially toxic material to be 
used. These systems are also often closed systems which can be controlled externally, 
outside the confines of a laboratory fumehood. This has major implications in 
radiochemistry whereby protective shielding (e.g. lead shielding) can be installed to 
separate the radiochemist from harmful radiation whilst allowing the microfluidic 
reaction to be controlled and monitored. 
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2.2.4 Microfluidics in PET Radiochemistry 
Due to the inherent advantage of miniaturisation, microfluidic technology is becoming 
an invaluable tool in the development of PET radiochemical methods, allowing the 
relative quantities of precursors/reagents/solvents to be significantly reduced 
facilitating timely isolation of the final radiolabelled product.245, 263-266 As discussed 
above, the rapid heat transfer and efficient mixing, coupled with the strict control of 
the reaction parameters, has the potential to enhance selectivity for the desired 
transformation over by-product generation, improve RCYs and thus increase the RCP. 
In addition, the high degree of reproducibility inherent to this approach is essential for 
the routine production of PET imaging agents. A critical advantage of microfluidic 
systems, in PET radiochemistry, when compared to conventional batch platforms, is 
that they enable multiple reactions to be conducted from a single batch of 
radioisotope allowing a degree of process optimisation not typically associated with 
short-lived radioisotopes. As mentioned above, the capacity to shield the radiation 
present throughout the microfluidic device from the radiochemist is an obvious 
advantage. The automation of microfluidic devices also promotes GMP standards for 
radiotracer production as the fine control of reaction conditions promotes 
reproducibility of the reaction yields and enhances the likelihood of outputs adhering 
to standards required for on-demand production of imaging agents. 
The radiosynthesis of [18F]FDG has dominated the proof-of-concept testing of various 
microfluidic devices, due to the broad application of this molecular imaging probe. 
Tseng and co-workers presented the most significant work in this field by building an 
integrated microfluidic device used to synthesise [18F]FDG in high RCY (38%) and high 
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RCP (97.6%) with short synthesis times (14 min) when compared to commercial 
synthesisers (~50 min).267 
 
Figure 37: Schematic diagram to show the steps involved in the microfluidic synthesis of [18F]FDG267 
Five sequential steps ([18F]fluoride concentration, water evaporation, 
radiofluorination, solvent exchange and hydrolytic deprotection) were performed in an 
integrated microfluidic chemical reaction circuit (Figure 37) designed to demonstrate 
the digital control of sequential chemical steps, in variable chemical environments and 
with variable physical conditions.  The fluoride solution was first concentrated using a 
miniature anion-exchange column before a solution of K2CO3 was used to elute the 
[18F]fluoride and create a solution of KF (Figure 37, A). Heat was applied to evaporate 
the water (Figure 37, B) before MeCN solution is introduced, wherein the 
[18F]fluorination reaction takes place, using Kryptofix to heighten the reactivity of the 
[18F]fluoride against the D-mannose triflate (Figure 37, C). A computer was used to 
control the temperature gradient within the reaction loop and therefore produce the 
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protected intermediate. After evaporation of the MeCN, an HCl solution is introduced 
into the reaction loop to hydrolyse the intermediate and give the final product (Figure 
37, D). 
This work was hugely significant to the field as the proof of concept result could be 
generalised to a range of radiolabelled substrates, thereby demonstrating the vast 
potential of microfluidics to the PET chemistry. 
Since then, microfluidic reactors have become commercially available as individual or 
modular devices and used to create a vast array of potential imaging agents (Table 10). 
Isotope System Product RCY 
(%) 
Processing time 
(residence time in 
reactor) 
Reference 
11C Custom  [11C]methyl ester 64 (DC) 10 min (12 s) Lu et al268 
11C Custom [11C]amides 44-88 
(DC) 
15 min (2 s - gas reagents) 
(2 min - liquid reagents) 
Miller et 
al269 
11C Advion 
NanoTek 
[11C]DASB 45 34 min (1 min) Ungersboeck 
et al270 
18F Custom [18F]FDG 20 18 min (9 s) Steel et al271 
18F Scintomics [18F]FDG 88 (DC) 7 min Wester272 
18F Advion 
NanoTek 
[18F]Fallypride 88 (DC) 50 min (4 min) Lu et al260 
124I Custom [124I]Annexin-V 
protein 
40 2 min Gillies et 
al273 
99mTc Advion 
Nanotek 
[99mTc]DTV-AHx-
insulin 
40 (15.7 min) Simms et 
al274 
Table 10: Selected examples of isotopic labelling reactions performed using various microfluidic devices 
2.2.5 Advion NanoTek Microfluidic system 
All microfluidic devices benefit from the features of miniaturisation and generate high 
RCYs, high RCPs and short residence times. The Advion NanoTek Microfluidic System 
(Advion Biosciences) is a commercially-available microfluidic system with the capacity 
to extend reaction conditions beyond those of conventional batch systems. The 
microreactor, central to the device, is a closed system capable of operating at 
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pressures of up to 400 psi (28 Bar) whilst tolerating temperatures up to 220 °C (Table 
11). 
Solvent Boiling Point at 14.7 psi 
(Atmospheric Pressure) 
Boiling Point at 400.0 psi 
(upper limit of NanoTek®) 
MeCN 82 186 
H2O 100 217 
DMF 153 312 
DMSO 189 383 
Table 11: Boiling Points of common solvents and boiling points within the NanoTek Microfluidic System (upper temperature limit – 
220 °C) 
The NanoTek system is also accompanied by a software package which operates the 
device and provides users with fine control of the reaction parameters (Image 2a). This 
makes the system highly reproducible, as the exact reaction parameters desired can be 
replicated with ease. The software also displays and records data regarding the system 
status (e.g. reactor temperature, Image 2b).  
.  
Image 2: Image taken from the NanoTek software showing (a) which reaction parameters can be manipulated following input from 
the user, and (b) the current and setpoint temperatures of the microreactors and the two CMs (Those parameters controlling 
‘Reaction 2’ are ignored as only one-step reactions were performed throughout this project). 
Due to these valuable features, the recent emergence in microfluidic technology for 
the preparation of PET imaging agents, has been dominated by the use of the NanoTek 
system (Figure 38), also thanks to the commercial availability of the device. The small 
system footprint, high through-put, and the ability to prepare both fluorine-18 and 
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carbon-11 radiolabelled materials, make this microfluidic system hugely attractive to 
the modern radiochemist. 
 
Figure 38: Graph to show number of publications reporting the syntheses of PET imaging agents performed using a microfluidic 
systems (1981-2013)275 
It should be noted that the GE prototype and Scintomics devices were custom built at 
the facilities wherein the radiochemical syntheses took place. The GE system was 
fabricated from from glass by incorporating a single two-stage microfluidic device with 
localized heating capabilities.271 The Scintomics device was assembled from various 
Scintomics modules.272 To this author’s knowledge, these devices are not commercially 
available. For the reasons described above, the NanoTek system was chosen to provide 
an efficient, versatile and convenient methodology for the rapid optimisation of 
microfluidic radiofluorination reactions, throughout this project. 
2.2.6 Significant Radiochemical Syntheses performed using the Advion NanoTek 
Microfluidic System 
Pike and colleagues reported the first synthesis of a PET imaging agent using the 
NanoTek system.260 [18F]Fallypride, which is widely used for imaging dopamine 
subtype-2 (D2) receptors in living animal 
276, 277 or human brain,278 was synthesised in 
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one convenient step from the corresponding tosylate precursor (Scheme 72). Small 
doses of precursor and [18F]fluoride ion were used to quickly optimise the labelling 
reaction, with respect to effects of precursor quantity, reaction temperature, flow rate 
(residence time) and [18F]fluoride to precursor ratio. Excellent RCYs of up to 88% were 
achieved and found to be reproducible. The small amounts of material used allowed 
crude [18F]fallypride to be purified rapidly using an in-line HPLC system, before 
formulation for intravenous injection. Scaling up the reaction was achieved by 
continuously infusing solutions of precursors.260 
 
Scheme 72: Synthesis of [18F]fallypride 238 in a single-step using the NanoTek system.260 
The NanoTek has also been used to optimise the radiosynthesis of a small library of 
related compounds. Pascali and colleagues adapted the NanoTek system to perform 
the synthesis and purification of [18F]fluoromethyl, [18F]fluoroethyl and 
[18F]fluoropropyl choline 241a-c.279 The corresponding alkyl-ditosylate precursors 
239a-c were used to generate [18F]fluoroalkyltosylates 240a-c which would then react 
with neat DMEA to produce the desired products (Scheme 73). Purifications were 
performed using an in-line recyclable SPE cartridge set. Good RCYs (22-54%) were 
obtained in short processing times (15 min). Most significantly, the synthetic 
procedure allows for sequential production of 241a-c using the same batch of isotope, 
which is strongly in accordance with the dose-on-demand (DOD) approach. Such 
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methodology allows for an efficient and direct comparison of 241a-c for the diagnosis 
of prostate cancer.279 
 
Scheme 73: Small library of [18F]fluorocholine analogues produced using the NanoTek system. In this example, a two-step 
microfluidic process has been used to create the products. Taken from 279 
More recently, Ungersboech and colleagues have optimised the radiosynthesis of 
[18F]Altanserin using the NanoTek system.280 [18F]Altanserin 243 has been found to 
have high binding affinities for 5-HT2A receptor sites and is, therefore, a specific 
radiotracer for the visualisation and quantification of this receptor subtype in vivo. The 
four parameters to be evaluated were precursor concentration, reaction temperature, 
flow rate and reagent volume. By applying optimised conditions, which required 
reaction temperatures of up to 220 °C, radiochemical incorporation yields (RCIYs) were 
raised to 54% for scaled-up syntheses of the one-step [18F]fluorodenitration (Scheme 
74).280 
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Scheme 74: Radiosynthesis of [18F]Altanserin 243 from corresponding nitro precursor, optimised using the NanoTek system.280 
Interestingly, the authors found that applying higher reaction volumes resulted in 
increased radiochemical incorporation yield (RCIY) a so-called “bolus” effect. The 
authors propose that this is the result of heterogeneous distribution within the 
reaction volume caused by diffusion at the bolus interface (i.e. the reactor contents 
have not reached a steady state) – an effect which is less pronounced in larger 
volumes. 
(RCIY is a recent term which has become frequently used to describe the extent to 
which the radioactive isotope has become incorporated into the precursor molecule 
thus creating the desired compound. The term differs from RCY, as it is calculated from 
the integration of peaks formed from a radio-chromatographic trace (e.g. radio-HPLC). 
When taking this approach to deduce the outcome of a radiochemical reaction, RCIY is 
a more appropriate descriptor. However, ‘RCY’ remains the conventional term and has 
been used to describe the outcome of radiosyntheses throughout this project, and the 
remainder of this report.) 
2.2.7 System configuration 
The NanoTek system consists of a base module (BM), and reactor module (RM) and 
concentrator module (CM) (Image 3) all are operated and controlled by the NanoTek 
1.4 software. 
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Image 3: Component modules of the Advion NanoTek Microfluidic System - (a) base module, BM (b) reactor module, RM (c) 
concentrator module, CM 
The BM consists of two reagent cartridges (P1 and P2) used to dispense metered 
amounts of reactants to the microreactors for radiolabelling reactions. These 
cartridges comprise of a high-pressure syringe pump connected to an eight-way 
bridged valve supporting a looped-reservoir from which reagents are dispensed 
towards the microreactor, housed within the RM. The RM is the ‘core’ of the system 
and consists of the isotope reagent (P3) and microreactor cartridges (up to four) 
(Image 4). 
 
Image 4: Advion NanoTek reactor cartridge bearing four microreactors 
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In our setup, P3 receives a solution of reactive isotope ([18F]fluoride) in a phase-
transfer system (PTS) from the CM module where it is prepared from a volume of 
cyclotron-produced [18F]fluoride in [18O]H2O. The CM module consists of a low-
pressure, six-way valve reagent cartridge (CM1) and vessel chamber capable of rapid 
heating and evaporation of solvent. It is possible to subject the CM vessel to a 
combination of reduced pressure and positive flow of N2 gas, thus allowing the 
[18F]fluoride to be dried via several azeotropic distillations with MeCN, in accordance 
with the traditional anion-exchange resin trapping of [18F]fluoride (Section 1.1.6). The 
apparatus was initially setup as shown (Figure 39).  
 
Figure 39: Initial NanoTek configuration 
Throughout this project, the crude reaction mixture was swept into an electronic 
injection valve for direct injection onto the radio-HPLC system. The enclosed fluid 
paths of this tandem synthetic and analytical system ensured that the results obtained 
were representative of the crude reaction mixture as potential volatile products could 
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not be lost.185 Operation of this valve and the initialisation of the HPLC analysis was 
controlled by the NanoTek software. 
The accompanying software may be operated in several modes; in ‘Discovery Mode’ 
user-directed macros automate all procedures involved in the synthetic process, 
thereby allowing simple and rapid throughput of multiple reactions. These procedures 
can also be divided into their constituent parts and controlled separately within 
‘Manual Mode’ which, therefore, allows for finer control of the system. In ‘Sequence 
Mode’ detailed macros can be written, manipulated and combined to enable extensive 
and complex processes to be performed with minimal user intervention. Throughout 
this project, user-control would fluctuate between the three modes, for optimal 
system management.  
2.2.8 Automating the preparation of the reactive [18F]fluoride in phase-transfer 
system 
Before microfluidic reactions can be performed using the NanoTek system, the 
reactive [18F]fluoride must be prepared from the solution of cyclotron-produced 
[18F]fluoride in [18O]H2O. The specific approach towards achieving this using the 
NanoTek (Figure 40) is reflects the traditional approach described in a previous section 
(Section 1.1.6). Cyclotron-produced [18F]fluoride (NCA) (5–100 mCi) in [18O]H2O (1–5 
mL)281 was adsorbed onto a pre-conditioned anion exchange resin (quaternary 
ammonium  resin: Waters Sep-Pak® Light Accell Plus). The phase-transfer agent (PTA) 
which is dissolved in MeCN and H2O (9:1) to create the phase-transfer system (PTS) is 
used to release the [18F]fluoride and create a solution of radiofluorinating agent (RFA). 
This solution is then dried by two successive azeotropic evaporations using MeCN (450 
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L) at 100 °C and under a positive flow of N2. The RFA complex was then dissolved in 
DMF (450 L) and loaded into the storage loop (P3) on the microfluidic system. 
 
Figure 40: Process of preparing reactive [18F]fluoride dissolved in PTS for microfluidic reactions using the NanoTek system. 
The NanoTek system has been designed to automate this process by allowing users to 
program a set of commands bearing instructions to be carried out by the system 
modules. A sequence of operations, or “macro,” can automate complex procedures 
and reduce the intervention made by users thereby elevating the reproducibility of 
routine processes. It was decided, therefore that the intial aim would be to develop a 
macro designed to automate the preparation of reactive [18F]fluoride-PTS, using the 
sequence mode of the NanoTek software. Following extensive and methodical testing, 
a robust, reproducible, custom macro was written, instructing the CM to prepare a 
solution of RFA dissolved in organic solvent (Image 5, for translation see Table 12).  
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Image 5: Image taken from the NanoTek software showing the programming which forms the macro used to prepare the reactive 
[18F]fluoride-PTS dissolved in organic solvent, from a solution of cyclotron-produced [18F]fluoride in [18O]H2O. 
This macro was used throughout the project to prepare reactive [18F]fluoride. Several 
other macros were written to aid the microfluidic work and maintenance of the 
system: 
1) Cleaning Macro 
A list of instructions used to thoroughly sweep the contents of the system components 
to waste, using fresh solvent. This was executed at the start and end of each working 
day. 
2) Preparation of the CM macro 
Before the “drying macro” could be performed, the capillaries of the CM are swept 
thoroughly using clean solvent and the lines primed with the appropriate reagent. This 
was performed before every preparation of the reactive [18F]fluoride-PTS, using the 
CM. 
3) HPLC start macro 
A robust method for automating the injection of the crude products into the HPLC 
system whilst initiating the start of the HPLC measurement was created. This was 
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designed to ensure that the retention times of the peaks were consistent and did not 
vary by manual injections. This was performed following every microfluidic reaction. 
Instruction Translation 
Wait 
 
Wait command used to prompt the user into 
cross-checking the system plumbing and that 
all reagents have been loaded onto the 
system. 
┐L39020000800056└┐L38020003000050E└ Set concentrator temperature to 80 °C. 
/6o1V1200A6000M3000o5V1200A0M2000R Load target H2O into concentrator, trapping 
the [18F]fluoride onto the QMA cartridge. 
/6o6V1200A6000M2000o3V1200A0R Remove [18O]H2O from the concentrator vial 
and collect in separate vial. 
┐L3902000100004F└┐L38020003000050E└ Set concentrator to 100 °C 
/7U2M5000U1M5000u2R Turn on the N2 flow to the concentrator. 
/6o2V1000P7200M200go5V400D1350M15000G4o2V2000A0R 
 
Load PTS (450 L) into the concentrator, 
releasing the [18F]fluoride from the QMA 
cartridge, and collecting the [18F]fluoride-PTS 
in the CM vial. 
/6M90000R Wait to allow the [18F]fluoride-PTS to dry by 
evaporating the MeCN present to 
azeotropically remove H2O. 
/6o4v1000P6000M2000o5V75D4200M2000o6V75D1200M2000o2V2000A0R 
 
Add 450 L of MeCN, passing through the 
QMA cartridge to collect any residual 
[18F]fluoride dissolved in PTS. 
/6M30000R 
 
Wait to allow the MeCN to evaporate and 
azeotropically remove H2O from the CM vial. 
/6o4V1000P6000M2000o6V75D5400M2000o2V2000A0R Add 450 L of MeCN, avoiding the QMA 
cartridge. 
/6M30000R Wait to allow the MeCN to evaporate and 
azeotropically remove H2O from the CM vial. 
/7u1R Turn off the flow of N2 to the concentrator 
vial. 
/3o1v2000A0M2000o8V2000A15600M2000o6V800A0R Add 325 L of DMF to the concentrator vial 
thereby re-dissolving the [18F]fluoride-PTS 
complex.  
/3go4V1600A19200M2000V3200A0M2000G6o8V3200A3600M2000o4V3200A0R 
 
Mix the DMF with the [18F]fluoride-PTS 
complex thoroughly by repeatedly refilling 
and emptying the storage loop of P3 with 
the solution of [18F]fluoride-PTS complex, 
using the syringe pump of P3. Add 75 L of 
DMF. 
┐L37020000250053└┐L3602000300004E└ Set the temperature of the concentrator to 
25 °C. 
Wait 
 
Wait command used to prompt the user into 
acknowledging that the drying macro has 
finished and that the storage loop of P3 can 
be prepared for executing reactions in 
‘Discovery Mode’. 
Table 12: Translation of drying macro instructions 
2.2.9 Development of an independent control reaction 
Before fluorine-18 studies using diaryliodonium salts could begin on the microfluidic 
system, independent control reactions, designed to ensure that the preparation and 
reactivity of [18F]fluoride was suitable for microfluidic reactions, were devised. If the 
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control reactions were to work as expected, then anomalus results produced from an 
experiment could dismiss the initial preparation and subsequent reactivity of the 
[18F]fluoride as a possible cause. Two reactions were investigated - (a) an 19F/18F 
isotopic exchange reaction, and (b) radiofluorodenitration reaction - with the intention 
of choosing one to be a model reaction. The 19F/18F isotopic exchange reaction282 may 
provide rapid access to preliminary PET imaging studies as the fluorine-19 derivative is 
often available directly from drug discovery programmes.6, 7 Conventional nucleophilic 
aromatic substitution is also a very common approach to the formation of electron-
deficient [18F]fluoroarenes. It is employed extensively where an electron-withdrawing 
group exists in the 4-position relative to the site for the introduction of fluorine-18, for 
example in the production of [18F]altanserin,283 [18F]MPPF,284 and [18F]setoperone.285  
For these reasons, nitroacetophenone 246 and fluoroacetophenone 245 were chosen 
as the precursor compounds for the potential model reactions.  
 
Scheme 75: Potential model reactions to be optimised using the NanoTek microfluidic system 
2.2.9.1 HPLC Method Development 
Before microfluidic reactions could begin, HPLC method development was required to 
separate the 246 from the 245 product and, therefore, allow for the RCY of the 
reaction to be calculated. RCYs were deduced by integration of the peak corresponding 
to the desired compound with the total radioactivity detected. The isotopic exchange 
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reaction would produce two isotopomers of identical retention times and, therefore, 
not require further method development. 
The ideal gradient was designed to fulfil two criteria: a) that the two compounds were 
fully resolved and b) that both peaks should be fully eluted with the shortest possible 
retention times. Following extensive work with the HPLC system, an optimal gradient 
for the separation of standard solutions of 246 and 244 was devised. Retention times 
were to be kept as low as possible to ensure that the activity of potential products 
from radiofluorination reactions would be as high as possible. An isocratic gradient at 
24% MeCN in H2O was found to be optimal (Image 6). 
 
Image 6: HPLC UV-trace showing the separation of fluoroacetophenone (Rt = 6.5 min) and nitroacetophenone (Rt = 8.5 min) 
2.2.9.2 Results of radiosyntheses using the traditional phase-transfer system 
The NanoTek system would be used to rapidly optimise the reaction parameters with 
respect to reaction temperature, flow rate and ratio of [18F]fluoride-PTS to precursor 
solutions. Kryptofix®222 and K2CO3 was chosen as the PTA as this mixture is well-
established (Section 1.1.6). MeCN was used as the solvent as it is a polar aprotic 
organic solvent with a low viscosity. Discovery mode would be used to quickly vary 
reaction parameters between reactions (Image 7). 
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Image 7: Image taken from the NanoTek software whilst in 'Discovery Mode'. P1 and P3 have been prepared for the execution of 
reactions. The lines leading to these reagent cartridges have been primed, the storage loops have been filled, and the lines leading 
to the microreactors have been loaded. 
Dry [18F]fluoride-PTS (5–100 mCi, 450 L DMF) and precursor solutions were loaded 
into their respective storage loops (loop 3 and loop 1 respectively). Capillaries that lead 
from P1 and P3 to the microreactor were primed with their respective reagents. Prior 
to recording data, several priming reaction runs were performed to confirm the 
integrity of the synthetic platform and the in-line analytical HPLC system. Set volumes 
(10–30 L) of both solutions were dispensed into the pre-heated microreactor (130–
190 °C) at pre-determined flow rates (10–30 L/min). This is achieved by the syringes 
of P1 and P3, simultaneously dispensing precursor and [18F]fluoride-PTS solutions from 
their respective loops, into the microreactor using a fixed volume of system solvent at 
a preset flow rate. The solutions initially mix at the entrance to the microreactor. User-
operated computer software determines the reaction parameters — temperature, 
time and stoichiometry (P1:P3), which were to be optimised throughout this study. 
Following completion of the reaction, P3 sweeps the crude mixture to the electronic 
injector and radio-HPLC system, allowing the RCY of the process to be immediately 
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determined. At the start and end of each series of experiments the BM, RM, 
microreactor and associated transfer lines were cleaned using DMF and the CM system 
with MeCN. 
2.2.9.3 Rapid optimisation of the radiofluorination of 4-nitroacetophenone 
Initially, 246 was reacted with [18F]KF/K222 to yield the 245 (Figure 42). Optimal 
conditions were found to be 20 L/min (Figure 42a) 190 °C (Figure 42b) with a ratio of 
RFA to precursor of 1:0.5 (Figure 42c). It was found that increasing the temperature 
increased RCY, whilst increasing the ratio of precursor to PTS decreased RCYs. One 
delivery of [18F]fluoride was used to create each graph which explains the broad range 
of RCYs from across the study. The variation may be a result of difference between 
production runs of [18F]fluoride, with regard to SA, contamination, starting activity 
upon delivery and isotope dilution (see Section 1.2 for reasoning). The extent to which 
the [18O]H2O is removed from the concentrator vial during the preparation of the 
reactive [18F]fluoride may also vary, slightly, thereby affecting the reactivity of the 
[18F]fluoride. Despite this, the optimised conditions gave good RCYs (e.g. Figure 41). 
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Figure 41: Radio-HPLC trace showing peaks corresponding to unreacted [18F]KF/K222 and 4-[18F]fluoroacetophenone.21, 286 
Throughout this preliminary work, the micro-channels of the NanoTek microfluidic 
system, frequently became blocked, resulting in the system pressure increasing 
beyond the maximum upper limit and the loss of capacity to execute reactions. Several 
deliveries of [18F]fluoride were required to produce the results as instances where 
blockages occurred, immediately halted work resulting in a loss of [18F]fluoride and 
significant decline in output. Despite this, simultaneous work proceeded with the 
optimisation of the isotopic exchange reaction (Scheme 75).  
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Figure 42: Graphs to show results of microfluidic reactions of 246 with [18F]KF/K222 (n=3) 
 
2.2.9.4 Rapid optimisation of the radiofluorination of 4-fluoroacetophenone 
244 was reacted with [18F]KF/K222 to yield the 245 (Figure 43). Optimal conditions 
were found to be 15 L/min (Figure 43a) 190 °C (Figure 43b) with a ratio of PTA-
[18F]fluoride complex to precursor of 1:1.5 (Figure 43c). Despite obtaining some high 
RCYs, the results were poor. No trends could be identified across the various reaction 
parameters optimised and when varying the reaction temperate, RCYs were 
particularly poor. This is due to, once again, the frequent blockages of the 
microreactors. 
As the precursors and reaction products are all highly soluble in organic solvent, it was 
proposed that reducing the concentration of the Kryptofix® 222/K2CO3 would prevent 
the micro-channels from being blocked. We propose that the large variation in RCYs 
observed across this study may be the result of the varying degrees of precipitation of 
the RFA. Total precipitation of reagents results in the blockage of the microreactors 
whilst zero precipitation leads to much improved RCYs demonstrated by the results. 
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It was found following various scoping studies that reducing the concentration 
continued to result in the blockage of the microreactors, although less frequently. 
Despite the improvement in output and efficiency, the potential for blocked reactors 
remained an issue and an alternative PTS was investigated. 
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Figure 43: Graphs to show results of microfluidic reactions of 244 with [18F]KF/K222 (n=3) 
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Tetraalkylammonium salts with their enhanced solubility in organic solvents have been 
widely used as an alternative to the Kryptofix® 222/K2CO3 system with Bu4N·HCO3 247 
(Figure 44) being the most common. This is usually prepared, with very limited 
characterisation, by treating an aqueous solution of the Bu4N.OH with carbon 
dioxide.287 Following elution of the [18F]fluoride from the anion exchange resin (QMA) 
with the PTS, the next step is, conventionally, the generation of anhydrous [18F]fluoride 
via azeotropic removal of the H2O using multiple evaporations with MeCN. Given the 
propensity for tetraalkylammonium salts, and in particular the tetrabutylammonium 
salts, to form clathrates288, 289 the generation of anhydrous [18F]Bu4N·F represents a 
significant challenge. 
 
Figure 44: Bu4N·HCO3 - alternative PTA 
[18F]Fluoroalkanes,290 16-[18F]fluorohexadecanoic acid291 and [18F]FDG292 have all been 
prepared successfully using the related [18F]Et4N·F. This reagent had been prepared 
from Et4N·OH, either by direct treatment with [
18F]fluoride or, via [18F]Me3SiF to 
generate an anhydrous reagent. However, given the complexity of these production 
methods we proposed that access to [18F]Et4N·F may be more readily achieved by 
using tetraethylammonium bicarbonate 248 (Et4N·HCO3) (Figure 45) as the PTA. Unlike 
the tetrabutyl- derivative Et4N·HCO3 is readily available as a crystalline solid facilitating 
drying and characterisation yet retaining the required solubility in anhydrous organic 
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solvents. In addition, hydration of the tetraethylammonium cation is much reduced293 
due to the shorter alkyl chains making anhydrous [18F]Et4N·F a more realistic 
proposition. Given these favourable characteristics of Et4N·HCO3 over Bu4N·HCO3 we 
decided to test this material as a PTA in the model, microfluidic reactions. 
 
Figure 45: Et4N·HCO3 - a potential, alternative PTA 
2.2.9.5 Rapid optimisation radiosyntheses using Et4N.HCO3 as the phase-transfer 
agent 
The Kryptofix®222/K2CO3 PTA was replaced by Et4N·HCO3, of equal concentration, 
whilst the step-wise process by which the RFA is prepared, remained unchanged, thus 
forming Et4N·[
18F]F. 
2.2.9.6 Rapid optimisation of the radiofluorination of 246 using an alternative PTA 
As before 246 was reacted with [18F]Et4N·F to yield the 245 (Figure 46). Optimal 
conditions were found to be 15 L/min (Figure 46a) 190 °C (Figure 46b) with a ratio of 
RFA to precursor of 1:1.5 (Figure 46c). Again, one delivery of [18F]fluoride was used to 
create each graph. Generally, faster flow rates produced lower RCYs whilst higher 
temperatures increased RCYs. No distinct trend could be observed upon varying the 
ratio of the reagents. Most significantly, no instances of the micro-channels becoming 
blocked occurred when using Et4N·HCO3 as the PTA. This drastically improved 
efficiency by increasing output, preventing the stoppages to work and, therefore, the 
forfeiture of [18F]fluoride. 
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2.2.9.7 Rapid optimisation of the radiofluorination of 244 using an alternative PTA 
Similar results were found upon repeating the optimisation of the isotopic exchange 
reaction of 246 (Figure 47). Again, higher RCYs were achieved with slower flow rates 
and higher temperatures. Interestingly, a clear trend could be observed upon varying 
the reagent ratio, with highest RCYs achieved with a higher ratio of precursor to PTS. 
Optimal conditions were found to be 10 L/min (Figure 47a) 190 °C (Figure 47b) with a 
ratio of RFA to precursor of 1:2 (Figure 47c). These promising results support the 
hypothesis that the conventional PTS causes the frequent blockages to the micro-
channels of the microfluidic system. Importantly, when using [18F]Et4N·F as the RFA, 
the RCYs were comparable to those achieved when using the conventional RFA. 
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Figure 46: Graphs to show results of microfluidic reactions of 246 with [18F]Et4N·F (n=3). 
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Figure 47: Graphs to show results of microfluidic reactions of 244 [18F]Et4N·F (n=3). 
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These results are highly promising but a more thorough investigation, involving the 
radiofluorination of diaryliodonium salts, is warranted before Et4N·HCO3 can be 
presented as a viable alternative to the conventional PTA for the preparation of 
reactive [18F]fluoride, within a microreactor. 
2.2.10 Conclusion 
Microfluidic technology has recently emerged as an invaluable tool in the development 
of PET radiochemistry allowing the quantities of reagents to be considerably reduced 
thus facilitating timely isolation of radiolabelled product. The Advion NanoTek 
Microfluidic System has dominated this recent emergence as it benefits from many 
distinct features which make it desirable to the radiochemist. This equipment has been 
used to optimise model reactions designed to evaluate the status of the system and 
validate investigations. It was noted that the use of conventional PTA 
(Kryptofix®222/K2CO3) causes blockages to the micro-channels wherein the 
radiochemical reactions take place. Et4N·HCO3 appears to be a potential alternative 
which does not cause blockages but does generate compounds in RCYs comparable to 
those obtained when successfully using the conventional PTS. Further investigations 
involving the radiofluorinations of diaryliodonium salts are required before this 
compound can be presented as a viable alternative to the conventional PTA for the 
preparation of reactive [18F]fluoride, within a microreactor. 
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2.3 Evaluation of tetraethylammonium bicarbonate as a phase-transfer 
agent in the formation of [18F]fluoroarenes using a microreactor 
Microfluidic technology is becoming a valuable tool for the synthetic chemist. 
Following the development of multiple custom microfluidic devices in the 1990s, 
numerous commercial microreactor systems have now become available. The 
emergence of this technology has coincided with increasing focus throughout the 
chemical industry, on sustainability and the principles of ‘green’ chemistry.294 Flow 
chemical systems have, therefore, become desirable as they generate less waste, 
lessen the requirement for chromatography and reduce solvent usage, whilst 
improving yields and reducing reaction times. Many people believe that flow chemistry 
and in particular, microfluidic technology, is destined to become highly utilised 
throughout the chemistry industry. However, as this practice continues to develop, the 
problem of blocked micro-channels has become inherent (e.g. Kryptofix®222/K2CO3, 
Section 2.2). Many solutions have been created to overcome individual instances of 
blockages. For example, Ley and co-workers have used ultra-sonication to prevent 
reagents from precipitating in solution and, therefore, blocking the micro-channels.295 
The acoustic irradiation produces concentrated areas of elevated temperature, causing 
cavitation which generates pressure pulses that keep small solids flowing through the 
micro-channels and prevent blockages caused by less soluble material.  
Such technology is not freely available and may not be able to, universally, prevent 
blockages to micro-channels. Individuals require unique solutions to address specific 
problems. Herein, we present a simple solution to one such instance of blocked 
microreactors. 
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2.3.1 Aims 
Previous work within this project has suggested that the traditional PTA used in 
radiofluorination reactions (Kryptofix®222/K2CO3) has caused the blockage of micro-
channels within the NanoTek system, thus preventing the microfluidic 
radiofluorination of arenes within the microreactor. Et4N∙HCO3 may be a viable 
alternative and warrants thorough evaluation. It was decided that the three most 
common approaches to generating [18F]fluoroarenes - (a) radiofluorodenitration (SNAr 
chemistry), (b) 19F/18F isotopic exchange (c) diaryliodonium salt chemistry, should be 
investigated to evaluate this reagent. It was also decided that the corresponding 
precursors chosen for this investigation should each produce ethyl 4-
[18F]fluorobenzoate, an initial target of the research project (Section 2.1.1), in one 
convenient step (Scheme 76). 
 
Scheme 76: Reactions to be evaluated using Et4N.HCO3 as a PTA. 
DMF was chosen as the solvent for each reaction as it is a polar, aprotic organic solvent 
of low viscosity, successfully used in the radiofluorination of diaryliodonium salts80, 200-
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202 and other substrates. The consistent use of solvent was an important factor, as 
varying solvents between reactions may influence the reactivity of the [18F]fluoride.  
2.3.2 Evaluating the elution capacity the PTA solution 
Before radiofluorination reactions could begin, the elution capacity of each PTS was 
compared. 
 
Method  Phase-transfer agent 
(PTA) 
Phase-transfer system 
(PTS) 
Radiofluorinating 
Agent (RFA) 
Method A Kryptofix® 222/K2CO3 
(K222/K2CO3) 
K2CO3 (1.18 mg; 8 
mol) and 
Kryptofix® 222 
(6.75 mg; 18 mol) 
in MeCN/H2O 
(9:1 v/v 450 L) 
PTS-1 [18F]KF/K222 
Method B Et4N∙HCO3 Et4N·HCO3 (3.4 mg; 
17 mol) in 
MeCN/H2O (9:1 v/v 
450 L) 
PTS-2 [18F]Et4N∙F 
Table 13: Definition of terms used throughout the evaluation of PTAs. 
 Following the loading of the [18F]fluoride in [18O]H2O onto a QMA cartridge, the total 
radioactivity absorbed by the cartridge was deduced. This was achieved by 
determining the amount of activity which passed through the cartridge unabsorbed, 
the residual activity remaining inside the target water vial and the initial activity of the 
target water (Equation 1.1).  The [18F]fluoride was then eluted from the QMA cartridge, 
using either PTS-1 or PTS-2. The amount of activity remaining on the QMA was then 
deducted from the total activity absorbed, and the value expressed as a percentage 
(Equation 1.2). 
Equation 1.1 
Initial Activity 
(target water 
vial) 
— Activity not 
trapped by QMA 
cartridge 
+ Activity remaining 
in target water vial 
= Activity trapped on 
QMA cartridge 
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Equation 1.2 
 Activity trapped on 
QMA cartridge 
— Activity remaining on QMA 
cartridge post PTS elution 
x 100 = PTS Elution 
Efficiency (%) 
Activity Trapped on QMA cartridge   
The amount of activity (5–100 mCi) and volume of [18O]H2O (1–5 mL) differed between 
batches, however, these broad variations had no observed affect in elution efficiency 
with PTS-2 able to elute >99% (n=10) of the radioactivity from the QMA cartridge 
which is consistent with the performance of the Kryptofix®222/K2CO3 system (99%). 
2.3.3 Radiofluorination reactions 
The NanoTek was set up as described previously (Section 2.2.7). Before 
radiofluorination reactions could take place, the HPLC conditions required to resolve 
the radioactive peaks were established. 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The data 
acquisition software used was Laura (LabLogic). 
2.3.3.1 Radioanalytical HPLC Methods 
248 from 247 
The radioactive product was separated on a PolymerX 5m RP-1 100 column eluting at 
1.1 mL/min with EtOH–water. Mobile phase composition started at 40% EtOH which 
increased linearly to 60% at EtOH over 2 min and then to 80% at 5 min which 
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continued at this composition for a further 7 min. Ethyl 4-[19F]fluorobenzoate tR = 6.2 
min. 
248 from 188d 
The radioactive product was detected on a PolymerX 5m RP-1 100 column eluting at 
1.1 mL/min with EtOH–water. Mobile phase composition started at 60% EtOH which 
increased linearly to 80% at EtOH over 6 min. Ethyl 4-[19F]fluorobenzoate tR = 4.5 min. 
248 from 193 
The radioactive product was separated on a PolymerX 5m RP-1 100 column 
(Phenomenex, USA) eluting at 1.1 mL/min with EtOH–water. Mobile phase 
composition started at 25% EtOH which increased linearly to 100% at EtOH over 7 min 
which continued at this composition for a further 2 min. Ethyl 4-[19F]fluorobenzoate 
tR = 7 min. 
Each reaction was optimised with respect to flow rate (residence time), reaction 
temperature, and ratio of precursor to RFA. 
2.3.4 Ethyl 4-[18F]fluorobenzoate from ethyl 4-nitrobenzoate 
 
Scheme 77: Formation of 248 by radiofluorodenitration 
247 was [18F]fluorinated via either method A or method B to produce 248 (Scheme 77). 
Optimal conditions were found to be 15 L/min (Figure 48a) 190 °C (Figure 48b) with a 
ratio of RFA to precursor of 1:1.5 (Figure 48c) when using method A. When using 
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method B, optimal conditions were found to be 10 L/min (Figure 48a) 190 °C (Figure 
48b) with a ratio of RFA to precursor of 1:1 (Figure 48c). It was noticed that longer 
residence times gave improved RCYs but the effect was more pronounced when using 
method A (Figure 48a). Conducting the reaction at higher temperatures resulted in 
excellent incorporation of the fluorine-18 for both methods (Figure 48b). The 
difference in the absolute RCYs were attributed to inter-batch variation of the starting 
[18F]fluoride due to the similarities observed during the evaluation of the other 
reaction parameters.296 Overall, RCYs achieved when using method B were higher than 
those obtained using method A. Most importantly, no blockage to the micro-channels 
of the microreactors occurred when using method B. Blockages continued to occur 
when using method A resulting in the use of several production runs of [18F]fluoride in 
order to obtain the results described here. 
These promising results demonstrated that Et4N·HCO3 system (method B) was a 
practical alternative to the Kryptofix®222/K2CO3 system (method A) for the 
fluorodenitration reaction. 
 
 
 Results and Discussion 
 
169 
 
 
 
Figure 48: Graphs to show results of microfluidic radiofluorination of 247 
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2.3.5 Ethyl 4-[18F]fluorobenzoate from ethyl 4-[19F]fluorobenzoate 
 
Scheme 78: Formation of 248 by isotopic exchange 
188d was [18F]fluorinated via either method A or method B to produce 248 (Scheme 
78). Optimal conditions were found to be 10 L/min (Figure 49a) 190 °C (Figure 49b) 
with a ratio of RFA to precursor of 1:2 (Figure 49c) when using method A. When using 
method B, optimal conditions were found to be 20 L/min (Figure 49a) 190 °C (Figure 
49b) with a ratio of RFA to precursor of 1:1 (Figure 49c). 
Again, the effect of flow-rate (Figure 49a) was found to be similar to that observed 
when using the ethyl 4-nitrobenzoate (Figure 48a) with the longer residence times 
producing higher RCYs. The effect was far less pronounced when using method B, with 
RCYs being approximately consistent across all flow rates investigated. Increasing the 
microreactor temperature had a positive effect when using either method with the 
best RCYs being obtained at 190 °C (Figure 49b). For method A, the effect of the RFA to 
precursor ratio was similar for both reaction types (Figure 48c and Figure 49c) with the 
preference for the 1:1 stoichiometry when using method B, strongly pronounced in 
both sets of results (Figure 48c and Figure 49c). Overall, the RCYs were comparable 
between both methods, however, no blockages to the micro-channels occurred when 
applying method B, whereas, blockages continued upon using method A. 
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Figure 49: Graphs to show results of microfluidic radiofluorination of 188d 
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2.3.6 Ethyl 4-[18F]fluorobenzoate from trifluoroacetyl(4-ethoxycarbonyl, 2-thienyl)-
3-iodane 
 
Scheme 79: Formation of 248 using diaryliodonium salt chemistry 
193 was [18F]fluorinated via either method A or method B to produce 248 (Scheme 79). 
The 2-thienyl derivative was chosen as previous studies have shown the an electron-
rich NTR induces selectivity for the incorporation of [18F]fluoride onto the electron-
deficient ring. Optimal conditions were found to be 30 L/min (Figure 50a) 190 °C 
(Figure 50b) with a ratio of RFA to precursor of 1:2 (Figure 50c) when using method A. 
When using method B, optimal conditions were found to be 10 L/min (Figure 50a) 
190 °C (Figure 50b) with a ratio of RFA to precursor of 1:1 (Figure 50c). 
Interestingly, for the diaryliodonium salt reaction, the effect of flow-rate (Figure 50a) 
was found to be opposite to that observed for the radiofluorodenitration and isotopic 
exchange reactions (Figure 49a and Figure 49a) with the longer residence times 
improving the RCYs obtained when using method B. However, increasing the 
microreactor temperature had a similar effect with the best RCYs being obtained at 
190 °C (Figure 50b). For method A, increasing the RFA to precursor ratio produced a 
large small improvement in RCYs whilst there was a clear optimal ratio of 1:1 when 
using method B (Figure 50c). Once again, RCYs were comparable between methods of 
radiofluorination with excellent RCYs being achieved when using method B. 
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Importantly, no blockages to the micro-channels occurred when applying this method, 
whilst the blockages continued throughout the use of method A.  
For the reasons described previously (Section 2.2) the RCYs obtained were found to 
vary between different batches of [18F]fluoride.296  
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Figure 50: Graphs to show results of microfluidic radiofluorination of 193 
It is of note to observe that throughout this study, the reaction temperatures (up to 
190 °C) exceeded the boiling point of the solvent (153 °C). This is possible due to the 
closed-system environment of the NanoTek microreactor which is able to tolerate high 
temperatures and pressures, and therefore, provide access to conditions not possible 
in batch methodology. This has resulted in the significant improvement of RCYs for 
these types of transformations. 
2.3.7 Conclusion 
We have demonstrated that Et4N·HCO3 is a viable alternative to the traditional PTA, 
Kryptofix®222/K2CO3, for the production of [
18F]fluoroarenes using a key range of 
synthetic methods. Of particular benefit, in a microreactor, was the performance of 
Et4N·HCO3 where the occurrence of blocked reactors experienced with the 
conventional phase-transfer system was eliminated thus dramatically increasing 
productivity. In addition, the Advion NanoTek Microfluidic System provided an 
efficient, versatile and convenient methodology for the rapid optimisation of 
radiofluorination reactions. Reaction temperatures were able to exceed the boiling 
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point of the solvent, thereby providing access to conditions not possible in batch 
methodology and, therefore, excellent RCYs.186, 203, 239, 297-300 
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2.4 Microfluidic radiofluorinations of diaryliodonium salts 
Following the conclusion that of Et4N.HCO3 is a viable alternative to the traditional PTS 
for the production of [18F]fluoroarenes using a microreactor, it was decided that this 
system should be used to investigate the microfluidic radiosynthesis of ethyl 4- and 3-
[18F]fluorobenzoate from various diaryliodonium salts. 
2.4.1 Aims 
This study had three aims: 
 Synthesise the 3- and 4-regioisomers of ethyl [18F]fluorobenzoate, which may 
serve as prosthetic groups for the indirect radiolabelling of macromolecules, 
and other species of biological interest. 
 Demonstrate regioselective control in the radiofluorination of diaryliodonium 
salts, induced by the NTR. 
 Investigate the effect of the presence of H2O upon the radiofluorination of 
diaryliodonium salts. 
In order to achieve these aims, the phenyl, 4-anisyl and 2-thienyl derivatives of the 4- 
and 3-ethoxycarbonylphenyl-3-iodanes were chosen. The use of both electron-rich 
and electron-neutral NTRs would show the significance of electronic effects in the 
selectivity of the reaction. DMF was, once again, chosen to be the solvent for the 
reasons described previously (Section 1.4.2.7). Previous work from within the group 
has found that performing radiofluorinations of diaryliodonium salts in a solution 5% 
H2O in DMF had a beneficial effect upon the RCYs.
301 It was decided that these 
conditions should be replicated and also compared to reactions performed in the 
absence of H2O. 
Throughout the investigation, the optimal reaction conditions achieved from the 
radiofluorination of 193 (Section 2.3.6) were applied (i.e. flow rate of 10 L/min, 
temperature of 190 °C, RFA to precursor ratio of 1:1). 
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2.4.2 Radiofluorination reactions of diaryliodonium salts 
Before the microfluidic reactions could begin, radio-HPLC conditions were to be 
optimised for the separation of all potential products of the radiofluorination 
reactions, including acid products which may form upon hydrolysis of the ester. 
2.4.2.1 Radioanalytical HPLC Methods 
For this study, a C18 column was used for radio-HPLC purification as it was found that 
a superior degree of resolution can be achieved when separating the various possible 
products. It was found that the same gradient conditions could be applied to the 
separation of products generated from radiofluorinating both 191-193 (Table 14) and 
193-196 (Table 15). The radioactive product was detected on a ThermoFisher 5m RP-
C18 100 column eluting at 1.1 mL/min with MeCN–water. Mobile phase composition 
started at 18% MeCN for 4 min, increasing to 40% at 4 min 30 s, remaining at this 
composition for 11 min 30 s, before decresing back to 18 % over 30 s, where the 
composition remained constant for a further 1 min 30 s.  
Compound Relevant starting 
material 
Retention Time 
(mm:ss) 
Starting material  02:00 
4-Fluorobenzoic acid  06:43 
4-Iodobenzoic acid 191-193 09:11 
Ethyl 4-fluorobenzoate  14:20 
Ethyl 4-Iodobenzoate  08:33 
Iodobenzene 191  09:09 
Fluorobenzene 191  10:29 
4-Iodoanisole 192  09:45 
4-Fluoroanisole 192 193 10:32 
2-Fluorothiophene 193 09:49 
2-Iodothiophene 193 16:27 
Table 14: Retention times (Rt) of possible products from all reactions of trifluoroacetyl(4-ethoxycarbonyl, aryl)-
3-iodanes 
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Compound Relevant starting 
material 
Retention Time 
(mm:ss) 
Starting material  02:00 
3-Fluorobenzoic acid  06:49 
Ethyl 3-Iodobenzoate 194-196 07:29 
3-Iodobenzoic acid  08:56 
Ethyl 3-fluorobenzoate  15:02 
Iodobenzene 194 09:09 
Fluorobenzene 194 10:29 
4-Iodoanisole 195 09:45 
4-Fluoroanisole 195 10:32 
2-Iodothiophene 196 16:27 
2-Fluorothiophene 196 09:49 
Table 15: Retention times (Rt) of possible products from all reactions of trifluoroacetyl(3-ethoxycarbonyl, aryl)-
3-iodanes 
2.4.2.2 Radiofluorination of trifluoroacetyl(4-ethoxycarbonyl, aryl)-λ3-iodanes, 191-
193 
 
Scheme 80: Radiofluorination of 191-193 to produce the desired 188a and undesired products 252-254 
Trifluoroacetyl(4-ethoxycarbonyl, aryl)-3-iodanes were reacted with [18F]Et4N∙F to 
yield 188d (Scheme 80). Radio-HPLC was used to calculate the RCYs of both the desired 
and undesired products (Figure 51). 
Overall, RCYs were very good. The highest RCYs were achieved using the 4-anisyl 
derivative and in the absence of water. Lowest RCYs of the desired product was 
obtained when using the 2-thienyl derivative and in the presence of water. Generally, 
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higher RCYs were achieved when reactions were performed without the addition of 
water. Interestingly, this is the opposite of the affect observed for the production of 4-
FBA.301  
The results clearly demonstrate selectivity in the radiofluorination of diaryliodonium 
salts with the ratio of desired [18F]fluoroarene to undesired [18F]fluoroarene, higher 
when using an electron-rich NTR. This selectivity was highest when radiofluorinating 
trifluoroacetyl(4-ethoxycarbonylphenyl, 2-thienyl)-3-iodane, which bears a very 
electron-rich NTR. However, radiofluorination of this species produced the lowest 
RCYs. This may be due to the reduced thermal stability of the compound - a result of 
the strong positive inductive effect of the 2-thienyl ring.  Trifluoroacetyl(4-
ethoxycarbonylphenyl, 4-anisyl)-3-iodane bears the 4-anisyl NTR which is of sufficient 
electron-density to promote the radiofluorination of the ester bearing ring, but 
insufficient to de-stabilise the starting material. This is reflected in the results which 
show that the 4-anisyl NTR generates the highest RCYs of ethyl 4[18F]-fluorobenzoate. 
Interestingly, the radiofluorination of trifluoroacetyl(4-ethoxycarbonylphenyl, phenyl)-
3-iodane produced RCYs comparable to those resulting from the radiofluorination of 
the 4-anisyl derivative. However, the ratio of desired [18F]fluoroarene to 
[18F]fluoroarene produce was lowest when using the phenyl derivative, which is to be 
expected from the selectivity of the reaction, as the phenyl group is effectively 
electron-neutral. 
Upon comparing the ratio of desired product to undesired product when reactions 
were conducted in the presence or absence of water, no distinct trend could be 
observed suggesting water has no effect upon the selectivity of this reaction. 
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Figure 51: Radiofluorination of 191-193 (n=3) 
Target of radiofluorination 
(Trifluoroacetyl(4-ethoxycarbonylphenyl, Ar)-3-
iodane 
Ratio  of RCYs 
(radioactive products) 
 Solvent Desired  
Product 
to Undesired 
Product 
191 
 
DMF 1 : 0.063 
5 % H2O in DMF 1 : 0.076 
192 DMF 1 : 0.005 
5 % H2O in DMF 1 : 0.004 
193 DMF 1 : 0 
5 % H2O in DMF 1 : 0 
Table 16: Ratio of desired [18F]fluoroarenes 188a to undesired [18F]fluoroarenes 252-254 
2.4.2.3 Radiofluorination of trifluoroacetyl(3-ethoxycarbonyl, aryl)-λ3-iodanes, 194-
196 
Trifluoroacetyl(3-ethoxycarbonyl, aryl)-3-iodanes were also reacted with [18F]Et4N.F to 
yield ethyl 3-[18F]fluorobenzoate (Scheme 80). Radio-HPLC was used to determine the 
RCYs of both the desired and undesired radioactive products (Figure 52). 
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Scheme 81: Radiofluorination of 194-196 to produce the desired 188b and undesired products 252–254 
Overall, RCYs were good with the highest RCYs of the desired product, once again, 
achieved when radiofluorinating trifluoroacetyl(3-ethoxycarbonyl, 4-anisyl)-3-iodane 
in DMF. Lowest RCYs were obtained upon radiofluorinating trifluoroacetyl(3-
ethoxycarbonyl, 2-thienyl)-3-iodanes in the presence of water. RCYs for ethyl 3-
[18F]fluorobenzoate were lower than those resulting from the radiosynthesis of ethyl 4-
[18F]fluorobenzoate. This may be a result of the electron density at the ipso carbon of 
the ester bearing ring. As discussed earlier (Section 1.4.2.2) the attack of the 
nucleophile at the iodine is dependent upon the electron-density at the carbon atoms 
of the C-I-C bonds. The ester group meta to the C-I bond of the target ring induces a 
positive mesomeric effect upon the ipso carbon and therefore increases the electron-
density at this site. This makes this carbon less electrophilic, and therefore, less 
susceptible to attack from the incoming [18F]fluoride. This is also reflected in the 
decrease in the ratio of desired product to undesired product, a trend which is 
observed when comparing the radiofluorinations of the 191-193 to the 
radiofluorinations of the 194-196. 
It was noted, however, that the ratio was, again, lowest when radiofluorinating the 
phenyl derivative, and highest when radiofluorinating that bearing the 2-thienyl NTR. 
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This is also in strongly accordance with the proposed selectivity of the reaction and 
corresponds to the results for the radiofluorination of the trifluoroacetyl(4-
ethoxycarbonyl, aryl)-3-iodanes. 
With the exception of one result, RCYs were lower when reactions were performed in 
the presence of water. However, the ratios of desired product to undesired product 
were higher when executed in pure DMF, suggesting that water has a negative effect 
on both the RCY and the selectivity of this reaction.  
 
Figure 52: Graph to show results of the radiofluorination of 194-196 (n=3) 
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Target of radiofluorination 
(Trifluoroacetyl(3-ethoxycarbonylphenyl, Ar)-3-iodane 
Ratio  of RCYs 
(radioactive products) 
 Solvent Desired 
Product 
to Undesired 
Product 
194 
 
DMF 1 : 0.294 
5 % H2O in DMF 1 : 0.392 
195 DMF 1 : 0.029 
5 % H2O in DMF 1 : 0.034 
196 DMF 1 : 0.012 
5 % H2O in DMF 1 : 0.019 
Table 17: Ratio of desired [18F]fluoroarenes 188b to undesired [18F]fluoroarenes 252-254. 
 
Previous work on the radiofluorination of diaryliodonium salts has focussed on the 
radiosynthesis of ethyl 3-[18F]fluorobenzoate. The RCYs presented here are generally 
higher and of greater reproducibility than those reported earlier.224 
 
Scheme 82: Previous syntheses of ethyl 3-[18F]fluorobenzoate using a batch reactor302 
Compound R n RCY (%) 
196 2-thienyl 6 21-80 
195 4-anisyl 6 4-35 
195a 2-anisyl 6 7-23 
Table 18: RCYs of previous syntheses of ethyl 3-[18F]fluorobenzoate using a batch reactor302 
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The previously reported results are, seemingly, of low reproducibility, whereas the 
reproducibility of the results reported here, using the microfluidic device was, 
generally, high. Higher yields were obtained here when using the 4-anisyl, whereas, 
lower RCYs were obtained when using the 2-thienyl derivative. As already stated, RCYs 
of radiofluorination reactions are difficult to compare and can be caused by various 
influences (Section 1.2) with the quality of the [18F]fluoride having profound affects.  
2.4.3 Conclusion 
We have demonstrated that Et4N.HCO3 is a viable alternative to the traditional PTA, 
K222/K2CO3, for the radiosynthesis of [
18F]fluoroarenes, using a microreactor and via a 
key range of radiosynthetic strategies. Of particular benefit, in a microreactor, was the 
performance of Et4N·HCO3 where the occurrence of blocked reactors experienced with 
the conventional PTS was eliminated thus dramatically increasing productivity. In 
addition, the Advion NanoTek Microfluidic System provided an efficient, versatile and 
convenient methodology for the rapid optimisation of radiofluorination reactions. 
Various diaryliodonium salts have been reacted with Et4N[
18F]F, to generate ethyl 4- 
and 3-[18F]fluorobenzoate with the synthesis of the 4-position regioisomer, generally, 
producing higher RCYs. Excellent RCYs and selectivity were achieved for both isomers 
when using precursors bearing a 4-anisyl ring. The selectivity of the nucleophilic attack 
of [18F]fluoride on a diaryliodonium salt has been clearly demonstrated using electron-
neutral and electron-rich derivatives. It was also found that the presence of water has 
a negative effect upon the selectivity of reactions producing the 3-regioisomer. 
With the evaluation of the PTS to generate [18F]fluoroarenes in a microreactor 
conclusive, it was decided that in order to substantiate our proposal – that this system 
is a viable alternative to the conventional PTS for the preparation of [18F]fluoride in a 
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radiochemistry laboratory – the new PTS must be evaluated on a commercially-
available automated batch reactor, using the expensive fluoride and starting materials, 
generated from complex organic chemistry.   
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2.5 Automated Batch Radiochemistry 
Integration of PET imaging into drug discovery programmes has generated high 
demands for the safe and reproducible preparation of PET radiopharmaceuticals. 
Fluorine-18 labelled radiotracers are of particular interest, due to the longer half-life of 
the isotope, increased availability from modern PET cyclotrons and high SA of the 
radiotracers. These advantages allow for large quantities of fluorine-18 labelled 
radiopharmaceuticals to be synthesised from a single production run for remote site 
application. Such syntheses require automated batch chemistry devices to protect 
chemists from harmful radiation, uphold high levels of reproducibility and reduce the 
time taken for synthesis, purification and formulation.  
The construction of automated devices for the synthesis of radiotracers has been an 
important focus of radiochemistry research since the introduction of PET into drug 
discovery programmes. Several systems are now commercially available and have been 
used in the large-scale radiosynthesis of potential imaging agents. These devices are 
often customisable and have the capacity to adapt for reproducible production of 
different radiotracers. This is an important feature as the development of fluorine-18 
labelled radiotracers can also involve various chemical transformations resulting in 
complex, multi-step labelling and purifying procedures. This becomes increasingly 
important when generating different radiotracers requiring diverse synthetic 
strategies. 
2.5.1 Aims 
Following the conclusion that Et4N∙HCO3 is a viable PTA for the generation of 
[18F]fluoroarenes in a microreactor, it was decided that the same PTS should be 
evaluated for syntheses of [18F]fluoroarenes on an automated batch chemistry 
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platform as this type of system is commonly found throughout radiochemistry 
laboratories. Diaryliodonium salts would be used to generate the initial targets of this 
project. 
2.5.2 Automated Batch Chemistry Platforms 
Automated batch chemistry platforms can be divided into two main categories. Firstly, 
“cassette-type” devices conduct the chemical synthesis within a disposable, 
readymade cassette mounted onto a stationary device. These cassettes, which contain 
reagents, vials and tubing, are connected to the mechanical syringes and valves of the 
computer-controlled unit. Cassettes can be removed and replaced after each batch 
thereby obviating a post-production cleaning procedure and promoting reproducibility 
of reactions corresponding to the cassette design. This also promotes the use of 
radiotracers made in this way for clinical studies. Examples of “cassette-type” devices 
are the TRACERlab Mx FDG synthesis module (GE Healthcare Technologies) and the 
PETtrace FDG II Microlab (GE Medical Systems). 
Alternative to these devices are stationary systems wherein all connections of the 
tubes (plumbing) and valves are permanent. Reagents are loaded onto such systems 
which automate the mechanical operations controlled by the accompanying computer 
software. The system is rinsed with solvent, without the removal of vials or tubing - a 
process often referred to as a “clean in place” (CIP) procedure. The CIP requires 
extensive validation to ensure of no cross-contamination between batches. In practice, 
both these types of systems are used once for each delivery of [18F]fluoride as levels of 
radiation remain at a harmful level after cleaning thus preventing the safe reloading of 
chemicals, and cartridges. Examples of such systems include the TRACERlab FxFDG 
module303 (GE Medical Systems) CPCU, Chemistry Process Control Unit (CTI), 
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EBCO/Jaltech FDG synthesis module (EBCO) and Synchrom (raytest, 
Isotopenmeesgerate GmbH). 
 
Image 8: TRACERlab FxFDG module (GE Medical Systems)303 
 
Automated synthetic chemistry platforms for the radiosynthesis of PET radiotracers 
have been reviewed elsewhere304, 305 and so will not be discussed in this report. Focus 
will lie with the specific automated batch reactor used for this project.  
2.5.3 The Modular-Lab  
The Modular Lab (Eckert & Ziegler) is a stationary, batch radiosynthetic device which 
uses modules to enable the automation of custom, radiopharmaceutical syntheses. A 
set of unit-operation modules, each designed to perform a different task, are 
connected by process tubing and communication cable. Automation of the modules is 
performed using the accompanying computer software. Due to its multi-functionality, 
the Modular-Lab can replace several single-purpose devices, such as HPLC system and 
batch-reactor, thereby significantly reducing cost, hot-cell space and total 
radiosynthesis times. The system can also be combined with disposable cassettes 
designed to prepare a variety of reactive radiolabelling agents.286 
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Image 9: Photo taken of the Eckert & Ziegler Modular-Lab housed within a “hot cell” of the Sir Bobby Robson Foundation PET 
Tracer Production Unit at Newcastle University 
The accompanying computer software is used to coordinate actions between modules 
to create an automated, multi-step synthesis. Reaction parameters such as 
temperature, activity, UV detector readings, flow rates or valve positions can also be 
monitored in real-time. 
2.5.3.1 Selected examples of radiochemical syntheses performed using the Modular-
Lab 
As the Eckert & Ziegler system is a recently developed device, there currently exists 
very few publications on the automated syntheses of radiotracers, within the 
literature. Herein this report, three examples have been presented. 
Pascail and co-workers have used the Modular-Lab to automate the large-scale 
production of [18F]fluoroethylcholine for PET imaging of prostate cancer.296 The system 
was used to automate the two-step/one-pot synthesis by, firstly, radiolabelling 
ethyleneglycolditosylate to produce [18F]fluoroethyltosylate. This was then coupled to 
DMEA before the final mixture was purified by means of SPE. The optimised procedure 
resulted in a RCY of 36% (NDC) (Scheme 83).296 
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Scheme 83: Reaction scheme for the automated, large scale production of [18F]fluoroethylcholine, performed using the Modular-
Lab.296 
The Modular-Lab has been specifically designed to allow for the use of a variety of 
isotopes in radiochemical syntheses with particular application in the preparation of 
gallium-68 radiolabelled materials.306 
Steinback and co-workers used the Modular-Lab to automate a reliable procedure for 
the 3-step radiosynthesis and preparative HPLC-purification of [18F]gefitinib 262 
(Scheme 84).307 [18F]Gefitinib has been used in a wide number of applications ranging 
from oncology to in vivo studies of drug transporter proteins. The modular system was 
used to, routinely, produce the radiotracer in 17.2 ± 3.3% RCY (DC) (n = 22) with an 
exceptional RCP of >99%. This synthesis demonstrates the multi-functionality of the 
system, with the ability to incorporate a HPLC module, and execute the routine 
production of radiopharmaceuticals.307 
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Scheme 84: Radiosynthesis of [18F]Gefitinib 262307 
The Modular-Lab has also been used for the radiosynthesis of tracers bearing inorganic 
radioisotopes and carbon-11. Passchier and colleagues have used the system to  
automate the GMP compatible radiosynthesis of the M1 receptor agonist GSK1034702 
with carbon-11 (Scheme 85).308 A palladium-catalysed Stille reaction of the 
trimethylstannyl precursor 263 with [11C]methyl iodide afforded [11C]GSK1034702 264 
in an estimated RCY of 10 ± 3 % (NDC). The process allows for the reliable production 
of pharmaceutical grade material in excellent chemical yields.308 
 
Scheme 85: Synthesis of [11C]GSK1034702308 
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2.5.3.2 System Configuration 
The Modular-Lab system was purchased, factory-configured for [18F]FEC production, 
however, after making minor adjustments to the plumbing, the system was ready to 
perform the preparation of the reactive RFA followed by a one-step radiofluorination 
reaction. The system consists of 1 x peltier reaction module (PRM) with transfer line 
fitted, 2 x single stopcock modules (SSM), 4 x solenoid valve modules (SVM), a vial 
holder module (VHM) to which was connected a pressure sensor and an activity 
detector in addition to the VHM’s internal detector (Image 10). The transfer of liquids 
was operated by applying positive or negative pressure through FEP tubings inserted 
directly into the septa-sealed vials. 
 
Image 10: Images of the modules used on the Modular Lab system. (left) Peltier reaction module (PRM) (left middle) Single 
stopcock modules (SSM) (right middle) Solenoid valve modules (SVM) (right) Vial holder module (VHM)286 
The computer software is used to create a programmed synthesis using a sequential 
flow-chart of control tasks (Figure 53) each created to automate a task and consisting 
of a series of commands or “macro blocks”. The execution of the synthesis, 
represented by the flowchart, is overseen by a graphical interface (Figure 54) wherein 
user prompts can be programmed in order to manage the program. The interface is 
constantly being updated throughout the execution of a reaction, to represent the 
status of the system. Total syntheses can then be automated and monitored, using the 
custom program. 
a) b
) 
c) d
) 
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Figure 53: Flow-chart of control tasks for the custom program written for the radiofluorination of a diaryliodonium salt. Image 
taken from the Modular-Lab software. 
Some macro-blocks perform simple and discrete actions (e.g. changing the position of 
a particular valve). Other macro-blocks are used to update the interface display 
representing the system status and the progress of a reaction. Combined sequentially, 
the macro-blocks automate a particular task (e.g. the preparation of the RFA) to form 
control tasks. Combining the control flasks, automates the radiosynthesis 
radiochemical synthesis (e.g. radiofluorodenitration of an arene). Each execution of 
program, or ‘batch’, is recorded by the software. 
 Results and Discussion 
 
195 
 
 
Figure 54: User-interface for the custom program written for the radiofluorination of a diaryliodonium salt. Image taken from the 
Modular-Lab software. 
2.5.4 Radiofluorination of diaryliodonium salts using the Eckert & Ziegler 
Modular-Lab 
Following extensive and methodical testing, a reproducible, custom program was 
written, instructing the modules to perform a simple reaction by combining solutions 
of diaryliodonium salt and RFA in the reactor vial and stirring for a specified time at a 
set temperature. 
2.5.4.1 Flow-chart for the radiofluorination of a diaryliodonium salt. 
‘Start’ 
The program is started by the user. The computer communicates with all the modules 
present to ensure that the configuration is correct. Non-essential functions of the 
software, such as program editing, are no longer accessible.  
‘A)INITSYSTEM’ (Figure 55) 
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The initial status of the system is displayed on the user interface. For example, macro 
blocks instruct the user interface to display the status of the vials. Generally, at this 
stage, the reagent vials are full whilst collection vials are empty. This information is 
displayed on the user interface. Actions are also taken to ensure that the system is 
prepared for the reaction. For example, valves are directed to the correct starting 
positions and the vacuum pump is turned on. 
‘Wait till Start button is pressed’ 
A user prompt is required to instruct the program to begin the reaction after 
satisfactory initialisation of the system. The user takes this moment to ensure that all 
systems are working correctly and that the images displayed on the user interface 
correspond to the physical arrangement of the system.  
‘Start batch’ 
This separates the synthesis stage of the process from the preparation of the system. 
The system has been prepared from the default status and shall now undergo the 
synthesis steps. 
‘Start audit trail’ 
The system begins recording an action-log of actions made throughout the 
programme. This is mainly of the purpose of creating an audit trail, a requirement of 
producing clinical-grade material. 
‘B)TRANSFER’ (Figure 55) 
The next step is to transfer the [18F]fluoride onto the Modular-Lab system. Cyclotron-
produced [18F]fluoride in [18O]H2O is transferred from the delivery vial to the collection 
vial, thereby trapping the [18F]fluoride on the QMA cartridge. The reactor is warmed to 
60 °C, in preparation of the azeotropic evaporation of H2O using MeCN for preparation 
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of the reactive RFA. A user prompt is required to ensure that all the [18F]fluoride has 
been transferred. The PTA is then transferred to the reactor vial, via the QMA cartridge 
thereby releasing the trapped [18F]fluoride and delivering the RFA to the reactor vial. 
The user is again prompted to ensure that the fluoride has been released from the 
QMA cartridge and delivered to the reactor vial. The reactor vial is then placed under a 
flow of N2. The user interface is updated to reflect the system status.  
‘C)DRYING’ (Figure 56) 
The reactor vial is placed under vacuum and heated to 110 °C for 4 min to perform the 
azeotropic evaporation of H2O and MeCN. The reactor was then cooled to 90 °C and 
placed under vacuum only for an extra 4 min to ensure the complete drying of the 
contents of the reactor vial. The reactor vial is then cooled to 30 °C and returned to 
atmospheric pressure. Preparation of the reactive RFA, located in the reactor vial, is 
complete.  
‘D)FLUORINATION’ (Figure 56) 
The solution of diaryliodonium salt is transferred to the reactor which is then heated to 
130 °C. The reaction is then stirred at this temperature for 30 min. 
‘E)WASHOUT’ (Figure 57) 
The reactor is cooled to room temperature and contents are transferred to a collection 
vial. The user is prompted into ensuring that the reactor has been emptied, before 
proceeding. The reactor vial is then rinsed with DMF (1 mL) and the washings are 
transferred to the collection vial. The user is then prompted to ensure the reactor has 
been, once again, emptied. This concludes the reaction. 
‘Stop Audit Trail’ 
The system stops recording an action-log of actions made throughout the programme. 
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‘Close batch’ 
This separates the synthesis stage of the process from reverting to the default status. 
The system has been completed the synthesis steps and is now being prepared to 
return to the default status. 
 ‘F)EXITSYSTEM’ 
The system is returned to a default status and the user interface is updated to reflect 
this. 
‘END’  
The system instructs the user that the process has ended. 
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2.5.4.2 Radiofluorination reactions 
A major drawback to the use of automated batch reactors for the synthesis of 
radiotracers is the limit of one radiosynthesis per production of isotope. The 
optimisation of reactions performed on such platforms is, therefore, very time-
consuming and hence expensive. As a result, it was decided that reaction conditions 
for the initial scoping studies would be based on the data provided in the literature.193 
However, the reported reaction times are too long for radiochemical syntheses and it 
was decided, therefore, that reaction times would be reduced to 30 min. It was 
hypothesised that this duration would allow for reaction to occur without significant 
radioactive decay. DMF was chosen as the solvent as this had been used successfully in 
the microfluidic study and also by other research groups (Section 1.4.2.7). It was 
decided that trifluoroacetyl(4-ethoxycarbonylphenyl, 2-thienyl)-3-iodane would be 
used to assess the ability of Et4N∙HCO3 as a PTA in the batch radiofluorination of a 
diaryliodonium salt. This salt was chosen as the microfluidic study showed that the 
2-thienyl derivative produced the highest selectivity when generating ethyl 4-
[18F]fluorobenzoate, the initial target of this project. 
2.5.4.3 Radiofluorinations of trifluoroacetyl(4-ethoxycarbonylphenyl, 2-thienyl)-3-
iodane 193 
Radio-HPLC conditions for this process were used as described previously (Section 
2.4.2.2). The PTS was prepared according to the conditions described for Method B of 
the microfluidic study. Using the custom program written, solutions of 193 were 
stirred with a vial charged with anhydrous [18F]Et4N∙F at 130 °C for 30 min. A sample of 
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the crude reaction mixture was then manually injected into the radio-HPLC system for 
assessment of RCY. 
 
Scheme 86: Automated batch radiofluorination of 191 to form the desired 248a and undesired products 
RCYs were low – the highest RCY achieved was 12% (Figure 58). However, the 
transformation is, generally, low yielding with chemical yields of around 20% reported 
for similar reactions performed over 90 min. Similar RCYs were achieved upon 
performing the same reaction using [18F]KF/K222 as the RFA. 
 
Figure 58: Radio-HPLC trace for the radiofluorination of 193 using the Modular Lab 
Due to time-constraints of the project, and limited availability of radioisotope, this 
investigation was limited to the initial scoping studies. Despite this, the results clearly 
demonstrate the potential application of Et4N∙HCO3 as a PTA in the automated batch 
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radiofluorination of a diaryliodonium salt. However, significant further investigation is 
required. 
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2.5.5 Conclusion 
The automation of radiochemical syntheses on a batch scale has become an important 
focus of practical radiochemistry since the introduction of PET. Systems capable of 
batch radiofluorinations allow for large quantities of fluorine-18 labelled 
radiopharmaceuticals to be synthesised from a single production of isotope, for 
remote site application. In this study, the Modular-Lab was used to generate ethyl 4-
[18F]fluorobenzoate from trifluoroacetyl(4-ethoxycarbonylphenyl, 2-thienyl)-3-iodane 
using [18F]Et4N∙F as the RFA. RCYs were low, however, the results have proved that 
[18F]Et4N∙F may be used as an RFA in automated batch radiofluorinations. Further 
studies are required to form a more definite conclusion. 
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3 Experimental 
Commercially available reagents were purchased from fine chemicals suppliers and 
used as received unless otherwise stated. Reactions requiring anhydrous conditions 
were performed using oven- or flame-dried glassware and conducted under a positive 
pressure of N2. Anhydrous solvents were prepared as follows: DCM and MeCN were 
refluxed over CaH2, toluene was refluxed over sodium and fluorobenzene was stored 
over 3Å molecular sieves. For radiofluorinations, MeCN (>99%) and DMF (>99%) were 
purchased from Fisher Chemicals (UK) and pre-dried on molecular sieves (24 h on 4 A˚ 
MS then stored on 3 A˚ MS) before being used. Thin-layer chromatography was 
performed using silica gel plates (Kieselgel 60F254; 0.2 mm) with aluminium backing 
and visualisation performed with UV light. Infrared spectra were recorded on a Varian 
Scimitar Series 800 FT-IR with internal calibration. 1H, 13C, 19F and 119Sn-NMR spectra 
were recorded on a Jeol ECS 400 MHz spectrometer, Jeol Lamda 500 MHz 
spectrometer or Bruker Avance Ultra 500MHz with residual tetramethylsilane solvent 
as the reference for 1H and 13C. 19F spectra were referenced with CFCl3 and 
119Sn 
spectra with Me4Sn. Multiplicities are indicated by s (singlet), d (doublet) dd (doublet 
of doublets), t (triplet), q (quartet), quin (quintet), or combinations thereof. Coupling 
constants (J) are measure in Hertz (Hz). Elemental analysis was carried out at London 
Metropolitan University and results are reported as the average of two runs. Mass 
spectrometry was recorded at the EPSRC Mass Spectrometry Service, Swansea. It 
should be noted that hypervalent iodine compounds are known to exist as mixtures 
(incl. dimers/trimers) and these are evident in the MS data, only the data for the 
monomer is reported. Melting points were recorded on a Gallenkamp MF-370 melting 
point apparatus and are uncorrected. Automated flash chromatography was 
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performed using a Varian (now Agilent) IntelliFlash 971-FP discovery scale flash 
purification system.  
CAUTION: Hypervalent iodine compounds are potentially explosive and should be 
handled taking appropriate precautions.309, 310 
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3.1 Ethyl 4-(tri-n-butylstannyl) benzoate, 201a 
 
3.1.1 Method A231 
Trifluoroacetic acid (50 µL, catalytic amount) was added to a reaction vessel containing 
zinc dust (355 mg, 5.43 mmol) and MeCN (0.5 mL). Cobalt bromide (79 mg, 0.36 mmol) 
was then added. After stirring for 5 min at RT, allyl chloride (88 µL, 1.08 mmol) was 
added. After 5 min of stirring, a solution of ethyl 4-iodobenzoate in MeCN (0.61 mL, 
3.62 mmol, in 2.41 mL of MeCN, 1.5 M) was added followed immediately by tri-n-
butyltin chloride (1.07 mL, 3.98 mmol). The solution was heated to 50 °C and allowed 
to stir for 1 h. After complete conversion of the iodo benzoate as determined by TLC, 
the reaction was quenched using sat. aq. ammonium chloride (30 mL) and the product 
extracted using diethyl ether (3 × 30 mL). The solvent was dried using MgSO4, before 
being removed in vacuo to give the crude product. Purification using reverse-phase 
flash column chromatography (MeCN) gave the pure product as a colourless oil (1.08 g, 
2.46 mmol, 85%). IR vmax(neat)
 2925, 1719, 1590, 1459, 1385, 1273; 1H-NMR (500 MHz; 
CDCl3) δ
 7.97 (2H, d, H2/H6 J = 8.1 Hz), 7.55 (2H, d, H3/H5 J = 8.1 Hz), 4.37 (2H, q, 
OCH2CH3 J = 7.1 Hz), 1.54 (6H, quin, H8 J = 7.8 Hz), 1.38 (3H, t, OCH2CH3 J =  7.1 Hz), 
1.33 (6H, h, H9 J = 7.3 Hz), 1.09 (6H, t, H7 J = 8.4 Hz), 0.88 (9H, t, H10 J = 7.3 Hz); 13C-
NMR (101 MHz; CDCl3) δ 166.91 (CO), 149.28 (C4), 149.28 (
119Sn satellites, d, C4  J = 
363.6 Hz), 149.28 (117Sn satellites, d , C4 J = 347.44 Hz), 136.40 (C2/C6), 136.40 (Sn 
satellites, d, C2/C6 J = 30.3 Hz), 130.07 (C1), 128.47 (C3/C5), 128.47 (Sn satellites, d, 
C3/C5 J = 39.3 Hz), 60.75 (OCH2CH3), 29.15 (C9), 29.15 (Sn satellites, d, C9, J = 20.2), 
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27.42 (C8), 27.42 (Sn satellites, d, C8, J = 55.5 Hz), 14.39 (OCH2CH3), 13.72 (C10), 9.71 
(C7), 9.71 (119Sn satellites, d, C7 J = 343.4 Hz), 9.71 (117Sn satellites, d, C7 J = 328.25 Hz); 
119Sn-NMR (149 MHz; SnMe3) δ -38.49 (ArSn); m/z (E.I.) 301 (100), 393 (12), 463 
([120Sn][M+Na]+, 14, plus isotope pattern). Found [M+Na]+, 463.1630. C21H36O2SnNa 
requires 463.1633. Anal. Calcd. for C21H36O2Sn: C,  57.4; H, 8.2. Found: C, 57.5; H, 8.3.  
3.2 Ethyl 3-(tri-n-butylstannyl) benzoate,231 201b 
 
3.2.1 Method A231 
Product prepared according to procedure outlined for 201a (Section 3.1.1) using ethyl 
3-iodobenzoate (1 g, 3.62 mmol). Purification using reverse-phase flash column 
chromatography (MeCN) gave the product as a colourless oil (0.99 g, 2.24 mmol, 62%).  
Rf = 0.9 (Petrol: EtOAc, 9:1) IR νmax/cm
-1 (neat) 2957, 1719, 1255; 1H-NMR (500 MHz, 
CDCl3) δ 8.17 (1H, s, H2), 7.97 (1H, d, H6 J = 7.8 Hz), 7.65 (1H, d, H4 J = 7.1 Hz), 7.38 
(1H, t, H5 J = 7.5 Hz), 4.38 (2H, q, OCH2CH3 J = 7.1 Hz), 1.56 (6H, p, H8 J = 7.7 Hz), 1.40 
(3H, t, OCH2CH3 J = 7.1 Hz), 1.35 (6H, h, H9 J = 7.4 Hz), 1.1 (6H, t, H7 J = 8.1 Hz), 0.89 
(9H, t, H10 J = 7 Hz); 13C-NMR (101 MHz; CDCl3) δ 167.24 (CO), 142.49 (C1), 140.97 
(C4), 140.97 (Sn satellites, d, C4, J = 30.3), 137.36 (C2), 137.36 (Sn satellites, d, C2 J = 
33.3 Hz), 129.76 (C3), 129.76 (Sn satellites, d, C3 J = 38.4 Hz), 129.17 (C6), 127.75 (C5), 
127.75 (Sn satellites, d, C5 J = 38.4 Hz), 60.91 (OCH2CH3), 29.13 (C9), 29.13 (Sn 
satellites, d, C9 J = 20.2 Hz), 27.42 (C8), 27.42 (Sn satellites, d, C8 J = 56.6 Hz), 14.43 
(OCH2CH3), 13.76 (C10), 9.71 (C7), 9.71 (
119Sn satellites, d, C7 J = 344.41 Hz), 9.71 (117Sn 
satellites, d, C7 J = 328.25 Hz); 119Sn-NMR  (149 MHz, CDCl3) δ -38.07 (ArSn); m/z (EI) 
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463 ([120Sn][M+Na]+, 100, plus isotope pattern), 347 (14), 235 (11), 178 (6). Found: 
[M+Na]+ 463.1628. C21H36O2SnNa requires 463.1633. Anal. Calcd. for C21H36O2Sn: C, 
57.43; H, 8.26. Found: C, 57.59; H, 8.10. 
3.3 Ethyl 2-(tri-n-butylstannyl) benzoate,231 201c 
 
Product prepared according to procedure outlined for 201a (Section 3.1.1) using ethyl 
2-iodobenzoate (1 g, 3.62 mmol). Purification using reverse-phase flash 
chromatography (MeCN) gave the product as a colourless oil (0.92 g, 2.1 mmol, 58%).  
Rf = 0.8 (Petrol: EtOAc, 9:1) IR  νmax/cm
-1 (neat) 2918, 1703, 1267; 1H-NMR (400 MHz, 
CDCl3) δ 8.10 (1H, d, H6 J = 7.7 Hz), 7.65 (1H, d, H3 J = 7.3 Hz), 7.48 (1H, td, H4 J = 7.3, J 
= 1.3 Hz), 7.37 (1H, td, H5 J = 7.6, J = 1.3 Hz), 4.37 (2H, q, OCH2CH3 J = 7 Hz), 1.49 (6H, 
quin, H8 J = 7.6, J =7.6), 1.39 (3H, t, OCH2CH3 J = 7.1 Hz), 1.3 (6H, h, H9 J = 7.2 Hz), 1.05 
(6H, t, H7 J = 8.2 Hz), 0.86 (9H, t, H10 J = 7.3 Hz); 13C-NMR (101 MHz, CDCl3) δ 168.69 
(CO), 147.20 (C2), 147.20 (119Sn satellites, d, C2 J = 384.81 Hz), 147.20 (117Sn satellites, 
d, C2 J = 367.64 Hz), 137.08 (C3), 137.08 (Sn satellites, d, C3 J = 29.29 Hz), 135.83 (C1), 
135.83 (Sn satellites, d, C1 J = 16.16 Hz), 131.73 (C4), 131.73 (Sn satellites, d, C4 J = 
45.45 Hz), 129.7 (C6), 129.7 (Sn satellites, d, C6 J = 26.26 Hz), 127.96 (C5), 61.23 
(OCH2CH3), 29.34 (C9), 29.34 (Sn satellites, d, C9 J = 18.18 Hz), 27.58 (C8), 27.58 (Sn 
satellites, d, C8 J = 60.59 Hz), 14.46 (OCH2CH3), 13.82 (C10), 11.21 (C7), 11.21 (
119Sn 
satellites, d, C7 J = 363.6 Hz) 11.21 (117Sn satellites, d, C7 J = 347.44 Hz) 119Sn-NMR (149 
MHz, CDCl3) δ -38.1 (ArSn); m/z (EI) 439 ([
120Sn][M-H]+ 17, plus isotope pattern), 413 
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(79), 383 (100), 379 (43), 304 (69). Found [M-H]+ 439.1649 C21H35O2Sn requires 
439.1657. Anal. Calcd. for C21H35O2Sn: C, 57.43; H, 8.26. Found: C, 57.33; H, 8.03. 
3.4 Diacetoxyiodo-4-anisole,237 205 
 
Sodium perborate tetrahydrate (101.56 g, 660 mmol) was added, in portions, to a 
solution of 2-iodoanisole (14.58 mL, 60 mmol) in acetic acid (540 mL) over 30 min. The 
mixture was then heated to 50 °C and stirred for 5 h before cooling to RT. Water (1 L) 
was added before the crude product was extracted with DCM (3 × 400 mL). The 
extracts were combined before being washed with water (1 L). The organic layer was 
concentrated in vacuo to give the crude product. Crystallisation gave the product as a 
white crystalline solid (7.26 g, 20.63 mmol, 33%); Mp 91–93 °C (from DCM–ether–
petrol) (lit.311 92.4–96.0 °C ); IR vmax/cm
-1 (neat) 2952, 1655, 1629, 1581, 1490, 1439, 
1365, 1293, 1253, 1178; 1H-NMR (400 MHz;CDCl3) δ 7.99 (2H, d, H2/H6 J = 9.0 Hz), 6.95 
(2H, d, H3/H5 J = 9.0 Hz), 3.85 (3H, s, OMe), 1.98 (6H, s, OAc).13C-NMR (101 MHz;CDCl3) 
δ 176.52, 162.25, 137.22, 116.74, 111.70, 55.69, 20.49; m/z (EI) 198 (13), 233 (48), 266 
(4), 311 (6), 374 (100), 390 (5). Found [M+Na]+, 374.9699. C11H13IO5 requires 374.9700. 
Anal. Calcd. for C11H13IO5: C, 37.52; H, 3.72. Found C, 37.48; H, 3.69. 
For an X-ray crystal structure of the compound, see Appendix I (Table 1) 
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3.5 Diacetoxyiodo-2-thiophene,237 206 
 
Product prepared according to procedure outlined for 205 (Section 3.4) using 2-
iodothiophene (2.21 mL, 20 mmol). Crystallisation gave the product as a white 
crystalline solid (2.8 g, 8.53 mmol, 42%); mp 118‒121 °C (decomp) (from DCM–ether) 
(lit.312, 120–122 °C ); IR vmax/cm
-1 (neat) 2360, 2342, 2185, 1634, 1365, 1267; 1H-NMR 
(400 MHz; CDCl3)
 δ 7.77 (1H, dd, H5 J = 3.8, J = 1.2 Hz), 7.63 (1H, dd, H4 J = 5.4, J = 1.3 
Hz,), 7.12 (1H, dd, H3 J = 5.4, J = 3.8 Hz), 2.01 (6H, s, OAc); 13C-NMR (101 MHz; CDCl3) 
177.09 (CO), 139.16 (C5), 134.96 (C3), 128.72 (C4), 106.32 (C2), 20.45 (CH3); m/z (E.I.) 
268 ([M-OAc]+, 100), 226 (26), 209 (97). Found [M-OAc]+ 268.9130. C6H6IO2S requires 
268.9128. Anal. Calcd. for C8H9IO4S: C, 29.3; H, 2.8. Found C, 29.2; H, 2.6. 
For an X-ray crystal structure of the compound, see Appendix I (Table 2).  
3.6 Trifluoroacetyl(4-ethoxycarbonylphenyl, phenyl)-3-iodane, 191 
 
Trifluoroacetic acid was added (0.74 mL, 10 mmol), dropwise at –30 °C under N2, to a 
solution of diacetoxyiodobenzene (1.61 g, 5 mmol) in DCM (50 mL, anhydrous). After 
30 min of stirring at –30 °C, the solution was warmed to RT and stirred for 1 h. The 
solution was recooled to –30 °C and 201a (1.74 mL, 5 mmol) was added. The solution 
was then allowed to warm to RT overnight whilst continuing to stir under N2. The 
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solvent was dried using MgSO4 before being removed in vacuo. The crude material was 
purified by recrystallisation in petrol to give the product (990 mg, 2.12 mmol, 56%). Rf 
=  0.25 (92:8 DCM:MeOH); M.p. = 153–155 °C (from DCM–ether–petrol); IR (neat) 
νmax/cm
-1 3059, 1712, 1660, 1122; 1H-NMR (400 MHz; d6-DMSO)
 δ 8.33 (2H, d, H3/H5 J 
= 8.5 Hz), 8.23 (2H, d, H2’/H6’ J = 7.4 Hz), 7.97 (2H, d, H2/H6 J = 8.6 Hz), 7.63 (1H, t, H4’ 
J = 7.5 Hz), 7.49 (2H, t, H3’/H5’ J = 7.7 Hz), 4.27 (2H, q, OCH2CH3 J = 7.1 Hz), 1.26 (3H, t, 
OCH2CH3 J = 7.1 Hz); 
13C-NMR (400 MHz; d6-DMSO) δ 165.13, 136.01, 135.84, 133.25, 
132.64, 132.33, 132.31, 122.08, 117.49, 61.97, 14.56. 19F-NMR (376 MHz, d6-DMSO) δ -
73.43 (CO2CF3). m/z (E.I.) 353 ([M]
+ 100, plus isotope model) 181 (3) Found [M]+, 
353.0033. C15H14IO2 requires 353.0031. Anal. Calcd. for C17H14F3IO4: C, 43.8; H, 3.0. 
Found C, 43.8; H, 3.0. 
For an X-ray crystal structure of the compound, see Appendix II (Table 1). 
3.7 Trifluoroacetyl(4-ethoxycarbonylphenyl, anis-4-yl)-3-iodane, 192 
 
Product prepared according to procedure outlined for 191 (Section 3.6) using 205 (1.76 
g, 5 mmol). White crystalline solid (1.71 g, 3.46 mmol, 73%). Rf =  0.25 (92:8 
DCM:MeOH); M.p. = 127–130°C (from DCM–ether–petrol) IR νmax/cm
-1 (neat) 3061, 
1703, 1650, 1129; 1H-NMR (400 MHz; CDCl3) δ 8.00 (2H, d, H3/H5 J = 8.2 Hz), 7.92 (2H, 
d, H’2/H’6 J = 7.3 Hz), 7.84 (2H, d, H2/H6 J = 7.9 Hz), 6.91 (2H, d, H’3/H’5 J = 8.6 Hz), 
4.36 (2H, q, OCH2CH3 J = 7.0 Hz), 3.82 (3H, s, OCH3), 1.36 (3H, t, OCH2CH3 J = 7.1 Hz); 
13C-NMR (400 MHz; CDCl3) δ 165.03, 162.70, 137.30, 134.05, 133.40, 132.39, 121.45, 
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117.80, 104.84, 61.86, 55.74, 14.28. 19F-NMR (376 MHz, CDCl3) -73.45 (CO2CF3). m/z 
(E.I) 383 ([M]+, 100, plus isotope pattern), 256 (5), 211 (3). Found [Cation]+, 383.0133. 
C16H16O3I requires 383.0139. Anal. Calc. for C18H16F3IO5, 43.5; H, 3.2. Found: C, 43.5; H, 
3.2. 
For an X-ray crystal structure of the compound, see Appendix II (Table 7). 
3.8 Trifluoroacetyl(4-ethoxycarbonylphenyl, thiophen-4-yl)-3-iodane, 193 
 
Product prepared according to procedure outlined for 191 (Section 3.6) using 206 (1.97 
g, 6 mmol). White crystalline solid (1.93 g, 4.1 mmol 68%). Rf = 0.31 (DCM:MeOH, 
93:7); M.p. = 136–138°C (decomp.) (from DCM–ether–petrol); IR νmax/cm
-1 (neat) 3087, 
1704, 1651; 1H-NMR (400 MHz, d6-DMSO) δ 8.32 (2H, d, H2/H6 J = 9 Hz), 8.05 (1H, dd, 
H3’ J = 4, J = 1 Hz), 7.97 (2H, d, H3/H5 J = 9 Hz), 7.94 (1H, dd, H4’ J = 5, J = 1 Hz), 7.14 
(1H, dd, H5’ J = 5, J = 4 Hz), 4.28 (2H, q, OCH2CH3 J = 7 Hz), 1.26 (3H, t, OCH2CH3 J = 7 
Hz) 13C-NMR (101 MHz, d6-DMSO) δ 165.10, 141.17, 138.03, 135.40, 133.24, 132.31, 
130.19, 124.73, 101.90, 61.98, 14.56. 19F-NMR (376 MHz, d6-DMSO) δ -73.36 (CO2CF3). 
m/z (E.I.) 358 ([Cation]+, 100, plus isotope pattern) 232 (7) 187 (6); Found 358.9588. 
C13H12IO2S requires 358.9597. Anal. Calcd. for C15H12F3IO4S: C, 38.2; H, 2.6. Found C, 
38.2; H, 2.6. 
For an X-ray crystal structure of the compound, see Appendix II (Table 12). 
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3.9 Trifluoroacetyl(3-ethoxycarbonylphenyl, phenyl)-3-iodane, 194 
 
Product prepared according to procedure outlined for 191 (Section 3.6) using 201b 
(2.18 g, 5 mmol) and diacetoxyiodobenzene (1.61 g, 5 mmol). White crystalline solid 
(1.3 g, 2.8 mmol, 56%).Rf = 0.31 (DCM:MeOH, 93:7); M.p. = 141–142°C (decomp.) 
(from DCM–ether–petrol); IR νmax/cm
-1 (neat) 3058, 1707, 1656, 1567, 1472, 1444, 
1422, 1366, 1272, 1176; 1H-NMR (400 MHz, d6-DMSO) δ 8.73 (1H, t, H2 J = 1.7 Hz), 8.44 
(1H, ddd, H6 J = 8.0, 1.8, 1.1 Hz) 8.26 (2H, dd, H2’/H6’ J = 8.4, 1.1 Hz), 8.12 (1H, d, H2 J 
= 8.2 Hz), 7.66 – 7.59 (2H, m, H5 and H4’), 7.49 (2H, t, H3’/H5’ J = 7.7 Hz), 4.30 (2H, q, 
OCH2CH3 J = 7.1 Hz), 1.28 (3H, t, OCH2CH3 J = 7.1 Hz); 
13C-NMR (101 MHz, d6-DMSO) δ 
165.10, 141.17, 138.03, 135.40, 133.24, 132.31, 130.19, 124.73, 101.90, 100.00, 61.98, 
14.56. 19F-NMR (376 MHz, d6-DMSO) δ -73.42 (CO2CF3). m/z (E.I.); 353 ([M]
+, 100, plus 
isotope pattern), 818 (22), 1284 (8), 1750 (9). Found [M]+, 353.0032. C15H14IO2 requires 
353.0033. Anal. Calcd. for C17H14F3IO4: C, 43.80; H, 3.03. Found C, 43.83; H, 2.97. 
For an X-ray crystal structure of the compound, see Appendix II (Table 194). 
3.10 Trifluoroacetyl(3-ethoxycarbonylphenyl, 4-anisyl)-3-iodane, 195 
 
Product prepared according to procedure outlined for 191 (Section 3.6) using 201b 
(2.16 g, 5 mmol) and 205 (1.76 g, 5 mmol). White crystalline solid (1.47 g, 2.96 mmol, 
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55%). Rf = 0.33 (DCM:MeOH, 92:8); M.p. = 106-108°C (decomp.) (from DCM–ether–
petrol); IR νmax/cm
-1 (neat) 2972, 1706, 1652, 1582, 1488, 1461, 1396, 1366, 1253, 
1170; 1H-NMR (400 MHz, d3-MeCN) δ 8.64 (1H, t, H2 J = 1.7 Hz), 8.27 – 8.22 (1H, m, 
H6), 8.15 (1H, dd, H’3 J = 7.8 Hz, J = 1.1 Hz), 7.86 (1H, dd, H’5 J = 3.8 Hz, J = 1.1 Hz), 7.74 
(1H, dd, H4 J = 5.3 Hz, J = 1.1 Hz), 7.54 (1H, t, H’4 J = 8.0 Hz), 7.09 (1H, dd, H5 J = 5.3 Hz, 
J = 3.8 Hz), 4.31 (2H, q, J = 7.1 Hz, OCH2CH3), 1.32 (3H, t, OCH2CH3 J = 7.1 Hz); 
13C-NMR 
(400 MHz; d6-DMSO) δ 164.54, 162.56, 139.57, 137.95, 135.56, 132.97, 132.54, 132.43, 
118.00, 117.79, 106.24, 62.09, 56.23, 14.60. 19F-NMR (376 MHz, d6-DMSO) δ -73.32 
(CO2CF3). m/z (E.I.) 232 (3), 358 (100), 879 (9), 1375 (2); Found [M]
+
, 383.0130. 
C16H16IO3 requires 383.0139. Anal. Calcd. for C18H16F3IO5: C, 43.57; H, 3.25. Found C, 
43.62; H, 3.28. 
For an X-ray crystal structure of the compound, see Appendix II (Table 22). 
3.11 Trifluoroacetyl(3-ethoxycarbonylphenyl, 2-thienyl)-3-iodane, 196 
 
Product prepared according to procedure outlined for 191 (Section 3.6) using 201b 
(2.98 g, 6.82 mmol) and 206 (2.24 g, 6.82 mmol). White crystalline solid (1.81 g, 3.82 
mmol, 56%). Rf = 0.34 (DCM:MeOH, 92:8); M.p. = 102–103 °C (decomp.) (from DCM–
ether–petrol); IR νmax/cm
-1 (neat) 3065, 1702, 1654; 1H-NMR (400 MHz, d3-MeCN) δ 
8.64 (1H, dd, H2 J = 1.9, 1.6 Hz), 8.24 (1H, ddd, H6 J = 7.9, 1.8, 0.9 Hz,), 8.15 (1H dt, H4 J 
= 7.8, 1.1 Hz, 1H), 7.86 (1H, dd, H3’ J = 3.8, 1.2 Hz), 7.74 (1H, dd, H5’ J = 5.4, 1.2 Hz), 
7.54 (1H, t, H5 J = 8.0 Hz), 7.09 (1H, dd, H4’ J = 5.3, 3.8 Hz), 4.31 (2H, q, OCH2CH3 J = 7.1 
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Hz), 1.32 (3H, t, OCH2CH3 J = 7.1 Hz). 
13C-NMR (400 MHz; d3-MeCN) 164.15, 140.63, 
138.08, 137.06, 134.65, 133.56, 132.32, 131.75, 129.76, 120.14, 102.19, 61.83, 13.50. 
19F-NMR (376 MHz, d6-DMSO) δ -74.87 (CO2CF3) m/z (E.I.) 358 ([M]
+, 100, plus isotope 
model) 232 (3) 830 (26) 1302 (4) 1774 (4); Found [M]+, 358.9595. C13H12IO2S requires 
358.9597. Anal. Calcd. for C15H12F3IO4S: C, 38.2; H, 2.6. Found C, 38.3; H, 2.5. 
For an X-ray crystal structure of the compound, see Appendix II (Table 28). 
3.12 Ethyl 4-fluorobenzoate, 188d 
 
3.12.1 Method A193 
A mixture of caesium fluoride (30.3 mg, 0.2 mmol) and 191 (90.8 mg, 0.2 mmol) in 
anhydrous N, N-dimethylformamide (3 mL) were added to a long glass tube flushed 
with N2. The solution was heated to 130 °C for 1.5 h under N2. When the mixture had 
cooled to room temperature, a sample was taken and diluted with CDCl3 (0.4 mL) and 
analysed by 19F NMR. For results see Section 2.1.5. 
3.12.2 Method B 
Product prepared according to procedure outlined for 188d (Section 3.12.1) using 192 
(96.8 mg, 0.2 mmol).  For results see Section 2.1.5. 
3.12.3 Method C 
Product prepared according to procedure outlined for 188d (Section 3.12.1) using 193 
(92 mg, 0.2 mmol).  For results see Section 2.1.5. 
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3.13 Ethyl 3-fluorobenzoate, 188e 
 
3.13.1 Method A193 
Product prepared according to procedure outlined for 188d (Section 3.12.1) using 194 
(90.8 mg, 0.2 mmol). For results see Section 2.1.5. 
3.13.2 Method B 
Product prepared according to procedure outlined for 188d (Section 3.12.1) using 195 
(96.8 mg, 0.2 mmol). For results see Section 2.1.5. 
3.13.3 Method C 
Product prepared according to procedure outlined for 188d (Section 3.12.1) using 196 
(92 mg, 0.2 mmol). For results see Section 2.1.5. 
3.14 4-[18F]fluoroacetophenone, 245 
 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The product were not isolated and the radiochemical yield (RCY) reported 
relates to the amount of radioactivity of the product relative to the total radioactivity 
detected by radio-HPLC on analysis of the reaction mixture. The radioactive product 
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was separated on a PolymerX 5 mm RP-1 100 column (Phenomenex, USA) eluting at 1.1 
mL/min with MeCN-water. An isocratic gradient of 24% MeCN was used. tR = 6.5 min. 
3.14.1 Method A 
NCA [18F]fluoride (5–100 mCi) in [18O]H2O (1–5 mL) was adsorbed onto a pre-
conditioned anion exchange resin (QMA: Waters Sep-Pak®Light Accell Plus) before 
being released using a solution of either K2CO3 (1.3 mg; 9.5 mol) and Kryptofix®222 
(7.2 mg; 19 mol) in MeCN/H2O (9:1 (v/v) 450 L) (PTS-1); or Et4N.HCO3 (3.7 mg; 19 
mol) in MeCN/H2O (9:1 (v/v) 450 L) (PTS-2) and into a V-vial (2 mL, Wheaton). The 
solutions were dried by two successive azeotropic evaporations using MeCN (450 L) 
at 100 °C and under a positive flow of N2. The [
18F]KF/Kryptofix®222 or [18F]Et4NF 
generated was then dissolved in DMF (450 L) and loaded into the storage loop (P3: 
401 L) on the microfluidic system. 
Dry PTA-[18F]fluoride (5–100 mCi, 450 L DMF) and 246 (in DMF at 5–10 mg/mL) were 
loaded into their respective storage loops (loop 3 and loop 1 respectively). Capillaries 
that lead from P1 and P3 to the microreactor were primed with their respective 
reagents. Prior to recording data several priming reaction runs were performed to 
confirm the integrity of the synthetic platform and the in-line analytical HPLC system. 
Set volumes (10–30 L) of both solutions were dispensed into the pre-heated 
microreactor (130–190 °C) at pre-determined flow rates (10–30 L/min). This is 
achieved by the syringes of P1 and P3, simultaneously dispensing precursor and 
[18F]fluoride solutions (either [18F]KF/Kryptofix®222 or [18F]Et4NF) from their respective 
loops, into the microreactor using a fixed volume of system solvent (DMF) at a preset 
flow rate. The solutions initially mix at the entrance to the microreactor. User-
operated computer software determines the reaction parameters — temperature, 
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time and stoichiometry (P1:P3). Following completion of the reaction, P3 sweeps the 
crude mixture to the electronic injector and radio-HPLC system allowing the RCY of the 
process to be determined. At the start and end of each series of experiments the base 
module, reactor module, microreactor and associated transfer lines were cleaned 
using DMF and the concentrator module, with MeCN. 
For a table of results, see Appendix III (Tables 2 and 4) 
3.14.2 Method B 
Product prepared according to procedure outlined for 245 (Section 3.14.1) using 244 
(10 mg/mL). 
For a table of results, see Appendix III (Tables 1 and 3) 
3.15 Ethyl 4-[18F]fluorobenzoate, 188a 
 
3.15.1 Method A 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 247 
(10 mg/mL). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was separated on a PolymerX 5 mm RP-1 100 column 
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(Phenomenex, USA) eluting at 1.1 mL/min with EtOH–water. Mobile phase 
composition started at 40% EtOH which increased linearly to 60% at EtOH over 2 min 
and then to 80% at 5 min which continued at this composition for a further 7 min. tR = 
6.2 min. 
For a table of results, see Appendix III (Tables 5 and 6)   
3.15.2 Method B 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 188d 
(10 mg/mL). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a PolymerX 5 mm RP-1 100 column (Phenomenex, 
USA) eluting at 1.1 mL/min with EtOH-water. 
Mobile phase composition started at 60% EtOH which increased linearly to 80% at 
EtOH over 6 min. tR = 4.5 min. 
For a table of results, see Appendix III (Tables 7 and 8). 
3.15.3 Method C 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 193 
(10 mg/ml). 
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HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The product was not isolated and the radiochemical yield (RCY) reported 
relates to the amount of radioactivity of the product relative to the total radioactivity 
detected by radio-HPLC on analysis of the reaction mixture. The radioactive product 
was separated on a PolymerX 5 mm RP-1 100 column (Phenomenex, USA) eluting at 
1.1 mL/min with EtOH–water. Mobile phase composition started at 25% EtOH which 
increased linearly to 100% at EtOH over 7 min which continued at this composition for 
a further 2 min. tR = 7 min. 
For a table of results, see Appendix III (Tables 9 and 10). 
3.15.4 Method D 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 191 
(10 mg/ml). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR =  
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For a table of results, see Appendix III (Tables 11 and 12). 
3.15.5 Method E 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 192 
(10 mg/ml). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR = 14 min 20 s 
For a table of results, see Appendix III (Tables 11 and 12). 
3.15.6 Method F 
The Eckert and Ziegler Modular Lab system performing the radiosyntheses consists of 
1 × peltier reaction module (PRM) with transfer line fitted, 2 × single stopcock modules 
(SSM), 4 × solenoid valve modules (SVM), a vial holder module (VHM) to which was 
connected a pressure sensor and an activity detector in addition to the VHM’s internal 
detector. 
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All the vials containing reagents as well as the reactor itself were standard glass 
Wheaton V-vial; the transfer of the liquids was operated by applying positive or 
negative pressure through FEP tubings directly inserted into vial septa. 
Using the Eckert & Ziegler Modular Lab System no-carrier-added [18F]fluoride (5–100 
mCi) in [18O]H2O (1–5 mL) was adsorbed onto a pre-conditioned anion-exchange resin 
cartridge before being released using a solution of either Kryptofix®222/K2CO3 or 
Et4N.HCO3 (0.19 mmol) in MeCN/H2O (9:1 (v/v) 1 mL) and into a v-vial. The solution 
was then heated to 110 °C under a positive flow of N2 for 4 min then cooled to 90 °C 
for a further 4 min before being cooled to RT. 193 in DMF (0.021 M) was then added 
and the reaction stirred at 130 °C whilst under a positive flow of N2 for 90 min. The 
reaction was then cooled to RT before being transferred to a collection vial. DMF (1 
mL) was then added to the reaction vial and stirred for 1 min before being transferred 
to the collection vessel. Radio-HPLC was used to calculate the RCY.  
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR = 14 min 20 s. 
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3.16 Ethyl 3-[18F]fluorobenzoate, 188b 
 
3.16.1 Method A 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 194 
(10 mg/mL). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR = 14 min 20 s. 
For a table of results, see Appendix III (Tables 11 and 12). 
3.16.2 Method B 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 195 
(10 mg/mL). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
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Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR = 14 min 20 s. 
For a table of results, see Appendix III (Tables 11 and 12). 
3.16.3 Method C 
Product prepared according to procedure outlined for 244 (Section 3.14.1) using 196 
(10 mg/mL). 
HPLC methods were carried out using an Agilent 1200 HPLC system equipped with a 
UV absorbance detector (lmax 254 nm) and a radioactivity detector (LabLogic Flow 
Count). The [18F]fluoroarenes were not isolated and the radiochemical yield (RCY) 
reported relates to the amount of radioactivity of the product relative to the total 
radioactivity detected by radio-HPLC on analysis of the reaction mixture. The 
radioactive product was detected on a ThermoFisher 5m RP-C18 100 column eluting 
at 1.1 mL/min with MeCN–water. Mobile phase composition started at 18% MeCN for 
4 min, increasing to 40% at 4 min 30 s, remaining at this composition for 11 min 30 s, 
before decreasing back to 18 % over 30 s, where the composition remained constant 
for a further 1 min 30 s. tR = 14 min 20 s. 
For a table of results, see Appendix III (Tables 11 and 12). 
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5 Appendix I – Crystallographic Data for compounds 205 and 206 
Compound 205 
Table 1.  Crystal data and structure refinement for 205. 
 
Identification code  mac120016 
Chemical formula (moiety) C11H13IO5·0.5CH2Cl2 
Chemical formula (total) C11.50H14ClIO5 
Formula weight  394.58 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.3053(5) Å  = 70.375(5)° 
 b = 8.9589(6) Å  = 71.410(4)° 
 c = 10.7489(5) Å  = 76.544(5)° 
Cell volume 706.92(7) Å3 
Z 2 
Calculated density  1.854 g/cm3 
Absorption coefficient  2.465 mm1 
F(000) 386 
Crystal colour and size colourless, 0.30  0.30  0.30 mm3 
Reflections for cell refinement 3881 ( range 2.9 to 28.6°) 
Data collection method Oxford Diffraction Gemini A Ultra 
diffractometer 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 11 to 9, k 8 to 11, l 11 to 12 
Completeness to  = 25.0° 99.8 %  
Reflections collected 5095 
Independent reflections 2903 (Rint = 0.0231) 
Reflections with F2>2 2694 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5251 and 0.5251 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0414, 1.2585 
Data / restraints / parameters 2903 / 0 / 185 
Final R indices [F2>2] R1 = 0.0311, wR2 = 0.0804 
R indices (all data) R1 = 0.0342, wR2 = 0.0836 
Goodness-of-fit on F2 1.069 
Extinction coefficient 0.0108(12) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 1.09 and 0.95 e Å3 
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Table 2.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 205.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I 0.25454(3) 0.52165(3) 0.41551(2) 0.02241(12) 
O(5) 0.1486(4) 0.2075(4) 0.5229(3) 0.0313(7) 
O(4) 0.2166(4) 0.3697(4) 0.3117(3) 0.0294(7) 
O(2) 0.3111(4) 0.7143(4) 0.4639(3) 0.0308(7) 
O(1) 0.4278(4) 0.9765(4)  0.1726(3) 0.0342(7) 
C(5) 0.2358(5) 0.9216(5) 0.0562(4) 0.0262(9) 
O(3) 0.3430(7) 0.8027(6) 0.6375(6) 0.0795(15) 
C(9) 0.2624(5) 0.5477(4) 0.6721(3) 0.0213(8) 
C(1) 0.3080(5) 0.6752(5) 0.2180(4) 0.0243(8) 
C(4) 0.3795(5) 0.8826(5)  0.0422(4) 0.0263(9) 
C(10) 0.1704(5) 0.2346(5) 0.4002(4) 0.0241(8) 
C(11) 0.1489(6) 0.1174(5) 0.3362(4) 0.0296(9) 
C(6) 0.1986(5) 0.8165(5) 0.1877(4) 0.0242(8) 
C(8) 0.2998(6) 0.6736(6) 0.5954(5) 0.0318(10) 
C(7) 0.3230(7) 1.1265(6)  0.2123(5) 0.0410(12) 
C(2) 0.4517(6) 0.6341(6) 0.1198(5) 0.0339(10) 
C(3) 0.4855(6) 0.7372(6)  0.0107(5) 0.0350(10) 
C(12) 0.0602(15) 0.4763(13) 1.0226(13) 0.049(3) 
Cl(1A) 0.0072(9) 0.6741(7) 0.9831(8) 0.0807(19) 
Cl(1B)  0.0741(6) 0.3728(8) 0.9975(8) 0.0737(19) 
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Table 3.   Bond lengths [Å] and angles [°] for 205. 
 
I–O(4)  2.155(3) I–O(2)  2.146(3) 
I–C(1)  2.079(4) O(5)–C(10)  1.219(5) 
O(4)–C(10)  1.314(5) O(2)–C(8)  1.313(5) 
O(1)–C(4)  1.357(5) O(1)–C(7)  1.432(6) 
C(5)–H(5A)  0.950 C(5)–C(4)  1.384(6) 
C(5)–C(6)  1.393(6) O(3)–C(8)  1.523(6) 
C(9)–H(9A)  0.980 C(9)–H(9B)  0.980 
C(9)–H(9C)  0.980 C(9)–C(8)  1.193(6) 
C(1)–C(6)  1.382(6) C(1)–C(2)  1.388(6) 
C(4)–C(3)  1.395(7) C(10)–C(11)  1.503(6) 
C(11)–H(11A)  0.980 C(11)–H(11B)  0.980 
C(11)–H(11C)  0.980 C(6)–H(6A)  0.950 
C(7)–H(7A)  0.980 C(7)–H(7B)  0.980 
C(7)–H(7C)  0.980 C(2)–H(2A)  0.950 
C(2)–C(3)  1.378(7) C(3)–H(3A)  0.950 
C(12)–H(12A)  0.990 C(12)–H(12B)  0.990 
C(12)–Cl(1A)  1.663(12) C(12)–Cl(1B)  1.738(11) 
 
O(4)–I–O(2) 164.58(11) O(4)–I–C(1) 81.98(13) 
O(2)–I–C(1) 82.62(14) I–O(4)–C(10) 110.2(2) 
I–O(2)–C(8) 109.4(3) C(4)–O(1)–C(7) 118.1(4) 
H(5A)–C(5)–C(4) 120.1 H(5A)–C(5)–C(6) 120.1 
C(4)–C(5)–C(6) 119.9(4) H(9A)–C(9)–H(9B) 109.5 
H(9A)–C(9)–H(9C) 109.5 H(9A)–C(9)–C(8) 109.5 
H(9B)–C(9)–H(9C) 109.5 H(9B)–C(9)–C(8) 109.5 
H(9C)–C(9)–C(8) 109.5 I–C(1)–C(6) 118.8(3) 
I–C(1)–C(2) 119.6(3) C(6)–C(1)–C(2) 121.6(4) 
O(1)–C(4)–C(5) 124.6(4) O(1)–C(4)–C(3) 115.3(4) 
C(5)–C(4)–C(3) 120.1(4) O(5)–C(10)–O(4) 122.5(4) 
O(5)–C(10)–C(11) 123.5(4) O(4)–C(10)–C(11) 114.0(3) 
C(10)–C(11)–H(11A) 109.5 C(10)–C(11)–H(11B) 109.5 
C(10)–C(11)–H(11C) 109.5 H(11A)–C(11)–H(11B) 109.5 
H(11A)–C(11)–H(11C) 109.5 H(11B)–C(11)–H(11C) 109.5 
C(5)–C(6)–C(1) 119.1(4) C(5)–C(6)–H(6A) 120.5 
C(1)–C(6)–H(6A) 120.5 O(2)–C(8)–O(3) 112.6(4) 
O(2)–C(8)–C(9) 123.1(4) O(3)–C(8)–C(9) 124.2(4) 
O(1)–C(7)–H(7A) 109.5 O(1)–C(7)–H(7B) 109.5 
O(1)–C(7)–H(7C) 109.5 H(7A)–C(7)–H(7B) 109.5 
H(7A)–C(7)–H(7C) 109.5 H(7B)–C(7)–H(7C) 109.5 
C(1)–C(2)–H(2A) 120.5 C(1)–C(2)–C(3) 118.9(4) 
H(2A)–C(2)–C(3) 120.5 C(4)–C(3)–C(2) 120.3(4) 
C(4)–C(3)–H(3A) 119.8 C(2)–C(3)–H(3A) 119.8 
H(12A)–C(12)–H(12B) 107.5 H(12A)–C(12)–Cl(1A) 108.4 
H(12A)–C(12)–Cl(1B) 108.4 H(12B)–C(12)–Cl(1A) 108.4 
H(12B)–C(12)–Cl(1B) 108.4 Cl(1A)–C(12)–Cl(1B) 115.4(6) 
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Table 4.   Anisotropic displacement parameters (Å2) for 205.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I 0.02495(18)  0.01731(17) 0.02162(16)  0.00432(10) 0.00180(10)   
0.00451(10) 
O(5) 0.0432(19)  0.0243(16) 0.0219(15)   0.0036(12)  0.0029(13)   
0.0085(14) 
O(4) 0.0399(18)  0.0230(16) 0.0241(14)   0.0047(12)  0.0037(13)   
0.0118(13) 
O(2) 0.0407(18)  0.0221(16) 0.0293(16)   0.0059(13)  0.0069(13)   
0.0089(13) 
O(1) 0.0372(18)  0.0411(19) 0.0208(14)   0.0011(13)  0.0052(12)   
0.0137(15) 
C(5) 0.032(2)  0.022(2) 0.025(2)   0.0047(17)  0.0073(17)   
0.0079(17) 
O(3) 0.105(4)  0.063(3) 0.085(4)   0.027(3)  0.037(3)   0.015(3) 
C(9) 0.043(2)  0.0107(18) 0.0087(16)   0.0006(14) 0.0008(15)   
0.0149(17) 
C(1) 0.032(2)  0.019(2) 0.0191(18)   0.0021(15)  0.0026(16)   
0.0093(17) 
C(4) 0.032(2)  0.028(2) 0.0220(19)   0.0036(17)  0.0064(16)   
0.0158(18) 
C(10) 0.019(2)  0.017(2) 0.030(2)   0.0033(17)  0.0032(16)   
0.0015(16) 
C(11) 0.031(2)  0.026(2) 0.030(2)   0.0071(18)  0.0019(18)   
0.0105(18) 
C(6) 0.029(2)  0.020(2) 0.0229(19)   0.0073(16)  0.0038(16)   
0.0059(17) 
C(8) 0.027(2)  0.040(3) 0.032(2)   0.019(2)  0.0074(18) 
 0.0039(19) 
C(7) 0.046(3)  0.043(3) 0.028(2)  0.007(2)  0.013(2)   0.014(2) 
C(2) 0.035(3)  0.025(2) 0.031(2)   0.0068(19) 0.0029(19)   
0.0028(19) 
C(3) 0.035(3)  0.036(3) 0.026(2)   0.0099(19) 0.0042(18)   
0.007(2) 
C(12) 0.056(7)  0.030(6) 0.069(7)  0.001(5)  0.036(6)   0.013(5) 
Cl(1A) 0.121(6)  0.038(2) 0.084(3)   0.026(2)  0.019(4)   0.009(3) 
Cl(1B) 0.051(3)  0.104(5) 0.097(4)   0.072(4)  0.001(2)   0.030(3) 
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Table 5.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 205. 
 
      x       y       z       U 
 
H(5A) 0.1625 1.0197 0.0342 0.031 
H(9A) 0.3280 0.4618 0.6312 0.032 
H(9B) 0.1394 0.5467 0.6894 0.032 
H(9C) 0.2893 0.5312 0.7586 0.032 
H(11A) 0.0583 0.0541 0.3990 0.044 
H(11B) 0.2570 0.0459 0.3174 0.044 
H(11C) 0.1173 0.1757 0.2503 0.044 
H(6A) 0.0995 0.8417 0.2556 0.029 
H(7A) 0.3755 1.1840  0.3069 0.061 
H(7B) 0.3132 1.1908  0.1516 0.061 
H(7C) 0.2086 1.1072  0.2053 0.061 
H(2A) 0.5255 0.5364 0.1422 0.041 
H(3A) 0.5816 0.7092  0.0795 0.042 
H(12A) 0.0620 0.4362 1.1200 0.059 
H(12B) 0.1782 0.4513 0.9672 0.059 
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Table 6.  Torsion angles [°] for 205. 
 
O(2)–I–O(4)–C(10) 178.0(4) C(1)–I–O(4)–C(10)  178.8(3) 
O(4)–I–O(2)–C(8)  174.9(4) C(1)–I–O(2)–C(8)  178.1(3) 
O(4)–I–C(1)–C(6) 114.0(3) O(4)–I–C(1)–C(2)  66.0(3) 
O(2)–I–C(1)–C(6)  66.9(3) O(2)–I–C(1)–C(2) 113.2(4) 
C(7)–O(1)–C(4)–C(5)  0.3(6) C(7)–O(1)–C(4)–C(3) 179.1(4) 
C(6)–C(5)–C(4)–O(1)  179.5(4) C(6)–C(5)–C(4)–C(3) 1.1(6) 
I–O(4)–C(10)–O(5) 2.1(5) I–O(4)–C(10)–C(11)  177.3(3) 
I–C(1)–C(6)–C(5) 178.7(3) C(2)–C(1)–C(6)–C(5)  1.4(6) 
C(4)–C(5)–C(6)–C(1) 0.8(6) I–O(2)–C(8)–O(3) 178.4(3) 
I–O(2)–C(8)–C(9)  0.4(6) I–C(1)–C(2)–C(3)  179.9(3) 
C(6)–C(1)–C(2)–C(3) 0.1(7) C(1)–C(2)–C(3)–C(4) 1.8(7) 
O(1)–C(4)–C(3)–C(2) 178.2(4) C(5)–C(4)–C(3)–C(2)  2.4(7) 
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Compound 206 
 
Table 7.  Crystal data and structure refinement for 206. 
 
Identification code  mac137 
Chemical formula (moiety) C8H9IO4S 
Chemical formula (total) C8H9IO4S 
Formula weight  328.11 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, C12/c1 
Unit cell parameters a = 16.5807(5) Å  = 90° 
 b = 17.4446(4) Å  = 107.211(3)° 
 c = 15.6122(4) Å  = 90° 
Cell volume 4313.5(2) Å3 
Z 16 
Calculated density  2.021 g/cm3 
Absorption coefficient  3.149 mm1 
F(000) 2528 
Reflections for cell refinement 11000 ( range 2.9 to 29.4°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 25.0° 
Index ranges h 19 to 19, k 20 to 20, l 18 to 18 
Completeness to  = 25.0° 99.8 %  
Reflections collected 31978 
Independent reflections 3804 (Rint = 0.0387) 
Reflections with F2>2 2611 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.86238 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0284, 187.8210 
Data / restraints / parameters 3804 / 260 / 367 
Final R indices [F2>2] R1 = 0.0548, wR2 = 0.1478 
R indices (all data) R1 = 0.0655, wR2 = 0.1709 
Goodness-of-fit on F2 1.205 
Largest and mean shift/su 1.622 and 0.406 
Largest diff. peak and hole 1.18 and 1.31 e Å3 
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Table 8.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 206.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I(1) 0.10151(5) 0.35104(5) 0.69720(5) 0.0169(3) 
S(1)  0.0598(3) 0.2702(2) 0.5547(3) 0.0362(9) 
C(1) 0.0418(10) 0.2891(8) 0.5749(10) 0.028(2) 
C(2) 0.0889(13) 0.2633(14) 0.5134(14) 0.024(2) 
C(3) 0.0127(12) 0.2247(10) 0.4453(12) 0.032(2) 
C(4)  0.0612(11) 0.2277(10) 0.4648(12) 0.032(2) 
I(1A) 0.14980(11) 0.39964(10) 0.80260(11) 0.0206(6) 
S(1A) 0.0561(6) 0.2310(5) 0.4502(6) 0.0349(17) 
C(1A)  0.047(2) 0.2080(17) 0.425(2) 0.030(3) 
C(2A)  0.090(2) 0.2358(19) 0.486(2) 0.031(3) 
C(3A)  0.010(3) 0.2741(18) 0.555(2) 0.034(3) 
C(4A) 0.073(3) 0.266(3) 0.521(3) 0.031(3) 
C(5) 0.1961(6) 0.2427(6) 0.8249(6) 0.028(2) 
C(6) 0.2314(7) 0.1688(6) 0.8671(7) 0.036(3) 
C(7) 0.0573(6) 0.5077(6) 0.6738(6) 0.030(2) 
C(8) 0.0207(7) 0.5812(6) 0.6324(7) 0.035(2) 
O(1) 0.2159(5) 0.3047(4) 0.8664(5) 0.042(2) 
O(2) 0.1451(4) 0.2405(4) 0.7455(5) 0.0313(16) 
O(3) 0.0345(5) 0.4467(4) 0.6275(5) 0.039(2) 
O(4) 0.1090(5) 0.5061(4) 0.7505(5) 0.0406(19) 
I(2)  0.14823(5) 0.10080(5) 0.19725(5) 0.0170(3) 
S(2)  0.3087(3) 0.0200(2) 0.0522(3) 0.0347(9) 
C(9)  0.2075(11) 0.0416(9) 0.0769(10) 0.027(3) 
C(10)  0.1598(13) 0.0159(15) 0.0160(16) 0.022(3) 
C(11)  0.2335(13)  0.0244(10)  0.0539(13) 0.032(3) 
C(12)  0.3067(12)  0.0230(10)  0.0354(14) 0.033(3) 
I(2A)  0.10102(11) 0.14981(10) 0.30204(11) 0.0205(6) 
S(2A) 0.3100(7) 0.4796(6) 0.9454(7) 0.046(2) 
C(9A) 0.207(2) 0.456(2) 0.923(2) 0.032(4) 
C(10A) 0.162(2) 0.4877(19) 0.987(2) 0.027(4) 
C(11A) 0.246(3) 0.523(2) 1.055(2) 0.035(4) 
C(12A) 0.320(3) 0.516(4) 1.024(5) 0.038(4) 
C(13)  0.0592(6)  0.0083(6) 0.3260(6) 0.027(2) 
C(14)  0.0250(7)  0.0826(6) 0.3668(7) 0.035(2) 
C(15)  0.1868(6) 0.2595(5) 0.1730(6) 0.025(2) 
C(16)  0.2231(7) 0.3336(6) 0.1322(7) 0.033(2) 
O(5)  0.0415(5) 0.0525(4) 0.3687(5) 0.040(2) 
O(6)  0.1079(5)  0.0102(4) 0.2448(5) 0.0353(18) 
O(7)  0.2089(5) 0.1988(4) 0.1250(5) 0.0330(17) 
O(8)  0.1379(5) 0.2565(4) 0.2506(5) 0.0369(18) 
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Table 9.   Bond lengths [Å] and angles [°] for 206. 
 
I(1)–C(1)  2.161(15) I(1)–O(2)  2.119(7) 
I(1)–O(3)  2.118(7) S(1)–C(1)  1.654(16) 
S(1)–C(4)  1.58(2) C(1)–C(2)  1.48(3) 
C(2)–H(2A)  0.950 C(2)–C(3)  1.54(3) 
C(3)–H(3A)  0.950 C(3)–C(4)  1.35(3) 
C(4)–H(4A)  0.950 I(1A)–O(1)  2.071(7) 
I(1A)–O(4)  2.059(8) I(1A)–C(9A)  2.08(4) 
S(1A)–C(1A)  1.68(3) S(1A)–C(4A)  1.22(5) 
C(1A)–C(2A)  1.44(5) C(1A)–I(2A)  2.12(3) 
C(2A)–H(2B)  0.950 C(2A)–C(3A)  1.58(5) 
C(3A)–H(3B)  0.950 C(3A)–C(4A)  1.62(6) 
C(4A)–H(4B)  0.950 C(5)–C(6)  1.487(14) 
C(5)–O(1)  1.254(12) C(5)–O(2)  1.279(11) 
C(6)–H(6A)  0.980 C(6)–H(6B)  0.980 
C(6)–H(6C)  0.980 C(7)–C(8)  1.482(14) 
C(7)–O(3)  1.280(12) C(7)–O(4)  1.250(12) 
C(8)–H(8A)  0.980 C(8)–H(8B)  0.980 
C(8)–H(8C)  0.980 I(2)–C(9)  2.115(15) 
I(2)–O(6)  2.111(7) I(2)–O(7)  2.130(7) 
S(2)–C(9)  1.650(17) S(2)–C(12)  1.57(2) 
C(9)–C(10)  1.47(3) C(10)–H(10A)  0.950 
C(10)–C(11)  1.54(3) C(11)–H(11A)  0.950 
C(11)–C(12)  1.33(3) C(12)–H(12A)  0.950 
I(2A)–O(5)  2.081(7) I(2A)–O(8)  2.048(7) 
S(2A)–C(9A)  1.69(4) S(2A)–C(12A)  1.35(7) 
C(9A)–C(10A)  1.52(5) C(10A)–H(10B)  0.950 
C(10A)–C(11A)  1.60(5) C(11A)–H(11B)  0.950 
C(11A)–C(12A)  1.46(7) C(12A)–H(12B)  0.950 
C(13)–C(14)  1.481(14) C(13)–O(5)  1.242(12) 
C(13)–O(6)  1.286(12) C(14)–H(14A)  0.980 
C(14)–H(14B)  0.980 C(14)–H(14C)  0.980 
C(15)–C(16)  1.487(14) C(15)–O(7)  1.286(11) 
C(15)–O(8)  1.244(11) C(16)–H(16A)  0.980 
C(16)–H(16B)  0.980 C(16)–H(16C)  0.980 
 
C(1)–I(1)–O(2) 83.0(4) C(1)–I(1)–O(3) 84.6(4) 
O(2)–I(1)–O(3) 166.4(3) C(1)–S(1)–C(4) 90.5(9) 
I(1)–C(1)–S(1) 116.3(9) I(1)–C(1)–C(2) 122.4(12) 
S(1)–C(1)–C(2) 121.3(13) C(1)–C(2)–H(2A) 132.4 
C(1)–C(2)–C(3) 95.6(14) H(2A)–C(2)–C(3) 131.9 
C(2)–C(3)–H(3A) 122.3 C(2)–C(3)–C(4) 116.2(17) 
H(3A)–C(3)–C(4) 121.4 S(1)–C(4)–C(3) 116.3(13) 
S(1)–C(4)–H(4A) 121.7 C(3)–C(4)–H(4A) 122.0 
O(1)–I(1A)–O(4) 167.4(3) O(1)–I(1A)–C(9A) 85.0(9) 
O(4)–I(1A)–C(9A) 86.3(9) C(1A)–S(1A)–C(4A) 106(2) 
S(1A)–C(1A)–C(2A) 115(3) S(1A)–C(1A)–I(2A) 117(2) 
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C(2A)–C(1A)–I(2A) 127(2) C(1A)–C(2A)–H(2B) 131.7 
C(1A)–C(2A)–C(3A) 97(3) H(2B)–C(2A)–C(3A) 131.6 
C(2A)–C(3A)–H(3B) 124.3 C(2A)–C(3A)–C(4A) 111(3) 
H(3B)–C(3A)–C(4A) 124.5 S(1A)–C(4A)–C(3A) 111(3) 
S(1A)–C(4A)–H(4B) 125.3 C(3A)–C(4A)–H(4B) 123.8 
C(6)–C(5)–O(1) 120.8(8) C(6)–C(5)–O(2) 117.6(9) 
O(1)–C(5)–O(2) 121.6(9) C(5)–C(6)–H(6A) 109.5 
C(5)–C(6)–H(6B) 109.5 C(5)–C(6)–H(6C) 109.4 
H(6A)–C(6)–H(6B) 109.5 H(6A)–C(6)–H(6C) 109.5 
H(6B)–C(6)–H(6C) 109.5 C(8)–C(7)–O(3) 117.3(8) 
C(8)–C(7)–O(4) 120.9(10) O(3)–C(7)–O(4) 121.8(9) 
C(7)–C(8)–H(8A) 109.4 C(7)–C(8)–H(8B) 109.6 
C(7)–C(8)–H(8C) 109.4 H(8A)–C(8)–H(8B) 109.5 
H(8A)–C(8)–H(8C) 109.5 H(8B)–C(8)–H(8C) 109.5 
I(1A)–O(1)–C(5) 114.9(6) I(1)–O(2)–C(5) 112.0(6) 
I(1)–O(3)–C(7) 110.0(6) I(1A)–O(4)–C(7) 116.8(7) 
C(9)–I(2)–O(6) 83.1(4) C(9)–I(2)–O(7) 84.2(4) 
O(6)–I(2)–O(7) 166.8(3) C(9)–S(2)–C(12) 91.8(10) 
I(2)–C(9)–S(2) 119.5(10) I(2)–C(9)–C(10) 121.7(13) 
S(2)–C(9)–C(10) 118.8(14) C(9)–C(10)–H(10A) 131.3 
C(9)–C(10)–C(11) 97.5(15) H(10A)–C(10)–C(11) 131.1 
C(10)–C(11)–H(11A) 122.2 C(10)–C(11)–C(12) 114.8(18) 
H(11A)–C(11)–C(12) 123.0 S(2)–C(12)–C(11) 117.0(15) 
S(2)–C(12)–H(12A) 121.7 C(11)–C(12)–H(12A) 121.2 
C(1A)–I(2A)–O(5) 85.8(8) C(1A)–I(2A)–O(8) 85.2(8) 
O(5)–I(2A)–O(8) 168.5(3) C(9A)–S(2A)–C(12A) 99(3) 
I(1A)–C(9A)–S(2A) 118(2) I(1A)–C(9A)–C(10A) 126(2) 
S(2A)–C(9A)–C(10A) 116(3) C(9A)–C(10A)–H(10B) 132.9 
C(9A)–C(10A)–C(11A) 95(3) H(10B)–C(10A)–C(11A) 132.4 
C(10A)–C(11A)–H(11B) 122.3 C(10A)–C(11A)–C(12A) 114(4) 
H(11B)–C(11A)–C(12A) 123.5 S(2A)–C(12A)–C(11A) 117(4) 
S(2A)–C(12A)–H(12B) 121.4 C(11A)–C(12A)–H(12B) 122.0 
C(14)–C(13)–O(5) 121.2(9) C(14)–C(13)–O(6) 116.7(9) 
O(5)–C(13)–O(6) 122.1(9) C(13)–C(14)–H(14A) 109.4 
C(13)–C(14)–H(14B) 109.5 C(13)–C(14)–H(14C) 109.5 
H(14A)–C(14)–H(14B) 109.5 H(14A)–C(14)–H(14C) 109.5 
H(14B)–C(14)–H(14C) 109.5 C(16)–C(15)–O(7) 117.2(8) 
C(16)–C(15)–O(8) 121.2(9) O(7)–C(15)–O(8) 121.7(9) 
C(15)–C(16)–H(16A) 109.5 C(15)–C(16)–H(16B) 109.4 
C(15)–C(16)–H(16C) 109.5 H(16A)–C(16)–H(16B) 109.5 
H(16A)–C(16)–H(16C) 109.5 H(16B)–C(16)–H(16C) 109.5 
I(2A)–O(5)–C(13) 115.3(6) I(2)–O(6)–C(13) 111.4(6) 
I(2)–O(7)–C(15) 110.1(6) I(2A)–O(8)–C(15) 116.9(6) 
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Table 10.   Anisotropic displacement parameters (Å2) for 206.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I(1) 0.0193(5)  0.0131(4) 0.0162(5)   0.0003(3) 0.0019(3)  0.0018(3) 
S(1) 0.034(2)  0.031(2) 0.036(2)   0.0015(17)  0.0004(18)   
0.0021(18) 
C(1) 0.023(4)  0.017(4) 0.031(4)  0.004(4)  0.012(4)   0.011(4) 
C(2) 0.025(4)  0.014(4) 0.022(5)  0.002(4)  0.011(4)   0.005(5) 
C(3) 0.030(5)  0.023(4) 0.031(4)   0.003(4)  0.009(4)   0.004(5) 
C(4) 0.029(4)  0.023(4) 0.030(5)   0.001(4)  0.013(4)   0.006(4) 
I(1A) 0.0233(10)  0.0177(9) 0.0188(9)   0.0001(7) 0.0033(7)  0.0011(7) 
S(1A) 0.033(4)  0.028(3) 0.033(3)   0.002(3)  0.006(3)   0.006(4) 
C(1A) 0.028(5)  0.022(5) 0.030(5)  0.004(5)  0.008(5)   0.008(5) 
C(2A) 0.030(5)  0.024(5) 0.027(5)  0.001(5)  0.009(5)   0.006(5) 
C(3A) 0.030(5)  0.026(5) 0.033(5)  0.000(4)  0.008(4)   0.007(5) 
C(4A) 0.030(5)  0.019(5) 0.030(5)  0.002(5)  0.012(5)   0.006(5) 
C(5) 0.029(5)  0.029(5) 0.021(5)   0.002(4) 0.001(4)   0.003(4) 
C(6) 0.042(6)  0.027(5) 0.034(5)  0.006(4) 0.004(5)   0.004(5) 
C(7) 0.034(5)  0.031(5) 0.020(5)  0.004(4) 0.001(4)  0.000(4) 
C(8) 0.040(6)  0.028(5) 0.033(5)  0.006(4) 0.004(5)  0.004(4) 
O(1) 0.045(5)  0.025(4) 0.043(4)   0.005(3)  0.006(4)  0.004(3) 
O(2) 0.032(4)  0.025(4) 0.030(4)  0.005(3)  0.002(3)  0.000(3) 
O(3) 0.042(5)  0.021(4) 0.043(5)   0.006(3)  0.005(4)  0.005(3) 
O(4) 0.046(5)  0.032(4) 0.033(4)  0.000(3)  0.005(4)   0.004(4) 
I(2) 0.0200(5)  0.0128(4) 0.0154(4)  0.0000(3) 0.0012(3)  0.0018(3) 
S(2) 0.032(2)  0.033(2) 0.033(2)   0.0011(18) 0.0004(18)   
0.0029(19) 
C(9) 0.026(5)  0.017(5) 0.027(5)   0.001(4)  0.010(5)   0.011(5) 
C(10) 0.024(5)  0.014(5) 0.016(6)  0.007(5)  0.010(5)   0.005(6) 
C(11) 0.031(7)  0.027(6) 0.027(6)   0.004(5)  0.006(5)   0.005(6) 
C(12) 0.030(5)  0.026(6) 0.027(6)  0.001(5)  0.018(5)   0.010(5) 
I(2A) 0.0228(10)  0.0172(9) 0.0185(10)  0.0000(7) 0.0014(7)  0.0013(7) 
S(2A) 0.036(5)  0.046(5) 0.044(5)   0.003(4)  0.007(4)   0.008(5) 
C(9A) 0.031(7)  0.028(8) 0.026(7)  0.006(7)  0.008(7)   0.011(7) 
C(10A) 0.030(7)  0.022(9) 0.014(8)  0.002(8)  0.015(7)   0.012(8) 
C(11A) 0.029(9)  0.032(9) 0.029(8)  0.002(7)  0.016(7)   0.012(9) 
C(12A) 0.030(8)  0.035(9) 0.033(8)  0.004(7)  0.014(7)   0.009(8) 
C(13) 0.031(5)  0.027(5) 0.021(5)  0.005(4) 0.002(4)   0.002(4) 
C(14) 0.040(6)  0.027(5) 0.031(5)  0.005(4) 0.002(5)  0.002(4) 
C(15) 0.028(5)  0.027(5) 0.018(5)  0.001(4) 0.004(4)   0.007(4) 
C(16) 0.040(6)  0.023(5) 0.033(5)  0.004(4) 0.007(5)   0.003(4) 
O(5) 0.045(5)  0.023(4) 0.040(4)   0.006(3)  0.006(4)  0.006(3) 
O(6) 0.039(4)  0.031(4) 0.028(4)  0.003(3)  0.003(3)   0.004(3) 
O(7) 0.039(4)  0.024(4) 0.030(4)  0.001(3) 0.000(3)  0.006(3) 
O(8) 0.042(4)  0.032(4) 0.028(4)  0.005(3)  0.004(3)   0.002(3) 
 Appendix I – Crystallographic Data for compounds 205 and 206 
 
261 
 
Table 11.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 206. 
 
      x       y       z       U 
 
H(2A) 0.1463 0.2687 0.5150 0.029 
H(3A) 0.0176 0.2002 0.3928 0.038 
H(4A)  0.1113 0.2054 0.4266 0.039 
H(2B)  0.1472 0.2323 0.4858 0.037 
H(3B)  0.0107 0.2985 0.6094 0.040 
H(4B) 0.1271 0.2861 0.5515 0.037 
H(6A) 0.2419 0.1721 0.9321 0.054 
H(6B) 0.2846 0.1581 0.8539 0.054 
H(6C) 0.1911 0.1274 0.8429 0.054 
H(8A) 0.0555 0.6238 0.6639 0.052 
H(8B)  0.0368 0.5865 0.6369 0.052 
H(8C) 0.0191 0.5818 0.5692 0.052 
H(10A)  0.1022 0.0221 0.0188 0.026 
H(11A)  0.2270  0.0483  0.1061 0.038 
H(12A)  0.3557  0.0469  0.0735 0.040 
H(10B) 0.1046 0.4869 0.9870 0.032 
H(11B) 0.2468 0.5453 1.1106 0.042 
H(12B) 0.3732 0.5368 1.0577 0.046 
H(14A)  0.0137  0.0798 0.4320 0.052 
H(14B) 0.0276  0.0940 0.3528 0.052 
H(14C)  0.0663  0.1233 0.3426 0.052 
H(16A)  0.1845 0.3754 0.1593 0.049 
H(16B)  0.2777 0.3420 0.1430 0.049 
H(16C)  0.2309 0.3322 0.0675 0.049 
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Table 12.  Torsion angles [°] for 206. 
 
C(4)–S(1)–C(1)–I(1)  179.4(9) C(4)–S(1)–C(1)–C(2)  0.7(15) 
O(2)–I(1)–C(1)–S(1) 100.5(8) O(2)–I(1)–C(1)–C(2)  78.2(14) 
O(3)–I(1)–C(1)–S(1)  73.8(7) O(3)–I(1)–C(1)–C(2) 107.5(14) 
I(1)–C(1)–C(2)–C(3) 179.4(11) S(1)–C(1)–C(2)–C(3) 0.7(19) 
C(1)–C(2)–C(3)–C(4) 0(2) C(2)–C(3)–C(4)–S(1) 0(2) 
C(1)–S(1)–C(4)–C(3) 0.4(15) C(4A)–S(1A)–C(1A)–C(2A) 2(4) 
C(4A)–S(1A)–C(1A)–I(2A) 177(3) S(1A)–C(1A)–C(2A)–C(3A)  3(3) 
I(2A)–C(1A)–C(2A)–C(3A)  177(2) C(1A)–C(2A)–C(3A)–C(4A) 2(4) 
C(1A)–S(1A)–C(4A)–C(3A) 0(4) C(2A)–C(3A)–C(4A)–S(1A)  1(5) 
C(6)–C(5)–O(1)–I(1A)  173.2(8) O(2)–C(5)–O(1)–I(1A) 6.8(14) 
O(4)–I(1A)–O(1)–C(5)  143.3(14) C(9A)–I(1A)–O(1)–C(5) 170.5(13) 
C(6)–C(5)–O(2)–I(1) 179.9(8) O(1)–C(5)–O(2)–I(1)  0.1(13) 
C(1)–I(1)–O(2)–C(5) 175.1(9) O(3)–I(1)–O(2)–C(5)  159.9(12) 
C(8)–C(7)–O(3)–I(1) 176.2(8) O(4)–C(7)–O(3)–I(1)  3.2(13) 
C(1)–I(1)–O(3)–C(7)  173.0(9) O(2)–I(1)–O(3)–C(7) 162.1(11) 
C(8)–C(7)–O(4)–I(1A) 176.7(8) O(3)–C(7)–O(4)–I(1A)  3.9(14) 
O(1)–I(1A)–O(4)–C(7) 142.6(14) C(9A)–I(1A)–O(4)–C(7)  171.3(14) 
C(12)–S(2)–C(9)–I(2)  177.4(10) C(12)–S(2)–C(9)–C(10)  0.1(15) 
O(6)–I(2)–C(9)–S(2) 98.4(9) O(6)–I(2)–C(9)–C(10)  78.8(15) 
O(7)–I(2)–C(9)–S(2)  78.1(8) O(7)–I(2)–C(9)–C(10) 104.7(15) 
I(2)–C(9)–C(10)–C(11) 177.9(12) S(2)–C(9)–C(10)–C(11) 1(2) 
C(9)–C(10)–C(11)–C(12)  1(2) C(10)–C(11)–C(12)–S(2) 1(3) 
C(9)–S(2)–C(12)–C(11)  0.7(17) S(1A)–C(1A)–I(2A)–O(5) 77.7(16) 
S(1A)–C(1A)–I(2A)–O(8)  95.1(16) C(2A)–C(1A)–I(2A)–O(5)  108(3) 
C(2A)–C(1A)–I(2A)–O(8) 80(3) C(12A)–S(2A)–C(9A)–I(1A) 178(4) 
C(12A)–S(2A)–C(9A)–C(10A) 5(4) O(1)–I(1A)–C(9A)–S(2A) 75.1(17) 
O(1)–I(1A)–C(9A)–C(10A)  113(3) O(4)–I(1A)–C(9A)–S(2A)  95.8(18) 
O(4)–I(1A)–C(9A)–C(10A) 76(3) I(1A)–C(9A)–C(10A)–C(11A)  178(2) 
S(2A)–C(9A)–C(10A)–C(11A)  6(3) C(9A)–C(10A)–C(11A)–C(12A) 5(5) 
C(9A)–S(2A)–C(12A)–C(11A)  1(6) C(10A)–C(11A)–C(12A)–S(2A)  3(7) 
C(14)–C(13)–O(5)–I(2A)  176.8(8) O(6)–C(13)–O(5)–I(2A) 3.0(14) 
C(1A)–I(2A)–O(5)–C(13) 173.4(13) O(8)–I(2A)–O(5)–C(13)  148.0(15) 
C(14)–C(13)–O(6)–I(2)  178.8(7) O(5)–C(13)–O(6)–I(2) 1.4(13) 
C(9)–I(2)–O(6)–C(13) 177.0(9) O(7)–I(2)–O(6)–C(13)  167.5(11) 
C(16)–C(15)–O(7)–I(2) 179.5(7) O(8)–C(15)–O(7)–I(2)  1.1(12) 
C(9)–I(2)–O(7)–C(15)  176.1(8) O(6)–I(2)–O(7)–C(15) 168.5(12) 
C(16)–C(15)–O(8)–I(2A) 174.8(8) O(7)–C(15)–O(8)–I(2A)  4.5(14) 
C(1A)–I(2A)–O(8)–C(15)  171.4(13) O(5)–I(2A)–O(8)–C(15) 150.0(15) 
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Appendix II – Crystallographic Data for compounds 191-
196 
 
Compound 191 
 
Table 1.  Crystal data and structure refinement for 191. 
 
Identification code  mac117 
Chemical formula (moiety) C15H14O2I
+·C2F3O2
  
Chemical formula (total) C17H14F3IO4 
Formula weight  466.18 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 5.2851(3) Å  = 113.169(11)° 
 b = 12.8616(16) Å  = 96.508(7)° 
 c = 13.7337(15) Å  = 98.752(7)° 
Cell volume 832.71(15) Å3 
Z 2 
Calculated density  1.859 g/cm3 
Absorption coefficient  1.974 mm1 
F(000) 456 
Crystal colour and size colourless, 0.30  0.30  0.25 mm3 
Reflections for cell refinement 3467 ( range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 7 to 6, k 16 to 16, l 14 to 16 
Completeness to  = 25.0° 99.9 %  
Reflections collected 6967 
Independent reflections 3479 (Rint = 0.0466) 
Reflections with F2>2 3159 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5889 and 0.6382 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0304, 0.0204 
Data / restraints / parameters 3479 / 0 / 227 
Final R indices [F2>2] R1 = 0.0345, wR2 = 0.0736 
R indices (all data) R1 = 0.0398, wR2 = 0.0788 
Goodness-of-fit on F2 1.070 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.30 and 1.30 e Å3 
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Table 2.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for mac117.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I 0.88325(4) 0.203014(18) 0.601201(18) 0.01859(9) 
O(1) 0.0918(5) 0.2082(2) 0.9805(2) 0.0271(6) 
O(2) 0.3371(6) 0.3867(3) 1.0714(2) 0.0374(7) 
O(3) 0.8097(5)  0.2151(2) 0.5389(2) 0.0288(6) 
O(4) 0.8170(6)  0.0269(2) 0.5918(3) 0.0384(8) 
F(1) 0.4019(5)  0.1134(2) 0.6825(2) 0.0408(6) 
F(2) 0.6616(5)  0.2117(2) 0.7154(2) 0.0432(7) 
F(3) 0.7696(5)  0.0265(2) 0.7875(2) 0.0479(7) 
C(1) 0.9567(7) 0.3779(3) 0.6269(3) 0.0171(7) 
C(2) 1.1947(7) 0.4476(3) 0.6873(3) 0.0227(8) 
C(3) 1.2444(7) 0.5625(3) 0.7038(3) 0.0245(8) 
C(4) 1.0608(8) 0.6060(3) 0.6606(3) 0.0242(8) 
C(5) 0.8230(7) 0.5336(3) 0.6012(3) 0.0219(8) 
C(6) 0.7665(7) 0.4182(3) 0.5826(3) 0.0196(8) 
C(7) 0.6755(7) 0.2348(3) 0.7298(3) 0.0193(8) 
C(8) 0.4642(7) 0.1504(3) 0.7195(3) 0.0201(8) 
C(9) 0.3341(7) 0.1684(3) 0.8051(3) 0.0222(8) 
C(10) 0.4133(7) 0.2709(3) 0.8986(3) 0.0200(8) 
C(11) 0.6239(8) 0.3542(3) 0.9065(3) 0.0267(9) 
C(12) 0.7578(8) 0.3354(3) 0.8219(3) 0.0270(9) 
C(13) 0.2806(8) 0.2963(3) 0.9928(3) 0.0244(8) 
C(14)  0.0466(8) 0.2306(4) 1.0706(3) 0.0284(9) 
C(15)  0.2458(9) 0.1243(4) 1.0462(4) 0.0380(11) 
C(16) 0.7751(7)  0.1196(3) 0.5992(3) 0.0201(8) 
C(17) 0.6552(7)  0.1185(3) 0.6970(3) 0.0210(8) 
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Table 3.   Bond lengths [Å] and angles [°] for 191. 
 
I–C(1)  2.100(3) I–C(7)  2.121(4) 
O(1)–C(13)  1.333(5) O(1)–C(14)  1.462(4) 
O(2)–C(13)  1.200(5) O(3)–C(16)  1.237(4) 
O(4)–C(16)  1.225(4) F(1)–C(17)  1.346(4) 
F(2)–C(17)  1.323(4) F(3)–C(17)  1.328(5) 
C(1)–C(2)  1.382(5) C(1)–C(6)  1.385(5) 
C(2)–H(2A)  0.950 C(2)–C(3)  1.382(5) 
C(3)–H(3A)  0.950 C(3)–C(4)  1.380(5) 
C(4)–H(4A)  0.950 C(4)–C(5)  1.388(6) 
C(5)–H(5A)  0.950 C(5)–C(6)  1.381(5) 
C(6)–H(6A)  0.950 C(7)–C(8)  1.385(5) 
C(7)–C(12)  1.372(5) C(8)–H(8A)  0.950 
C(8)–C(9)  1.388(5) C(9)–H(9A)  0.950 
C(9)–C(10)  1.392(5) C(10)–C(11)  1.384(5) 
C(10)–C(13)  1.489(5) C(11)–H(11A)  0.950 
C(11)–C(12)  1.388(5) C(12)–H(12A)  0.950 
C(14)–H(14A)  0.990 C(14)–H(14B)  0.990 
C(14)–C(15)  1.486(6) C(15)–H(15A)  0.980 
C(15)–H(15B)  0.980 C(15)–H(15C)  0.980 
C(16)–C(17)  1.546(5)  
 
C(1)–I–C(7) 92.40(13) C(13)–O(1)–C(14) 114.5(3) 
I–C(1)–C(2) 118.1(2) I–C(1)–C(6) 118.9(3) 
C(2)–C(1)–C(6) 122.9(3) C(1)–C(2)–H(2A) 120.8 
C(1)–C(2)–C(3) 118.3(3) H(2A)–C(2)–C(3) 120.8 
C(2)–C(3)–H(3A) 119.7 C(2)–C(3)–C(4) 120.6(4) 
H(3A)–C(3)–C(4) 119.7 C(3)–C(4)–H(4A) 120.3 
C(3)–C(4)–C(5) 119.4(3) H(4A)–C(4)–C(5) 120.3 
C(4)–C(5)–H(5A) 119.2 C(4)–C(5)–C(6) 121.7(3) 
H(5A)–C(5)–C(6) 119.2 C(1)–C(6)–C(5) 117.1(4) 
C(1)–C(6)–H(6A) 121.5 C(5)–C(6)–H(6A) 121.5 
I–C(7)–C(8) 118.5(3) I–C(7)–C(12) 119.7(3) 
C(8)–C(7)–C(12) 121.7(3) C(7)–C(8)–H(8A) 120.6 
C(7)–C(8)–C(9) 118.9(4) H(8A)–C(8)–C(9) 120.6 
C(8)–C(9)–H(9A) 120.0 C(8)–C(9)–C(10) 120.0(3) 
H(9A)–C(9)–C(10) 120.0 C(9)–C(10)–C(11) 119.9(3) 
C(9)–C(10)–C(13) 122.8(3) C(11)–C(10)–C(13) 117.3(4) 
C(10)–C(11)–H(11A) 119.9 C(10)–C(11)–C(12) 120.2(4) 
H(11A)–C(11)–C(12) 119.9 C(7)–C(12)–C(11) 119.3(4) 
C(7)–C(12)–H(12A) 120.4 C(11)–C(12)–H(12A) 120.4 
O(1)–C(13)–O(2) 123.6(4) O(1)–C(13)–C(10) 112.9(3) 
O(2)–C(13)–C(10) 123.6(4) O(1)–C(14)–H(14A) 110.1 
O(1)–C(14)–H(14B) 110.1 O(1)–C(14)–C(15) 108.2(3) 
H(14A)–C(14)–H(14B) 108.4 H(14A)–C(14)–C(15) 110.1 
H(14B)–C(14)–C(15) 110.1 C(14)–C(15)–H(15A) 109.5 
C(14)–C(15)–H(15B) 109.5 C(14)–C(15)–H(15C) 109.5 
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H(15A)–C(15)–H(15B) 109.5 H(15A)–C(15)–H(15C) 109.5 
H(15B)–C(15)–H(15C) 109.5 O(3)–C(16)–O(4) 129.8(4) 
O(3)–C(16)–C(17) 114.7(3) O(4)–C(16)–C(17) 115.5(3) 
F(1)–C(17)–F(2) 105.7(3) F(1)–C(17)–F(3) 105.6(3) 
F(1)–C(17)–C(16) 111.0(3) F(2)–C(17)–F(3) 107.7(3) 
F(2)–C(17)–C(16) 114.0(3) F(3)–C(17)–C(16) 112.3(3) 
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Table 4.   Anisotropic displacement parameters (Å2) for 191.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I 0.02076(15)  0.01656(14) 0.02252(16)  0.01080(11) 0.00845(10) 
 0.00518(10) 
O(1) 0.0277(15)  0.0298(15) 0.0235(15)  0.0100(12) 0.0120(12) 
 0.0037(13) 
O(2) 0.051(2)  0.0299(16) 0.0278(17)  0.0076(14) 0.0177(15) 
 0.0022(15) 
O(3) 0.0350(16)  0.0187(14) 0.0339(17)  0.0090(13) 0.0179(14) 
 0.0066(12) 
O(4) 0.061(2)  0.0245(16) 0.0427(19)  0.0210(15) 0.0293(17) 
 0.0123(15) 
F(1) 0.0282(13)  0.0539(17) 0.0566(18)  0.0343(15) 0.0231(13) 
 0.0132(12) 
F(2) 0.0658(18)  0.0401(15) 0.0511(17)  0.0364(14) 0.0345(15) 
 0.0248(14) 
F(3) 0.0584(18)  0.0436(16) 0.0232(14)  0.0017(12) 0.0124(13)   
0.0112(13) 
C(1) 0.0195(18)  0.0155(17) 0.0206(19)  0.0092(15) 0.0113(15) 
 0.0058(15) 
C(2) 0.0195(19)  0.027(2) 0.026(2)  0.0135(17) 0.0076(17) 
 0.0067(16) 
C(3) 0.023(2)  0.023(2) 0.024(2)  0.0067(16) 0.0090(17)   
0.0001(17) 
C(4) 0.031(2)  0.0182(19) 0.027(2)  0.0101(17) 0.0151(18) 
 0.0073(17) 
C(5) 0.026(2)  0.022(2) 0.023(2)  0.0128(17) 0.0078(17) 
 0.0084(17) 
C(6) 0.0190(19)  0.0216(19) 0.020(2)  0.0094(16) 0.0075(16) 
 0.0063(16) 
C(7) 0.0215(19)  0.0213(19) 0.020(2)  0.0114(16) 0.0079(16) 
 0.0086(16) 
C(8) 0.0202(19)  0.0187(18) 0.022(2)  0.0086(16) 0.0047(16) 
 0.0055(15) 
C(9) 0.0203(19)  0.0218(19) 0.025(2)  0.0114(16) 0.0054(16) 
 0.0012(16) 
C(10) 0.0207(19)  0.024(2) 0.020(2)  0.0136(16) 0.0035(16) 
 0.0068(16) 
C(11) 0.034(2)  0.021(2) 0.024(2)  0.0095(17) 0.0080(18) 
 0.0025(17) 
C(12) 0.030(2)  0.023(2) 0.029(2)  0.0129(18) 0.0075(18) 
 0.0011(17) 
C(13) 0.028(2)  0.024(2) 0.027(2)  0.0132(18) 0.0087(18) 
 0.0101(17) 
C(14) 0.030(2)  0.039(2) 0.021(2)  0.0138(18) 0.0143(18) 
 Appendix I – Crystallographic Data for compounds 205 and 206 
 
268 
 
 0.0081(19) 
C(15) 0.039(3)  0.046(3) 0.037(3)  0.023(2) 0.021(2)  0.008(2) 
C(16) 0.0172(18)  0.0165(18) 0.027(2)  0.0103(16) 0.0050(16) 
 0.0011(15) 
C(17) 0.023(2)  0.0181(19) 0.021(2)  0.0084(16) 0.0057(16) 
 0.0031(16) 
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Table 5.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 191. 
 
      x       y       z       U 
 
H(2A) 1.3209 0.4172 0.7167 0.027 
H(3A) 1.4065 0.6120 0.7453 0.029 
H(4A) 1.0968 0.6848 0.6714 0.029 
H(5A) 0.6958 0.5642 0.5727 0.026 
H(6A) 0.6042 0.3686 0.5413 0.024 
H(8A) 0.4093 0.0814 0.6549 0.024 
H(9A) 0.1910 0.1108 0.7999 0.027 
H(11A) 0.6768 0.4244 0.9700 0.032 
H(12A) 0.9049 0.3916 0.8278 0.032 
H(14A)  0.1318 0.2964 1.0801 0.034 
H(14B) 0.0775 0.2504 1.1381 0.034 
H(15A)  0.3411 0.1377 1.1057 0.057 
H(15B)  0.1596 0.0598 1.0373 0.057 
H(15C)  0.3681 0.1056 0.9794 0.057 
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Table 6.  Torsion angles [°] for 191. 
 
C(7)–I–C(1)–C(2) 97.2(3) C(7)–I–C(1)–C(6)  83.0(3) 
I–C(1)–C(2)–C(3) 179.6(3) C(6)–C(1)–C(2)–C(3)  0.2(5) 
C(1)–C(2)–C(3)–C(4)  0.2(5) C(2)–C(3)–C(4)–C(5) 0.8(6) 
C(3)–C(4)–C(5)–C(6)  1.1(6) C(4)–C(5)–C(6)–C(1) 0.7(5) 
I–C(1)–C(6)–C(5)  179.9(2) C(2)–C(1)–C(6)–C(5)  0.1(5) 
C(1)–I–C(7)–C(8) 145.0(3) C(1)–I–C(7)–C(12)  37.3(3) 
I–C(7)–C(8)–C(9) 177.3(2) C(12)–C(7)–C(8)–C(9)  0.3(5) 
C(7)–C(8)–C(9)–C(10) 1.2(5) C(8)–C(9)–C(10)–C(11)  0.8(5) 
C(8)–C(9)–C(10)–C(13) 179.3(3) C(9)–C(10)–C(11)–C(12)  0.6(5) 
C(13)–C(10)–C(11)–C(12) 179.4(3) I–C(7)–C(12)–C(11)  178.6(3) 
C(8)–C(7)–C(12)–C(11)  1.0(5) C(10)–C(11)–C(12)–C(7) 1.5(5) 
C(14)–O(1)–C(13)–O(2) 0.9(5) C(14)–O(1)–C(13)–C(10)  178.9(3) 
C(9)–C(10)–C(13)–O(1) 4.2(5) C(9)–C(10)–C(13)–O(2)  175.7(4) 
C(11)–C(10)–C(13)–O(1)  175.8(3) C(11)–C(10)–C(13)–O(2) 4.3(5) 
C(13)–O(1)–C(14)–C(15)  178.9(3) O(3)–C(16)–C(17)–F(1)  104.7(4) 
O(3)–C(16)–C(17)–F(2) 14.4(5) O(3)–C(16)–C(17)–F(3) 137.3(3) 
O(4)–C(16)–C(17)–F(1) 74.0(4) O(4)–C(16)–C(17)–F(2)  166.9(3) 
O(4)–C(16)–C(17)–F(3)  44.1(5)  
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Table 7.  Crystal data and structure refinement for 192. 
 
Identification code  mac12 
Chemical formula (moiety) C16H16O3I
+·C2O2F3
 ·C2H4O2 
Chemical formula (total) C20H20F3IO7 
Formula weight  556.26 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.1419(3) Å  = 94.411(3)° 
 b = 10.6745(4) Å  = 107.271(4)° 
 c = 13.2025(6) Å  = 91.471(3)° 
Cell volume 1091.04(8) Å3 
Z 2 
Calculated density  1.693 g/cm3 
Absorption coefficient  1.531 mm1 
F(000) 552 
Crystal colour and size colourless, 0.40  0.30  0.30 mm3 
Reflections for cell refinement 5049 ( range 3.2 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.2 to 28.6° 
Index ranges h 9 to 10, k 13 to 14, l 17 to 14 
Completeness to  = 25.0° 99.8 %  
Reflections collected 8569 
Independent reflections 4499 (Rint = 0.0279) 
Reflections with F2>2 4025 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5794 and 0.6565 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0264, 0.7938 
Data / restraints / parameters 4499 / 1 / 311 
Final R indices [F2>2] R1 = 0.0323, wR2 = 0.0694 
R indices (all data) R1 = 0.0393, wR2 = 0.0738 
Goodness-of-fit on F2 1.095 
Extinction coefficient 0.0000(3) 
Largest and mean shift/su 1.561 and 0.005 
Largest diff. peak and hole 0.77 and 0.50 e Å3 
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Table 8.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 192.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I(1) 1.62883(3) 0.050390(19) 0.364561(17) 0.02348(9) 
O(1) 2.0142(3)  0.1744(2)  0.01436(19) 0.0286(5) 
O(2) 2.2593(3)  0.1083(2) 0.1129(2) 0.0358(6) 
O(3) 1.4415(3) 0.5220(2) 0.1162(2) 0.0347(6) 
O(4) 1.2275(4) 0.1836(2) 0.5649(2) 0.0490(8) 
O(5) 1.3874(4) 0.1377(2) 0.4602(2) 0.0410(7) 
F(1) 1.1434(4) 0.3069(3) 0.3464(2) 0.0825(10) 
F(2) 1.3855(3) 0.3900(2) 0.4337(3) 0.0748(10) 
F(3) 1.1734(4) 0.4077(2) 0.4939(2) 0.0721(9) 
C(1) 1.7864(4)  0.0069(3) 0.2702(3) 0.0208(7) 
C(2) 1.7077(4)  0.0539(3) 0.1663(3) 0.0224(7) 
C(3) 1.8107(4)  0.0903(3) 0.1038(3) 0.0228(7) 
C(4) 1.9899(4)  0.0795(3) 0.1459(3) 0.0207(7) 
C(5) 2.0649(4)  0.0300(3) 0.2505(3) 0.0241(7) 
C(6) 1.9635(4) 0.0061(3) 0.3147(3) 0.0237(7) 
C(7) 2.1048(4)  0.1210(3) 0.0812(3) 0.0244(7) 
C(8) 2.1077(5)  0.2350(3)  0.0819(3) 0.0326(8) 
C(9) 2.1029(5)  0.3729(4)  0.0737(4) 0.0443(10) 
C(10) 1.5671(4) 0.2138(3) 0.2849(3) 0.0215(7) 
C(11) 1.6751(4) 0.3205(3) 0.3190(3) 0.0265(7) 
C(12) 1.6372(4) 0.4265(3) 0.2639(3) 0.0265(7) 
C(13) 1.4912(4) 0.4247(3) 0.1764(3) 0.0235(7) 
C(14) 1.3846(4) 0.3160(3) 0.1437(3) 0.0276(8) 
C(15) 1.4209(4) 0.2100(3) 0.1979(3) 0.0263(7) 
C(16) 1.5513(5) 0.6338(3) 0.1402(4) 0.0401(10) 
C(17) 1.2496(5) 0.3295(3) 0.4432(3) 0.0310(8) 
C(18) 1.2950(4) 0.2054(3) 0.4954(3) 0.0254(7) 
O(7) 1.0830(7) 0.7367(6) 0.4212(5) 0.0408(16) 
O(6) 0.9611(6) 0.6427(5) 0.2620(5) 0.0539(18) 
C(20) 1.2643(9) 0.6660(8) 0.3267(6) 0.049(2) 
O(6A) 0.9213(19) 0.6897(16) 0.3157(15) 0.045(6) 
C(20A) 1.194(10) 0.645(4) 0.267(6) 0.27(5) 
O(7A) 1.133(6) 0.756(3) 0.444(3) 0.140(18) 
C(19) 1.0904(5) 0.6821(4) 0.3373(4) 0.0456(11) 
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Table 9.   Bond lengths [Å] and angles [°] for 192. 
 
I(1)–C(1)  2.108(3) I(1)–C(10)  2.100(3) 
O(1)–C(7)  1.333(4) O(1)–C(8)  1.461(4) 
O(2)–C(7)  1.203(4) O(3)–C(13)  1.353(4) 
O(3)–C(16)  1.430(4) O(4)–C(18)  1.235(4) 
O(5)–C(18)  1.220(4) F(1)–C(17)  1.312(4) 
F(2)–C(17)  1.310(4) F(3)–C(17)  1.311(4) 
C(1)–C(2)  1.378(5) C(1)–C(6)  1.385(4) 
C(2)–H(2A)  0.950 C(2)–C(3)  1.384(5) 
C(3)–H(3A)  0.950 C(3)–C(4)  1.397(4) 
C(4)–C(5)  1.389(5) C(4)–C(7)  1.496(5) 
C(5)–H(5A)  0.950 C(5)–C(6)  1.389(5) 
C(6)–H(6A)  0.950 C(8)–H(8A)  0.990 
C(8)–H(8B)  0.990 C(8)–C(9)  1.484(5) 
C(9)–H(9A)  0.980 C(9)–H(9B)  0.980 
C(9)–H(9C)  0.980 C(10)–C(11)  1.382(5) 
C(10)–C(15)  1.385(5) C(11)–H(11A)  0.950 
C(11)–C(12)  1.384(4) C(12)–H(12A)  0.950 
C(12)–C(13)  1.388(5) C(13)–C(14)  1.391(5) 
C(14)–H(14A)  0.950 C(14)–C(15)  1.376(5) 
C(15)–H(15A)  0.950 C(16)–H(16A)  0.980 
C(16)–H(16B)  0.980 C(16)–H(16C)  0.980 
C(17)–C(18)  1.543(5) O(7)–C(19)  1.230(8) 
O(6)–C(19)  1.251(6) C(20)–H(20A)  0.980 
C(20)–H(20B)  0.980 C(20)–H(20C)  0.980 
C(20)–C(19)  1.477(8) O(6A)–C(19)  1.326(17) 
C(20A)–H(20D)  0.980 C(20A)–H(20E)  0.980 
C(20A)–H(20F)  0.980 C(20A)–C(19)  1.469(19) 
O(7A)–C(19)  1.50(3)  
 
C(1)–I(1)–C(10) 91.74(12) C(7)–O(1)–C(8) 118.2(3) 
C(13)–O(3)–C(16) 118.1(3) I(1)–C(1)–C(2) 118.2(2) 
I(1)–C(1)–C(6) 118.7(2) C(2)–C(1)–C(6) 123.1(3) 
C(1)–C(2)–H(2A) 120.8 C(1)–C(2)–C(3) 118.4(3) 
H(2A)–C(2)–C(3) 120.8 C(2)–C(3)–H(3A) 119.9 
C(2)–C(3)–C(4) 120.3(3) H(3A)–C(3)–C(4) 119.9 
C(3)–C(4)–C(5) 119.8(3) C(3)–C(4)–C(7) 121.6(3) 
C(5)–C(4)–C(7) 118.6(3) C(4)–C(5)–H(5A) 119.7 
C(4)–C(5)–C(6) 120.7(3) H(5A)–C(5)–C(6) 119.7 
C(1)–C(6)–C(5) 117.7(3) C(1)–C(6)–H(6A) 121.1 
C(5)–C(6)–H(6A) 121.1 O(1)–C(7)–O(2) 124.9(3) 
O(1)–C(7)–C(4) 111.5(3) O(2)–C(7)–C(4) 123.6(3) 
O(1)–C(8)–H(8A) 109.8 O(1)–C(8)–H(8B) 109.8 
O(1)–C(8)–C(9) 109.5(3) H(8A)–C(8)–H(8B) 108.2 
H(8A)–C(8)–C(9) 109.8 H(8B)–C(8)–C(9) 109.8 
C(8)–C(9)–H(9A) 109.5 C(8)–C(9)–H(9B) 109.5 
C(8)–C(9)–H(9C) 109.5 H(9A)–C(9)–H(9B) 109.5 
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H(9A)–C(9)–H(9C) 109.5 H(9B)–C(9)–H(9C) 109.5 
I(1)–C(10)–C(11) 119.3(2) I(1)–C(10)–C(15) 118.7(2) 
C(11)–C(10)–C(15) 121.9(3) C(10)–C(11)–H(11A) 120.5 
C(10)–C(11)–C(12) 119.1(3) H(11A)–C(11)–C(12) 120.5 
C(11)–C(12)–H(12A) 120.1 C(11)–C(12)–C(13) 119.9(3) 
H(12A)–C(12)–C(13) 120.1 O(3)–C(13)–C(12) 125.2(3) 
O(3)–C(13)–C(14) 114.9(3) C(12)–C(13)–C(14) 119.9(3) 
C(13)–C(14)–H(14A) 119.6 C(13)–C(14)–C(15) 120.8(3) 
H(14A)–C(14)–C(15) 119.6 C(10)–C(15)–C(14) 118.4(3) 
C(10)–C(15)–H(15A) 120.8 C(14)–C(15)–H(15A) 120.8 
O(3)–C(16)–H(16A) 109.5 O(3)–C(16)–H(16B) 109.5 
O(3)–C(16)–H(16C) 109.5 H(16A)–C(16)–H(16B) 109.5 
H(16A)–C(16)–H(16C) 109.5 H(16B)–C(16)–H(16C) 109.5 
F(1)–C(17)–F(2) 106.3(3) F(1)–C(17)–F(3) 106.0(3) 
F(1)–C(17)–C(18) 110.4(3) F(2)–C(17)–F(3) 107.4(3) 
F(2)–C(17)–C(18) 112.1(3) F(3)–C(17)–C(18) 114.1(3) 
O(4)–C(18)–O(5) 127.4(3) O(4)–C(18)–C(17) 116.1(3) 
O(5)–C(18)–C(17) 116.4(3) H(20A)–C(20)–H(20B) 109.5 
H(20A)–C(20)–H(20C) 109.5 H(20A)–C(20)–C(19) 109.5 
H(20B)–C(20)–H(20C) 109.5 H(20B)–C(20)–C(19) 109.5 
H(20C)–C(20)–C(19) 109.5 H(20D)–C(20A)–H(20E) 109.5 
H(20D)–C(20A)–H(20F) 109.5 H(20D)–C(20A)–C(19) 109.5 
H(20E)–C(20A)–H(20F) 109.5 H(20E)–C(20A)–C(19) 109.5 
H(20F)–C(20A)–C(19) 109.5 O(7)–C(19)–O(6) 124.0(5) 
O(7)–C(19)–C(20) 116.5(5) O(7)–C(19)–O(6A) 79.8(10) 
O(7)–C(19)–C(20A) 149(3) O(7)–C(19)–O(7A) 15.5(18) 
O(6)–C(19)–C(20) 119.5(6) O(6)–C(19)–O(6A) 44.4(8) 
O(6)–C(19)–C(20A) 87(3) O(6)–C(19)–O(7A) 139.2(17) 
C(20)–C(19)–O(6A) 162.9(11) C(20)–C(19)–C(20A) 33(4) 
C(20)–C(19)–O(7A) 101.1(18) O(6A)–C(19)–C(20A) 130(4) 
O(6A)–C(19)–O(7A) 94.8(18) C(20A)–C(19)–O(7A) 133(3) 
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Table 10.   Anisotropic displacement parameters (Å2) for 192.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I(1) 0.02970(13)  0.02115(13) 0.02352(13)  0.00311(9) 0.01367(10) 
 0.00133(8) 
O(1) 0.0294(12)  0.0331(13) 0.0257(14)   0.0038(11) 0.0136(11) 
 0.0018(10) 
O(2) 0.0224(12)  0.0465(16) 0.0387(16)   0.0038(12) 0.0117(12)   
0.0012(11) 
O(3) 0.0325(13)  0.0262(13) 0.0417(16)  0.0126(12) 0.0032(12) 
 0.0001(10) 
O(4) 0.077(2)  0.0382(16) 0.056(2)  0.0207(14) 0.0510(18) 
 0.0219(15) 
O(5) 0.0555(17)  0.0331(14) 0.0497(18)  0.0110(13) 0.0363(15) 
 0.0157(12) 
F(1) 0.115(2)  0.0559(17) 0.0470(18)  0.0121(14)  0.0241(18) 
 0.0092(16) 
F(2) 0.0636(17)  0.0449(15) 0.133(3)  0.0413(17) 0.0473(19) 
 0.0005(13) 
F(3) 0.128(3)  0.0395(14) 0.081(2)  0.0216(14) 0.073(2)  0.0394(16) 
C(1) 0.0270(16)  0.0182(16) 0.0217(17)  0.0039(13) 0.0138(14)   
0.0013(13) 
C(2) 0.0192(15)  0.0243(17) 0.0234(18)  0.0011(14) 0.0062(14) 
 0.0009(13) 
C(3) 0.0245(16)  0.0222(16) 0.0200(17)   0.0026(13) 0.0052(14)   
0.0012(13) 
C(4) 0.0242(16)  0.0167(15) 0.0246(18)  0.0052(13) 0.0118(14)   
0.0006(12) 
C(5) 0.0221(16)  0.0246(17) 0.0251(18)  0.0034(14) 0.0065(14)   
0.0033(13) 
C(6) 0.0278(17)  0.0217(17) 0.0206(17)  0.0019(14) 0.0063(14)   
0.0055(13) 
C(7) 0.0258(17)  0.0221(17) 0.0285(19)  0.0053(14) 0.0119(15) 
 0.0024(13) 
C(8) 0.0362(19)  0.037(2) 0.030(2)   0.0002(16) 0.0184(17) 
 0.0052(16) 
C(9) 0.046(2)  0.036(2) 0.059(3)  0.004(2) 0.028(2)  0.0123(18) 
C(10) 0.0275(16)  0.0194(16) 0.0211(17)  0.0026(13) 0.0124(14) 
 0.0021(13) 
C(11) 0.0249(16)  0.0267(18) 0.0260(19)  0.0026(15) 0.0049(15)   
0.0008(14) 
C(12) 0.0268(17)  0.0216(17) 0.031(2)  0.0014(15) 0.0097(15)   
0.0043(13) 
C(13) 0.0214(15)  0.0231(17) 0.0278(19)  0.0046(14) 0.0094(14) 
 0.0028(13) 
C(14) 0.0231(16)  0.0291(18) 0.0280(19)  0.0022(15) 0.0039(15)   
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0.0005(14) 
C(15) 0.0274(17)  0.0235(17) 0.0283(19)   0.0009(15) 0.0102(15)   
0.0054(14) 
C(16) 0.038(2)  0.0245(19) 0.057(3)  0.0147(19) 0.011(2)   
0.0006(16) 
C(17) 0.039(2)  0.0290(19) 0.029(2)  0.0027(16) 0.0155(17) 
 0.0017(16) 
C(18) 0.0301(17)  0.0214(17) 0.0252(19)  0.0026(14) 0.0090(16)   
0.0020(14) 
O(7) 0.045(3)  0.046(4) 0.037(4)  0.009(3) 0.020(2)  0.013(2) 
O(6) 0.040(2)  0.056(3) 0.054(4)   0.010(3) 0.002(2)   0.008(2) 
C(20) 0.055(4)  0.043(5) 0.058(4)  0.017(3) 0.028(3)  0.015(3) 
O(6A) 0.049(9)  0.041(9) 0.048(11)   0.002(8) 0.021(7)   0.020(6) 
C(20A) 0.37(9)  0.05(2) 0.58(13)   0.05(5) 0.44(11)   0.01(4) 
O(7A) 0.31(5)  0.032(11) 0.037(13)   0.008(9)  0.01(2)   0.041(18) 
C(19) 0.042(2)  0.037(2) 0.057(3)  0.023(2) 0.010(2)  0.0015(19) 
 Appendix I – Crystallographic Data for compounds 205 and 206 
 
277 
 
Table 11.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 192. 
 
      x       y       z       U 
 
H(2A) 1.5857  0.0612 0.1384 0.027 
H(3A) 1.7593  0.1228 0.0319 0.027 
H(5A) 2.1868  0.0207 0.2784 0.029 
H(6A) 2.0140 0.0385 0.3867 0.028 
H(8A) 2.2287  0.2012  0.0591 0.039 
H(8B) 2.0544  0.2172  0.1568 0.039 
H(9A) 2.1645  0.4136  0.1197 0.067 
H(9B) 1.9830  0.4059  0.0963 0.067 
H(9C) 2.1581  0.3901 0.0002 0.067 
H(11A) 1.7740 0.3212 0.3795 0.032 
H(12A) 1.7110 0.5003 0.2859 0.032 
H(14A) 1.2855 0.3149 0.0834 0.033 
H(15A) 1.3475 0.1361 0.1761 0.032 
H(16A) 1.4989 0.6967 0.0917 0.060 
H(16B) 1.6635 0.6141 0.1314 0.060 
H(16C) 1.5669 0.6673 0.2138 0.060 
H(20A) 1.2548 0.6217 0.2572 0.073 
H(20B) 1.3306 0.6169 0.3833 0.073 
H(20C) 1.3230 0.7487 0.3325 0.073 
H(20D) 1.3165 0.6628 0.3054 0.411 
H(20E) 1.1622 0.6937 0.2044 0.411 
H(20F) 1.1730 0.5554 0.2441 0.411 
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Compound 193 
 
Table 12.  Crystal data and structure refinement for 193. 
 
Identification code  mac116 
Chemical formula (moiety) C15H12F3IO4S 
Chemical formula (total) C15H12F3IO4S 
Formula weight  472.21 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.0310(4) Å  = 113.271(6)° 
 b = 9.7726(6) Å  = 93.574(5)° 
 c = 11.7901(7) Å  = 100.238(5)° 
Cell volume 827.48(8) Å3 
Z 2 
Calculated density  1.895 g/cm3 
Absorption coefficient  2.109 mm1 
F(000) 460 
Reflections for cell refinement 2826 ( range 3.0 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 28.5° 
Index ranges h 10 to 8, k 12 to 10, l 14 to 15 
Completeness to  = 25.0° 99.8 %  
Reflections collected 6081 
Independent reflections 3430 (Rint = 0.0431) 
Reflections with F2>2 3153 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.72417 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0324, 0.9665 
Data / restraints / parameters 3430 / 0 / 218 
Final R indices [F2>2] R1 = 0.0326, wR2 = 0.0749 
R indices (all data) R1 = 0.0376, wR2 = 0.0815 
Goodness-of-fit on F2 1.084 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.97 and 0.97 e Å3 
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Table 13.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 193.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I 0.73610(2) 0.80544(2) 0.38224(2) 0.01508(9) 
S 0.81437(14) 0.55660(13) 0.11302(11) 0.0303(2) 
O(1)  0.0214(3) 0.2790(3) 0.3125(3) 0.0229(6) 
O(2)  0.1252(3) 0.4901(3) 0.3669(3) 0.0254(6) 
O(3) 0.6873(3) 0.8989(3) 0.6188(3) 0.0226(6) 
O(4) 0.9490(3) 1.0401(3) 0.6466(3) 0.0261(6) 
F(1) 0.7599(4) 1.1603(4) 0.8703(3) 0.0566(9) 
F(2) 0.9842(3) 1.0770(4) 0.8853(3) 0.0429(7) 
F(3) 0.7411(4) 0.9326(3) 0.8546(3) 0.0480(8) 
C(1)  0.2850(6) 0.1564(6) 0.1661(5) 0.0367(11) 
C(2)  0.1949(5) 0.1897(5) 0.2922(4) 0.0233(9) 
C(3)  0.0067(4) 0.4275(4) 0.3473(4) 0.0177(8) 
C(4) 0.1723(4) 0.5124(4) 0.3598(4) 0.0158(7) 
C(5) 0.3123(4) 0.4440(4) 0.3522(4) 0.0181(8) 
C(6) 0.4748(5) 0.5275(4) 0.3615(4) 0.0185(8) 
C(7) 0.4932(4) 0.6785(4) 0.3771(3) 0.0146(7) 
C(8) 0.3570(5) 0.7481(4) 0.3857(4) 0.0203(8) 
C(9) 0.1961(5) 0.6640(4) 0.3768(4) 0.0197(8) 
C(10) 0.7191(5) 0.7031(4) 0.1891(4) 0.0202(8) 
C(11) 0.6331(5) 0.7477(5) 0.1084(4) 0.0227(8) 
C(12) 0.6508(6) 0.6574(5)  0.0164(4) 0.0329(10) 
C(13) 0.7436(5) 0.5518(5)  0.0279(4) 0.0321(10) 
C(14) 0.8244(4) 0.9871(4) 0.6821(4) 0.0160(7) 
C(15) 0.8284(5) 1.0392(5) 0.8240(4) 0.0220(8) 
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Table 14.   Bond lengths [Å] and angles [°] for 193. 
 
I–C(7)  2.101(3) I–C(10)  2.078(4) 
S–C(10)  1.703(4) S–C(13)  1.702(5) 
O(1)–C(2)  1.457(4) O(1)–C(3)  1.323(4) 
O(2)–C(3)  1.206(4) O(3)–C(14)  1.251(4) 
O(4)–C(14)  1.218(4) F(1)–C(15)  1.327(5) 
F(2)–C(15)  1.318(5) F(3)–C(15)  1.332(5) 
C(1)–H(1A)  0.980 C(1)–H(1B)  0.980 
C(1)–H(1C)  0.980 C(1)–C(2)  1.496(6) 
C(2)–H(2A)  0.990 C(2)–H(2B)  0.990 
C(3)–C(4)  1.494(5) C(4)–C(5)  1.396(5) 
C(4)–C(9)  1.390(5) C(5)–H(5)  0.950 
C(5)–C(6)  1.383(5) C(6)–H(6)  0.950 
C(6)–C(7)  1.392(5) C(7)–C(8)  1.376(5) 
C(8)–H(8)  0.950 C(8)–C(9)  1.376(5) 
C(9)–H(9)  0.950 C(10)–C(11)  1.388(5) 
C(11)–H(11)  0.950 C(11)–C(12)  1.416(6) 
C(12)–H(12)  0.950 C(12)–C(13)  1.347(7) 
C(13)–H(13)  0.950 C(14)–C(15)  1.541(5) 
 
C(7)–I–C(10) 91.97(14) C(10)–S–C(13) 91.5(2) 
C(2)–O(1)–C(3) 115.7(3) H(1A)–C(1)–H(1B) 109.5 
H(1A)–C(1)–H(1C) 109.5 H(1A)–C(1)–C(2) 109.5 
H(1B)–C(1)–H(1C) 109.5 H(1B)–C(1)–C(2) 109.5 
H(1C)–C(1)–C(2) 109.5 O(1)–C(2)–C(1) 110.8(3) 
O(1)–C(2)–H(2A) 109.5 O(1)–C(2)–H(2B) 109.5 
C(1)–C(2)–H(2A) 109.5 C(1)–C(2)–H(2B) 109.5 
H(2A)–C(2)–H(2B) 108.1 O(1)–C(3)–O(2) 124.0(3) 
O(1)–C(3)–C(4) 113.5(3) O(2)–C(3)–C(4) 122.4(3) 
C(3)–C(4)–C(5) 122.4(3) C(3)–C(4)–C(9) 117.4(3) 
C(5)–C(4)–C(9) 120.1(3) C(4)–C(5)–H(5) 120.1 
C(4)–C(5)–C(6) 119.9(3) H(5)–C(5)–C(6) 120.1 
C(5)–C(6)–H(6) 120.8 C(5)–C(6)–C(7) 118.3(3) 
H(6)–C(6)–C(7) 120.8 I–C(7)–C(6) 119.4(2) 
I–C(7)–C(8) 117.9(3) C(6)–C(7)–C(8) 122.6(3) 
C(7)–C(8)–H(8) 120.8 C(7)–C(8)–C(9) 118.4(3) 
H(8)–C(8)–C(9) 120.8 C(4)–C(9)–C(8) 120.6(3) 
C(4)–C(9)–H(9) 119.7 C(8)–C(9)–H(9) 119.7 
I–C(10)–S 123.1(2) I–C(10)–C(11) 124.3(3) 
S–C(10)–C(11) 112.7(3) C(10)–C(11)–H(11) 125.1 
C(10)–C(11)–C(12) 109.7(4) H(11)–C(11)–C(12) 125.1 
C(11)–C(12)–H(12) 122.9 C(11)–C(12)–C(13) 114.2(4) 
H(12)–C(12)–C(13) 122.9 S–C(13)–C(12) 111.8(3) 
S–C(13)–H(13) 124.1 C(12)–C(13)–H(13) 124.1 
O(3)–C(14)–O(4) 128.8(4) O(3)–C(14)–C(15) 113.9(3) 
O(4)–C(14)–C(15) 117.2(3) F(1)–C(15)–F(2) 107.3(4) 
F(1)–C(15)–F(3) 106.9(3) F(1)–C(15)–C(14) 110.1(3) 
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F(2)–C(15)–F(3) 105.7(3) F(2)–C(15)–C(14) 113.2(3) 
F(3)–C(15)–C(14) 113.2(3)  
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Table 15.   Anisotropic displacement parameters (Å2) for 193.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I 0.01236(14)  0.01063(14) 0.02036(15)  0.00567(11) 0.00207(9)   
0.00022(9) 
S 0.0331(6)  0.0274(6) 0.0271(6)  0.0062(5) 0.0075(4)  0.0097(5) 
O(1) 0.0136(13)  0.0148(14) 0.0391(18)  0.0118(13) 0.0027(11)   
0.0013(10) 
O(2) 0.0147(13)  0.0178(15) 0.0408(19)  0.0092(14) 0.0060(12) 
 0.0024(11) 
O(3) 0.0160(13)  0.0224(15) 0.0245(16)  0.0080(13) 0.0004(11)   
0.0032(11) 
O(4) 0.0209(14)  0.0252(16) 0.0305(17)  0.0134(14) 0.0055(11)   
0.0043(11) 
F(1) 0.085(2)  0.054(2) 0.0331(18)  0.0062(15) 0.0167(16) 
 0.0450(18) 
F(2) 0.0293(14)  0.063(2) 0.0269(15)  0.0148(14)  0.0044(11)   
0.0024(13) 
F(3) 0.0568(18)  0.0474(19) 0.0294(16)  0.0179(14) 0.0073(13)   
0.0194(14) 
C(1) 0.028(2)  0.031(3) 0.041(3)  0.011(2)  0.009(2)   
0.0048(19) 
C(2) 0.0165(18)  0.016(2) 0.036(2)  0.0117(18) 0.0012(16)   
0.0026(15) 
C(3) 0.0148(18)  0.016(2) 0.022(2)  0.0093(17) 0.0016(14)   
0.0001(14) 
C(4) 0.0152(17)  0.0122(19) 0.0187(19)  0.0059(16) 0.0011(13) 
 0.0013(14) 
C(5) 0.0177(18)  0.0113(19) 0.024(2)  0.0075(16) 0.0005(14) 
 0.0011(14) 
C(6) 0.0164(18)  0.0133(19) 0.025(2)  0.0070(17) 0.0034(14) 
 0.0030(14) 
C(7) 0.0095(16)  0.0157(19) 0.0152(18)  0.0048(15) 0.0011(13)   
0.0018(13) 
C(8) 0.0232(19)  0.0095(19) 0.028(2)  0.0066(17) 0.0036(15) 
 0.0044(15) 
C(9) 0.0166(18)  0.019(2) 0.025(2)  0.0093(17) 0.0052(15) 
 0.0059(15) 
C(10) 0.0169(18)  0.014(2) 0.023(2)  0.0044(17) 0.0052(15)   
0.0032(14) 
C(11) 0.024(2)  0.019(2) 0.024(2)  0.0087(18) 0.0028(15) 
 0.0013(16) 
C(12) 0.034(2)  0.036(3) 0.025(2)  0.015(2)  0.0009(18)   
0.006(2) 
C(13) 0.030(2)  0.031(3) 0.022(2)  0.001(2) 0.0076(17)   
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0.0033(19) 
C(14) 0.0174(18)  0.0075(18) 0.023(2)  0.0068(16) 0.0023(14) 
 0.0020(14) 
C(15) 0.0177(19)  0.020(2) 0.024(2)  0.0054(17) 0.0038(15) 
 0.0012(15) 
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Table 15.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 193. 
 
      x       y       z       U 
 
H(1A)  0.4030 0.1006 0.1559 0.055 
H(1B)  0.2255 0.0942 0.1015 0.055 
H(1C)  0.2854 0.2525 0.1584 0.055 
H(2A)  0.2590 0.2469 0.3573 0.028 
H(2B)  0.1910 0.0925 0.2990 0.028 
H(5) 0.2959 0.3404 0.3406 0.022 
H(6) 0.5714 0.4829 0.3574 0.022 
H(8) 0.3737 0.8519 0.3976 0.024 
H(9) 0.1004 0.7100 0.3823 0.024 
H(11) 0.5716 0.8268 0.1330 0.027 
H(12) 0.6014 0.6701  0.0859 0.039 
H(13) 0.7669 0.4829  0.1054 0.039 
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Table 16.  Torsion angles [°] for 193. 
 
C(3)–O(1)–C(2)–C(1) 80.9(4) C(2)–O(1)–C(3)–O(2) 3.1(5) 
C(2)–O(1)–C(3)–C(4)  176.7(3) O(1)–C(3)–C(4)–C(5)  8.3(5) 
O(1)–C(3)–C(4)–C(9) 170.2(3) O(2)–C(3)–C(4)–C(5) 171.9(4) 
O(2)–C(3)–C(4)–C(9)  9.6(6) C(3)–C(4)–C(5)–C(6) 178.4(4) 
C(9)–C(4)–C(5)–C(6) 0.0(6) C(4)–C(5)–C(6)–C(7)  0.7(6) 
C(5)–C(6)–C(7)–I  176.8(3) C(5)–C(6)–C(7)–C(8) 1.2(6) 
C(10)–I–C(7)–C(6) 79.1(3) C(10)–I–C(7)–C(8)  99.0(3) 
I–C(7)–C(8)–C(9) 177.1(3) C(6)–C(7)–C(8)–C(9)  0.9(6) 
C(7)–C(8)–C(9)–C(4) 0.2(6) C(3)–C(4)–C(9)–C(8)  178.3(4) 
C(5)–C(4)–C(9)–C(8) 0.3(6) C(13)–S–C(10)–I  178.3(2) 
C(13)–S–C(10)–C(11) 0.4(3) C(7)–I–C(10)–S  99.7(2) 
C(7)–I–C(10)–C(11) 81.7(3) I–C(10)–C(11)–C(12) 178.3(3) 
S–C(10)–C(11)–C(12)  0.4(4) C(10)–C(11)–C(12)–C(13) 0.2(5) 
C(11)–C(12)–C(13)–S 0.1(5) C(10)–S–C(13)–C(12)  0.3(3) 
O(3)–C(14)–C(15)–F(1)  85.8(4) O(3)–C(14)–C(15)–F(2) 154.1(3) 
O(3)–C(14)–C(15)–F(3) 33.8(5) O(4)–C(14)–C(15)–F(1) 91.5(4) 
O(4)–C(14)–C(15)–F(2)  28.6(5) O(4)–C(14)–C(15)–F(3)  149.0(3) 
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Compound 194 
Table 17.  Crystal data and structure refinement for 194. 
 
Identification code  mac124 
Chemical formula (moiety) C15H14O2I
+·C2O2F3
  
Chemical formula (total) C17H14F3IO4 
Formula weight  466.18 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 12.5807(8) Å  = 90° 
 b = 13.1447(9) Å  = 94.017(5)° 
 c = 20.9719(12) Å  = 90° 
Cell volume 3459.6(4) Å3 
Z 8 
Calculated density  1.790 g/cm3 
Absorption coefficient  1.901 mm1 
F(000) 1824 
Reflections for cell refinement 7630 ( range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 12 to 15, k 14 to 17, l 27 to 25 
Completeness to  = 25.0° 99.8 %  
Reflections collected 20543 
Independent reflections 7542 (Rint = 0.0267) 
Reflections with F2>2 6420 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.61754 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0274, 5.9644 
Data / restraints / parameters 7542 / 0 / 454 
Final R indices [F2>2] R1 = 0.0315, wR2 = 0.0687 
R indices (all data) R1 = 0.0423, wR2 = 0.0761 
Goodness-of-fit on F2 1.084 
Extinction coefficient 0.00007(5) 
Largest and mean shift/su 0.003 and 0.000 
Largest diff. peak and hole 1.01 and 1.31 e Å3 
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Table 18.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 194.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I(1) 0.488259(17) 0.822233(18) 0.523213(10) 0.02655(7) 
I(2) 0.449177(16) 0.855849(16) 0.742365(9) 0.01983(7) 
O(1) 0.7817(2) 0.45106(19) 0.41336(11) 0.0319(6) 
O(2) 0.6211(2) 0.4292(2) 0.45157(13) 0.0387(6) 
O(3)  0.03025(18) 0.99071(17) 0.82795(10) 0.0230(5) 
O(4) 0.08344(19) 1.08579(18) 0.77586(11) 0.0281(5) 
O(5) 0.2973(3) 0.9085(3) 0.53160(15) 0.0767(13) 
O(6) 0.3347(2) 0.9417(3) 0.63416(13) 0.0534(8) 
O(7) 0.66103(19) 0.8773(2) 0.73395(10) 0.0296(6) 
O(8) 0.6267(2) 0.8321(2) 0.63232(12) 0.0418(7) 
F(1) 0.1005(3) 0.9006(3) 0.6052(2) 0.1198(17) 
F(2) 0.1536(3) 1.0467(3) 0.63083(15) 0.0925(13) 
F(3) 0.1186(2) 1.0103(2) 0.53511(12) 0.0588(7) 
F(4) 0.8050(2) 0.9440(2) 0.61181(12) 0.0623(8) 
F(5) 0.8509(2) 0.8028(3) 0.65070(18) 0.0828(10) 
F(6) 0.8539(2) 0.9351(4) 0.70921(13) 0.0991(14) 
C(1) 0.8851(4) 0.3323(3) 0.3601(2) 0.0474(11) 
C(2) 0.7792(3) 0.3483(3) 0.38760(18) 0.0373(9) 
C(3) 0.6959(3) 0.4824(3) 0.44255(15) 0.0260(7) 
C(4) 0.7057(3) 0.5914(3) 0.46166(14) 0.0229(7) 
C(5) 0.6160(3) 0.6407(3) 0.48116(14) 0.0227(7) 
C(6) 0.6242(3) 0.7427(3) 0.49677(15) 0.0240(7) 
C(7) 0.7191(3) 0.7956(3) 0.49549(16) 0.0282(8) 
C(8) 0.8079(3) 0.7451(3) 0.47704(18) 0.0354(9) 
C(9) 0.8015(3) 0.6434(3) 0.45953(17) 0.0301(8) 
C(10) 0.4179(3) 0.8174(3) 0.42940(15) 0.0221(7) 
C(11) 0.4409(3) 0.8945(3) 0.38777(17) 0.0320(8) 
C(12) 0.3955(3) 0.8899(3) 0.32583(18) 0.0351(9) 
C(13) 0.3287(3) 0.8105(3) 0.30680(17) 0.0305(8) 
C(14) 0.3077(3) 0.7340(3) 0.34935(16) 0.0289(8) 
C(15) 0.3529(3) 0.7368(3) 0.41150(15) 0.0245(7) 
C(16)  0.1992(3) 1.0483(3) 0.85958(19) 0.0353(9) 
C(17)  0.0952(3) 1.0812(3) 0.83528(17) 0.0289(8) 
C(18) 0.0576(3) 1.0048(2) 0.79795(13) 0.0192(6) 
C(19) 0.1255(2) 0.9123(2) 0.79522(14) 0.0192(6) 
C(20) 0.2267(2) 0.9230(3) 0.77307(14) 0.0208(7) 
C(21) 0.2919(3) 0.8393(2) 0.77197(14) 0.0197(7) 
C(22) 0.2600(3) 0.7443(3) 0.79204(15) 0.0231(7) 
C(23) 0.1588(3) 0.7343(3) 0.81369(16) 0.0260(7) 
C(24) 0.0922(3) 0.8176(2) 0.81568(15) 0.0216(7) 
C(25) 0.5173(2) 0.8144(3) 0.83308(14) 0.0205(7) 
C(26) 0.5303(3) 0.7123(3) 0.84746(16) 0.0268(7) 
C(27) 0.5725(3) 0.6858(3) 0.90816(18) 0.0358(9) 
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C(28) 0.6000(3) 0.7596(4) 0.95222(17) 0.0402(10) 
C(29) 0.5876(3) 0.8612(4) 0.93703(17) 0.0395(10) 
C(30) 0.5460(3) 0.8901(3) 0.87653(16) 0.0290(8) 
C(31) 0.2772(3) 0.9372(3) 0.58487(16) 0.0264(7) 
C(32) 0.1620(3) 0.9738(3) 0.58926(17) 0.0300(8) 
C(33) 0.6838(3) 0.8634(2) 0.67806(15) 0.0227(7) 
C(34) 0.7993(3) 0.8872(3) 0.66339(17) 0.0354(9) 
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Table 19.   Bond lengths [Å] and angles [°] for 194. 
 
I(1)–C(6)  2.112(3) I(1)–C(10)  2.101(3) 
I(2)–C(21)  2.125(3) I(2)–C(25)  2.103(3) 
O(1)–C(2)  1.454(4) O(1)–C(3)  1.343(4) 
O(2)–C(3)  1.198(4) O(3)–C(17)  1.457(4) 
O(3)–C(18)  1.322(4) O(4)–C(18)  1.215(4) 
O(5)–C(31)  1.222(4) O(6)–C(31)  1.221(4) 
O(7)–C(33)  1.240(4) O(8)–C(33)  1.229(4) 
F(1)–C(32)  1.294(5) F(2)–C(32)  1.304(4) 
F(3)–C(32)  1.316(4) F(4)–C(34)  1.321(4) 
F(5)–C(34)  1.321(5) F(6)–C(34)  1.304(4) 
C(1)–H(1A)  0.980 C(1)–H(1B)  0.980 
C(1)–H(1C)  0.980 C(1)–C(2)  1.504(6) 
C(2)–H(2A)  0.990 C(2)–H(2B)  0.990 
C(3)–C(4)  1.490(5) C(4)–C(5)  1.388(5) 
C(4)–C(9)  1.389(5) C(5)–H(5A)  0.950 
C(5)–C(6)  1.382(5) C(6)–C(7)  1.383(5) 
C(7)–H(7A)  0.950 C(7)–C(8)  1.378(5) 
C(8)–H(8A)  0.950 C(8)–C(9)  1.387(5) 
C(9)–H(9A)  0.950 C(10)–C(11)  1.381(5) 
C(10)–C(15)  1.374(5) C(11)–H(11A)  0.950 
C(11)–C(12)  1.383(5) C(12)–H(12A)  0.950 
C(12)–C(13)  1.381(5) C(13)–H(13A)  0.950 
C(13)–C(14)  1.382(5) C(14)–H(14A)  0.950 
C(14)–C(15)  1.386(5) C(15)–H(15A)  0.950 
C(16)–H(16A)  0.980 C(16)–H(16B)  0.980 
C(16)–H(16C)  0.980 C(16)–C(17)  1.500(5) 
C(17)–H(17A)  0.990 C(17)–H(17B)  0.990 
C(18)–C(19)  1.490(4) C(19)–C(20)  1.392(4) 
C(19)–C(24)  1.391(4) C(20)–H(20A)  0.950 
C(20)–C(21)  1.374(5) C(21)–C(22)  1.387(5) 
C(22)–H(22A)  0.950 C(22)–C(23)  1.388(5) 
C(23)–H(23A)  0.950 C(23)–C(24)  1.380(5) 
C(24)–H(24A)  0.950 C(25)–C(26)  1.382(5) 
C(25)–C(30)  1.380(5) C(26)–H(26A)  0.950 
C(26)–C(27)  1.389(5) C(27)–H(27A)  0.950 
C(27)–C(28)  1.367(6) C(28)–H(28A)  0.950 
C(28)–C(29)  1.379(6) C(29)–H(29A)  0.950 
C(29)–C(30)  1.391(5) C(30)–H(30A)  0.950 
C(31)–C(32)  1.536(5) C(33)–C(34)  1.538(5) 
 
C(6)–I(1)–C(10) 92.02(12) C(21)–I(2)–C(25) 92.17(12) 
C(2)–O(1)–C(3) 117.2(3) C(17)–O(3)–C(18) 115.5(3) 
H(1A)–C(1)–H(1B) 109.5 H(1A)–C(1)–H(1C) 109.5 
H(1A)–C(1)–C(2) 109.5 H(1B)–C(1)–H(1C) 109.5 
H(1B)–C(1)–C(2) 109.5 H(1C)–C(1)–C(2) 109.5 
O(1)–C(2)–C(1) 106.0(3) O(1)–C(2)–H(2A) 110.5 
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O(1)–C(2)–H(2B) 110.5 C(1)–C(2)–H(2A) 110.5 
C(1)–C(2)–H(2B) 110.5 H(2A)–C(2)–H(2B) 108.7 
O(1)–C(3)–O(2) 123.9(3) O(1)–C(3)–C(4) 111.3(3) 
O(2)–C(3)–C(4) 124.8(3) C(3)–C(4)–C(5) 118.4(3) 
C(3)–C(4)–C(9) 121.4(3) C(5)–C(4)–C(9) 120.3(3) 
C(4)–C(5)–H(5A) 120.8 C(4)–C(5)–C(6) 118.3(3) 
H(5A)–C(5)–C(6) 120.8 I(1)–C(6)–C(5) 119.6(2) 
I(1)–C(6)–C(7) 118.2(3) C(5)–C(6)–C(7) 122.2(3) 
C(6)–C(7)–H(7A) 120.6 C(6)–C(7)–C(8) 118.8(3) 
H(7A)–C(7)–C(8) 120.6 C(7)–C(8)–H(8A) 119.8 
C(7)–C(8)–C(9) 120.3(4) H(8A)–C(8)–C(9) 119.8 
C(4)–C(9)–C(8) 120.1(3) C(4)–C(9)–H(9A) 120.0 
C(8)–C(9)–H(9A) 120.0 I(1)–C(10)–C(11) 118.5(3) 
I(1)–C(10)–C(15) 118.8(2) C(11)–C(10)–C(15) 122.7(3) 
C(10)–C(11)–H(11A) 121.0 C(10)–C(11)–C(12) 118.1(3) 
H(11A)–C(11)–C(12) 121.0 C(11)–C(12)–H(12A) 119.8 
C(11)–C(12)–C(13) 120.5(3) H(12A)–C(12)–C(13) 119.8 
C(12)–C(13)–H(13A) 119.9 C(12)–C(13)–C(14) 120.2(3) 
H(13A)–C(13)–C(14) 119.9 C(13)–C(14)–H(14A) 119.9 
C(13)–C(14)–C(15) 120.2(3) H(14A)–C(14)–C(15) 119.9 
C(10)–C(15)–C(14) 118.3(3) C(10)–C(15)–H(15A) 120.8 
C(14)–C(15)–H(15A) 120.8 H(16A)–C(16)–H(16B) 109.5 
H(16A)–C(16)–H(16C) 109.5 H(16A)–C(16)–C(17) 109.5 
H(16B)–C(16)–H(16C) 109.5 H(16B)–C(16)–C(17) 109.5 
H(16C)–C(16)–C(17) 109.5 O(3)–C(17)–C(16) 108.1(3) 
O(3)–C(17)–H(17A) 110.1 O(3)–C(17)–H(17B) 110.1 
C(16)–C(17)–H(17A) 110.1 C(16)–C(17)–H(17B) 110.1 
H(17A)–C(17)–H(17B) 108.4 O(3)–C(18)–O(4) 124.0(3) 
O(3)–C(18)–C(19) 113.9(3) O(4)–C(18)–C(19) 122.1(3) 
C(18)–C(19)–C(20) 118.1(3) C(18)–C(19)–C(24) 122.2(3) 
C(20)–C(19)–C(24) 119.7(3) C(19)–C(20)–H(20A) 120.5 
C(19)–C(20)–C(21) 119.0(3) H(20A)–C(20)–C(21) 120.5 
I(2)–C(21)–C(20) 119.5(2) I(2)–C(21)–C(22) 118.4(2) 
C(20)–C(21)–C(22) 122.0(3) C(21)–C(22)–H(22A) 120.8 
C(21)–C(22)–C(23) 118.4(3) H(22A)–C(22)–C(23) 120.8 
C(22)–C(23)–H(23A) 119.7 C(22)–C(23)–C(24) 120.5(3) 
H(23A)–C(23)–C(24) 119.7 C(19)–C(24)–C(23) 120.2(3) 
C(19)–C(24)–H(24A) 119.9 C(23)–C(24)–H(24A) 119.9 
I(2)–C(25)–C(26) 118.9(2) I(2)–C(25)–C(30) 118.8(3) 
C(26)–C(25)–C(30) 122.3(3) C(25)–C(26)–H(26A) 120.8 
C(25)–C(26)–C(27) 118.4(3) H(26A)–C(26)–C(27) 120.8 
C(26)–C(27)–H(27A) 119.9 C(26)–C(27)–C(28) 120.2(4) 
H(27A)–C(27)–C(28) 119.9 C(27)–C(28)–H(28A) 119.6 
C(27)–C(28)–C(29) 120.8(3) H(28A)–C(28)–C(29) 119.6 
C(28)–C(29)–H(29A) 119.9 C(28)–C(29)–C(30) 120.3(4) 
H(29A)–C(29)–C(30) 119.9 C(25)–C(30)–C(29) 118.0(4) 
C(25)–C(30)–H(30A) 121.0 C(29)–C(30)–H(30A) 121.0 
O(5)–C(31)–O(6) 129.8(4) O(5)–C(31)–C(32) 114.1(3) 
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O(6)–C(31)–C(32) 116.1(3) F(1)–C(32)–F(2) 107.2(4) 
F(1)–C(32)–F(3) 105.9(4) F(1)–C(32)–C(31) 111.5(3) 
F(2)–C(32)–F(3) 105.1(3) F(2)–C(32)–C(31) 113.1(3) 
F(3)–C(32)–C(31) 113.5(3) O(7)–C(33)–O(8) 128.8(3) 
O(7)–C(33)–C(34) 116.3(3) O(8)–C(33)–C(34) 114.9(3) 
F(4)–C(34)–F(5) 104.7(3) F(4)–C(34)–F(6) 105.9(4) 
F(4)–C(34)–C(33) 112.6(3) F(5)–C(34)–F(6) 108.3(4) 
F(5)–C(34)–C(33) 110.7(3) F(6)–C(34)–C(33) 114.0(3) 
 
 Appendix I – Crystallographic Data for compounds 205 and 206 
 
292 
 
Table 20.   Anisotropic displacement parameters (Å2) for 194.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I(1) 0.02202(13)  0.03214(13) 0.02554(12)  0.01003(9) 0.00210(8) 
 0.00253(9) 
I(2) 0.01593(11)  0.02448(12) 0.01913(11)  0.00202(8) 0.00151(8)   
0.00061(8) 
O(1) 0.0363(15)  0.0279(13) 0.0318(13)   0.0018(10) 0.0049(11) 
 0.0095(11) 
O(2) 0.0334(16)  0.0313(14) 0.0519(17)   0.0007(12) 0.0057(12)   
0.0025(13) 
O(3) 0.0201(12)  0.0205(12) 0.0293(12)   0.0016(9) 0.0066(9) 
 0.0017(10) 
O(4) 0.0250(13)  0.0212(12) 0.0386(13)  0.0061(10) 0.0051(10)   
0.0014(10) 
O(5) 0.053(2)  0.133(4) 0.0428(18)   0.035(2)  0.0041(15)  0.052(2) 
O(6) 0.0368(17)  0.092(3) 0.0304(15)  0.0068(15)  0.0052(12) 
 0.0154(17) 
O(7) 0.0221(13)  0.0477(16) 0.0192(11)  0.0041(10) 0.0017(9)   
0.0024(11) 
O(8) 0.0323(15)  0.0617(19) 0.0309(14)   0.0114(13)  0.0001(11)   
0.0132(14) 
F(1) 0.0439(19)  0.079(2) 0.242(5)  0.079(3) 0.049(2)  0.0046(18) 
F(2) 0.083(2)  0.116(3) 0.075(2)   0.060(2)  0.0221(17)  0.063(2) 
F(3) 0.0403(15)  0.087(2) 0.0478(14)  0.0036(14)  0.0087(11) 
 0.0270(14) 
F(4) 0.0618(18)  0.080(2) 0.0459(14)  0.0127(13) 0.0115(12)   
0.0387(16) 
F(5) 0.0449(18)  0.085(2) 0.123(3)  0.014(2) 0.0405(18) 
 0.0208(17) 
F(6) 0.0417(17)  0.211(4) 0.0454(16)   0.044(2) 0.0100(13)   
0.066(2) 
C(1) 0.060(3)  0.037(2) 0.046(2)   0.0039(19) 0.011(2)  0.021(2) 
C(2) 0.048(3)  0.0277(19) 0.035(2)   0.0001(16)  0.0047(18) 
 0.0125(18) 
C(3) 0.029(2)  0.0290(19) 0.0193(15)  0.0023(13)  0.0006(13) 
 0.0070(16) 
C(4) 0.0223(17)  0.0275(18) 0.0189(15)  0.0011(13) 0.0007(12) 
 0.0046(14) 
C(5) 0.0196(17)  0.0285(17) 0.0197(15)  0.0011(13) 0.0001(12)   
0.0018(14) 
C(6) 0.0185(17)  0.0327(19) 0.0207(15)   0.0030(13) 0.0012(12) 
 0.0023(14) 
C(7) 0.0243(19)  0.0307(19) 0.0302(18)   0.0044(15) 0.0060(14)   
0.0024(15) 
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C(8) 0.027(2)  0.037(2) 0.043(2)   0.0027(17) 0.0078(16)   
0.0053(17) 
C(9) 0.0244(19)  0.035(2) 0.0313(18)  0.0003(15) 0.0064(14) 
 0.0062(16) 
C(10) 0.0174(16)  0.0266(17) 0.0223(16)   0.0047(13) 0.0019(12) 
 0.0049(14) 
C(11) 0.037(2)  0.0219(17) 0.037(2)   0.0054(15) 0.0048(16)   
0.0019(16) 
C(12) 0.045(2)  0.0246(18) 0.036(2)  0.0056(16) 0.0043(17) 
 0.0093(17) 
C(13) 0.027(2)  0.034(2) 0.0302(18)   0.0026(15) 0.0010(15) 
 0.0113(16) 
C(14) 0.0174(17)  0.035(2) 0.0336(18)   0.0054(15)  0.0007(14)   
0.0009(15) 
C(15) 0.0173(17)  0.0292(18) 0.0276(17)  0.0002(14) 0.0049(13) 
 0.0002(14) 
C(16) 0.030(2)  0.034(2) 0.043(2)   0.0047(17) 0.0100(16) 
 0.0052(17) 
C(17) 0.0270(19)  0.0239(18) 0.0369(19)   0.0030(15) 0.0099(15) 
 0.0052(15) 
C(18) 0.0211(17)  0.0211(16) 0.0150(14)   0.0020(12)  0.0012(12)   
0.0006(13) 
C(19) 0.0176(16)  0.0217(16) 0.0181(14)   0.0013(12)  0.0008(12)   
0.0029(13) 
C(20) 0.0179(16)  0.0239(17) 0.0205(15)  0.0007(13) 0.0007(12)   
0.0024(13) 
C(21) 0.0163(16)  0.0256(17) 0.0174(14)   0.0015(12) 0.0014(12)   
0.0012(13) 
C(22) 0.0200(17)  0.0222(17) 0.0275(16)   0.0042(13) 0.0038(13)   
0.0009(14) 
C(23) 0.0278(19)  0.0194(17) 0.0313(18)  0.0003(14) 0.0062(14)   
0.0040(14) 
C(24) 0.0188(17)  0.0227(16) 0.0236(16)   0.0015(13) 0.0038(13)   
0.0028(13) 
C(25) 0.0130(15)  0.0329(18) 0.0159(14)  0.0016(13) 0.0026(11)   
0.0005(14) 
C(26) 0.0197(18)  0.0316(19) 0.0289(17)  0.0049(15)  0.0002(13)   
0.0042(15) 
C(27) 0.0231(19)  0.050(2) 0.035(2)  0.0165(18) 0.0026(15)   
0.0018(18) 
C(28) 0.027(2)  0.070(3) 0.0233(18)  0.0092(18) 0.0001(15)   
0.003(2) 
C(29) 0.024(2)  0.069(3) 0.0251(18)   0.0166(19)  0.0012(15)   
0.0051(19) 
C(30) 0.0234(18)  0.037(2) 0.0270(17)   0.0083(15) 0.0040(14)   
0.0025(16) 
C(31) 0.0275(19)  0.0242(17) 0.0273(17)  0.0013(14) 0.0011(14) 
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 0.0023(15) 
C(32) 0.030(2)  0.0282(19) 0.0322(19)   0.0029(15) 0.0045(15) 
 0.0044(16) 
C(33) 0.0240(18)  0.0213(16) 0.0227(16)  0.0042(13)  0.0003(13) 
 0.0010(14) 
C(34) 0.027(2)  0.052(2) 0.0276(18)   0.0007(17) 0.0072(15)   
0.0060(19) 
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Table 21.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 194. 
 
      x       y       z       U 
 
H(1A) 0.8873 0.2642 0.3412 0.071 
H(1B) 0.9423 0.3388 0.3941 0.071 
H(1C) 0.8949 0.3835 0.3270 0.071 
H(2A) 0.7204 0.3410 0.3540 0.045 
H(2B) 0.7687 0.2981 0.4218 0.045 
H(5A) 0.5506 0.6053 0.4837 0.027 
H(7A) 0.7230 0.8654 0.5071 0.034 
H(8A) 0.8739 0.7802 0.4763 0.042 
H(9A) 0.8626 0.6093 0.4461 0.036 
H(11A) 0.4866 0.9491 0.4013 0.038 
H(12A) 0.4104 0.9418 0.2962 0.042 
H(13A) 0.2971 0.8085 0.2643 0.037 
H(14A) 0.2621 0.6793 0.3359 0.035 
H(15A) 0.3393 0.6844 0.4410 0.029 
H(16A)  0.2420 1.1084 0.8682 0.053 
H(16B)  0.1856 1.0092 0.8991 0.053 
H(16C)  0.2380 1.0058 0.8274 0.053 
H(17A)  0.1079 1.1162 0.7937 0.035 
H(17B)  0.0583 1.1289 0.8659 0.035 
H(20A) 0.2503 0.9873 0.7589 0.025 
H(22A) 0.3063 0.6873 0.7910 0.028 
H(23A) 0.1351 0.6697 0.8273 0.031 
H(24A) 0.0234 0.8102 0.8311 0.026 
H(26A) 0.5108 0.6615 0.8166 0.032 
H(27A) 0.5824 0.6161 0.9191 0.043 
H(28A) 0.6280 0.7407 0.9938 0.048 
H(29A) 0.6075 0.9116 0.9680 0.047 
H(30A) 0.5377 0.9598 0.8654 0.035 
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Table 21.  Torsion angles [°] for 194. 
 
C(3)–O(1)–C(2)–C(1)  178.1(3) C(2)–O(1)–C(3)–O(2) 4.4(5) 
C(2)–O(1)–C(3)–C(4)  175.3(3) O(1)–C(3)–C(4)–C(5) 167.9(3) 
O(1)–C(3)–C(4)–C(9)  11.4(4) O(2)–C(3)–C(4)–C(5)  11.8(5) 
O(2)–C(3)–C(4)–C(9) 169.0(3) C(3)–C(4)–C(5)–C(6)  177.8(3) 
C(9)–C(4)–C(5)–C(6) 1.5(5) C(4)–C(5)–C(6)–I(1) 177.6(2) 
C(4)–C(5)–C(6)–C(7)  2.1(5) C(10)–I(1)–C(6)–C(5)  70.6(3) 
C(10)–I(1)–C(6)–C(7) 109.1(3) I(1)–C(6)–C(7)–C(8)  178.7(3) 
C(5)–C(6)–C(7)–C(8) 1.0(5) C(6)–C(7)–C(8)–C(9) 0.6(5) 
C(7)–C(8)–C(9)–C(4)  1.2(6) C(3)–C(4)–C(9)–C(8) 179.4(3) 
C(5)–C(4)–C(9)–C(8) 0.1(5) C(6)–I(1)–C(10)–C(11)  88.1(3) 
C(6)–I(1)–C(10)–C(15) 90.5(3) I(1)–C(10)–C(11)–C(12) 179.0(3) 
C(15)–C(10)–C(11)–C(12) 0.5(5) C(10)–C(11)–C(12)–C(13) 0.4(5) 
C(11)–C(12)–C(13)–C(14)  0.9(6) C(12)–C(13)–C(14)–C(15) 0.5(5) 
I(1)–C(10)–C(15)–C(14)  179.4(2) C(11)–C(10)–C(15)–C(14)  0.9(5) 
C(13)–C(14)–C(15)–C(10) 0.4(5) C(18)–O(3)–C(17)–C(16) 170.3(3) 
C(17)–O(3)–C(18)–O(4)  1.9(4) C(17)–O(3)–C(18)–C(19) 176.1(3) 
O(3)–C(18)–C(19)–C(20)  170.7(3) O(3)–C(18)–C(19)–C(24) 7.4(4) 
O(4)–C(18)–C(19)–C(20) 7.3(4) O(4)–C(18)–C(19)–C(24)  174.6(3) 
C(18)–C(19)–C(20)–C(21) 178.1(3) C(24)–C(19)–C(20)–C(21)  0.1(4) 
C(19)–C(20)–C(21)–I(2)  177.2(2) C(19)–C(20)–C(21)–C(22) 0.2(5) 
C(25)–I(2)–C(21)–C(20) 115.9(3) C(25)–I(2)–C(21)–C(22)  61.6(3) 
I(2)–C(21)–C(22)–C(23) 177.5(2) C(20)–C(21)–C(22)–C(23) 0.1(5) 
C(21)–C(22)–C(23)–C(24)  0.6(5) C(22)–C(23)–C(24)–C(19) 0.8(5) 
C(18)–C(19)–C(24)–C(23)  178.5(3) C(20)–C(19)–C(24)–C(23)  0.4(5) 
C(21)–I(2)–C(25)–C(26) 84.6(3) C(21)–I(2)–C(25)–C(30)  94.5(3) 
I(2)–C(25)–C(26)–C(27)  178.2(3) C(30)–C(25)–C(26)–C(27) 0.9(5) 
C(25)–C(26)–C(27)–C(28) 0.2(5) C(26)–C(27)–C(28)–C(29)  0.8(6) 
C(27)–C(28)–C(29)–C(30) 0.5(6) I(2)–C(25)–C(30)–C(29) 177.9(3) 
C(26)–C(25)–C(30)–C(29)  1.2(5) C(28)–C(29)–C(30)–C(25) 0.5(5) 
O(5)–C(31)–C(32)–F(1) 91.5(5) O(5)–C(31)–C(32)–F(2)  147.6(4) 
O(5)–C(31)–C(32)–F(3)  28.0(5) O(6)–C(31)–C(32)–F(1)  89.0(5) 
O(6)–C(31)–C(32)–F(2) 31.8(5) O(6)–C(31)–C(32)–F(3) 151.4(4) 
O(7)–C(33)–C(34)–F(4)  131.7(3) O(7)–C(33)–C(34)–F(5) 111.5(4) 
O(7)–C(33)–C(34)–F(6)  10.9(5) O(8)–C(33)–C(34)–F(4) 49.0(5) 
O(8)–C(33)–C(34)–F(5)  67.9(4) O(8)–C(33)–C(34)–F(6) 169.7(4) 
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Table 22.  Crystal data and structure refinement for 195. 
 
Identification code  mac134 
Chemical formula (moiety) C18H16F3IO5 
Chemical formula (total) C18H16F3IO5 
Formula weight  496.21 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 13.1851(3) Å  = 104.315(2)° 
 b = 13.4508(3) Å  = 103.687(2)° 
 c = 22.7604(5) Å  = 94.474(2)° 
Cell volume 3760.00(15) Å3 
Z 8 
Calculated density  1.753 g/cm3 
Absorption coefficient  1.758 mm1 
F(000) 1952 
Crystal colour and size colourless, 0.30  0.20  0.20 mm3 
Reflections for cell refinement 21891 ( range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 15 to 17, k 15 to 17, l 30 to 27 
Completeness to  = 25.0° 99.8 %  
Reflections collected 47991 
Independent reflections 16184 (Rint = 0.0354) 
Reflections with F2>2 13220 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.6205 and 0.7200 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0201, 3.1903 
Data / restraints / parameters 16184 / 0 / 981 
Final R indices [F2>2] R1 = 0.0319, wR2 = 0.0602 
R indices (all data) R1 = 0.0458, wR2 = 0.0667 
Goodness-of-fit on F2 1.053 
Largest and mean shift/su 0.003 and 0.000 
Largest diff. peak and hole 1.08 and 0.76 e Å3 
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Table 23.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
for 195.  Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I(1) 0.303045(16) 0.945440(15) 0.979191(8) 0.02082(5) 
I(2) 0.223270(17) 0.569427(15) 0.897321(9) 0.02216(5) 
I(3) 0.663237(16) 0.917159(15) 0.483554(9) 0.02203(5) 
I(4) 0.679795(16) 0.578073(15) 0.506471(8) 0.02053(5) 
O(1)  0.08452(18) 1.21026(19) 0.90447(11) 0.0341(6) 
O(2)  0.08884(18) 1.08776(19) 0.95503(11) 0.0328(6) 
O(3) 0.4865(2) 1.31764(19) 1.21454(11) 0.0371(6) 
O(4) 0.10829(17) 0.27636(17) 1.07440(10) 0.0251(5) 
O(5) 0.01511(19) 0.39370(19) 1.04178(11) 0.0346(6) 
O(6)  0.0591(2) 0.18331(18) 0.70333(10) 0.0381(6) 
O(7) 0.3817(2) 0.7005(2) 1.00377(11) 0.0406(6) 
O(8) 0.4366(2) 0.86452(18) 1.06209(10) 0.0325(6) 
O(9) 0.2273(2) 0.8027(2) 0.86249(11) 0.0445(7) 
O(10) 0.1451(2) 0.64862(19) 0.80232(10) 0.0435(7) 
O(11) 1.01243(18) 1.34274(17) 0.60468(10) 0.0281(5) 
O(12) 1.04473(19) 1.18263(19) 0.56385(11) 0.0343(6) 
O(13) 0.6547(2) 0.99725(18) 0.22616(10) 0.0329(6) 
O(14) 0.94608(18) 0.19796(17) 0.41335(10) 0.0278(5) 
O(15) 1.01266(18) 0.36577(18) 0.45818(10) 0.0305(5) 
O(16) 0.80409(19) 0.54078(19) 0.78021(9) 0.0309(5) 
O(17) 0.6712(2) 0.94137(18) 0.60657(10) 0.0358(6) 
O(18) 0.6441(3) 0.7692(2) 0.57461(11) 0.0523(8) 
O(19) 0.5749(2) 0.71828(19) 0.41539(11) 0.0441(7) 
O(20) 0.6157(2) 0.56175(19) 0.37671(10) 0.0343(6) 
F(1) 0.45612(18) 0.63123(16) 1.10232(10) 0.0430(5) 
F(2) 0.58011(16) 0.75816(18) 1.12790(10) 0.0459(6) 
F(3) 0.44099(18) 0.77833(17) 1.16016(9) 0.0430(5) 
F(4) 0.0477(2) 0.73758(19) 0.71752(10) 0.0578(7) 
F(5) 0.21032(19) 0.78107(18) 0.72448(10) 0.0493(6) 
F(6) 0.12616(18) 0.88669(16) 0.77441(10) 0.0455(6) 
F(7) 0.7677(3) 0.8078(2) 0.70056(11) 0.0856(11) 
F(8) 0.6040(3) 0.7895(2) 0.68915(11) 0.0856(10) 
F(9) 0.6920(2) 0.93842(17) 0.72375(9) 0.0548(7) 
F(10) 0.6438(2) 0.7076(2) 0.29608(10) 0.0620(7) 
F(11) 0.4851(2) 0.72261(19) 0.29904(10) 0.0652(8) 
F(12) 0.52481(18) 0.57538(15) 0.26079(8) 0.0421(5) 
C(1)  0.1993(3) 1.3347(3) 0.89668(17) 0.0357(9) 
C(2)  0.1791(3) 1.2429(3) 0.92134(18) 0.0357(9) 
C(3)  0.0459(3) 1.1339(2) 0.92634(14) 0.0249(7) 
C(4) 0.0563(2) 1.1154(2) 0.91228(13) 0.0204(6) 
C(5) 0.0961(3) 1.1632(3) 0.87347(14) 0.0251(7) 
C(6) 0.1932(3) 1.1452(3) 0.86293(15) 0.0284(8) 
C(7) 0.2516(3) 1.0817(3) 0.89205(14) 0.0260(7) 
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C(8) 0.2104(2) 1.0352(2) 0.93097(13) 0.0203(6) 
C(9) 0.1135(2) 1.0508(2) 0.94170(13) 0.0214(7) 
C(10) 0.3637(2) 1.0736(2) 1.05763(13) 0.0201(7) 
C(11) 0.4503(3) 1.1381(2) 1.05811(14) 0.0237(7) 
C(12) 0.4940(3) 1.2217(3) 1.11021(15) 0.0267(7) 
C(13) 0.4481(3) 1.2398(3) 1.16037(14) 0.0267(7) 
C(14) 0.3586(3) 1.1765(3) 1.15742(14) 0.0281(7) 
C(15) 0.3160(3) 1.0914(3) 1.10634(14) 0.0264(7) 
C(16) 0.5900(3) 1.3673(3) 1.2271(2) 0.0509(11) 
C(17) 0.0705(3) 0.1801(3) 1.14327(17) 0.0379(9) 
C(18) 0.0286(3) 0.2515(3) 1.10540(16) 0.0295(8) 
C(19) 0.0917(3) 0.3494(2) 1.04481(14) 0.0228(7) 
C(20) 0.1805(2) 0.3743(2) 1.01774(13) 0.0200(6) 
C(21) 0.2745(3) 0.3348(2) 1.03022(14) 0.0247(7) 
C(22) 0.3561(3) 0.3654(3) 1.00735(15) 0.0299(8) 
C(23) 0.3441(3) 0.4344(3) 0.97055(14) 0.0262(7) 
C(24) 0.2494(3) 0.4715(2) 0.95801(13) 0.0203(7) 
C(25) 0.1666(3) 0.4430(2) 0.98069(13) 0.0219(7) 
C(26) 0.1255(3) 0.4459(2) 0.82660(13) 0.0218(7) 
C(27) 0.1697(3) 0.3728(2) 0.78997(14) 0.0260(7) 
C(28) 0.1050(3) 0.2874(3) 0.74816(14) 0.0297(8) 
C(29)  0.0023(3) 0.2733(2) 0.74316(13) 0.0275(8) 
C(30)  0.0460(3) 0.3497(3) 0.77849(15) 0.0308(8) 
C(31) 0.0187(3) 0.4363(3) 0.82042(14) 0.0279(7) 
C(32)  0.1639(3) 0.1590(3) 0.70656(17) 0.0468(10) 
C(33) 0.4249(2) 0.7693(3) 1.05209(14) 0.0229(7) 
C(34) 0.4756(3) 0.7341(3) 1.11122(15) 0.0277(7) 
C(35) 0.1739(3) 0.7423(3) 0.81389(14) 0.0252(7) 
C(36) 0.1384(3) 0.7871(3) 0.75724(15) 0.0288(8) 
C(37) 1.1376(3) 1.4939(3) 0.65438(16) 0.0359(8) 
C(38) 1.1230(3) 1.3841(3) 0.61641(15) 0.0299(8) 
C(39) 0.9838(3) 1.2418(3) 0.57737(14) 0.0249(7) 
C(40) 0.8691(2) 1.2102(2) 0.56603(13) 0.0213(7) 
C(41) 0.8019(3) 1.2800(3) 0.58293(14) 0.0263(7) 
C(42) 0.6964(3) 1.2465(3) 0.57249(16) 0.0308(8) 
C(43) 0.6552(3) 1.1431(3) 0.54450(15) 0.0275(7) 
C(44) 0.7236(2) 1.0748(2) 0.52774(13) 0.0201(6) 
C(45) 0.8286(2) 1.1065(2) 0.53759(13) 0.0211(7) 
C(46) 0.6577(3) 0.9387(2) 0.39466(13) 0.0213(7) 
C(47) 0.5659(3) 0.9633(2) 0.36172(14) 0.0246(7) 
C(48) 0.5616(3) 0.9828(2) 0.30425(14) 0.0249(7) 
C(49) 0.6502(3) 0.9773(2) 0.28117(13) 0.0239(7) 
C(50) 0.7414(3) 0.9517(2) 0.31466(14) 0.0246(7) 
C(51) 0.7463(3) 0.9312(2) 0.37211(14) 0.0237(7) 
C(52) 0.5726(3) 1.0473(3) 0.19793(16) 0.0423(10) 
C(53) 1.0392(3) 0.0625(3) 0.37585(19) 0.0416(9) 
C(54) 1.0512(3) 0.1740(3) 0.41179(16) 0.0323(8) 
C(55) 0.9386(3) 0.2970(3) 0.43792(13) 0.0221(7) 
 Appendix I – Crystallographic Data for compounds 205 and 206 
 
300 
 
C(56) 0.8279(2) 0.3129(2) 0.43775(13) 0.0198(6) 
C(57) 0.7446(3) 0.2330(2) 0.41087(14) 0.0240(7) 
C(58) 0.6430(3) 0.2508(3) 0.41150(15) 0.0297(8) 
C(59) 0.6240(3) 0.3495(3) 0.43885(15) 0.0272(7) 
C(60) 0.7079(2) 0.4282(2) 0.46451(13) 0.0195(6) 
C(61) 0.8105(2) 0.4126(2) 0.46501(13) 0.0199(6) 
C(62) 0.7220(3) 0.5602(2) 0.59811(13) 0.0212(7) 
C(63) 0.6422(3) 0.5393(3) 0.62476(14) 0.0254(7) 
C(64) 0.6670(3) 0.5322(3) 0.68614(14) 0.0276(8) 
C(65) 0.7716(3) 0.5453(2) 0.71927(14) 0.0235(7) 
C(66) 0.8522(3) 0.5650(3) 0.69192(14) 0.0263(7) 
C(67) 0.8265(3) 0.5734(2) 0.63096(14) 0.0234(7) 
C(68) 0.7236(3) 0.5180(3) 0.80893(15) 0.0356(9) 
C(69) 0.6654(3) 0.8539(3) 0.61425(14) 0.0258(7) 
C(70) 0.6853(3) 0.8488(3) 0.68257(15) 0.0335(8) 
C(71) 0.5862(3) 0.6456(3) 0.37350(14) 0.0257(7) 
C(72) 0.5590(3) 0.6630(3) 0.30707(15) 0.0311(8) 
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Table 24.   Bond lengths [Å] and angles [°] for 195. 
 
I(1)–C(8)  2.099(3) I(1)–C(10)  2.094(3) 
I(2)–C(24)  2.123(3) I(2)–C(26)  2.092(3) 
I(3)–C(44)  2.108(3) I(3)–C(46)  2.099(3) 
I(4)–C(60)  2.108(3) I(4)–C(62)  2.106(3) 
O(1)–C(2)  1.457(4) O(1)–C(3)  1.332(4) 
O(2)–C(3)  1.206(4) O(3)–C(13)  1.362(4) 
O(3)–C(16)  1.404(5) O(4)–C(18)  1.459(4) 
O(4)–C(19)  1.325(4) O(5)–C(19)  1.209(4) 
O(6)–C(29)  1.357(4) O(6)–C(32)  1.418(5) 
O(7)–C(33)  1.228(4) O(8)–C(33)  1.235(4) 
O(9)–C(35)  1.216(4) O(10)–C(35)  1.231(4) 
O(11)–C(38)  1.457(4) O(11)–C(39)  1.328(4) 
O(12)–C(39)  1.212(4) O(13)–C(49)  1.358(4) 
O(13)–C(52)  1.427(4) O(14)–C(54)  1.454(4) 
O(14)–C(55)  1.333(4) O(15)–C(55)  1.207(4) 
O(16)–C(65)  1.370(3) O(16)–C(68)  1.423(4) 
O(17)–C(69)  1.231(4) O(18)–C(69)  1.229(4) 
O(19)–C(71)  1.231(4) O(20)–C(71)  1.234(4) 
F(1)–C(34)  1.342(4) F(2)–C(34)  1.330(4) 
F(3)–C(34)  1.326(4) F(4)–C(36)  1.326(4) 
F(5)–C(36)  1.334(4) F(6)–C(36)  1.334(4) 
F(7)–C(70)  1.283(4) F(8)–C(70)  1.345(4) 
F(9)–C(70)  1.313(4) F(10)–C(72)  1.332(4) 
F(11)–C(72)  1.318(4) F(12)–C(72)  1.334(4) 
C(1)–H(1A)  0.980 C(1)–H(1B)  0.980 
C(1)–H(1C)  0.980 C(1)–C(2)  1.494(5) 
C(2)–H(2A)  0.990 C(2)–H(2B)  0.990 
C(3)–C(4)  1.482(4) C(4)–C(5)  1.385(4) 
C(4)–C(9)  1.387(4) C(5)–H(5A)  0.950 
C(5)–C(6)  1.385(4) C(6)–H(6A)  0.950 
C(6)–C(7)  1.379(4) C(7)–H(7A)  0.950 
C(7)–C(8)  1.386(4) C(8)–C(9)  1.378(4) 
C(9)–H(9A)  0.950 C(10)–C(11)  1.376(5) 
C(10)–C(15)  1.380(4) C(11)–H(11A)  0.950 
C(11)–C(12)  1.385(5) C(12)–H(12A)  0.950 
C(12)–C(13)  1.393(4) C(13)–C(14)  1.379(5) 
C(14)–H(14A)  0.950 C(14)–C(15)  1.382(5) 
C(15)–H(15A)  0.950 C(16)–H(16A)  0.980 
C(16)–H(16B)  0.980 C(16)–H(16C)  0.980 
C(17)–H(17A)  0.980 C(17)–H(17B)  0.980 
C(17)–H(17C)  0.980 C(17)–C(18)  1.495(4) 
C(18)–H(18A)  0.990 C(18)–H(18B)  0.990 
C(19)–C(20)  1.497(4) C(20)–C(21)  1.383(4) 
C(20)–C(25)  1.392(4) C(21)–H(21A)  0.950 
C(21)–C(22)  1.378(5) C(22)–H(22A)  0.950 
C(22)–C(23)  1.391(4) C(23)–H(23A)  0.950 
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C(23)–C(24)  1.374(4) C(24)–C(25)  1.380(4) 
C(25)–H(25A)  0.950 C(26)–C(27)  1.384(4) 
C(26)–C(31)  1.374(5) C(27)–H(27A)  0.950 
C(27)–C(28)  1.369(5) C(28)–H(28A)  0.950 
C(28)–C(29)  1.387(5) C(29)–C(30)  1.392(5) 
C(30)–H(30A)  0.950 C(30)–C(31)  1.381(5) 
C(31)–H(31A)  0.950 C(32)–H(32A)  0.980 
C(32)–H(32B)  0.980 C(32)–H(32C)  0.980 
C(33)–C(34)  1.556(4) C(35)–C(36)  1.545(4) 
C(37)–H(37A)  0.980 C(37)–H(37B)  0.980 
C(37)–H(37C)  0.980 C(37)–C(38)  1.486(5) 
C(38)–H(38A)  0.990 C(38)–H(38B)  0.990 
C(39)–C(40)  1.482(4) C(40)–C(41)  1.388(4) 
C(40)–C(45)  1.388(4) C(41)–H(41A)  0.950 
C(41)–C(42)  1.374(5) C(42)–H(42A)  0.950 
C(42)–C(43)  1.384(5) C(43)–H(43A)  0.950 
C(43)–C(44)  1.387(4) C(44)–C(45)  1.365(4) 
C(45)–H(45A)  0.950 C(46)–C(47)  1.375(4) 
C(46)–C(51)  1.384(4) C(47)–H(47A)  0.950 
C(47)–C(48)  1.385(4) C(48)–H(48A)  0.950 
C(48)–C(49)  1.389(5) C(49)–C(50)  1.380(4) 
C(50)–H(50A)  0.950 C(50)–C(51)  1.390(4) 
C(51)–H(51A)  0.950 C(52)–H(52A)  0.980 
C(52)–H(52B)  0.980 C(52)–H(52C)  0.980 
C(53)–H(53A)  0.980 C(53)–H(53B)  0.980 
C(53)–H(53C)  0.980 C(53)–C(54)  1.497(5) 
C(54)–H(54A)  0.990 C(54)–H(54B)  0.990 
C(55)–C(56)  1.491(4) C(56)–C(57)  1.381(5) 
C(56)–C(61)  1.393(4) C(57)–H(57A)  0.950 
C(57)–C(58)  1.382(5) C(58)–H(58A)  0.950 
C(58)–C(59)  1.388(5) C(59)–H(59A)  0.950 
C(59)–C(60)  1.376(5) C(60)–C(61)  1.383(4) 
C(61)–H(61A)  0.950 C(62)–C(63)  1.377(4) 
C(62)–C(67)  1.378(4) C(63)–H(63A)  0.950 
C(63)–C(64)  1.387(4) C(64)–H(64A)  0.950 
C(64)–C(65)  1.380(5) C(65)–C(66)  1.392(4) 
C(66)–H(66A)  0.950 C(66)–C(67)  1.383(4) 
C(67)–H(67A)  0.950 C(68)–H(68A)  0.980 
C(68)–H(68B)  0.980 C(68)–H(68C)  0.980 
C(69)–C(70)  1.534(4) C(71)–C(72)  1.550(4) 
 
C(8)–I(1)–C(10) 91.41(11) C(24)–I(2)–C(26) 89.62(11) 
C(44)–I(3)–C(46) 91.25(11) C(60)–I(4)–C(62) 93.63(11) 
C(2)–O(1)–C(3) 116.6(2) C(13)–O(3)–C(16) 117.9(3) 
C(18)–O(4)–C(19) 116.4(2) C(29)–O(6)–C(32) 117.2(3) 
C(38)–O(11)–C(39) 117.3(3) C(49)–O(13)–C(52) 117.0(3) 
C(54)–O(14)–C(55) 116.4(3) C(65)–O(16)–C(68) 116.6(3) 
H(1A)–C(1)–H(1B) 109.5 H(1A)–C(1)–H(1C) 109.5 
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H(1A)–C(1)–C(2) 109.5 H(1B)–C(1)–H(1C) 109.5 
H(1B)–C(1)–C(2) 109.5 H(1C)–C(1)–C(2) 109.5 
O(1)–C(2)–C(1) 105.8(3) O(1)–C(2)–H(2A) 110.6 
O(1)–C(2)–H(2B) 110.6 C(1)–C(2)–H(2A) 110.6 
C(1)–C(2)–H(2B) 110.6 H(2A)–C(2)–H(2B) 108.7 
O(1)–C(3)–O(2) 123.4(3) O(1)–C(3)–C(4) 111.7(3) 
O(2)–C(3)–C(4) 124.9(3) C(3)–C(4)–C(5) 122.1(3) 
C(3)–C(4)–C(9) 117.2(3) C(5)–C(4)–C(9) 120.7(3) 
C(4)–C(5)–H(5A) 120.1 C(4)–C(5)–C(6) 119.9(3) 
H(5A)–C(5)–C(6) 120.1 C(5)–C(6)–H(6A) 119.8 
C(5)–C(6)–C(7) 120.4(3) H(6A)–C(6)–C(7) 119.8 
C(6)–C(7)–H(7A) 120.7 C(6)–C(7)–C(8) 118.7(3) 
H(7A)–C(7)–C(8) 120.7 I(1)–C(8)–C(7) 118.6(2) 
I(1)–C(8)–C(9) 119.1(2) C(7)–C(8)–C(9) 122.2(3) 
C(4)–C(9)–C(8) 118.2(3) C(4)–C(9)–H(9A) 120.9 
C(8)–C(9)–H(9A) 120.9 I(1)–C(10)–C(11) 117.9(2) 
I(1)–C(10)–C(15) 119.8(2) C(11)–C(10)–C(15) 122.3(3) 
C(10)–C(11)–H(11A) 120.4 C(10)–C(11)–C(12) 119.2(3) 
H(11A)–C(11)–C(12) 120.4 C(11)–C(12)–H(12A) 120.3 
C(11)–C(12)–C(13) 119.4(3) H(12A)–C(12)–C(13) 120.3 
O(3)–C(13)–C(12) 124.2(3) O(3)–C(13)–C(14) 115.6(3) 
C(12)–C(13)–C(14) 120.2(3) C(13)–C(14)–H(14A) 119.6 
C(13)–C(14)–C(15) 120.8(3) H(14A)–C(14)–C(15) 119.6 
C(10)–C(15)–C(14) 118.1(3) C(10)–C(15)–H(15A) 120.9 
C(14)–C(15)–H(15A) 120.9 O(3)–C(16)–H(16A) 109.5 
O(3)–C(16)–H(16B) 109.5 O(3)–C(16)–H(16C) 109.5 
H(16A)–C(16)–H(16B) 109.5 H(16A)–C(16)–H(16C) 109.5 
H(16B)–C(16)–H(16C) 109.5 H(17A)–C(17)–H(17B) 109.5 
H(17A)–C(17)–H(17C) 109.5 H(17A)–C(17)–C(18) 109.5 
H(17B)–C(17)–H(17C) 109.5 H(17B)–C(17)–C(18) 109.5 
H(17C)–C(17)–C(18) 109.5 O(4)–C(18)–C(17) 107.2(3) 
O(4)–C(18)–H(18A) 110.3 O(4)–C(18)–H(18B) 110.3 
C(17)–C(18)–H(18A) 110.3 C(17)–C(18)–H(18B) 110.3 
H(18A)–C(18)–H(18B) 108.5 O(4)–C(19)–O(5) 123.8(3) 
O(4)–C(19)–C(20) 112.7(3) O(5)–C(19)–C(20) 123.5(3) 
C(19)–C(20)–C(21) 122.5(3) C(19)–C(20)–C(25) 117.2(3) 
C(21)–C(20)–C(25) 120.2(3) C(20)–C(21)–H(21A) 120.0 
C(20)–C(21)–C(22) 120.1(3) H(21A)–C(21)–C(22) 120.0 
C(21)–C(22)–H(22A) 119.7 C(21)–C(22)–C(23) 120.6(3) 
H(22A)–C(22)–C(23) 119.7 C(22)–C(23)–H(23A) 120.8 
C(22)–C(23)–C(24) 118.3(3) H(23A)–C(23)–C(24) 120.8 
I(2)–C(24)–C(23) 119.9(2) I(2)–C(24)–C(25) 117.5(2) 
C(23)–C(24)–C(25) 122.5(3) C(20)–C(25)–C(24) 118.3(3) 
C(20)–C(25)–H(25A) 120.8 C(24)–C(25)–H(25A) 120.8 
I(2)–C(26)–C(27) 119.8(2) I(2)–C(26)–C(31) 118.5(2) 
C(27)–C(26)–C(31) 121.6(3) C(26)–C(27)–H(27A) 120.7 
C(26)–C(27)–C(28) 118.7(3) H(27A)–C(27)–C(28) 120.7 
C(27)–C(28)–H(28A) 119.6 C(27)–C(28)–C(29) 120.9(3) 
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H(28A)–C(28)–C(29) 119.6 O(6)–C(29)–C(28) 116.8(3) 
O(6)–C(29)–C(30) 123.6(3) C(28)–C(29)–C(30) 119.6(3) 
C(29)–C(30)–H(30A) 120.2 C(29)–C(30)–C(31) 119.6(3) 
H(30A)–C(30)–C(31) 120.2 C(26)–C(31)–C(30) 119.4(3) 
C(26)–C(31)–H(31A) 120.3 C(30)–C(31)–H(31A) 120.3 
O(6)–C(32)–H(32A) 109.5 O(6)–C(32)–H(32B) 109.5 
O(6)–C(32)–H(32C) 109.5 H(32A)–C(32)–H(32B) 109.5 
H(32A)–C(32)–H(32C) 109.5 H(32B)–C(32)–H(32C) 109.5 
O(7)–C(33)–O(8) 130.4(3) O(7)–C(33)–C(34) 116.8(3) 
O(8)–C(33)–C(34) 112.7(3) F(1)–C(34)–F(2) 105.9(3) 
F(1)–C(34)–F(3) 106.7(3) F(1)–C(34)–C(33) 113.2(3) 
F(2)–C(34)–F(3) 107.6(3) F(2)–C(34)–C(33) 111.3(3) 
F(3)–C(34)–C(33) 111.8(3) O(9)–C(35)–O(10) 129.3(3) 
O(9)–C(35)–C(36) 116.5(3) O(10)–C(35)–C(36) 114.1(3) 
F(4)–C(36)–F(5) 106.9(3) F(4)–C(36)–F(6) 106.3(3) 
F(4)–C(36)–C(35) 113.4(3) F(5)–C(36)–F(6) 106.8(3) 
F(5)–C(36)–C(35) 110.3(3) F(6)–C(36)–C(35) 112.8(3) 
H(37A)–C(37)–H(37B) 109.5 H(37A)–C(37)–H(37C) 109.5 
H(37A)–C(37)–C(38) 109.5 H(37B)–C(37)–H(37C) 109.5 
H(37B)–C(37)–C(38) 109.5 H(37C)–C(37)–C(38) 109.5 
O(11)–C(38)–C(37) 106.9(3) O(11)–C(38)–H(38A) 110.3 
O(11)–C(38)–H(38B) 110.3 C(37)–C(38)–H(38A) 110.3 
C(37)–C(38)–H(38B) 110.3 H(38A)–C(38)–H(38B) 108.6 
O(11)–C(39)–O(12) 123.8(3) O(11)–C(39)–C(40) 112.0(3) 
O(12)–C(39)–C(40) 124.2(3) C(39)–C(40)–C(41) 122.6(3) 
C(39)–C(40)–C(45) 117.9(3) C(41)–C(40)–C(45) 119.5(3) 
C(40)–C(41)–H(41A) 119.8 C(40)–C(41)–C(42) 120.4(3) 
H(41A)–C(41)–C(42) 119.8 C(41)–C(42)–H(42A) 119.6 
C(41)–C(42)–C(43) 120.7(3) H(42A)–C(42)–C(43) 119.6 
C(42)–C(43)–H(43A) 121.0 C(42)–C(43)–C(44) 118.0(3) 
H(43A)–C(43)–C(44) 121.0 I(3)–C(44)–C(43) 119.0(2) 
I(3)–C(44)–C(45) 118.7(2) C(43)–C(44)–C(45) 122.3(3) 
C(40)–C(45)–C(44) 119.2(3) C(40)–C(45)–H(45A) 120.4 
C(44)–C(45)–H(45A) 120.4 I(3)–C(46)–C(47) 118.0(2) 
I(3)–C(46)–C(51) 119.5(2) C(47)–C(46)–C(51) 122.4(3) 
C(46)–C(47)–H(47A) 120.4 C(46)–C(47)–C(48) 119.3(3) 
H(47A)–C(47)–C(48) 120.4 C(47)–C(48)–H(48A) 120.3 
C(47)–C(48)–C(49) 119.3(3) H(48A)–C(48)–C(49) 120.3 
O(13)–C(49)–C(48) 123.8(3) O(13)–C(49)–C(50) 115.6(3) 
C(48)–C(49)–C(50) 120.6(3) C(49)–C(50)–H(50A) 119.7 
C(49)–C(50)–C(51) 120.6(3) H(50A)–C(50)–C(51) 119.7 
C(46)–C(51)–C(50) 117.8(3) C(46)–C(51)–H(51A) 121.1 
C(50)–C(51)–H(51A) 121.1 O(13)–C(52)–H(52A) 109.5 
O(13)–C(52)–H(52B) 109.5 O(13)–C(52)–H(52C) 109.5 
H(52A)–C(52)–H(52B) 109.5 H(52A)–C(52)–H(52C) 109.5 
H(52B)–C(52)–H(52C) 109.5 H(53A)–C(53)–H(53B) 109.5 
H(53A)–C(53)–H(53C) 109.5 H(53A)–C(53)–C(54) 109.5 
H(53B)–C(53)–H(53C) 109.5 H(53B)–C(53)–C(54) 109.5 
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H(53C)–C(53)–C(54) 109.5 O(14)–C(54)–C(53) 107.1(3) 
O(14)–C(54)–H(54A) 110.3 O(14)–C(54)–H(54B) 110.3 
C(53)–C(54)–H(54A) 110.3 C(53)–C(54)–H(54B) 110.3 
H(54A)–C(54)–H(54B) 108.5 O(14)–C(55)–O(15) 124.0(3) 
O(14)–C(55)–C(56) 112.1(3) O(15)–C(55)–C(56) 123.9(3) 
C(55)–C(56)–C(57) 121.9(3) C(55)–C(56)–C(61) 117.5(3) 
C(57)–C(56)–C(61) 120.6(3) C(56)–C(57)–H(57A) 119.9 
C(56)–C(57)–C(58) 120.3(3) H(57A)–C(57)–C(58) 119.9 
C(57)–C(58)–H(58A) 119.9 C(57)–C(58)–C(59) 120.1(3) 
H(58A)–C(58)–C(59) 119.9 C(58)–C(59)–H(59A) 120.7 
C(58)–C(59)–C(60) 118.6(3) H(59A)–C(59)–C(60) 120.7 
I(4)–C(60)–C(59) 118.8(2) I(4)–C(60)–C(61) 118.5(2) 
C(59)–C(60)–C(61) 122.6(3) C(56)–C(61)–C(60) 117.8(3) 
C(56)–C(61)–H(61A) 121.1 C(60)–C(61)–H(61A) 121.1 
I(4)–C(62)–C(63) 118.0(2) I(4)–C(62)–C(67) 120.6(2) 
C(63)–C(62)–C(67) 121.4(3) C(62)–C(63)–H(63A) 120.2 
C(62)–C(63)–C(64) 119.6(3) H(63A)–C(63)–C(64) 120.2 
C(63)–C(64)–H(64A) 120.4 C(63)–C(64)–C(65) 119.3(3) 
H(64A)–C(64)–C(65) 120.4 O(16)–C(65)–C(64) 123.7(3) 
O(16)–C(65)–C(66) 115.3(3) C(64)–C(65)–C(66) 121.0(3) 
C(65)–C(66)–H(66A) 120.4 C(65)–C(66)–C(67) 119.2(3) 
H(66A)–C(66)–C(67) 120.4 C(62)–C(67)–C(66) 119.5(3) 
C(62)–C(67)–H(67A) 120.2 C(66)–C(67)–H(67A) 120.2 
O(16)–C(68)–H(68A) 109.5 O(16)–C(68)–H(68B) 109.5 
O(16)–C(68)–H(68C) 109.5 H(68A)–C(68)–H(68B) 109.5 
H(68A)–C(68)–H(68C) 109.5 H(68B)–C(68)–H(68C) 109.5 
O(17)–C(69)–O(18) 129.0(3) O(17)–C(69)–C(70) 116.0(3) 
O(18)–C(69)–C(70) 114.9(3) F(7)–C(70)–F(8) 105.9(3) 
F(7)–C(70)–F(9) 108.2(3) F(7)–C(70)–C(69) 113.0(3) 
F(8)–C(70)–F(9) 104.3(3) F(8)–C(70)–C(69) 110.2(3) 
F(9)–C(70)–C(69) 114.5(3) O(19)–C(71)–O(20) 129.7(3) 
O(19)–C(71)–C(72) 114.5(3) O(20)–C(71)–C(72) 115.8(3) 
F(10)–C(72)–F(11) 107.2(3) F(10)–C(72)–F(12) 106.0(3) 
F(10)–C(72)–C(71) 110.8(3) F(11)–C(72)–F(12) 105.9(3) 
F(11)–C(72)–C(71) 113.1(3) F(12)–C(72)–C(71) 113.5(3) 
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Table 25.   Anisotropic displacement parameters (Å2) for 195.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I(1) 0.02199(11)  0.02206(11) 0.02159(9)  0.00952(8) 0.00689(8) 
 0.00702(8) 
I(2) 0.02844(12)  0.01948(11) 0.02015(9)  0.00785(8) 0.00743(9) 
 0.00192(9) 
I(3) 0.02601(12)  0.01880(11) 0.02103(10)  0.00753(8) 0.00461(8) 
 0.00007(8) 
I(4) 0.02634(12)  0.01635(11) 0.02099(9)  0.00636(8) 0.00856(8) 
 0.00418(8) 
O(1) 0.0273(14)  0.0406(15) 0.0536(15)  0.0307(12) 0.0236(12) 
 0.0195(12) 
O(2) 0.0289(14)  0.0377(15) 0.0460(14)  0.0259(12) 0.0201(12) 
 0.0106(11) 
O(3) 0.0337(15)  0.0343(15) 0.0343(13)   0.0011(11) 0.0034(11) 
 0.0038(12) 
O(4) 0.0276(13)  0.0246(13) 0.0314(12)  0.0150(10) 0.0145(10) 
 0.0073(10) 
O(5) 0.0270(14)  0.0429(16) 0.0480(14)  0.0281(12) 0.0171(12) 
 0.0150(12) 
O(6) 0.0551(18)  0.0254(14) 0.0255(12)   0.0013(10) 0.0063(12)   
0.0025(12) 
O(7) 0.0446(17)  0.0363(15) 0.0297(12)  0.0012(11) 0.0005(12)   
0.0055(13) 
O(8) 0.0447(16)  0.0243(14) 0.0288(12)  0.0107(10) 0.0057(11) 
 0.0084(11) 
O(9) 0.0592(19)  0.0304(15) 0.0292(13)  0.0042(11)  0.0089(13)   
0.0022(13) 
O(10) 0.076(2)  0.0247(15) 0.0278(12)  0.0121(11) 0.0065(13) 
 0.0009(14) 
O(11) 0.0226(13)  0.0245(13) 0.0330(12)  0.0054(10) 0.0052(10)   
0.0066(10) 
O(12) 0.0261(14)  0.0309(14) 0.0451(14)  0.0080(11) 0.0105(11) 
 0.0035(11) 
O(13) 0.0471(16)  0.0346(14) 0.0231(11)  0.0150(10) 0.0115(11) 
 0.0122(12) 
O(14) 0.0251(13)  0.0229(13) 0.0355(12)  0.0057(10) 0.0090(10) 
 0.0079(10) 
O(15) 0.0242(13)  0.0299(14) 0.0369(12)  0.0057(11) 0.0113(11) 
 0.0020(11) 
O(16) 0.0325(14)  0.0407(15) 0.0201(11)  0.0116(10) 0.0037(10) 
 0.0077(11) 
O(17) 0.0593(18)  0.0211(13) 0.0251(11)  0.0080(10) 0.0085(12)   
0.0025(12) 
O(18) 0.106(3)  0.0248(15) 0.0294(13)  0.0069(11) 0.0226(15) 
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 0.0197(16) 
O(19) 0.077(2)  0.0240(14) 0.0287(12)  0.0035(11) 0.0148(13) 
 0.0032(14) 
O(20) 0.0449(16)  0.0313(15) 0.0301(12)  0.0117(10) 0.0104(11) 
 0.0132(12) 
F(1) 0.0472(14)  0.0287(12) 0.0579(13)  0.0226(10) 0.0119(11) 
 0.0058(10) 
F(2) 0.0225(12)  0.0561(15) 0.0602(13)  0.0319(12)  0.0021(10) 
 0.0015(10) 
F(3) 0.0573(15)  0.0518(14) 0.0265(10)  0.0166(10) 0.0156(10) 
 0.0129(12) 
F(4) 0.0516(16)  0.0547(16) 0.0532(13)  0.0304(12)  0.0207(12)   
0.0184(13) 
F(5) 0.0629(16)  0.0620(16) 0.0408(12)  0.0298(11) 0.0289(12) 
 0.0153(13) 
F(6) 0.0573(16)  0.0315(13) 0.0517(13)  0.0211(10) 0.0100(11) 
 0.0123(11) 
F(7) 0.111(3)  0.109(2) 0.0389(13)  0.0220(14) 0.0017(15)  0.075(2) 
F(8) 0.112(3)  0.096(2) 0.0433(14)  0.0255(14) 0.0208(15)   
0.0407(19) 
F(9) 0.096(2)  0.0410(14) 0.0263(10)  0.0032(10) 0.0189(12) 
 0.0160(13) 
F(10) 0.0749(19)  0.0677(17) 0.0398(12)  0.0196(12) 0.0162(12)   
0.0301(14) 
F(11) 0.094(2)  0.0514(16) 0.0456(13)  0.0154(11)  0.0011(13) 
 0.0357(15) 
F(12) 0.0644(16)  0.0287(12) 0.0238(9)  0.0024(8) 0.0025(10)   
0.0043(11) 
C(1) 0.032(2)  0.032(2) 0.051(2)  0.0150(17) 0.0180(18) 
 0.0123(17) 
C(2) 0.027(2)  0.041(2) 0.054(2)  0.0269(18) 0.0205(18) 
 0.0165(17) 
C(3) 0.0273(19)  0.0211(18) 0.0300(16)  0.0109(14) 0.0093(15) 
 0.0061(14) 
C(4) 0.0197(17)  0.0215(17) 0.0198(14)  0.0058(12) 0.0043(13) 
 0.0038(13) 
C(5) 0.0235(18)  0.0291(19) 0.0261(16)  0.0144(14) 0.0050(14) 
 0.0071(14) 
C(6) 0.031(2)  0.036(2) 0.0285(16)  0.0195(15) 0.0154(15) 
 0.0076(16) 
C(7) 0.0222(18)  0.038(2) 0.0240(15)  0.0136(14) 0.0108(14) 
 0.0091(15) 
C(8) 0.0214(17)  0.0201(17) 0.0201(14)  0.0075(12) 0.0041(13) 
 0.0055(13) 
C(9) 0.0225(18)  0.0225(17) 0.0203(14)  0.0081(12) 0.0054(13) 
 0.0024(13) 
C(10) 0.0224(17)  0.0211(17) 0.0197(14)  0.0097(12) 0.0054(13) 
 0.0080(13) 
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C(11) 0.0258(18)  0.0271(19) 0.0266(16)  0.0143(14) 0.0127(14) 
 0.0128(15) 
C(12) 0.0190(18)  0.0273(19) 0.0369(18)  0.0151(15) 0.0064(15) 
 0.0050(14) 
C(13) 0.0255(19)  0.0267(19) 0.0282(16)  0.0101(14) 0.0025(15) 
 0.0108(15) 
C(14) 0.0281(19)  0.034(2) 0.0237(16)  0.0069(14) 0.0107(15) 
 0.0051(16) 
C(15) 0.0232(18)  0.033(2) 0.0273(16)  0.0137(15) 0.0102(14) 
 0.0028(15) 
C(16) 0.033(2)  0.042(3) 0.062(3)   0.007(2) 0.004(2)  0.004(2) 
C(17) 0.040(2)  0.038(2) 0.048(2)  0.0263(18) 0.0209(19) 
 0.0081(18) 
C(18) 0.028(2)  0.036(2) 0.0344(18)  0.0173(15) 0.0179(16) 
 0.0053(16) 
C(19) 0.0228(18)  0.0244(18) 0.0220(15)  0.0076(13) 0.0058(14) 
 0.0043(14) 
C(20) 0.0244(18)  0.0187(17) 0.0162(13)  0.0032(12) 0.0059(13) 
 0.0023(13) 
C(21) 0.0304(19)  0.0224(18) 0.0264(16)  0.0128(13) 0.0094(15) 
 0.0085(14) 
C(22) 0.028(2)  0.033(2) 0.0364(18)  0.0158(15) 0.0128(16) 
 0.0129(16) 
C(23) 0.0251(19)  0.030(2) 0.0268(16)  0.0117(14) 0.0090(14) 
 0.0049(15) 
C(24) 0.0283(19)  0.0147(16) 0.0183(14)  0.0064(12) 0.0049(13) 
 0.0020(13) 
C(25) 0.0247(18)  0.0216(17) 0.0200(14)  0.0066(12) 0.0057(13) 
 0.0039(14) 
C(26) 0.0315(19)  0.0179(17) 0.0151(13)  0.0058(12) 0.0036(13) 
 0.0013(14) 
C(27) 0.033(2)  0.0254(19) 0.0239(15)  0.0100(14) 0.0118(15) 
 0.0081(15) 
C(28) 0.048(2)  0.0240(19) 0.0212(15)  0.0070(14) 0.0149(16) 
 0.0119(17) 
C(29) 0.046(2)  0.0193(18) 0.0161(14)  0.0077(13) 0.0035(15) 
 0.0049(16) 
C(30) 0.034(2)  0.028(2) 0.0292(17)  0.0080(15) 0.0053(16) 
 0.0034(16) 
C(31) 0.034(2)  0.0212(18) 0.0273(16)  0.0048(14) 0.0063(15) 
 0.0067(15) 
C(32) 0.059(3)  0.035(2) 0.036(2)  0.0006(17) 0.008(2)   0.014(2) 
C(33) 0.0177(17)  0.030(2) 0.0250(16)  0.0098(14) 0.0094(14) 
 0.0076(14) 
C(34) 0.0239(19)  0.027(2) 0.0339(18)  0.0128(15) 0.0072(15) 
 0.0028(15) 
C(35) 0.031(2)  0.026(2) 0.0243(16)  0.0110(14) 0.0122(15) 
 0.0089(15) 
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C(36) 0.033(2)  0.0244(19) 0.0299(17)  0.0120(14) 0.0055(16) 
 0.0001(15) 
C(37) 0.035(2)  0.034(2) 0.0337(18)  0.0096(16) 0.0049(17)   
0.0074(17) 
C(38) 0.0212(18)  0.034(2) 0.0291(17)  0.0065(15) 0.0017(15)   
0.0061(15) 
C(39) 0.0263(19)  0.0267(19) 0.0215(15)  0.0113(14) 0.0027(14)   
0.0007(15) 
C(40) 0.0225(18)  0.0210(17) 0.0222(15)  0.0115(13) 0.0039(13) 
 0.0010(13) 
C(41) 0.033(2)  0.0176(17) 0.0284(16)  0.0071(13) 0.0081(15) 
 0.0012(15) 
C(42) 0.028(2)  0.025(2) 0.0402(19)  0.0080(15) 0.0112(16) 
 0.0083(15) 
C(43) 0.0225(18)  0.0267(19) 0.0341(17)  0.0102(15) 0.0076(15) 
 0.0022(15) 
C(44) 0.0232(17)  0.0172(16) 0.0192(14)  0.0083(12) 0.0024(13)   
0.0013(13) 
C(45) 0.0241(18)  0.0217(17) 0.0194(14)  0.0093(12) 0.0049(13) 
 0.0046(14) 
C(46) 0.0269(18)  0.0157(16) 0.0214(14)  0.0072(12) 0.0048(14) 
 0.0026(13) 
C(47) 0.0241(18)  0.0207(18) 0.0275(16)  0.0046(13) 0.0070(14) 
 0.0000(14) 
C(48) 0.0246(19)  0.0236(18) 0.0243(15)  0.0076(13) 0.0003(14) 
 0.0060(14) 
C(49) 0.034(2)  0.0151(17) 0.0207(15)  0.0044(12) 0.0036(14) 
 0.0035(14) 
C(50) 0.0259(19)  0.0208(18) 0.0279(16)  0.0059(13) 0.0097(14) 
 0.0034(14) 
C(51) 0.0227(18)  0.0211(18) 0.0249(15)  0.0061(13) 0.0015(14) 
 0.0035(14) 
C(52) 0.067(3)  0.039(2) 0.0262(17)  0.0178(16) 0.0072(18)  0.022(2) 
C(53) 0.034(2)  0.033(2) 0.060(2)  0.0106(19) 0.016(2)  0.0166(18) 
C(54) 0.026(2)  0.035(2) 0.0401(19)  0.0110(16) 0.0131(16) 
 0.0137(16) 
C(55) 0.0268(19)  0.0233(18) 0.0180(14)  0.0085(13) 0.0060(14) 
 0.0045(15) 
C(56) 0.0243(18)  0.0198(17) 0.0186(14)  0.0087(12) 0.0071(13) 
 0.0072(13) 
C(57) 0.0287(19)  0.0156(17) 0.0250(15)  0.0027(13) 0.0050(14) 
 0.0043(14) 
C(58) 0.0260(19)  0.0192(18) 0.0389(18)  0.0030(14) 0.0052(16) 
 0.0008(15) 
C(59) 0.0232(19)  0.0227(19) 0.0350(17)  0.0067(14) 0.0075(15) 
 0.0036(14) 
C(60) 0.0250(18)  0.0153(16) 0.0178(14)  0.0041(12) 0.0049(13) 
 0.0041(13) 
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C(61) 0.0246(18)  0.0192(17) 0.0168(14)  0.0065(12) 0.0056(13) 
 0.0024(13) 
C(62) 0.0308(19)  0.0173(17) 0.0168(14)  0.0061(12) 0.0072(14) 
 0.0037(14) 
C(63) 0.0230(18)  0.0294(19) 0.0249(15)  0.0115(14) 0.0034(14) 
 0.0070(15) 
C(64) 0.028(2)  0.033(2) 0.0295(17)  0.0149(15) 0.0140(15) 
 0.0095(15) 
C(65) 0.031(2)  0.0190(17) 0.0220(15)  0.0078(13) 0.0067(14) 
 0.0085(14) 
C(66) 0.0209(18)  0.0273(19) 0.0286(16)  0.0081(14) 0.0021(14) 
 0.0029(14) 
C(67) 0.0214(18)  0.0193(17) 0.0271(16)  0.0040(13) 0.0051(14) 
 0.0008(13) 
C(68) 0.044(2)  0.042(2) 0.0232(16)  0.0130(15) 0.0072(16) 
 0.0081(18) 
C(69) 0.030(2)  0.027(2) 0.0243(16)  0.0093(14) 0.0109(15) 
 0.0059(15) 
C(70) 0.047(2)  0.029(2) 0.0271(17)  0.0110(15) 0.0111(17) 
 0.0075(18) 
C(71) 0.0265(19)  0.0237(19) 0.0237(16)  0.0051(14) 0.0048(14)   
0.0048(15) 
C(72) 0.040(2)  0.0211(19) 0.0275(17)  0.0051(14) 0.0041(16)   
0.0031(16) 
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Table 26.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for 195. 
 
      x       y       z       U 
 
H(1A)  0.2563 1.3662 0.9117 0.054 
H(1B)  0.2199 1.3125 0.8506 0.054 
H(1C)  0.1351 1.3856 0.9115 0.054 
H(2A)  0.1677 1.2621 0.9675 0.043 
H(2B)  0.2396 1.1865 0.9020 0.043 
H(5A) 0.0569 1.2083 0.8541 0.030 
H(6A) 0.2196 1.1767 0.8355 0.034 
H(7A) 0.3188 1.0702 0.8856 0.031 
H(9A) 0.0866 1.0181 0.9685 0.026 
H(11A) 0.4798 1.1255 1.0232 0.028 
H(12A) 0.5547 1.2663 1.1117 0.032 
H(14A) 0.3257 1.1916 1.1909 0.034 
H(15A) 0.2557 1.0464 1.1048 0.032 
H(16A) 0.6126 1.4111 1.2706 0.076 
H(16B) 0.5925 1.4104 1.1983 0.076 
H(16C) 0.6373 1.3151 1.2211 0.076 
H(17A) 0.0169 0.1579 1.1625 0.057 
H(17B) 0.1340 0.2164 1.1763 0.057 
H(17C) 0.0881 0.1193 1.1158 0.057 
H(18A)  0.0383 0.2173 1.0737 0.035 
H(18B) 0.0149 0.3154 1.1331 0.035 
H(21A) 0.2829 0.2865 1.0546 0.030 
H(22A) 0.4210 0.3391 1.0168 0.036 
H(23A) 0.4000 0.4554 0.9545 0.031 
H(25A) 0.1019 0.4697 0.9713 0.026 
H(27A) 0.2433 0.3816 0.7938 0.031 
H(28A) 0.1341 0.2371 0.7222 0.036 
H(30A)  0.1200 0.3423 0.7738 0.037 
H(31A)  0.0103 0.4889 0.8448 0.033 
H(32A)  0.1955 0.0913 0.6769 0.070 
H(32B)  0.2055 0.2123 0.6957 0.070 
H(32C)  0.1632 0.1565 0.7493 0.070 
H(37A) 1.2101 1.5261 0.6608 0.054 
H(37B) 1.1243 1.4963 0.6952 0.054 
H(37C) 1.0882 1.5315 0.6322 0.054 
H(38A) 1.1412 1.3802 0.5762 0.036 
H(38B) 1.1690 1.3439 0.6396 0.036 
H(41A) 0.8290 1.3513 0.6018 0.032 
H(42A) 0.6513 1.2948 0.5846 0.037 
H(43A) 0.5822 1.1196 0.5370 0.033 
H(45A) 0.8735 1.0580 0.5251 0.025 
H(47A) 0.5060 0.9669 0.3782 0.030 
H(48A) 0.4988 0.9997 0.2809 0.030 
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H(50A) 0.8013 0.9481 0.2983 0.029 
H(51A) 0.8084 0.9125 0.3951 0.028 
H(52A) 0.5933 1.0737 0.1654 0.064 
H(52B) 0.5604 1.1051 0.2301 0.064 
H(52C) 0.5077 0.9975 0.1789 0.064 
H(53A) 1.1091 0.0418 0.3767 0.062 
H(53B) 0.9993 0.0531 0.3322 0.062 
H(53C) 1.0013 0.0194 0.3951 0.062 
H(54A) 1.0964 0.1857 0.4551 0.039 
H(54B) 1.0842 0.2189 0.3908 0.039 
H(57A) 0.7572 0.1655 0.3919 0.029 
H(58A) 0.5861 0.1955 0.3932 0.036 
H(59A) 0.5545 0.3623 0.4398 0.033 
H(61A) 0.8673 0.4681 0.4834 0.024 
H(63A) 0.5706 0.5298 0.6013 0.030 
H(64A) 0.6126 0.5185 0.7052 0.033 
H(66A) 0.9240 0.5726 0.7148 0.032 
H(67A) 0.8806 0.5882 0.6119 0.028 
H(68A) 0.7559 0.5149 0.8518 0.053 
H(68B) 0.6813 0.4510 0.7844 0.053 
H(68C) 0.6782 0.5723 0.8104 0.053 
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Table 27.  Torsion angles [°] for 195. 
 
C(3)–O(1)–C(2)–C(1) 174.6(3) C(2)–O(1)–C(3)–O(2) 5.0(5) 
C(2)–O(1)–C(3)–C(4)  173.6(3) O(1)–C(3)–C(4)–C(5)  8.3(4) 
O(1)–C(3)–C(4)–C(9) 169.1(3) O(2)–C(3)–C(4)–C(5) 173.0(3) 
O(2)–C(3)–C(4)–C(9)  9.5(5) C(3)–C(4)–C(5)–C(6) 178.5(3) 
C(9)–C(4)–C(5)–C(6) 1.1(5) C(4)–C(5)–C(6)–C(7)  1.5(5) 
C(5)–C(6)–C(7)–C(8) 1.2(5) C(6)–C(7)–C(8)–I(1)  176.6(2) 
C(6)–C(7)–C(8)–C(9)  0.4(5) C(10)–I(1)–C(8)–C(7) 92.4(3) 
C(10)–I(1)–C(8)–C(9)  84.0(3) I(1)–C(8)–C(9)–C(4) 176.2(2) 
C(7)–C(8)–C(9)–C(4) 0.0(5) C(3)–C(4)–C(9)–C(8)  177.9(3) 
C(5)–C(4)–C(9)–C(8)  0.3(5) C(8)–I(1)–C(10)–C(11)  85.9(2) 
C(8)–I(1)–C(10)–C(15) 93.5(2) I(1)–C(10)–C(11)–C(12)  178.1(2) 
C(15)–C(10)–C(11)–C(12) 2.5(5) C(10)–C(11)–C(12)–C(13)  1.3(4) 
C(16)–O(3)–C(13)–C(12)  15.3(5) C(16)–O(3)–C(13)–C(14) 164.1(3) 
C(11)–C(12)–C(13)–O(3) 177.9(3) C(11)–C(12)–C(13)–C(14)  1.6(5) 
O(3)–C(13)–C(14)–C(15)  176.2(3) C(12)–C(13)–C(14)–C(15) 3.3(5) 
I(1)–C(10)–C(15)–C(14) 179.8(2) C(11)–C(10)–C(15)–C(14)  0.9(5) 
C(13)–C(14)–C(15)–C(10)  2.0(5) C(19)–O(4)–C(18)–C(17)  171.7(3) 
C(18)–O(4)–C(19)–O(5)  1.1(5) C(18)–O(4)–C(19)–C(20) 176.6(3) 
O(4)–C(19)–C(20)–C(21)  8.2(4) O(4)–C(19)–C(20)–C(25) 174.2(3) 
O(5)–C(19)–C(20)–C(21) 169.4(3) O(5)–C(19)–C(20)–C(25)  8.2(5) 
C(19)–C(20)–C(21)–C(22)  175.9(3) C(25)–C(20)–C(21)–C(22) 1.7(5) 
C(20)–C(21)–C(22)–C(23)  1.3(5) C(21)–C(22)–C(23)–C(24) 0.4(5) 
C(22)–C(23)–C(24)–I(2)  176.1(2) C(22)–C(23)–C(24)–C(25) 0.2(5) 
C(26)–I(2)–C(24)–C(23) 105.3(3) C(26)–I(2)–C(24)–C(25)  71.2(2) 
I(2)–C(24)–C(25)–C(20) 176.5(2) C(23)–C(24)–C(25)–C(20) 0.1(5) 
C(19)–C(20)–C(25)–C(24) 176.6(3) C(21)–C(20)–C(25)–C(24)  1.1(5) 
C(24)–I(2)–C(26)–C(27)  81.8(2) C(24)–I(2)–C(26)–C(31) 94.3(2) 
I(2)–C(26)–C(27)–C(28) 173.8(2) C(31)–C(26)–C(27)–C(28)  2.2(4) 
C(26)–C(27)–C(28)–C(29)  1.0(4) C(32)–O(6)–C(29)–C(28) 168.3(3) 
C(32)–O(6)–C(29)–C(30)  11.3(4) C(27)–C(28)–C(29)–O(6)  176.0(3) 
C(27)–C(28)–C(29)–C(30) 3.7(4) O(6)–C(29)–C(30)–C(31) 176.5(3) 
C(28)–C(29)–C(30)–C(31)  3.2(5) I(2)–C(26)–C(31)–C(30)  173.3(2) 
C(27)–C(26)–C(31)–C(30) 2.7(5) C(29)–C(30)–C(31)–C(26) 0.0(5) 
O(7)–C(33)–C(34)–F(1)  5.9(4) O(7)–C(33)–C(34)–F(2) 113.3(3) 
O(7)–C(33)–C(34)–F(3)  126.5(3) O(8)–C(33)–C(34)–F(1) 175.0(3) 
O(8)–C(33)–C(34)–F(2)  65.9(4) O(8)–C(33)–C(34)–F(3) 54.4(4) 
O(9)–C(35)–C(36)–F(4)  151.0(3) O(9)–C(35)–C(36)–F(5) 89.1(4) 
O(9)–C(35)–C(36)–F(6)  30.2(4) O(10)–C(35)–C(36)–F(4) 30.5(4) 
O(10)–C(35)–C(36)–F(5)  89.4(4) O(10)–C(35)–C(36)–F(6) 151.4(3) 
C(39)–O(11)–C(38)–C(37)  172.6(2) C(38)–O(11)–C(39)–O(12) 2.6(4) 
C(38)–O(11)–C(39)–C(40)  178.0(2) O(11)–C(39)–C(40)–C(41)  0.4(4) 
O(11)–C(39)–C(40)–C(45) 179.9(2) O(12)–C(39)–C(40)–C(41) 179.1(3) 
O(12)–C(39)–C(40)–C(45)  0.6(4) C(39)–C(40)–C(41)–C(42)  178.7(3) 
C(45)–C(40)–C(41)–C(42) 0.9(4) C(40)–C(41)–C(42)–C(43)  0.6(5) 
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C(41)–C(42)–C(43)–C(44) 0.3(5) C(42)–C(43)–C(44)–I(3)  178.9(2) 
C(42)–C(43)–C(44)–C(45)  0.4(4) C(46)–I(3)–C(44)–C(43) 98.5(2) 
C(46)–I(3)–C(44)–C(45)  80.1(2) I(3)–C(44)–C(45)–C(40) 179.31(19) 
C(43)–C(44)–C(45)–C(40) 0.8(4) C(39)–C(40)–C(45)–C(44) 178.7(2) 
C(41)–C(40)–C(45)–C(44)  1.1(4) C(44)–I(3)–C(46)–C(47)  91.5(3) 
C(44)–I(3)–C(46)–C(51) 86.5(3) I(3)–C(46)–C(47)–C(48) 177.0(2) 
C(51)–C(46)–C(47)–C(48)  1.0(5) C(46)–C(47)–C(48)–C(49)  0.1(5) 
C(52)–O(13)–C(49)–C(48) 13.7(5) C(52)–O(13)–C(49)–C(50)  165.5(3) 
C(47)–C(48)–C(49)–O(13)  178.5(3) C(47)–C(48)–C(49)–C(50) 0.7(5) 
O(13)–C(49)–C(50)–C(51) 179.0(3) C(48)–C(49)–C(50)–C(51)  0.1(5) 
I(3)–C(46)–C(51)–C(50)  176.5(2) C(47)–C(46)–C(51)–C(50) 1.5(5) 
C(49)–C(50)–C(51)–C(46)  0.9(5) C(55)–O(14)–C(54)–C(53)  173.4(3) 
C(54)–O(14)–C(55)–O(15) 0.2(4) C(54)–O(14)–C(55)–C(56)  179.5(2) 
O(14)–C(55)–C(56)–C(57)  4.0(4) O(14)–C(55)–C(56)–C(61) 177.0(2) 
O(15)–C(55)–C(56)–C(57) 176.3(3) O(15)–C(55)–C(56)–C(61)  2.7(4) 
C(55)–C(56)–C(57)–C(58)  179.9(3) C(61)–C(56)–C(57)–C(58)  0.9(4) 
C(56)–C(57)–C(58)–C(59) 0.4(5) C(57)–C(58)–C(59)–C(60) 0.5(5) 
C(58)–C(59)–C(60)–I(4)  179.7(2) C(58)–C(59)–C(60)–C(61)  1.1(5) 
C(62)–I(4)–C(60)–C(59) 97.5(2) C(62)–I(4)–C(60)–C(61)  81.2(2) 
I(4)–C(60)–C(61)–C(56) 179.27(19) C(59)–C(60)–C(61)–C(56) 0.6(4) 
C(55)–C(56)–C(61)–C(60) 179.4(2) C(57)–C(56)–C(61)–C(60) 0.4(4) 
C(60)–I(4)–C(62)–C(63)  101.9(3) C(60)–I(4)–C(62)–C(67) 80.7(3) 
I(4)–C(62)–C(63)–C(64)  176.8(2) C(67)–C(62)–C(63)–C(64) 0.6(5) 
C(62)–C(63)–C(64)–C(65)  0.6(5) C(68)–O(16)–C(65)–C(64) 2.1(4) 
C(68)–O(16)–C(65)–C(66)  178.4(3) C(63)–C(64)–C(65)–O(16) 179.3(3) 
C(63)–C(64)–C(65)–C(66)  0.3(5) O(16)–C(65)–C(66)–C(67)  178.4(3) 
C(64)–C(65)–C(66)–C(67) 1.2(5) I(4)–C(62)–C(67)–C(66) 177.7(2) 
C(63)–C(62)–C(67)–C(66) 0.4(5) C(65)–C(66)–C(67)–C(62)  1.2(5) 
O(17)–C(69)–C(70)–F(7)  115.9(4) O(17)–C(69)–C(70)–F(8) 125.9(4) 
O(17)–C(69)–C(70)–F(9) 8.8(5) O(18)–C(69)–C(70)–F(7) 65.3(5) 
O(18)–C(69)–C(70)–F(8)  53.0(4) O(18)–C(69)–C(70)–F(9)  170.1(3) 
O(19)–C(71)–C(72)–F(10) 89.9(4) O(19)–C(71)–C(72)–F(11)  30.5(4) 
O(19)–C(71)–C(72)–F(12)  151.1(3) O(20)–C(71)–C(72)–F(10)  90.2(4) 
O(20)–C(71)–C(72)–F(11) 149.5(3) O(20)–C(71)–C(72)–F(12) 28.9(5) 
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Compound 196 
 
Table 1.  Crystal data and structure refinement for 196. 
 
Identification code  mac140002 
Chemical formula (moiety) C30H24F6I2O8S2·C2H3N 
Chemical formula (total) C32H27F6I2NO8S2 
Formula weight  985.46 
Temperature  100(2) K 
Radiation, wavelength  synchrotron, 0.6889 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 12.228(2) Å  = 86.152(2)° 
 b = 12.497(2) Å  = 74.917(2)° 
 c = 13.466(3) Å  = 64.079(2)° 
Cell volume 1784.4(6) Å3 
Z 2 
Calculated density  1.834 g/cm3 
Absorption coefficient  1.749 mm1 
F(000) 964 
Crystal colour and size colourless, 0.300  0.010  0.010 mm3 
Reflections for cell refinement 9712 ( range 2.4 to 29.3°) 
Data collection method Rigaku Saturn 724+ on kappa 
diffractometer 
 wide-frame  scans 
 range for data collection 1.5 to 27.3° 
Index ranges h 16 to 16, k 16 to 15, l 17 to 17 
Completeness to  = 24.4° 97.1 %  
Reflections collected 18147 
Independent reflections 8329 (Rint = 0.0432) 
Reflections with F2>2 6644 
Absorption correction multi-scan 
Min. and max. transmission 0.60 and 0.98 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0943, 6.7894 
Data / restraints / parameters 8329 / 255 / 516 
Final R indices [F2>2] R1 = 0.0621, wR2 = 0.1706 
R indices (all data) R1 = 0.0743, wR2 = 0.1797 
Goodness-of-fit on F2 1.042 
Largest and mean shift/su 0.002 and 0.000 
Largest diff. peak and hole 3.02 and 1.95 e Å3 
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Table 2.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) for 
196.   
Ueq is defined as one third of the trace of the orthogonalized U
ij tensor. 
 
      x      y      z      Ueq 
 
I(1) 0.04069(3) 0.47596(3) 0.31908(3) 0.03258(13) 
C(1)  0.1407(6) 0.4875(5) 0.3620(4) 0.0368(12) 
C(2)  0.192(2) 0.453(3) 0.3001(17) 0.042(4) 
C(3)  0.320(2) 0.479(4) 0.348(2) 0.048(5) 
C(4)  0.357(2) 0.531(3) 0.445(2) 0.046(4) 
S(1)  0.2402(6) 0.5523(7) 0.4772(4) 0.0444(14) 
C(2')  0.2284(18) 0.544(2) 0.4475(14) 0.048(4) 
C(3')  0.3455(19) 0.542(3) 0.451(2) 0.054(4) 
C(4')  0.3339(17) 0.479(3) 0.3657(15) 0.044(4) 
S(1')  0.1882(5) 0.4296(5) 0.2803(4) 0.0447(12) 
C(5)  0.0172(5) 0.6342(5) 0.2388(4) 0.0315(11) 
C(6)  0.0375(6) 0.6316(5) 0.1427(5) 0.0330(12) 
C(7)  0.0830(6) 0.7392(5) 0.0952(4) 0.0328(12) 
C(8)  0.1070(6) 0.8442(5) 0.1439(5) 0.0367(13) 
C(9)  0.0831(7) 0.8435(6) 0.2393(5) 0.0409(14) 
C(10)  0.0374(6) 0.7369(5) 0.2887(5) 0.0364(13) 
C(11)  0.1019(6) 0.7362(5)  0.0089(5) 0.0343(12) 
C(12)  0.1862(7) 0.8560(6)  0.1403(5) 0.0430(14) 
C(13)  0.2449(9) 0.9848(8)  0.1579(6) 0.063(2) 
O(1)  0.0676(5) 0.6476(4)  0.0612(4) 0.0444(11) 
O(2)  0.1613(4) 0.8464(4)  0.0395(3) 0.0372(9) 
I(2) 0.47421(4) 0.21715(4) 0.25123(4) 0.04827(16) 
C(14) 0.6511(6) 0.1923(6) 0.1647(6) 0.0516(18) 
C(15) 0.6904(6) 0.1821(6) 0.0602(6) 0.0466(16) 
C(16) 0.8196(8) 0.1576(7) 0.0261(9) 0.074(3) 
C(17) 0.8720(8) 0.1493(7) 0.1054(9) 0.079(3) 
S(2) 0.7661(3) 0.1744(2) 0.2217(3) 0.0818(8) 
C(18) 0.5315(7) 0.0301(5) 0.2537(6) 0.0455(16) 
C(19) 0.5433(6)  0.0301(6) 0.1677(6) 0.0418(14) 
C(20) 0.5850(6)  0.1541(6) 0.1709(6) 0.0418(15) 
C(21) 0.6117(7)  0.2111(6) 0.2584(6) 0.0484(17) 
C(22) 0.5996(10)  0.1471(7) 0.3442(7) 0.069(3) 
C(23) 0.5567(9)  0.0234(7) 0.3419(6) 0.064(2) 
C(24) 0.5974(6)  0.2199(5) 0.0771(6) 0.0415(15) 
C(25) 0.6746(7)  0.4088(6)  0.0056(6) 0.0485(16) 
C(26) 0.7286(7)  0.5368(6) 0.0254(6) 0.0492(16) 
O(3) 0.5578(5)  0.1722(4) 0.0041(4) 0.0521(12) 
O(4) 0.6578(5)  0.3368(4) 0.0829(4) 0.0441(11) 
O(5) 0.2601(5) 0.4987(5) 0.2534(5) 0.0553(14) 
O(6) 0.4591(6) 0.4395(5) 0.2554(7) 0.077(2) 
C(27) 0.3539(6) 0.5132(6) 0.2510(6) 0.0409(14) 
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C(28) 0.3389(7) 0.6431(7) 0.2367(8) 0.057(2) 
F(1) 0.3985(7) 0.6510(7) 0.1360(6) 0.108(2) 
F(2) 0.2284(5) 0.7222(5) 0.2479(7) 0.100(2) 
F(3) 0.3999(5) 0.6688(5) 0.2930(6) 0.0853(18) 
O(7) 0.2559(7) 0.2168(7) 0.3471(8) 0.112(3) 
O(8) 0.0663(6) 0.2861(6) 0.4467(5) 0.0672(17) 
C(29) 0.1728(7) 0.2077(6) 0.4154(5) 0.0453(15) 
C(30) 0.2027(11) 0.0918(10) 0.4595(7) 0.084(3) 
F(4) 0.1103(7) 0.0768(5) 0.5262(5) 0.0900(19) 
F(5) 0.2745(7)  0.0039(5) 0.3962(5) 0.093(2) 
F(6) 0.2844(8) 0.0796(9) 0.5212(6) 0.124(3) 
N 1.013(3) 0.085(2) 0.345(3) 0.259(19) 
C(31) 0.9191(15) 0.1472(16) 0.4012(14) 0.078(4) 
C(32) 0.8255(12) 0.2156(13) 0.4997(12) 0.106(4) 
N' 0.626(2) 0.209(2) 0.4525(17) 0.075(6) 
C(31') 0.712(2) 0.213(2) 0.470(2) 0.074(6) 
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Table 3.   Bond lengths [Å] and angles [°] for 196. 
 
I(1)–C(1)  2.083(6) I(1)–C(5)  2.114(6) 
I(1)–O(5)  2.731(5) I(1)–O(8)  2.787(5) 
C(1)–C(2)  1.355(16) C(1)–S(1)  1.693(7) 
C(1)–C(2')  1.335(15) C(1)–S(1')  1.697(7) 
C(2)–H(2)  0.950 C(2)–C(3)  1.423(19) 
C(3)–H(3)  0.950 C(3)–C(4)  1.368(15) 
C(4)–H(4)  0.950 C(4)–S(1)  1.721(16) 
C(2')–H(2')  0.950 C(2')–C(3')  1.436(18) 
C(3')–H(3')  0.950 C(3')–C(4')  1.372(15) 
C(4')–H(4')  0.950 C(4')–S(1')  1.716(14) 
C(5)–C(6)  1.385(8) C(5)–C(10)  1.383(8) 
C(6)–H(6)  0.950 C(6)–C(7)  1.393(8) 
C(7)–C(8)  1.385(8) C(7)–C(11)  1.484(8) 
C(8)–H(8)  0.950 C(8)–C(9)  1.387(9) 
C(9)–H(9)  0.950 C(9)–C(10)  1.397(9) 
C(10)–H(10)  0.950 C(11)–O(1)  1.201(7) 
C(11)–O(2)  1.342(7) C(12)–H(12A)  0.990 
C(12)–H(12B)  0.990 C(12)–C(13)  1.479(11) 
C(12)–O(2)  1.453(8) C(13)–H(13A)  0.980 
C(13)–H(13B)  0.980 C(13)–H(13C)  0.980 
I(2)–C(14)  2.070(7) I(2)–C(18)  2.128(6) 
I(2)–O(6)  2.707(6) I(2)–O(7)  2.647(7) 
C(14)–C(15)  1.358(10) C(14)–S(2)  1.697(7) 
C(15)–H(15)  0.950 C(15)–C(16)  1.420(10) 
C(16)–H(16)  0.950 C(16)–C(17)  1.359(13) 
C(17)–H(17)  0.950 C(17)–S(2)  1.698(10) 
C(18)–C(19)  1.364(10) C(18)–C(23)  1.363(11) 
C(19)–H(19)  0.950 C(19)–C(20)  1.406(9) 
C(20)–C(21)  1.373(10) C(20)–C(24)  1.491(10) 
C(21)–H(21)  0.950 C(21)–C(22)  1.388(12) 
C(22)–H(22)  0.950 C(22)–C(23)  1.399(11) 
C(23)–H(23)  0.950 C(24)–O(3)  1.214(9) 
C(24)–O(4)  1.326(8) C(25)–H(25A)  0.990 
C(25)–H(25B)  0.990 C(25)–C(26)  1.517(9) 
C(25)–O(4)  1.458(9) C(26)–H(26A)  0.980 
C(26)–H(26B)  0.980 C(26)–H(26C)  0.980 
O(5)–C(27)  1.229(8) O(6)–C(27)  1.226(9) 
C(27)–C(28)  1.556(10) C(28)–F(1)  1.382(11) 
C(28)–F(2)  1.254(9) C(28)–F(3)  1.330(9) 
O(7)–C(29)  1.222(10) O(8)–C(29)  1.220(9) 
C(29)–C(30)  1.456(12) C(30)–F(4)  1.325(13) 
C(30)–F(5)  1.325(12) C(30)–F(6)  1.412(14) 
N–C(31)  1.16(2) C(31)–C(32)  1.52(2) 
C(32)–C(31')  1.55(2) N'–C(31')  1.16(2) 
 
C(1)–I(1)–C(5) 91.9(2) C(1)–I(1)–O(5) 170.5(2) 
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C(1)–I(1)–O(8) 77.5(2) C(5)–I(1)–O(5) 78.83(19) 
C(5)–I(1)–O(8) 168.5(2) O(5)–I(1)–O(8) 111.57(18) 
I(1)–C(1)–C(2) 124.4(9) I(1)–C(1)–S(1) 121.0(3) 
I(1)–C(1)–C(2') 125.2(9) I(1)–C(1)–S(1') 119.2(3) 
C(2)–C(1)–S(1) 114.5(9) C(2')–C(1)–S(1') 115.5(9) 
C(1)–C(2)–H(2) 124.4 C(1)–C(2)–C(3) 111.2(15) 
H(2)–C(2)–C(3) 124.4 C(2)–C(3)–H(3) 124.3 
C(2)–C(3)–C(4) 111.5(18) H(3)–C(3)–C(4) 124.3 
C(3)–C(4)–H(4) 123.6 C(3)–C(4)–S(1) 112.9(16) 
H(4)–C(4)–S(1) 123.6 C(1)–S(1)–C(4) 90.0(8) 
C(1)–C(2')–H(2') 124.4 C(1)–C(2')–C(3') 111.1(14) 
H(2')–C(2')–C(3') 124.4 C(2')–C(3')–H(3') 124.8 
C(2')–C(3')–C(4') 110.4(16) H(3')–C(3')–C(4') 124.8 
C(3')–C(4')–H(4') 123.2 C(3')–C(4')–S(1') 113.7(13) 
H(4')–C(4')–S(1') 123.2 C(1)–S(1')–C(4') 89.2(7) 
I(1)–C(5)–C(6) 119.6(4) I(1)–C(5)–C(10) 116.8(4) 
C(6)–C(5)–C(10) 123.6(6) C(5)–C(6)–H(6) 121.2 
C(5)–C(6)–C(7) 117.7(5) H(6)–C(6)–C(7) 121.2 
C(6)–C(7)–C(8) 120.3(6) C(6)–C(7)–C(11) 117.8(5) 
C(8)–C(7)–C(11) 121.9(6) C(7)–C(8)–H(8) 119.7 
C(7)–C(8)–C(9) 120.6(6) H(8)–C(8)–C(9) 119.7 
C(8)–C(9)–H(9) 119.8 C(8)–C(9)–C(10) 120.4(6) 
H(9)–C(9)–C(10) 119.8 C(5)–C(10)–C(9) 117.5(6) 
C(5)–C(10)–H(10) 121.3 C(9)–C(10)–H(10) 121.3 
C(7)–C(11)–O(1) 125.5(6) C(7)–C(11)–O(2) 111.4(5) 
O(1)–C(11)–O(2) 123.1(6) H(12A)–C(12)–H(12B) 108.6 
H(12A)–C(12)–C(13) 110.5 H(12A)–C(12)–O(2) 110.5 
H(12B)–C(12)–C(13) 110.5 H(12B)–C(12)–O(2) 110.5 
C(13)–C(12)–O(2) 106.4(6) C(12)–C(13)–H(13A) 109.5 
C(12)–C(13)–H(13B) 109.5 C(12)–C(13)–H(13C) 109.5 
H(13A)–C(13)–H(13B) 109.5 H(13A)–C(13)–H(13C) 109.5 
H(13B)–C(13)–H(13C) 109.5 C(11)–O(2)–C(12) 117.0(5) 
C(14)–I(2)–C(18) 91.5(3) C(14)–I(2)–O(6) 77.7(2) 
C(14)–I(2)–O(7) 170.9(3) C(18)–I(2)–O(6) 165.6(2) 
C(18)–I(2)–O(7) 80.6(3) O(6)–I(2)–O(7) 110.8(2) 
I(2)–C(14)–C(15) 125.6(5) I(2)–C(14)–S(2) 121.2(5) 
C(15)–C(14)–S(2) 113.1(5) C(14)–C(15)–H(15) 124.5 
C(14)–C(15)–C(16) 110.9(8) H(15)–C(15)–C(16) 124.5 
C(15)–C(16)–H(16) 123.7 C(15)–C(16)–C(17) 112.5(9) 
H(16)–C(16)–C(17) 123.7 C(16)–C(17)–H(17) 123.9 
C(16)–C(17)–S(2) 112.2(7) H(17)–C(17)–S(2) 123.9 
C(14)–S(2)–C(17) 91.2(5) I(2)–C(18)–C(19) 119.1(5) 
I(2)–C(18)–C(23) 117.3(6) C(19)–C(18)–C(23) 123.6(6) 
C(18)–C(19)–H(19) 121.2 C(18)–C(19)–C(20) 117.7(7) 
H(19)–C(19)–C(20) 121.2 C(19)–C(20)–C(21) 120.3(7) 
C(19)–C(20)–C(24) 117.7(6) C(21)–C(20)–C(24) 122.0(6) 
C(20)–C(21)–H(21) 119.8 C(20)–C(21)–C(22) 120.4(6) 
H(21)–C(21)–C(22) 119.8 C(21)–C(22)–H(22) 120.2 
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C(21)–C(22)–C(23) 119.5(8) H(22)–C(22)–C(23) 120.2 
C(18)–C(23)–C(22) 118.5(8) C(18)–C(23)–H(23) 120.8 
C(22)–C(23)–H(23) 120.8 C(20)–C(24)–O(3) 124.2(6) 
C(20)–C(24)–O(4) 111.7(6) O(3)–C(24)–O(4) 124.1(7) 
H(25A)–C(25)–H(25B) 108.8 H(25A)–C(25)–C(26) 110.6 
H(25A)–C(25)–O(4) 110.6 H(25B)–C(25)–C(26) 110.6 
H(25B)–C(25)–O(4) 110.6 C(26)–C(25)–O(4) 105.6(6) 
C(25)–C(26)–H(26A) 109.5 C(25)–C(26)–H(26B) 109.5 
C(25)–C(26)–H(26C) 109.5 H(26A)–C(26)–H(26B) 109.5 
H(26A)–C(26)–H(26C) 109.5 H(26B)–C(26)–H(26C) 109.5 
C(24)–O(4)–C(25) 115.7(6) I(1)–O(5)–C(27) 163.2(5) 
I(2)–O(6)–C(27) 110.0(4) O(5)–C(27)–O(6) 129.4(7) 
O(5)–C(27)–C(28) 115.7(6) O(6)–C(27)–C(28) 114.9(6) 
C(27)–C(28)–F(1) 108.3(7) C(27)–C(28)–F(2) 115.8(6) 
C(27)–C(28)–F(3) 111.2(7) F(1)–C(28)–F(2) 104.0(8) 
F(1)–C(28)–F(3) 104.6(7) F(2)–C(28)–F(3) 112.0(7) 
I(2)–O(7)–C(29) 160.3(9) I(1)–O(8)–C(29) 107.5(4) 
O(7)–C(29)–O(8) 125.4(8) O(7)–C(29)–C(30) 116.7(8) 
O(8)–C(29)–C(30) 117.8(7) C(29)–C(30)–F(4) 117.6(9) 
C(29)–C(30)–F(5) 117.5(7) C(29)–C(30)–F(6) 106.1(11) 
F(4)–C(30)–F(5) 110.7(10) F(4)–C(30)–F(6) 102.1(8) 
F(5)–C(30)–F(6) 99.8(9) N–C(31)–C(32) 160(3) 
C(32)–C(31')–N' 177(2)  
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Table 4.  Torsion angles [°] for 196. 
 
I(1)–C(1)–C(2)–C(3)  176(2) S(1)–C(1)–C(2)–C(3) 0(3) 
C(2')–C(1)–C(2)–C(3)  4(3) S(1')–C(1)–C(2)–C(3) 142(13) 
C(1)–C(2)–C(3)–C(4)  1(5) C(2)–C(3)–C(4)–S(1) 1(5) 
I(1)–C(1)–S(1)–C(4) 176.8(14) C(2)–C(1)–S(1)–C(4) 1(2) 
C(2')–C(1)–S(1)–C(4) 42(12) S(1')–C(1)–S(1)–C(4)  3.9(15) 
C(3)–C(4)–S(1)–C(1)  1(3) I(1)–C(1)–C(2')–C(3') 176(2) 
C(2)–C(1)–C(2')–C(3') 5(3) S(1)–C(1)–C(2')–C(3')  136(14) 
S(1')–C(1)–C(2')–C(3') 1(3) C(1)–C(2')–C(3')–C(4') 1(4) 
C(2')–C(3')–C(4')–S(1')  2(4) I(1)–C(1)–S(1')–C(4')  177.8(12) 
C(2)–C(1)–S(1')–C(4')  37(11) S(1)–C(1)–S(1')–C(4') 2.9(13) 
C(2')–C(1)–S(1')–C(4')  1.8(19) C(3')–C(4')–S(1')–C(1) 2(3) 
I(1)–C(5)–C(6)–C(7) 176.1(4) C(10)–C(5)–C(6)–C(7)  1.3(9) 
C(5)–C(6)–C(7)–C(8)  0.2(8) C(5)–C(6)–C(7)–C(11) 178.5(5) 
C(6)–C(7)–C(8)–C(9) 1.6(9) C(11)–C(7)–C(8)–C(9)  177.1(6) 
C(7)–C(8)–C(9)–C(10)  1.6(10) I(1)–C(5)–C(10)–C(9)  176.2(5) 
C(6)–C(5)–C(10)–C(9) 1.3(9) C(8)–C(9)–C(10)–C(5) 0.2(9) 
C(6)–C(7)–C(11)–O(1)  9.3(9) C(6)–C(7)–C(11)–O(2) 171.8(5) 
C(8)–C(7)–C(11)–O(1) 169.4(6) C(8)–C(7)–C(11)–O(2)  9.5(8) 
C(7)–C(11)–O(2)–C(12)  179.7(5) O(1)–C(11)–O(2)–C(12) 1.3(8) 
C(13)–C(12)–O(2)–C(11)  176.9(6) I(2)–C(14)–C(15)–C(16)  175.9(5) 
S(2)–C(14)–C(15)–C(16) 0.6(8) C(14)–C(15)–C(16)–C(17) 0.6(9) 
C(15)–C(16)–C(17)–S(2)  1.5(9) C(16)–C(17)–S(2)–C(14) 1.5(7) 
I(2)–C(14)–S(2)–C(17) 175.5(4) C(15)–C(14)–S(2)–C(17)  1.2(6) 
I(2)–C(18)–C(19)–C(20) 178.1(5) C(23)–C(18)–C(19)–C(20)  0.6(11) 
C(18)–C(19)–C(20)–C(21) 0.4(9) C(18)–C(19)–C(20)–C(24) 179.8(6) 
C(19)–C(20)–C(21)–C(22)  1.0(11) C(24)–C(20)–C(21)–C(22) 179.7(7) 
C(20)–C(21)–C(22)–C(23) 1.8(13) I(2)–C(18)–C(23)–C(22)  177.4(7) 
C(19)–C(18)–C(23)–C(22) 1.4(14) C(21)–C(22)–C(23)–C(18)  1.9(14) 
C(19)–C(20)–C(24)–O(3)  10.6(9) C(19)–C(20)–C(24)–O(4) 168.9(5) 
C(21)–C(20)–C(24)–O(3) 168.7(6) C(21)–C(20)–C(24)–O(4)  11.7(8) 
C(20)–C(24)–O(4)–C(25)  180.0(5) O(3)–C(24)–O(4)–C(25)  0.4(9) 
C(26)–C(25)–O(4)–C(24)  172.4(5) I(2)–O(6)–C(27)–O(5) 6.3(11) 
I(2)–O(6)–C(27)–C(28)  171.5(5) I(1)–O(5)–C(27)–O(6) 88.8(18) 
I(1)–O(5)–C(27)–C(28)  93.4(18) O(5)–C(27)–C(28)–F(1)  103.8(8) 
O(5)–C(27)–C(28)–F(2) 12.5(12) O(5)–C(27)–C(28)–F(3) 141.9(7) 
O(6)–C(27)–C(28)–F(1) 74.4(9) O(6)–C(27)–C(28)–F(2)  169.4(9) 
O(6)–C(27)–C(28)–F(3)  40.0(10) I(1)–O(8)–C(29)–O(7) 6.6(12) 
I(1)–O(8)–C(29)–C(30)  170.4(7) I(2)–O(7)–C(29)–O(8) 121.9(18) 
I(2)–O(7)–C(29)–C(30)  61(2) O(7)–C(29)–C(30)–F(4)  173.4(10) 
O(7)–C(29)–C(30)–F(5)  37.2(16) O(7)–C(29)–C(30)–F(6) 73.3(11) 
O(8)–C(29)–C(30)–F(4) 3.9(14) O(8)–C(29)–C(30)–F(5) 140.1(10) 
O(8)–C(29)–C(30)–F(6)  109.4(9) N–C(31)–C(32)–C(31')  151(5) 
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Table 5.   Anisotropic displacement parameters (Å2) for 196.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
I(1) 0.0296(2)  0.0268(2) 0.0421(2)  0.00477(14) 0.00778(15)   
0.01414(17) 
C(1) 0.032(3)  0.033(3) 0.048(3)  0.008(2)  0.009(2)   0.019(3) 
C(2) 0.042(7)  0.032(10) 0.059(7)  0.011(5)  0.018(5)   0.020(6) 
C(3) 0.042(7)  0.040(10) 0.066(8)  0.007(8)  0.013(5)   0.023(6) 
C(4) 0.036(6)  0.039(9) 0.064(7)  0.010(6)  0.010(5)   0.021(6) 
S(1) 0.035(2)  0.048(3) 0.046(3)  0.003(2)  0.0005(18)   
0.021(2) 
C(2') 0.042(6)  0.047(8) 0.057(7)  0.009(6)  0.010(5)   0.023(5) 
C(3') 0.041(6)  0.057(10) 0.067(7)  0.003(6)  0.007(5)   0.026(6) 
C(4') 0.040(6)  0.041(7) 0.060(7)  0.016(6)  0.012(4)   0.029(5) 
S(1') 0.043(2)  0.041(3) 0.061(2)  0.0056(17)  0.0146(16)   
0.0284(18) 
C(5) 0.028(3)  0.023(3) 0.040(3)  0.002(2)  0.004(2)   0.011(2) 
C(6) 0.034(3)  0.024(3) 0.044(3)  0.001(2)  0.008(2)   0.016(3) 
C(7) 0.029(3)  0.030(3) 0.039(3)  0.002(2)  0.004(2)   0.016(3) 
C(8) 0.037(3)  0.023(3) 0.045(3)  0.003(2)  0.007(3)   0.011(3) 
C(9) 0.050(4)  0.025(3) 0.046(3)   0.002(2)  0.007(3)   0.018(3) 
C(10) 0.040(3)  0.028(3) 0.040(3)   0.001(2)  0.005(2)   0.017(3) 
C(11) 0.034(3)  0.027(3) 0.045(3)  0.004(2)  0.008(2)   0.018(3) 
C(12) 0.044(4)  0.042(4) 0.044(3)  0.003(3)  0.013(3)   0.019(3) 
C(13) 0.071(6)  0.058(5) 0.045(4)  0.005(3)  0.016(4)   0.015(5) 
O(1) 0.058(3)  0.033(2) 0.046(2)  0.0010(18)  0.015(2)   0.022(2) 
O(2) 0.038(2)  0.030(2) 0.043(2)  0.0073(17)  0.0141(18)   
0.013(2) 
I(2) 0.0433(3)  0.0247(2) 0.0674(3)   0.00307(19) 0.0062(2)   
0.0100(2) 
C(14) 0.036(4)  0.028(3) 0.087(5)  0.001(3)  0.009(4)   0.014(3) 
C(15) 0.035(3)  0.024(3) 0.078(5)  0.004(3)  0.005(3)   0.016(3) 
C(16) 0.046(5)  0.035(4) 0.123(8)  0.009(5) 0.005(5)   0.019(4) 
C(17) 0.042(4)  0.033(4) 0.162(11)  0.011(5)  0.016(6)   0.023(4) 
S(2) 0.0791(17)  0.0381(11) 0.149(3)  0.0051(13)  0.0616(18)   
0.0260(12) 
C(18) 0.043(4)  0.018(3) 0.063(4)  0.005(3)  0.003(3)   0.008(3) 
C(19) 0.031(3)  0.023(3) 0.065(4)  0.006(3)  0.003(3)   0.011(3) 
C(20) 0.030(3)  0.025(3) 0.065(4)  0.003(3)  0.002(3)   0.012(3) 
C(21) 0.044(4)  0.025(3) 0.062(4)  0.008(3) 0.004(3)   0.013(3) 
C(22) 0.088(7)  0.038(4) 0.058(4)  0.012(3) 0.002(4)   0.021(5) 
C(23) 0.079(6)  0.035(4) 0.053(4)   0.001(3) 0.000(4)   0.012(4) 
C(24) 0.028(3)  0.020(3) 0.072(4)  0.005(3)  0.002(3)   0.012(3) 
C(25) 0.052(4)  0.026(3) 0.070(4)  0.005(3)  0.021(4)   0.016(3) 
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C(26) 0.049(4)  0.025(3) 0.069(4)  0.004(3)  0.013(3)   0.013(3) 
O(3) 0.055(3)  0.030(3) 0.074(3)  0.006(2)  0.020(3)   0.020(2) 
O(4) 0.045(3)  0.022(2) 0.062(3)  0.0033(19)  0.011(2)   0.014(2) 
O(5) 0.034(3)  0.043(3) 0.093(4)  0.004(3)  0.010(3)   0.024(2) 
O(6) 0.048(3)  0.038(3) 0.155(7)   0.007(3)  0.040(4)   0.018(3) 
C(27) 0.028(3)  0.031(3) 0.060(4)   0.004(3)  0.008(3)   0.011(3) 
C(28) 0.035(4)  0.042(4) 0.099(6)   0.005(4)  0.015(4)   0.019(4) 
F(1) 0.116(6)  0.112(6) 0.117(5)  0.048(4)  0.026(4)   0.075(5) 
F(2) 0.061(3)  0.036(3) 0.210(8)  0.011(4)  0.052(4)   0.019(3) 
F(3) 0.074(4)  0.048(3) 0.155(6)   0.009(3)  0.051(4)   0.032(3) 
O(7) 0.057(4)  0.068(5) 0.159(8)  0.028(5) 0.018(5)   0.010(4) 
O(8) 0.056(4)  0.055(4) 0.074(4)  0.026(3)  0.004(3)   0.019(3) 
C(29) 0.049(4)  0.039(4) 0.041(3)   0.005(3) 0.001(3)   0.018(3) 
C(30) 0.088(8)  0.071(7) 0.048(4)  0.016(4)  0.004(5)   0.004(6) 
F(4) 0.134(6)  0.064(4) 0.074(3)  0.018(3)  0.009(3)   0.056(4) 
F(5) 0.126(6)  0.050(3) 0.081(4)   0.007(3)  0.007(4)   0.029(3) 
F(6) 0.123(7)  0.134(7) 0.099(5)  0.001(5)  0.044(5)   0.032(5) 
N 0.23(2)  0.102(13) 0.29(3)  0.020(13) 0.16(2)   0.066(13) 
C(31) 0.069(8)  0.089(10) 0.096(9)  0.030(7)  0.027(6)   0.052(8) 
C(32) 0.094(7)  0.108(9) 0.122(8)  0.014(7)  0.010(6)   0.061(7) 
N' 0.078(11)  0.067(13) 0.081(12)  0.019(10)  0.007(9)   
0.042(10) 
C(31') 0.075(10)  0.066(14) 0.079(13)  0.019(10)  0.002(9)   
0.041(10) 
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Table 6.   Hydrogen coordinates and isotropic displacement parameters (Å2) for 196. 
 
      x       y       z       U 
 
H(2)  0.1484 0.4155 0.2332 0.051 
H(3)  0.3729 0.4628 0.3175 0.057 
H(4)  0.4388 0.5538 0.4896 0.055 
H(2')  0.2151 0.5818 0.4994 0.058 
H(3')  0.4204 0.5780 0.5045 0.065 
H(4')  0.4002 0.4649 0.3551 0.053 
H(6)  0.0209 0.5590 0.1102 0.040 
H(8)  0.1400 0.9174 0.1118 0.044 
H(9)  0.0979 0.9158 0.2712 0.049 
H(10)  0.0209 0.7351 0.3541 0.044 
H(12A)  0.2437 0.8202  0.1419 0.052 
H(12B)  0.1069 0.8143  0.1941 0.052 
H(13A)  0.2637 0.9960  0.2253 0.094 
H(13B)  0.1870 1.0189  0.1560 0.094 
H(13C)  0.3231 1.0248  0.1039 0.094 
H(15) 0.6385 0.1903 0.0159 0.056 
H(16) 0.8644 0.1480  0.0444 0.088 
H(17) 0.9579 0.1315 0.0968 0.094 
H(19) 0.5239 0.0104 0.1078 0.050 
H(21) 0.6385  0.2947 0.2603 0.058 
H(22) 0.6204  0.1870 0.4039 0.082 
H(23) 0.5455 0.0222 0.4006 0.077 
H(25A) 0.7332  0.3975  0.0669 0.058 
H(25B) 0.5930  0.3866  0.0216 0.058 
H(26A) 0.7423  0.5900  0.0314 0.074 
H(26B) 0.6696  0.5462 0.0864 0.074 
H(26C) 0.8090  0.5570 0.0414 0.074 
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6 Appendix III – Results tables from microfluidic radiofluorinations 
Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 65.62 
10 190 10 10 10 76.42 
10 190 10 10 10 79.34 
10 190 10 10 15 77.93 
10 190 10 10 15 79.39 
10 190 10 10 15 80.21 
10 190 10 10 20 82.66 
10 190 10 10 20 82.16 
10 190 10 10 20 83.11 
10 190 10 10 25 81.2 
10 190 10 10 25 80.11 
10 190 10 10 25 78.48 
10 190 10 10 30 82.36 
10 190 10 10 30 74.88 
10 190 10 10 30 73.12 
10 190 10 10 10 43.74 
10 190 10 10 10 34.24 
10 190 10 10 10 43.24 
10 170 10 10 10 34.44 
10 170 10 10 10 33.6 
10 170 10 10 10 32.5 
10 150 10 10 10 16.77 
10 150 10 10 10 14.31 
10 150 10 10 10 15.33 
10 130 10 10 10 3.58 
10 130 10 10 10 2.83 
10 130 10 10 10 2.83 
10 110 10 10 10 3.02 
10 110 10 10 10 0.94 
10 110 10 10 10 0.59 
10 190 20 20 30 87.82 
10 190 20 20 30 82.3 
10 190 20 20 30 86.16 
10 190 30 20 30 81.78 
10 190 30 20 30 80.1 
10 190 30 20 30 78.73 
10 190 10 20 30 86.29 
10 190 10 20 30 85.79 
10 190 10 20 30 85.67 
Table 19: Results of radiosynthesis of 4-[18F]acetophenone from nitroacetophenone using [18F]KF/K222 as the RFA 
Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
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10 190 10 10 10 28.71 
10 190 10 10 10 23.04 
10 190 10 10 10 27.9 
10 190 10 10 15 35.73 
10 190 10 10 15 49.2 
10 190 10 10 15 70.58 
10 190 10 10 20 5.75 
10 190 10 10 20 33.9 
10 190 10 10 20 0 
10 190 10 10 25 25.14 
10 190 10 10 25 25.28 
10 190 10 10 25 35.94 
10 190 10 10 30 37.38 
10 190 10 10 30 37.38 
10 190 10 10 30 0 
10 190 10 10 15 9.74 
10 190 10 10 15 8.88 
10 190 10 10 15 7.79 
10 170 10 10 15 0 
10 170 10 10 15 0 
10 170 10 10 15 0 
10 150 10 10 15 0 
10 150 10 10 15 0 
10 150 10 10 15 0 
10 130 10 10 15 0 
10 130 10 10 15 0 
10 130 10 10 15 0 
10 190 5 10 15 70.89 
10 190 5 10 15 68.67 
10 190 5 10 15 73.69 
10 190 10 10 15 54.72 
10 190 10 10 15 61.96 
10 190 10 10 15 65.09 
10 190 15 10 15 80.43 
10 190 15 10 15 72.1 
10 190 15 10 15 85.69 
10 190 20 10 15 74.74 
10 190 20 10 15 69.05 
10 190 20 10 15 73.15 
Table 20: Results of radiosynthesis of 4-[18F]acetophenone from fluoroacetophenone using [18F]KF/K222 as the RFA 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 86.78 
10 190 10 10 10 84.54 
10 190 10 10 10 82.9 
10 190 10 10 15 86.16 
10 190 10 10 15 86.87 
10 190 10 10 15 89.02 
10 190 10 10 20 88.41 
10 190 10 10 20 85.16 
10 190 10 10 20 85.32 
10 190 10 10 25 81.98 
10 190 10 10 25 82 
10 190 10 10 25 69.61 
10 190 10 10 30 77.96 
10 190 10 10 30 76.66 
10 190 10 10 30 68.97 
10 190 10 10 15 86.16 
10 190 10 10 15 86.87 
10 190 10 10 15 89.02 
10 170 10 10 15 66.54 
10 170 10 10 15 66.99 
10 170 10 10 15 67.31 
10 150 10 10 15 47.15 
10 150 10 10 15 43.9 
10 150 10 10 15 40.98 
10 130 10 10 15 14.33 
10 130 10 10 15 13.76 
10 130 10 10 15 11.58 
10 190 10 10 15 70.59 
10 190 10 10 15 69.87 
10 190 10 10 15 77.19 
10 190 15 10 15 81.85 
10 190 15 10 15 82.17 
10 190 15 10 15 82.08 
10 190 5 10 15 79.65 
10 190 5 10 15 81.42 
10 190 5 10 15 78.45 
Table 21: Results of radiosynthesis of 4-[18F]acetophenone from nitroacetophenone using [18F]NEt4.F as the RFA 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope 
Volume (L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 44.12 
10 190 10 10 10 37.99 
10 190 10 10 10 49.73 
10 190 10 10 15 20.58 
10 190 10 10 15 36.51 
10 190 10 10 15 31.01 
10 190 10 10 20 8.6 
10 190 10 10 20 10.8 
10 190 10 10 20 17.73 
10 190 10 10 25 20.41 
10 190 10 10 25 36.27 
10 190 10 10 25 32.41 
10 190 10 10 30 20.21 
10 190 10 10 30 21.21 
10 190 10 10 30 28.95 
10 190 10 10 15 82.25 
10 190 10 10 15 83.56 
10 190 10 10 15 65.93 
10 170 10 10 15 41.04 
10 170 10 10 15 36.99 
10 170 10 10 15 31.94 
10 150 10 10 15 22.22 
10 150 10 10 15 15.02 
10 150 10 10 15 14.33 
10 130 10 10 15 5.92 
10 130 10 10 15 5.06 
10 130 10 10 15 3.29 
10 190 5 10 10 5.9 
10 190 5 10 10 6.98 
10 190 5 10 10 6.49 
10 190 10 10 10 44.12 
10 190 10 10 10 37.99 
10 190 10 10 10 49.73 
10 190 15 10 10 39 
10 190 15 10 10 57.73 
10 190 15 10 10 60.47 
10 190 20 10 10 55.87 
10 190 20 10 10 60.79 
10 190 20 10 10 59.38 
Table 22: Results of radiosynthesis of 4-[18F]acetophenone from fluoroacetophenone using [18F]NEt4.F as the RFA 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 53.79 
10 190 10 10 10 61.44 
10 190 10 10 10 60.59 
10 190 10 10 15 59.13 
10 190 10 10 15 59.59 
10 190 10 10 15 58.24 
10 190 10 10 20 56.7 
10 190 10 10 20 53.58 
10 190 10 10 20 47.45 
10 190 10 10 25 40.85 
10 190 10 10 25 36.95 
10 190 10 10 25 34.34 
10 190 10 10 30 31.51 
10 190 10 10 30 31.25 
10 190 10 10 30 30.13 
10 190 10 10 15 59.13 
10 190 10 10 15 59.59 
10 190 10 10 15 58.24 
10 170 10 10 15 25.66 
10 170 10 10 15 23.33 
10 170 10 10 15 22.44 
10 150 10 10 15 14.52 
10 150 10 10 15 12.97 
10 150 10 10 15 10.36 
10 130 10 10 15 3.84 
10 130 10 10 15 3.36 
10 130 10 10 15 2.96 
10 190 5 10 10 18.11 
10 190 5 10 10 17.16 
10 190 5 10 10 15.15 
10 190 10 10 10 24.33 
10 190 10 10 10 25.74 
10 190 10 10 10 27.51 
10 190 15 10 10 31.82 
10 190 15 10 10 31.98 
10 190 15 10 10 19.78 
10 190 20 10 10 21.69 
10 190 20 10 10 21.1 
10 190 20 10 10 24.06 
Table 23: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from ethyl 4-nitrobenzoate using [18F]KF/K222 as the RFA 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 69.46 
10 190 10 10 10 69.47 
10 190 10 10 10 69.22 
10 190 10 10 15 67.45 
10 190 10 10 15 65.47 
10 190 10 10 15 64.28 
10 190 10 10 20 67.49 
10 190 10 10 20 70.81 
10 190 10 10 20 66.44 
10 190 10 10 25 65.32 
10 190 10 10 25 64.99 
10 190 10 10 25 66.13 
10 190 10 10 30 63.65 
10 190 10 10 30 62.98 
10 190 10 10 30 60.3 
10 190 10 10 20 67.49 
10 190 10 10 20 70.81 
10 190 10 10 20 66.44 
10 170 10 10 20 56.43 
10 170 10 10 20 56.15 
10 170 10 10 20 55.15 
10 150 10 10 20 32.18 
10 150 10 10 20 29.2 
10 150 10 10 20 26.33 
10 130 10 10 20 9.67 
10 130 10 10 20 9.7 
10 130 10 10 20 7.36 
10 190 5 10 10 61.39 
10 190 5 10 10 60.53 
10 190 5 10 10 55.41 
10 190 10 10 10 70.05 
10 190 10 10 10 75.99 
10 190 10 10 10 69.57 
10 190 15 10 10 66.59 
10 190 15 10 10 60.49 
10 190 15 10 10 62.94 
10 190 20 10 10 64.08 
10 190 20 10 10 65.62 
10 190 20 10 10 65.95 
Table 24: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from ethyl 4-nitrobenzoate using [18F]NEt4.F as the RFA 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 71.01 
10 190 10 10 10 71.22 
10 190 10 10 10 71.44 
10 190 10 10 15 65.07 
10 190 10 10 15 69.98 
10 190 10 10 15 69.41 
10 190 10 10 20 68.43 
10 190 10 10 20 67.31 
10 190 10 10 20 63.86 
10 190 10 10 25 59.6 
10 190 10 10 25 59.99 
10 190 10 10 25 59.61 
10 190 10 10 30 51.56 
10 190 10 10 30 46.09 
10 190 10 10 30 41.51 
10 190 10 10 10 71.01 
10 190 10 10 10 69.7 
10 190 10 10 10 71.22 
10 190 10 10 10 71.44 
10 170 10 10 10 35.59 
10 170 10 10 10 33.85 
10 170 10 10 10 34.12 
10 150 10 10 10 20.35 
10 150 10 10 10 14.33 
10 150 10 10 10 13.84 
10 130 10 10 10 4.08 
10 130 10 10 10 4.76 
10 130 10 10 10 3.06 
10 190 5 10 10 16.09 
10 190 5 10 10 14.96 
10 190 5 10 10 16.03 
10 190 10 10 10 20.69 
10 190 10 10 10 20.54 
10 190 10 10 10 21.58 
10 190 15 10 10 21.54 
10 190 15 10 10 22.61 
10 190 15 10 10 23.37 
10 190 20 10 10 22.59 
10 190 20 10 10 22.81 
10 190 20 10 10 23.74 
Table 25: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from ethyl 4-[19F]fluorobenzoate using [18F]KF/K222  as the RFA. 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 56.42 
10 190 10 10 10 45.45 
10 190 10 10 10 43.16 
10 190 10 10 15 42.45 
10 190 10 10 15 43.44 
10 190 10 10 15 47.74 
10 190 10 10 20 50.06 
10 190 10 10 20 49.64 
10 190 10 10 20 49.53 
10 190 10 10 25 48.99 
10 190 10 10 25 42.55 
10 190 10 10 25 45.24 
10 190 10 10 30 45.39 
10 190 10 10 30 44.17 
10 190 10 10 30 44.13 
10 190 10 10 20 50.06 
10 190 10 10 20 49.64 
10 190 10 10 20 49.53 
10 170 10 10 20 38.96 
10 170 10 10 20 34.23 
10 170 10 10 20 35.36 
10 150 10 10 20 15.43 
10 150 10 10 20 13.49 
10 150 10 10 20 13.03 
10 130 10 10 20 3.06 
10 130 10 10 20 3.07 
10 130 10 10 20 3.69 
10 190 5 10 20 34.11 
10 190 5 10 20 34.04 
10 190 5 10 20 36.04 
10 190 10 10 20 50.06 
10 190 10 10 20 49.64 
10 190 10 10 20 49.53 
10 190 15 10 20 44.63 
10 190 15 10 20 42.81 
10 190 15 10 20 46.31 
10 190 20 10 20 47.2 
10 190 20 10 20 46.66 
10 190 20 10 20 44.88 
Table 26: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from ethyl 4-[19F]fluorobenzoate using [18F]NEt4.F as the RFA. 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
5 190 10 10 10 32.93 
5 190 10 10 10 27.81 
5 190 10 10 10 14.43 
5 190 10 10 15 9.34 
5 190 10 10 15 16.94 
5 190 10 10 15 8.99 
5 190 10 10 20 11.29 
5 190 10 10 20 25.99 
5 190 10 10 20 16.95 
5 190 10 10 25 11.68 
5 190 10 10 25 20.55 
5 190 10 10 25 32.82 
5 190 10 10 30 22.12 
5 190 10 10 30 26.71 
5 190 10 10 30 24.42 
5 190 10 10 30 24.42 
5 190 10 10 30 22.12 
5 190 10 10 30 26.71 
5 170 10 10 30 15.17 
5 170 10 10 30 10.42 
5 170 10 10 30 10.95 
5 150 10 10 30 14.08 
5 150 10 10 30 5.66 
5 150 10 10 30 5.12 
5 130 10 10 30 2.99 
5 130 10 10 30 9.64 
5 130 10 10 30 2.06 
5 190 5 10 25 5.98 
5 190 5 10 25 5.96 
5 190 5 10 25 6 
5 190 10 10 25 5.79 
5 190 10 10 25 5.58 
5 190 10 10 25 5.32 
5 190 15 10 25 2.88 
5 190 15 10 25 1.9 
5 190 15 10 25 7.47 
5 190 20 10 25 7.03 
5 190 20 10 25 2.05 
5 190 20 10 25 1.82 
Table 27: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from trifluoroacetyl(4-ethoxycarbonylphenyl, 4-anisyl)-3-iodane 
using [18F]KF/K222 as the RFA. 
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Precursor 
Concentration 
(mg/mL) 
Reaction 
Temperature 
(°C) 
Precursor 
Volume (L) 
Isotope Volume 
(L) 
Pump 3 Rate 
(L/min) 
RCY (%) 
10 190 10 10 10 47.19 
10 190 10 10 10 38.07 
10 190 10 10 10 40.65 
10 190 10 10 15 29.37 
10 190 10 10 15 26.34 
10 190 10 10 15 26.95 
10 190 10 10 20 22.91 
10 190 10 10 20 23.76 
10 190 10 10 20 20.05 
10 190 10 10 25 16.41 
10 190 10 10 25 24.88 
10 190 10 10 25 19.62 
10 190 10 10 30 20.05 
10 190 10 10 30 20.37 
10 190 10 10 30 14.34 
10 190 10 10 10 22.03 
10 190 10 10 10 22.27 
10 190 10 10 10 21.79 
10 170 10 10 10 20.02 
10 170 10 10 10 18.96 
10 170 10 10 10 19.54 
10 150 10 10 10 13.09 
10 150 10 10 10 15.34 
10 150 10 10 10 17.29 
10 130 10 10 10 16.34 
10 130 10 10 10 14.78 
10 130 10 10 10 17.43 
10 190 5 10 10 10.03 
10 190 5 10 10 11.63 
10 190 5 10 10 12.11 
10 190 10 10 10 34.71 
10 190 10 10 10 31.72 
10 190 10 10 10 33.05 
10 190 15 10 10 23.41 
10 190 15 10 10 26.55 
10 190 15 10 10 27.61 
10 190 20 10 10 20.65 
10 190 20 10 10 17.19 
10 190 20 10 10 15.52 
Table 28: Results of radiosynthesis of ethyl 4-[18F]fluorobenzoate from trifluoroacetyl(4-ethoxycarbonylphenyl, 4-thienyl)-3-
iodane using [18F]NEt4.F as the RFA. 
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Compound NTR RCY (%) 
191 phenyl 56.99 
191 phenyl 58.72 
191 phenyl 56.97 
192 4-anisyl 71.83 
192 4-anisyl 54.37 
192 4-anisyl 68.56 
193 2-thienyl 22.07 
193 2-thienyl 26.45 
193 2-thienyl 25.05 
194 phenyl 25.23 
194 phenyl 31.25 
194 phenyl 29.5 
195 4-anisyl 51.27 
195 4-anisyl 52.17 
195 4-anisyl 43.22 
196 2-thienyl 25.73 
196 2-thienyl 27.9 
196 2-thienyl 24.83 
Table 29: Results of the radiosynthesis of ethyl 4-[18F]fluorobenzoate and ethyl 3-[18F]fluorobenzoate from compounds 191–196.  
Optimal reaction conditions achieved were applied (i.e. flow rate of 10 L/min, temperature of 190 °C, RFA to precursor ratio of 
1:1). Reaction conducted in dry DMF (10mg/mL). 
Compound NTR RCY (%) 
191 phenyl 55.64 
191 phenyl 52.67 
191 phenyl 51.74 
192 4-anisyl 58.13 
192 4-anisyl 56.84 
192 4-anisyl 57.9 
193 2-thienyl 28.81 
193 2-thienyl 21.8 
193 2-thienyl 21.83 
194 phenyl 22.48 
194 phenyl 22.54 
194 phenyl 22.88 
195 4-anisyl 26.33 
195 4-anisyl 29.18 
195 4-anisyl 29.58 
196 2-thienyl 22.53 
196 2-thienyl 17.87 
196 2-thienyl 17.86 
Table 30: Results of the radiosynthesis of ethyl 4-[18F]fluorobenzoate and ethyl 3-[18F]fluorobenzoate from compounds 191–196. 
Optimal reaction conditions achieved were applied (i.e. flow rate of 10 L/min, temperature of 190 °C, RFA to precursor ratio of 
1:1). Reaction conducted in DMF and H2O (5% H2O). 
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